1	Suramin	N	I-Claim
2	is	N	I-Claim
3	a	N	I-Claim
4	novel	N	I-Claim
5	agent	N	I-Claim
6	that	N	I-Claim
7	has	N	I-Claim
8	demonstrated	N	I-Claim
9	preliminary	N	I-Claim
10	evidence	N	I-Claim
11	of	N	I-Claim
12	antitumor	N	I-Claim
13	activity	N	I-Claim
14	in	N	I-Claim
15	hormone-refractory	N	I-Claim
16	prostate	N	I-Claim
17	cancer	N	I-Claim
18	(	N	I-Claim
19	HRPC	N	I-Claim
20	)	N	I-Claim
21	.	N	I-Claim

22	A	N	O
23	prospective	N	O
24	randomized	N	O
25	clinical	N	O
26	trial	N	O
27	was	N	O
28	designed	N	O
29	to	N	O
30	evaluate	N	O
31	pain	N	O
32	and	N	O
33	opioid	N	O
34	analgesic	N	O
35	intake	N	O
36	as	N	O
37	surrogates	N	O
38	for	N	O
39	antitumor	N	O
40	response	N	O
41	in	N	O
42	HRPC	N	O
43	patients	N	O
44	with	N	O
45	significant	N	O
46	,	N	O
47	opioid	N	O
48	analgesic-dependent	N	O
49	pain	N	O
50	.	N	O

51	A	N	O
52	double-blind	N	O
53	,	N	O
54	placebo-controlled	N	O
55	trial	N	O
56	randomized	N	O
57	patients	N	O
58	to	N	O
59	receive	N	O
60	a	N	O
61	78-day	N	O
62	,	N	O
63	outpatient	N	O
64	regimen	N	O
65	of	N	O
66	either	N	O
67	suramin	N	O
68	plus	N	O
69	hydrocortisone	N	O
70	(	N	O
71	HC	N	O
72	,	N	O
73	40	N	O
74	mg/d	N	O
75	)	N	O
76	or	N	O
77	placebo	N	O
78	plus	N	O
79	HC	N	O
80	.	N	O

81	Treatment	N	O
82	assignment	N	O
83	was	N	O
84	unblinded	N	O
85	when	N	O
86	either	N	O
87	disease	N	O
88	progression	N	O
89	or	N	O
90	dose-limiting	N	O
91	toxicity	N	O
92	occurred	N	O
93	;	N	O
94	placebo	N	O
95	patients	N	O
96	were	N	O
97	allowed	N	O
98	to	N	O
99	cross-over	N	O
100	to	N	O
101	open-label	N	O
102	suramin	N	O
103	plus	N	O
104	HC	N	O
105	.	N	O

106	In	N	O
107	addition	N	O
108	to	N	O
109	pain	N	O
110	and	N	O
111	opioid	N	O
112	analgesic	N	O
113	intake	N	O
114	,	N	O
115	prostate-specific	N	O
116	antigen	N	O
117	(	N	O
118	PSA	N	O
119	)	N	O
120	response	N	O
121	,	N	O
122	time	N	O
123	to	N	O
124	disease	N	O
125	progression	N	O
126	,	N	O
127	quality	N	O
128	of	N	O
129	life	N	O
130	,	N	O
131	performance	N	O
132	status	N	O
133	,	N	O
134	and	N	O
135	survival	N	O
136	were	N	O
137	compared	N	O
138	.	N	O

139	Overall	N	I-Premise
140	mean	N	I-Premise
141	reductions	N	I-Premise
142	in	N	I-Premise
143	combined	N	I-Premise
144	pain	N	I-Premise
145	and	N	I-Premise
146	opioid	N	I-Premise
147	analgesic	N	I-Premise
148	intake	N	I-Premise
149	were	N	I-Premise
150	greater	N	I-Premise
151	for	N	I-Premise
152	suramin	N	I-Premise
153	plus	N	I-Premise
154	HC	N	I-Premise
155	(	N	I-Premise
156	rank	N	I-Premise
157	sum	N	I-Premise
158	P	N	I-Premise
159	=.0001	N	I-Premise
160	)	N	I-Premise
161	.	N	I-Premise

162	Pain	N	I-Premise
163	response	N	I-Premise
164	was	N	I-Premise
165	achieved	N	I-Premise
166	in	N	I-Premise
167	a	N	I-Premise
168	higher	N	I-Premise
169	proportion	N	I-Premise
170	of	N	I-Premise
171	patients	N	I-Premise
172	receiving	N	I-Premise
173	suramin	N	I-Premise
174	than	N	I-Premise
175	placebo	N	I-Premise
176	(	N	I-Premise
177	43	N	I-Premise
178	%	N	I-Premise
179	v	N	I-Premise
180	28	N	I-Premise
181	%	N	I-Premise
182	;	N	I-Premise
183	P	N	I-Premise
184	=.001	N	I-Premise
185	)	N	I-Premise
186	,	N	I-Premise
187	and	N	O
188	duration	N	I-Premise
189	of	N	I-Premise
190	response	N	I-Premise
191	was	N	I-Premise
192	longer	N	I-Premise
193	for	N	I-Premise
194	suramin	N	I-Premise
195	responders	N	I-Premise
196	(	N	I-Premise
197	median	N	I-Premise
198	,	N	I-Premise
199	240	N	I-Premise
200	v	N	I-Premise
201	69	N	I-Premise
202	days	N	I-Premise
203	;	N	I-Premise
204	P	N	I-Premise
205	=.0027	N	I-Premise
206	)	N	I-Premise
207	.	N	I-Premise

208	Time	N	I-Premise
209	to	N	I-Premise
210	disease	N	I-Premise
211	progression	N	I-Premise
212	was	N	I-Premise
213	longer	N	I-Premise
214	(	N	I-Premise
215	relative	N	I-Premise
216	risk	N	I-Premise
217	=	N	I-Premise
218	1.5	N	I-Premise
219	;	N	I-Premise
220	95	N	I-Premise
221	%	N	I-Premise
222	confidence	N	I-Premise
223	interval	N	I-Premise
224	,	N	I-Premise
225	1.2	N	I-Premise
226	to	N	I-Premise
227	1.9	N	I-Premise
228	)	N	I-Premise
229	and	N	O
230	the	N	I-Premise
231	proportion	N	I-Premise
232	of	N	I-Premise
233	patients	N	I-Premise
234	with	N	I-Premise
235	a	N	I-Premise
236	greater	N	I-Premise
237	than	N	I-Premise
238	50	N	I-Premise
239	%	N	I-Premise
240	decline	N	I-Premise
241	in	N	I-Premise
242	PSA	N	I-Premise
243	was	N	I-Premise
244	higher	N	I-Premise
245	(	N	I-Premise
246	33	N	I-Premise
247	%	N	I-Premise
248	v	N	I-Premise
249	16	N	I-Premise
250	%	N	I-Premise
251	;	N	I-Premise
252	P	N	I-Premise
253	=.01	N	I-Premise
254	)	N	I-Premise
255	in	N	I-Premise
256	patients	N	I-Premise
257	who	N	I-Premise
258	received	N	I-Premise
259	suramin	N	I-Premise
260	.	N	I-Premise

261	Neither	N	I-Premise
262	quality	N	I-Premise
263	of	N	I-Premise
264	life	N	I-Premise
265	nor	N	I-Premise
266	performance	N	I-Premise
267	status	N	I-Premise
268	was	N	I-Premise
269	decreased	N	I-Premise
270	by	N	I-Premise
271	suramin	N	I-Premise
272	treatment	N	I-Premise
273	,	N	I-Premise
274	and	N	O
275	overall	N	I-Premise
276	survival	N	I-Premise
277	was	N	I-Premise
278	similar	N	I-Premise
279	.	N	I-Premise

280	Most	N	I-Premise
281	adverse	N	I-Premise
282	events	N	I-Premise
283	were	N	I-Premise
284	of	N	I-Premise
285	mild	N	I-Premise
286	or	N	I-Premise
287	moderate	N	I-Premise
288	intensity	N	I-Premise
289	and	N	I-Premise
290	were	N	I-Premise
291	easily	N	I-Premise
292	managed	N	I-Premise
293	medically	N	I-Premise
294	.	N	I-Premise

295	Outpatient	N	I-Claim
296	treatment	N	I-Claim
297	with	N	I-Claim
298	suramin	N	I-Claim
299	plus	N	I-Claim
300	HC	N	I-Claim
301	is	N	I-Claim
302	well	N	I-Claim
303	tolerated	N	I-Claim
304	and	N	I-Claim
305	provides	N	I-Claim
306	moderate	N	I-Claim
307	palliative	N	I-Claim
308	benefit	N	I-Claim
309	and	N	I-Claim
310	delay	N	I-Claim
311	in	N	I-Claim
312	disease	N	I-Claim
313	progression	N	I-Claim
314	for	N	I-Claim
315	patients	N	I-Claim
316	with	N	I-Claim
317	symptomatic	N	I-Claim
318	HRPC	N	I-Claim
319	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	whether	N	O
4	treatment	N	O
5	with	N	O
6	single-agent	N	O
7	docetaxel	N	O
8	would	N	O
9	result	N	O
10	in	N	O
11	longer	N	O
12	survival	N	O
13	than	N	O
14	would	N	O
15	best	N	O
16	supportive	N	O
17	care	N	O
18	in	N	O
19	patients	N	O
20	with	N	O
21	non-small-cell	N	O
22	lung	N	O
23	cancer	N	O
24	who	N	O
25	had	N	O
26	previously	N	O
27	been	N	O
28	treated	N	O
29	with	N	O
30	platinum-based	N	O
31	chemotherapy	N	O
32	.	N	O

33	Secondary	N	O
34	end	N	O
35	points	N	O
36	included	N	O
37	assessment	N	O
38	of	N	O
39	response	N	O
40	(	N	O
41	docetaxel	N	O
42	arm	N	O
43	only	N	O
44	)	N	O
45	,	N	O
46	toxicity	N	O
47	,	N	O
48	and	N	O
49	quality	N	O
50	of	N	O
51	life	N	O
52	.	N	O

53	Patients	N	O
54	with	N	O
55	performance	N	O
56	statuses	N	O
57	of	N	O
58	0	N	O
59	to	N	O
60	2	N	O
61	and	N	O
62	stage	N	O
63	IIIB/IV	N	O
64	non-small-cell	N	O
65	lung	N	O
66	cancer	N	O
67	with	N	O
68	either	N	O
69	measurable	N	O
70	or	N	O
71	evaluable	N	O
72	lesions	N	O
73	were	N	O
74	eligible	N	O
75	for	N	O
76	entry	N	O
77	onto	N	O
78	the	N	O
79	study	N	O
80	if	N	O
81	they	N	O
82	had	N	O
83	undergone	N	O
84	one	N	O
85	or	N	O
86	more	N	O
87	platinum-based	N	O
88	chemotherapy	N	O
89	regimens	N	O
90	and	N	O
91	if	N	O
92	they	N	O
93	had	N	O
94	adequate	N	O
95	hematology	N	O
96	and	N	O
97	biochemistry	N	O
98	parameters	N	O
99	.	N	O

100	They	N	O
101	were	N	O
102	excluded	N	O
103	if	N	O
104	they	N	O
105	had	N	O
106	symptomatic	N	O
107	brain	N	O
108	metastases	N	O
109	or	N	O
110	if	N	O
111	they	N	O
112	had	N	O
113	previously	N	O
114	been	N	O
115	treated	N	O
116	with	N	O
117	paclitaxel	N	O
118	.	N	O

119	Patients	N	O
120	were	N	O
121	stratified	N	O
122	by	N	O
123	performance	N	O
124	status	N	O
125	and	N	O
126	best	N	O
127	response	N	O
128	to	N	O
129	cisplatin	N	O
130	chemotherapy	N	O
131	and	N	O
132	were	N	O
133	then	N	O
134	randomized	N	O
135	to	N	O
136	treatment	N	O
137	with	N	O
138	docetaxel	N	O
139	100	N	O
140	mg/m	N	O
141	(	N	O
142	2	N	O
143	)	N	O
144	(	N	O
145	49	N	O
146	patients	N	O
147	)	N	O
148	or	N	O
149	75	N	O
150	mg/m	N	O
151	(	N	O
152	2	N	O
153	)	N	O
154	(	N	O
155	55	N	O
156	patients	N	O
157	)	N	O
158	or	N	O
159	best	N	O
160	supportive	N	O
161	care	N	O
162	.	N	O

163	Patients	N	O
164	in	N	O
165	both	N	O
166	arms	N	O
167	were	N	O
168	assessed	N	O
169	every	N	O
170	3	N	O
171	weeks	N	O
172	.	N	O

173	One	N	O
174	hundred	N	O
175	four	N	O
176	patients	N	O
177	(	N	O
178	103	N	O
179	of	N	O
180	whom	N	O
181	were	N	O
182	eligible	N	O
183	for	N	O
184	entry	N	O
185	onto	N	O
186	the	N	O
187	study	N	O
188	)	N	O
189	were	N	O
190	well	N	O
191	balanced	N	O
192	for	N	O
193	prognostic	N	O
194	factors	N	O
195	.	N	O

196	Of	N	O
197	84	N	O
198	patients	N	O
199	with	N	O
200	measurable	N	O
201	lesions	N	O
202	,	N	O
203	six	N	O
204	(	N	O
205	7	N	O
206	.	N	O

207	1	N	O
208	%	N	O
209	)	N	O
210	achieved	N	O
211	partial	N	O
212	responses	N	O
213	(	N	O
214	three	N	O
215	patients	N	O
216	at	N	O
217	each	N	O
218	dose	N	O
219	level	N	O
220	)	N	O
221	.	N	O

222	Time	N	I-Premise
223	to	N	I-Premise
224	progression	N	I-Premise
225	was	N	I-Premise
226	longer	N	I-Premise
227	for	N	I-Premise
228	docetaxel	N	I-Premise
229	patients	N	I-Premise
230	than	N	I-Premise
231	for	N	I-Premise
232	best	N	I-Premise
233	supportive	N	I-Premise
234	care	N	I-Premise
235	patients	N	I-Premise
236	(	N	I-Premise
237	10.6	N	I-Premise
238	v	N	I-Premise
239	6.7	N	I-Premise
240	weeks	N	I-Premise
241	,	N	I-Premise
242	respectively	N	I-Premise
243	;	N	I-Premise
244	P	N	I-Premise
245	<	N	I-Premise
246	.001	N	I-Premise
247	)	N	I-Premise
248	,	N	I-Premise
249	as	N	I-Premise
250	was	N	I-Premise
251	median	N	I-Premise
252	survival	N	I-Premise
253	(	N	I-Premise
254	7.0	N	I-Premise
255	v	N	I-Premise
256	4.6	N	I-Premise
257	months	N	I-Premise
258	;	N	I-Premise
259	log-rank	N	I-Premise
260	test	N	I-Premise
261	,	N	I-Premise
262	P	N	I-Premise
263	=.047	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	The	N	I-Premise
267	difference	N	I-Premise
268	was	N	I-Premise
269	more	N	I-Premise
270	significant	N	I-Premise
271	for	N	I-Premise
272	docetaxel	N	I-Premise
273	75	N	I-Premise
274	mg/m	N	I-Premise
275	(	N	I-Premise
276	2	N	I-Premise
277	)	N	I-Premise
278	patients	N	I-Premise
279	,	N	I-Premise
280	compared	N	I-Premise
281	with	N	I-Premise
282	corresponding	N	I-Premise
283	best	N	I-Premise
284	supportive	N	I-Premise
285	care	N	I-Premise
286	patients	N	I-Premise
287	(	N	I-Premise
288	7.5	N	I-Premise
289	v	N	I-Premise
290	4.6	N	I-Premise
291	months	N	I-Premise
292	;	N	I-Premise
293	log-rank	N	I-Premise
294	test	N	I-Premise
295	,	N	I-Premise
296	P	N	I-Premise
297	=.010	N	I-Premise
298	;	N	I-Premise
299	1-year	N	I-Premise
300	survival	N	I-Premise
301	,	N	I-Premise
302	37	N	I-Premise
303	%	N	I-Premise
304	v	N	I-Premise
305	11	N	I-Premise
306	%	N	I-Premise
307	;	N	I-Premise
308	chi	N	I-Premise
309	(	N	I-Premise
310	2	N	I-Premise
311	)	N	I-Premise
312	test	N	I-Premise
313	,	N	I-Premise
314	P	N	I-Premise
315	=.003	N	I-Premise
316	)	N	I-Premise
317	.	N	I-Premise

318	Febrile	N	I-Premise
319	neutropenia	N	I-Premise
320	occurred	N	I-Premise
321	in	N	I-Premise
322	11	N	I-Premise
323	patients	N	I-Premise
324	treated	N	I-Premise
325	with	N	I-Premise
326	docetaxel	N	I-Premise
327	100	N	I-Premise
328	mg/m	N	I-Premise
329	(	N	I-Premise
330	2	N	I-Premise
331	)	N	I-Premise
332	,	N	I-Premise
333	three	N	I-Premise
334	of	N	I-Premise
335	whom	N	I-Premise
336	died	N	I-Premise
337	,	N	I-Premise
338	and	N	I-Premise
339	in	N	I-Premise
340	one	N	I-Premise
341	patient	N	I-Premise
342	treated	N	I-Premise
343	with	N	I-Premise
344	docetaxel	N	I-Premise
345	75	N	I-Premise
346	mg/m	N	I-Premise
347	(	N	I-Premise
348	2	N	I-Premise
349	)	N	I-Premise
350	.	N	I-Premise

351	Grade	N	I-Premise
352	3	N	I-Premise
353	or	N	I-Premise
354	4	N	I-Premise
355	nonhematologic	N	I-Premise
356	toxicity	N	I-Premise
357	,	N	I-Premise
358	with	N	I-Premise
359	the	N	I-Premise
360	exception	N	I-Premise
361	of	N	I-Premise
362	diarrhea	N	I-Premise
363	,	N	I-Premise
364	occurred	N	I-Premise
365	at	N	I-Premise
366	a	N	I-Premise
367	similar	N	I-Premise
368	rate	N	I-Premise
369	in	N	I-Premise
370	both	N	I-Premise
371	the	N	I-Premise
372	docetaxel	N	I-Premise
373	and	N	I-Premise
374	best	N	I-Premise
375	supportive	N	I-Premise
376	care	N	I-Premise
377	groups	N	I-Premise
378	.	N	I-Premise

379	Treatment	N	I-Claim
380	with	N	I-Claim
381	docetaxel	N	I-Claim
382	is	N	I-Claim
383	associated	N	I-Claim
384	with	N	I-Claim
385	significant	N	I-Claim
386	prolongation	N	I-Claim
387	of	N	I-Claim
388	survival	N	I-Claim
389	,	N	I-Claim
390	and	N	O
391	at	N	I-Claim
392	a	N	I-Claim
393	dose	N	I-Claim
394	of	N	I-Claim
395	75	N	I-Claim
396	mg/m	N	I-Claim
397	(	N	I-Claim
398	2	N	I-Claim
399	)	N	I-Claim
400	,	N	I-Claim
401	the	N	I-Claim
402	benefits	N	I-Claim
403	of	N	I-Claim
404	docetaxel	N	I-Claim
405	therapy	N	I-Claim
406	outweigh	N	I-Claim
407	the	N	I-Claim
408	risks	N	I-Claim
409	.	N	I-Claim

1	In	N	I-Claim
2	the	N	I-Claim
3	context	N	I-Claim
4	of	N	I-Claim
5	chronic	N	I-Claim
6	physical	N	I-Claim
7	illness	N	I-Claim
8	,	N	I-Claim
9	such	N	I-Claim
10	as	N	I-Claim
11	breast	N	I-Claim
12	cancer	N	I-Claim
13	,	N	I-Claim
14	depression	N	I-Claim
15	is	N	I-Claim
16	associated	N	I-Claim
17	with	N	I-Claim
18	increased	N	I-Claim
19	morbidity	N	I-Claim
20	,	N	I-Claim
21	longer	N	I-Claim
22	periods	N	I-Claim
23	of	N	I-Claim
24	hospitalization	N	I-Claim
25	,	N	I-Claim
26	and	N	I-Claim
27	greater	N	I-Claim
28	overall	N	I-Claim
29	disability	N	I-Claim
30	.	N	I-Claim

31	Prompt	N	I-Claim
32	diagnosis	N	I-Claim
33	and	N	I-Claim
34	effective	N	I-Claim
35	treatment	N	I-Claim
36	is	N	I-Claim
37	,	N	I-Claim
38	therefore	N	I-Claim
39	,	N	I-Claim
40	essential	N	I-Claim
41	.	N	I-Claim

42	Several	N	O
43	small	N	O
44	studies	N	O
45	have	N	O
46	established	N	O
47	the	N	O
48	efficacy	N	O
49	of	N	O
50	tricyclic	N	O
51	antidepressants	N	O
52	(	N	O
53	TCAs	N	O
54	)	N	O
55	in	N	O
56	this	N	O
57	setting	N	O
58	,	N	O
59	and	N	O
60	the	N	O
61	selective	N	O
62	serotonin	N	O
63	reuptake	N	O
64	inhibitors	N	O
65	(	N	O
66	SSRIs	N	O
67	)	N	O
68	would	N	O
69	appear	N	O
70	to	N	O
71	be	N	O
72	an	N	O
73	alternative	N	O
74	therapeutic	N	O
75	option	N	O
76	because	N	O
77	of	N	O
78	their	N	O
79	established	N	O
80	efficacy	N	O
81	and	N	O
82	better	N	O
83	tolerability	N	O
84	profile	N	O
85	.	N	O

86	This	N	O
87	was	N	O
88	a	N	O
89	multicenter	N	O
90	.	N	O

91	double-blind	N	O
92	,	N	O
93	parallel-group	N	O
94	study	N	O
95	in	N	O
96	which	N	O
97	179	N	O
98	women	N	O
99	with	N	O
100	breast	N	O
101	cancer	N	O
102	were	N	O
103	randomized	N	O
104	to	N	O
105	treatment	N	O
106	with	N	O
107	either	N	O
108	the	N	O
109	SSRI	N	O
110	paroxetine	N	O
111	(	N	O
112	20-40	N	O
113	mg/day	N	O
114	)	N	O
115	,	N	O
116	or	N	O
117	the	N	O
118	TCA	N	O
119	,	N	O
120	amitriptyline	N	O
121	(	N	O
122	75-150	N	O
123	mg/day	N	O
124	)	N	O
125	.	N	O

126	After	N	I-Premise
127	8-weeks	N	I-Premise
128	treatment	N	I-Premise
129	,	N	I-Premise
130	depressive	N	I-Premise
131	symptomatology	N	I-Premise
132	had	N	I-Premise
133	improved	N	I-Premise
134	markedly	N	I-Premise
135	and	N	I-Premise
136	to	N	I-Premise
137	a	N	I-Premise
138	similar	N	I-Premise
139	extent	N	I-Premise
140	in	N	I-Premise
141	both	N	I-Premise
142	groups	N	I-Premise
143	on	N	I-Premise
144	the	N	I-Premise
145	Montgomery	N	I-Premise
146	Asberg	N	I-Premise
147	Depression	N	I-Premise
148	Rating	N	I-Premise
149	Scale	N	I-Premise
150	.	N	I-Premise

151	Clinical	N	I-Premise
152	global	N	I-Premise
153	impression	N	I-Premise
154	(	N	I-Premise
155	CGI	N	I-Premise
156	)	N	I-Premise
157	Global	N	I-Premise
158	improvement	N	I-Premise
159	and	N	I-Premise
160	Patient	N	I-Premise
161	global	N	I-Premise
162	evaluation	N	I-Premise
163	scales	N	I-Premise
164	indicated	N	I-Premise
165	that	N	I-Premise
166	patients	N	I-Premise
167	were	N	I-Premise
168	minimally	N	I-Premise
169	to	N	I-Premise
170	much	N	I-Premise
171	improved	N	I-Premise
172	at	N	I-Premise
173	study	N	I-Premise
174	endpoint	N	I-Premise
175	:	N	I-Premise
176	a	N	I-Premise
177	change	N	I-Premise
178	from	N	I-Premise
179	moderately/mildly	N	I-Premise
180	ill	N	I-Premise
181	to	N	I-Premise
182	borderline	N	I-Premise
183	ill	N	I-Premise
184	on	N	I-Premise
185	the	N	I-Premise
186	CGI	N	I-Premise
187	severity	N	I-Premise
188	of	N	I-Premise
189	Illness	N	I-Premise
190	scale	N	I-Premise
191	.	N	I-Premise

192	A	N	I-Claim
193	steady	N	I-Claim
194	improvement	N	I-Claim
195	in	N	I-Claim
196	quality	N	I-Claim
197	of	N	I-Claim
198	life	N	I-Claim
199	was	N	I-Claim
200	also	N	I-Claim
201	observed	N	I-Claim
202	in	N	I-Claim
203	both	N	I-Claim
204	groups	N	I-Claim
205	.	N	I-Claim

206	There	N	I-Premise
207	were	N	I-Premise
208	no	N	I-Premise
209	clinically	N	I-Premise
210	significant	N	I-Premise
211	differences	N	I-Premise
212	between	N	I-Premise
213	the	N	I-Premise
214	groups	N	I-Premise
215	.	N	I-Premise

216	In	N	I-Premise
217	total	N	I-Premise
218	,	N	I-Premise
219	47	N	I-Premise
220	(	N	I-Premise
221	53.4	N	I-Premise
222	%	N	I-Premise
223	)	N	I-Premise
224	patients	N	I-Premise
225	in	N	I-Premise
226	the	N	I-Premise
227	paroxetine	N	I-Premise
228	group	N	I-Premise
229	and	N	I-Premise
230	53	N	I-Premise
231	(	N	I-Premise
232	59.6	N	I-Premise
233	%	N	I-Premise
234	)	N	I-Premise
235	patients	N	I-Premise
236	in	N	I-Premise
237	the	N	I-Premise
238	amitriptyline	N	I-Premise
239	group	N	I-Premise
240	had	N	I-Premise
241	adverse	N	I-Premise
242	experiences	N	I-Premise
243	,	N	I-Premise
244	the	N	I-Premise
245	most	N	I-Premise
246	common	N	I-Premise
247	of	N	I-Premise
248	which	N	I-Premise
249	were	N	I-Premise
250	the	N	I-Premise
251	well-recognized	N	I-Premise
252	side-effects	N	I-Premise
253	of	N	I-Premise
254	the	N	I-Premise
255	antidepressant	N	I-Premise
256	medications	N	I-Premise
257	or	N	I-Premise
258	chemotherapy	N	I-Premise
259	.	N	I-Premise

260	Anticholinergic	N	I-Premise
261	effects	N	I-Premise
262	were	N	I-Premise
263	almost	N	I-Premise
264	twice	N	I-Premise
265	as	N	I-Premise
266	frequent	N	I-Premise
267	in	N	I-Premise
268	the	N	I-Premise
269	amitriptyline	N	I-Premise
270	group	N	I-Premise
271	(	N	I-Premise
272	19.1	N	I-Premise
273	%	N	I-Premise
274	)	N	I-Premise
275	compared	N	I-Premise
276	with	N	I-Premise
277	paroxetine	N	I-Premise
278	(	N	I-Premise
279	11.4	N	I-Premise
280	%	N	I-Premise
281	)	N	I-Premise
282	.	N	I-Premise

283	This	N	O
284	study	N	O
285	has	N	O
286	demonstrated	N	O
287	that	N	O
288	paroxetine	N	I-Claim
289	is	N	I-Claim
290	a	N	I-Claim
291	suitable	N	I-Claim
292	alternative	N	I-Claim
293	to	N	I-Claim
294	amitriptyline	N	I-Claim
295	for	N	I-Claim
296	the	N	I-Claim
297	treatment	N	I-Claim
298	of	N	I-Claim
299	depression	N	I-Claim
300	in	N	I-Claim
301	patients	N	I-Claim
302	with	N	I-Claim
303	breast	N	I-Claim
304	cancer	N	I-Claim
305	.	N	I-Claim

1	In	N	I-Claim
2	a	N	I-Claim
3	randomized	N	I-Claim
4	clinical	N	I-Claim
5	trial	N	I-Claim
6	in	N	I-Claim
7	patients	N	I-Claim
8	with	N	I-Claim
9	advanced	N	I-Claim
10	non-small-cell	N	I-Claim
11	lung	N	I-Claim
12	cancer	N	I-Claim
13	(	N	I-Claim
14	NSCLC	N	I-Claim
15	)	N	I-Claim
16	,	N	I-Claim
17	infusion	N	I-Claim
18	with	N	I-Claim
19	adenosine	N	I-Claim
20	5'-triphosphate	N	I-Claim
21	(	N	I-Claim
22	ATP	N	I-Claim
23	)	N	I-Claim
24	inhibited	N	I-Claim
25	loss	N	I-Claim
26	of	N	I-Claim
27	body	N	I-Claim
28	weight	N	I-Claim
29	and	N	I-Claim
30	quality	N	I-Claim
31	of	N	I-Claim
32	life	N	I-Claim
33	.	N	I-Claim

34	In	N	O
35	the	N	O
36	present	N	O
37	article	N	O
38	,	N	O
39	the	N	O
40	effects	N	O
41	of	N	O
42	ATP	N	O
43	on	N	O
44	body	N	O
45	composition	N	O
46	,	N	O
47	energy	N	O
48	intake	N	O
49	,	N	O
50	and	N	O
51	energy	N	O
52	expenditure	N	O
53	as	N	O
54	secondary	N	O
55	outcome	N	O
56	measures	N	O
57	in	N	O
58	the	N	O
59	same	N	O
60	patients	N	O
61	are	N	O
62	reported	N	O
63	.	N	O

64	Patients	N	O
65	with	N	O
66	NSCLC	N	O
67	,	N	O
68	stage	N	O
69	IIIB	N	O
70	or	N	O
71	IV	N	O
72	,	N	O
73	were	N	O
74	randomized	N	O
75	to	N	O
76	receive	N	O
77	either	N	O
78	10	N	O
79	intravenous	N	O
80	,	N	O
81	30-hour	N	O
82	ATP	N	O
83	infusions	N	O
84	every	N	O
85	2	N	O
86	to	N	O
87	4	N	O
88	weeks	N	O
89	or	N	O
90	no	N	O
91	ATP	N	O
92	.	N	O

93	Fat	N	O
94	mass	N	O
95	(	N	O
96	FM	N	O
97	)	N	O
98	,	N	O
99	fat-free	N	O
100	mass	N	O
101	(	N	O
102	FFM	N	O
103	)	N	O
104	,	N	O
105	and	N	O
106	arm	N	O
107	muscle	N	O
108	area	N	O
109	were	N	O
110	assessed	N	O
111	at	N	O
112	4-week	N	O
113	intervals	N	O
114	for	N	O
115	28	N	O
116	weeks	N	O
117	.	N	O

118	Food	N	O
119	intake	N	O
120	,	N	O
121	body	N	O
122	cell	N	O
123	mass	N	O
124	(	N	O
125	BCM	N	O
126	)	N	O
127	,	N	O
128	and	N	O
129	resting	N	O
130	energy	N	O
131	expenditure	N	O
132	(	N	O
133	REE	N	O
134	)	N	O
135	were	N	O
136	assessed	N	O
137	at	N	O
138	8-week	N	O
139	intervals	N	O
140	for	N	O
141	16	N	O
142	weeks	N	O
143	.	N	O

144	Between-group	N	O
145	differences	N	O
146	were	N	O
147	tested	N	O
148	for	N	O
149	statistical	N	O
150	significance	N	O
151	by	N	O
152	repeated-measures	N	O
153	analysis	N	O
154	of	N	O
155	covariance	N	O
156	.	N	O

157	Fifty-eight	N	O
158	patients	N	O
159	were	N	O
160	randomized	N	O
161	(	N	O
162	28	N	O
163	ATP	N	O
164	,	N	O
165	30	N	O
166	control	N	O
167	)	N	O
168	.	N	O

169	No	N	I-Premise
170	change	N	I-Premise
171	in	N	I-Premise
172	body	N	I-Premise
173	composition	N	I-Premise
174	over	N	I-Premise
175	the	N	I-Premise
176	28-week	N	I-Premise
177	follow-up	N	I-Premise
178	period	N	I-Premise
179	was	N	I-Premise
180	found	N	I-Premise
181	in	N	I-Premise
182	the	N	I-Premise
183	ATP	N	I-Premise
184	group	N	I-Premise
185	,	N	I-Premise
186	whereas	N	I-Premise
187	,	N	I-Premise
188	per	N	I-Premise
189	4	N	I-Premise
190	weeks	N	I-Premise
191	,	N	I-Premise
192	the	N	I-Premise
193	control	N	I-Premise
194	group	N	I-Premise
195	lost	N	I-Premise
196	0.6	N	I-Premise
197	kg	N	I-Premise
198	of	N	I-Premise
199	FM	N	I-Premise
200	(	N	I-Premise
201	P	N	I-Premise
202	=.004	N	I-Premise
203	)	N	I-Premise
204	,	N	I-Premise
205	0.5	N	I-Premise
206	kg	N	I-Premise
207	of	N	I-Premise
208	FFM	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	=.02	N	I-Premise
212	)	N	I-Premise
213	,	N	I-Premise
214	1.8	N	I-Premise
215	%	N	I-Premise
216	of	N	I-Premise
217	arm	N	I-Premise
218	muscle	N	I-Premise
219	area	N	I-Premise
220	(	N	I-Premise
221	P	N	I-Premise
222	=.02	N	I-Premise
223	)	N	I-Premise
224	,	N	I-Premise
225	and	N	I-Premise
226	0.6	N	I-Premise
227	%	N	I-Premise
228	of	N	I-Premise
229	BCM/kg	N	I-Premise
230	body	N	I-Premise
231	weight	N	I-Premise
232	(	N	I-Premise
233	P	N	I-Premise
234	=.054	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	decreased	N	I-Premise
238	568	N	I-Premise
239	KJ/d	N	I-Premise
240	in	N	I-Premise
241	energy	N	I-Premise
242	intake	N	I-Premise
243	(	N	I-Premise
244	P	N	I-Premise
245	=.0001	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	Appetite	N	I-Premise
249	also	N	I-Premise
250	remained	N	I-Premise
251	stable	N	I-Premise
252	in	N	I-Premise
253	the	N	I-Premise
254	ATP	N	I-Premise
255	group	N	I-Premise
256	but	N	I-Premise
257	decreased	N	I-Premise
258	significantly	N	I-Premise
259	in	N	I-Premise
260	the	N	I-Premise
261	control	N	I-Premise
262	group	N	I-Premise
263	(	N	I-Premise
264	P	N	I-Premise
265	=.0004	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	No	N	I-Premise
269	significant	N	I-Premise
270	differences	N	I-Premise
271	in	N	I-Premise
272	REE	N	I-Premise
273	between	N	I-Premise
274	the	N	I-Premise
275	ATP	N	I-Premise
276	and	N	I-Premise
277	control	N	I-Premise
278	groups	N	I-Premise
279	were	N	I-Premise
280	observed	N	I-Premise
281	.	N	I-Premise

282	The	N	I-Claim
283	inhibition	N	I-Claim
284	of	N	I-Claim
285	weight	N	I-Claim
286	loss	N	I-Claim
287	by	N	I-Claim
288	ATP	N	I-Claim
289	infusions	N	I-Claim
290	in	N	I-Claim
291	patients	N	I-Claim
292	with	N	I-Claim
293	advanced	N	I-Claim
294	NSCLC	N	I-Claim
295	is	N	I-Claim
296	attributed	N	I-Claim
297	to	N	I-Claim
298	counteracting	N	I-Claim
299	the	N	I-Claim
300	loss	N	I-Claim
301	of	N	I-Claim
302	both	N	I-Claim
303	metabolically	N	I-Claim
304	active	N	I-Claim
305	and	N	I-Claim
306	inactive	N	I-Claim
307	tissues	N	I-Claim
308	.	N	I-Claim

309	These	N	I-Premise
310	effects	N	I-Premise
311	are	N	I-Premise
312	partly	N	I-Premise
313	ascribed	N	I-Premise
314	to	N	I-Premise
315	maintenance	N	I-Premise
316	of	N	I-Premise
317	energy	N	I-Premise
318	intake	N	I-Premise
319	.	N	I-Premise

1	The	N	O
2	purpose	N	O
3	of	N	O
4	the	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	response	N	O
10	rate	N	O
11	,	N	O
12	clinical	N	O
13	outcome	N	O
14	,	N	O
15	organ/function	N	O
16	preservation	N	O
17	and	N	O
18	toxicity	N	O
19	in	N	O
20	head	N	O
21	and	N	O
22	neck	N	O
23	cancer	N	O
24	patients	N	O
25	treated	N	O
26	with	N	O
27	induction	N	O
28	chemotherapy	N	O
29	followed	N	O
30	by	N	O
31	concomitant	N	O
32	chemoradiotherapy	N	O
33	and	N	O
34	,	N	O
35	when	N	O
36	necessary	N	O
37	,	N	O
38	limited	N	O
39	surgery	N	O
40	.	N	O

41	The	N	O
42	study	N	O
43	design	N	O
44	was	N	O
45	a	N	O
46	phase	N	O
47	II	N	O
48	non-randomized	N	O
49	trial	N	O
50	in	N	O
51	hospitalized	N	O
52	patients	N	O
53	setting	N	O
54	.	N	O

55	The	N	O
56	treatment	N	O
57	plan	N	O
58	consisted	N	O
59	of	N	O
60	3	N	O
61	cycles	N	O
62	of	N	O
63	induction	N	O
64	chemotherapy	N	O
65	with	N	O
66	cisplatin	N	O
67	,	N	O
68	fluorouracil	N	O
69	(	N	O
70	5-FU	N	O
71	)	N	O
72	,	N	O
73	l-leucovorin	N	O
74	and	N	O
75	interferon	N	O
76	alpha2b	N	O
77	(	N	O
78	PFL-IFN	N	O
79	)	N	O
80	followed	N	O
81	by	N	O
82	7	N	O
83	cycles	N	O
84	of	N	O
85	5-FU	N	O
86	,	N	O
87	hydroxyurea	N	O
88	and	N	O
89	concomitant	N	O
90	radiation	N	O
91	for	N	O
92	5	N	O
93	days	N	O
94	(	N	O
95	FHX	N	O
96	)	N	O
97	for	N	O
98	a	N	O
99	total	N	O
100	radiation	N	O
101	dose	N	O
102	of	N	O
103	70	N	O
104	Gy	N	O
105	.	N	O

106	13	N	O
107	Cis-retinoic	N	O
108	acid	N	O
109	was	N	O
110	added	N	O
111	to	N	O
112	treatment	N	O
113	regimen	N	O
114	for	N	O
115	chemoprevention	N	O
116	and	N	O
117	a	N	O
118	systematic	N	O
119	prophylaxis	N	O
120	of	N	O
121	mucositis	N	O
122	was	N	O
123	administered	N	O
124	to	N	O
125	all	N	O
126	patients	N	O
127	during	N	O
128	FHX	N	O
129	.	N	O

130	Conservative	N	O
131	surgical	N	O
132	resection	N	O
133	was	N	O
134	reserved	N	O
135	to	N	O
136	patients	N	O
137	with	N	O
138	no	N	O
139	optimal	N	O
140	response	N	O
141	(	N	O
142	PR	N	O
143	>	N	O
144	or	N	O
145	=70	N	O
146	%	N	O
147	)	N	O
148	,	N	O
149	whereas	N	O
150	radical	N	O
151	surgery	N	O
152	was	N	O
153	performed	N	O
154	as	N	O
155	salvage	N	O
156	treatment	N	O
157	.	N	O

158	Twenty-six	N	O
159	patients	N	O
160	were	N	O
161	treated	N	O
162	at	N	O
163	one	N	O
164	institution	N	O
165	:	N	O
166	more	N	O
167	than	N	O
168	90	N	O
169	%	N	O
170	had	N	O
171	stage	N	O
172	IV	N	O
173	disease	N	O
174	and	N	O
175	only	N	O
176	19.2	N	O
177	%	N	O
178	had	N	O
179	laryngeal	N	O
180	cancer	N	O
181	.	N	O

182	Eighty-one	N	O
183	percent	N	O
184	of	N	O
185	patients	N	O
186	had	N	O
187	performance	N	O
188	status	N	O
189	0	N	O
190	and	N	O
191	23.1	N	O
192	%	N	O
193	of	N	O
194	patients	N	O
195	had	N	O
196	>	N	O
197	5	N	O
198	%	N	O
199	weight	N	O
200	loss	N	O
201	at	N	O
202	the	N	O
203	start	N	O
204	of	N	O
205	treatment	N	O
206	.	N	O

207	Nineteen	N	O
208	patients	N	O
209	were	N	O
210	analyzed	N	O
211	for	N	O
212	response	N	O
213	to	N	O
214	PFL-IFN	N	O
215	:	N	O
216	3/19	N	O
217	(	N	O
218	15.8	N	O
219	%	N	O
220	)	N	O
221	patients	N	O
222	achieved	N	O
223	a	N	O
224	CR	N	O
225	and	N	O
226	7/19	N	O
227	(	N	O
228	36.8	N	O
229	%	N	O
230	)	N	O
231	achieved	N	O
232	a	N	O
233	PR	N	O
234	for	N	O
235	an	N	O
236	ORR	N	O
237	of	N	O
238	52.6	N	O
239	%	N	O
240	.	N	O

241	FHX	N	O
242	was	N	O
243	administered	N	O
244	on	N	O
245	protocol	N	O
246	to	N	O
247	12	N	O
248	patients	N	O
249	:	N	O
250	6	N	O
251	patients	N	O
252	(	N	O
253	50	N	O
254	%	N	O
255	)	N	O
256	had	N	O
257	CR	N	O
258	,	N	O
259	1	N	O
260	patient	N	O
261	(	N	O
262	8.3	N	O
263	%	N	O
264	)	N	O
265	had	N	O
266	PR	N	O
267	for	N	O
268	an	N	O
269	ORR	N	O
270	of	N	O
271	58.3	N	O
272	%	N	O
273	,	N	O
274	2	N	O
275	patients	N	O
276	(	N	O
277	16.7	N	O
278	%	N	O
279	)	N	O
280	had	N	O
281	SD	N	O
282	and	N	O
283	3	N	O
284	patients	N	O
285	(	N	O
286	25	N	O
287	%	N	O
288	)	N	O
289	had	N	O
290	PD	N	O
291	.	N	O

292	At	N	O
293	the	N	O
294	completion	N	O
295	of	N	O
296	FHX	N	O
297	,	N	O
298	no	N	O
299	patient	N	O
300	underwent	N	O
301	local	N	O
302	therapy	N	O
303	according	N	O
304	to	N	O
305	treatment	N	O
306	plan	N	O
307	.	N	O

308	At	N	I-Premise
309	a	N	I-Premise
310	median	N	I-Premise
311	follow-up	N	I-Premise
312	time	N	I-Premise
313	of	N	I-Premise
314	13.5	N	I-Premise
315	months	N	I-Premise
316	(	N	I-Premise
317	range	N	I-Premise
318	1-28+	N	I-Premise
319	)	N	I-Premise
320	at	N	I-Premise
321	June	N	I-Premise
322	2001	N	I-Premise
323	,	N	I-Premise
324	among	N	I-Premise
325	26	N	I-Premise
326	patients	N	I-Premise
327	enrolled	N	I-Premise
328	12	N	I-Premise
329	(	N	I-Premise
330	46.1	N	I-Premise
331	%	N	I-Premise
332	)	N	I-Premise
333	were	N	I-Premise
334	still	N	I-Premise
335	alive	N	I-Premise
336	and	N	I-Premise
337	9	N	I-Premise
338	(	N	I-Premise
339	75	N	I-Premise
340	%	N	I-Premise
341	)	N	I-Premise
342	of	N	I-Premise
343	them	N	I-Premise
344	were	N	I-Premise
345	progression-free	N	I-Premise
346	.	N	I-Premise

347	The	N	I-Premise
348	median	N	I-Premise
349	duration	N	I-Premise
350	of	N	I-Premise
351	response	N	I-Premise
352	was	N	I-Premise
353	9	N	I-Premise
354	months	N	I-Premise
355	(	N	I-Premise
356	range	N	I-Premise
357	0-25+	N	I-Premise
358	)	N	I-Premise
359	,	N	I-Premise
360	the	N	I-Premise
361	median	N	I-Premise
362	progression-free	N	I-Premise
363	survival	N	I-Premise
364	was	N	I-Premise
365	10.5	N	I-Premise
366	months	N	I-Premise
367	(	N	I-Premise
368	range	N	I-Premise
369	0-28+	N	I-Premise
370	)	N	I-Premise
371	,	N	I-Premise
372	the	N	I-Premise
373	median	N	I-Premise
374	overall	N	I-Premise
375	survival	N	I-Premise
376	time	N	I-Premise
377	was	N	I-Premise
378	9	N	I-Premise
379	months	N	I-Premise
380	(	N	I-Premise
381	range	N	I-Premise
382	1-22	N	I-Premise
383	)	N	I-Premise
384	.	N	I-Premise

385	The	N	I-Premise
386	toxicity	N	I-Premise
387	was	N	I-Premise
388	significant	N	I-Premise
389	and	N	I-Premise
390	consisted	N	I-Premise
391	mainly	N	I-Premise
392	of	N	I-Premise
393	mucositis	N	I-Premise
394	and	N	I-Premise
395	,	N	I-Premise
396	to	N	I-Premise
397	a	N	I-Premise
398	lesser	N	I-Premise
399	extent	N	I-Premise
400	,	N	I-Premise
401	neutropenia/thrombocytopenia	N	I-Premise
402	.	N	I-Premise

403	In	N	O
404	the	N	O
405	present	N	O
406	study	N	O
407	,	N	O
408	the	N	I-Claim
409	low	N	I-Claim
410	serum	N	I-Claim
411	levels	N	I-Claim
412	of	N	I-Claim
413	leptin	N	I-Claim
414	and	N	I-Claim
415	the	N	I-Claim
416	high	N	I-Claim
417	serum	N	I-Claim
418	levels	N	I-Claim
419	of	N	I-Claim
420	proinflammatory	N	I-Claim
421	cytokines	N	I-Claim
422	in	N	I-Claim
423	advanced	N	I-Claim
424	stage	N	I-Claim
425	cancer	N	I-Claim
426	patients	N	I-Claim
427	were	N	I-Claim
428	confirmed	N	I-Claim
429	.	N	I-Claim

430	In	N	O
431	conclusion	N	O
432	,	N	O
433	this	N	I-Claim
434	sequential	N	I-Claim
435	induction	N	I-Claim
436	chemotherapy	N	I-Claim
437	and	N	I-Claim
438	chemoradiotherapy	N	I-Claim
439	program	N	I-Claim
440	has	N	I-Claim
441	been	N	I-Claim
442	found	N	I-Claim
443	moderately	N	I-Claim
444	active	N	I-Claim
445	and	N	I-Claim
446	significantly	N	I-Claim
447	toxic	N	I-Claim
448	;	N	I-Claim
449	moreover	N	O
450	,	N	O
451	the	N	O
452	long	N	O
453	overall	N	O
454	treatment	N	O
455	duration	N	O
456	must	N	O
457	be	N	O
458	taken	N	O
459	into	N	O
460	consideration	N	O
461	.	N	O

462	For	N	O
463	these	N	O
464	reasons	N	O
465	,	N	O
466	this	N	I-MajorClaim
467	regimen	N	I-MajorClaim
468	could	N	I-MajorClaim
469	not	N	I-MajorClaim
470	be	N	I-MajorClaim
471	recommended	N	I-MajorClaim
472	for	N	I-MajorClaim
473	a	N	I-MajorClaim
474	phase	N	I-MajorClaim
475	III	N	I-MajorClaim
476	randomized	N	I-MajorClaim
477	study	N	I-MajorClaim
478	.	N	I-MajorClaim

1	Laparoscopic-assisted	N	I-Claim
2	colectomy	N	I-Claim
3	(	N	I-Claim
4	LAC	N	I-Claim
5	)	N	I-Claim
6	has	N	I-Claim
7	emerged	N	I-Claim
8	as	N	I-Claim
9	the	N	I-Claim
10	preferred	N	I-Claim
11	minimally	N	I-Claim
12	invasive	N	I-Claim
13	surgical	N	I-Claim
14	strategy	N	I-Claim
15	for	N	I-Claim
16	diseases	N	I-Claim
17	of	N	I-Claim
18	the	N	I-Claim
19	colon	N	I-Claim
20	.	N	I-Claim

21	The	N	I-MajorClaim
22	safety	N	I-MajorClaim
23	and	N	I-MajorClaim
24	efficacy	N	I-MajorClaim
25	of	N	I-MajorClaim
26	LAC	N	I-MajorClaim
27	for	N	I-MajorClaim
28	colon	N	I-MajorClaim
29	cancer	N	I-MajorClaim
30	are	N	I-MajorClaim
31	unknown	N	I-MajorClaim
32	,	N	I-MajorClaim
33	and	N	O
34	the	N	I-MajorClaim
35	nature	N	I-MajorClaim
36	and	N	I-MajorClaim
37	magnitude	N	I-MajorClaim
38	of	N	I-MajorClaim
39	any	N	I-MajorClaim
40	quality-of-life	N	I-MajorClaim
41	(	N	I-MajorClaim
42	QOL	N	I-MajorClaim
43	)	N	I-MajorClaim
44	benefit	N	I-MajorClaim
45	resulting	N	I-MajorClaim
46	from	N	I-MajorClaim
47	LAC	N	I-MajorClaim
48	for	N	I-MajorClaim
49	colon	N	I-MajorClaim
50	cancer	N	I-MajorClaim
51	is	N	I-MajorClaim
52	also	N	I-MajorClaim
53	unknown	N	I-MajorClaim
54	.	N	I-MajorClaim

55	To	N	O
56	compare	N	O
57	short-term	N	O
58	QOL	N	O
59	outcomes	N	O
60	after	N	O
61	LAC	N	O
62	vs	N	O
63	open	N	O
64	colectomy	N	O
65	for	N	O
66	colon	N	O
67	cancer	N	O
68	.	N	O

69	Multicenter	N	O
70	,	N	O
71	randomized	N	O
72	controlled	N	O
73	trial	N	O
74	(	N	O
75	Clinical	N	O
76	Outcomes	N	O
77	of	N	O
78	Surgical	N	O
79	Therapy	N	O
80	[	N	O
81	COST	N	O
82	]	N	O
83	)	N	O
84	.	N	O

85	Between	N	O
86	September	N	O
87	1994	N	O
88	and	N	O
89	February	N	O
90	1999	N	O
91	,	N	O
92	37	N	O
93	of	N	O
94	48	N	O
95	centers	N	O
96	provided	N	O
97	data	N	O
98	for	N	O
99	the	N	O
100	QOL	N	O
101	component	N	O
102	of	N	O
103	the	N	O
104	trial	N	O
105	for	N	O
106	449	N	O
107	consecutive	N	O
108	patients	N	O
109	with	N	O
110	clinically	N	O
111	resectable	N	O
112	colon	N	O
113	cancer	N	O
114	.	N	O

115	Scores	N	O
116	on	N	O
117	the	N	O
118	Symptoms	N	O
119	Distress	N	O
120	Scale	N	O
121	(	N	O
122	SDS	N	O
123	)	N	O
124	,	N	O
125	Quality	N	O
126	of	N	O
127	Life	N	O
128	Index	N	O
129	,	N	O
130	and	N	O
131	a	N	O
132	single-item	N	O
133	global	N	O
134	rating	N	O
135	scale	N	O
136	at	N	O
137	2	N	O
138	days	N	O
139	,	N	O
140	2	N	O
141	weeks	N	O
142	,	N	O
143	and	N	O
144	2	N	O
145	months	N	O
146	postoperative	N	O
147	;	N	O
148	duration	N	O
149	of	N	O
150	postoperative	N	O
151	in-hospital	N	O
152	analgesic	N	O
153	use	N	O
154	;	N	O
155	and	N	O
156	length	N	O
157	of	N	O
158	stay	N	O
159	.	N	O

160	Of	N	O
161	449	N	O
162	patients	N	O
163	,	N	O
164	428	N	O
165	provided	N	O
166	QOL	N	O
167	data	N	O
168	.	N	O

169	In	N	I-Premise
170	an	N	I-Premise
171	intention-to-treat	N	I-Premise
172	analysis	N	I-Premise
173	comparing	N	I-Premise
174	SDS	N	I-Premise
175	pain	N	I-Premise
176	intensity	N	I-Premise
177	,	N	I-Premise
178	SDS	N	I-Premise
179	summary	N	I-Premise
180	,	N	I-Premise
181	QOL	N	I-Premise
182	Index	N	I-Premise
183	summary	N	I-Premise
184	,	N	I-Premise
185	and	N	I-Premise
186	global	N	I-Premise
187	rating	N	I-Premise
188	scale	N	I-Premise
189	scores	N	I-Premise
190	at	N	I-Premise
191	each	N	I-Premise
192	time	N	I-Premise
193	point	N	I-Premise
194	,	N	I-Premise
195	the	N	I-Premise
196	only	N	I-Premise
197	statistically	N	I-Premise
198	significant	N	I-Premise
199	difference	N	I-Premise
200	observed	N	I-Premise
201	between	N	I-Premise
202	groups	N	I-Premise
203	was	N	I-Premise
204	the	N	I-Premise
205	global	N	I-Premise
206	rating	N	I-Premise
207	scale	N	I-Premise
208	score	N	I-Premise
209	for	N	I-Premise
210	2	N	I-Premise
211	weeks	N	I-Premise
212	postsurgery	N	I-Premise
213	.	N	I-Premise

214	The	N	I-Premise
215	mean	N	I-Premise
216	(	N	I-Premise
217	median	N	I-Premise
218	)	N	I-Premise
219	global	N	I-Premise
220	rating	N	I-Premise
221	scale	N	I-Premise
222	scores	N	I-Premise
223	for	N	I-Premise
224	2	N	I-Premise
225	weeks	N	I-Premise
226	postsurgery	N	I-Premise
227	were	N	I-Premise
228	76.9	N	I-Premise
229	(	N	I-Premise
230	80	N	I-Premise
231	)	N	I-Premise
232	for	N	I-Premise
233	LAC	N	I-Premise
234	vs	N	I-Premise
235	74.4	N	I-Premise
236	(	N	I-Premise
237	75	N	I-Premise
238	)	N	I-Premise
239	for	N	I-Premise
240	open	N	I-Premise
241	colectomy	N	I-Premise
242	(	N	I-Premise
243	P	N	I-Premise
244	=.009	N	I-Premise
245	)	N	I-Premise
246	.	N	I-Premise

247	While	N	I-Premise
248	in	N	I-Premise
249	the	N	I-Premise
250	hospital	N	I-Premise
251	,	N	I-Premise
252	patients	N	I-Premise
253	assigned	N	I-Premise
254	to	N	I-Premise
255	LAC	N	I-Premise
256	required	N	I-Premise
257	fewer	N	I-Premise
258	days	N	I-Premise
259	of	N	I-Premise
260	both	N	I-Premise
261	parenteral	N	I-Premise
262	analgesics	N	I-Premise
263	compared	N	I-Premise
264	with	N	I-Premise
265	patients	N	I-Premise
266	assigned	N	I-Premise
267	to	N	I-Premise
268	open	N	I-Premise
269	colectomy	N	I-Premise
270	(	N	I-Premise
271	mean	N	I-Premise
272	[	N	I-Premise
273	median	N	I-Premise
274	]	N	I-Premise
275	,	N	I-Premise
276	3.2	N	I-Premise
277	[	N	I-Premise
278	3	N	I-Premise
279	]	N	I-Premise
280	vs	N	I-Premise
281	4.0	N	I-Premise
282	[	N	I-Premise
283	4	N	I-Premise
284	]	N	I-Premise
285	days	N	I-Premise
286	;	N	I-Premise
287	P	N	I-Premise
288	<	N	I-Premise
289	.001	N	I-Premise
290	)	N	I-Premise
291	and	N	I-Premise
292	oral	N	I-Premise
293	analgesics	N	I-Premise
294	(	N	I-Premise
295	mean	N	I-Premise
296	[	N	I-Premise
297	median	N	I-Premise
298	]	N	I-Premise
299	,	N	I-Premise
300	1.9	N	I-Premise
301	[	N	I-Premise
302	1	N	I-Premise
303	]	N	I-Premise
304	vs	N	I-Premise
305	2.2	N	I-Premise
306	[	N	I-Premise
307	2	N	I-Premise
308	]	N	I-Premise
309	days	N	I-Premise
310	;	N	I-Premise
311	P	N	I-Premise
312	=.03	N	I-Premise
313	)	N	I-Premise
314	.	N	I-Premise

315	Only	N	I-Claim
316	minimal	N	I-Claim
317	short-term	N	I-Claim
318	QOL	N	I-Claim
319	benefits	N	I-Claim
320	were	N	I-Claim
321	found	N	I-Claim
322	with	N	I-Claim
323	LAC	N	I-Claim
324	for	N	I-Claim
325	colon	N	I-Claim
326	cancer	N	I-Claim
327	compared	N	I-Claim
328	with	N	I-Claim
329	standard	N	I-Claim
330	open	N	I-Claim
331	colectomy	N	I-Claim
332	.	N	I-Claim

333	Until	N	I-Claim
334	ongoing	N	I-Claim
335	trials	N	I-Claim
336	establish	N	I-Claim
337	that	N	I-Claim
338	LAC	N	I-Claim
339	is	N	I-Claim
340	as	N	I-Claim
341	effective	N	I-Claim
342	as	N	I-Claim
343	open	N	I-Claim
344	colectomy	N	I-Claim
345	in	N	I-Claim
346	preventing	N	I-Claim
347	recurrence	N	I-Claim
348	and	N	I-Claim
349	death	N	I-Claim
350	from	N	I-Claim
351	colon	N	I-Claim
352	cancer	N	I-Claim
353	,	N	I-Claim
354	this	N	I-Claim
355	procedure	N	I-Claim
356	should	N	I-Claim
357	not	N	I-Claim
358	be	N	I-Claim
359	offered	N	I-Claim
360	to	N	I-Claim
361	patients	N	I-Claim
362	with	N	I-Claim
363	colon	N	I-Claim
364	cancer	N	I-Claim
365	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	safety	N	O
7	of	N	O
8	first-line	N	O
9	,	N	O
10	single-agent	N	O
11	trastuzumab	N	O
12	in	N	O
13	women	N	O
14	with	N	O
15	HER2-overexpressing	N	O
16	metastatic	N	O
17	breast	N	O
18	cancer	N	O
19	.	N	O

20	One	N	O
21	hundred	N	O
22	fourteen	N	O
23	women	N	O
24	with	N	O
25	HER2-overexpressing	N	O
26	metastatic	N	O
27	breast	N	O
28	cancer	N	O
29	were	N	O
30	randomized	N	O
31	to	N	O
32	receive	N	O
33	first-line	N	O
34	treatment	N	O
35	with	N	O
36	trastuzumab	N	O
37	4	N	O
38	mg/kg	N	O
39	loading	N	O
40	dose	N	O
41	,	N	O
42	followed	N	O
43	by	N	O
44	2	N	O
45	mg/kg	N	O
46	weekly	N	O
47	,	N	O
48	or	N	O
49	a	N	O
50	higher	N	O
51	8	N	O
52	mg/kg	N	O
53	loading	N	O
54	dose	N	O
55	,	N	O
56	followed	N	O
57	by	N	O
58	4	N	O
59	mg/kg	N	O
60	weekly	N	O
61	.	N	O

62	The	N	I-Premise
63	objective	N	I-Premise
64	response	N	I-Premise
65	rate	N	I-Premise
66	was	N	I-Premise
67	26	N	I-Premise
68	%	N	I-Premise
69	(	N	I-Premise
70	95	N	I-Premise
71	%	N	I-Premise
72	confidence	N	I-Premise
73	interval	N	I-Premise
74	[	N	I-Premise
75	CI	N	I-Premise
76	]	N	I-Premise
77	,	N	I-Premise
78	18.2	N	I-Premise
79	%	N	I-Premise
80	to	N	I-Premise
81	34.4	N	I-Premise
82	%	N	I-Premise
83	)	N	I-Premise
84	,	N	I-Premise
85	with	N	I-Premise
86	seven	N	I-Premise
87	complete	N	I-Premise
88	and	N	I-Premise
89	23	N	I-Premise
90	partial	N	I-Premise
91	responses	N	I-Premise
92	.	N	I-Premise

93	Response	N	I-Premise
94	rates	N	I-Premise
95	in	N	I-Premise
96	111	N	I-Premise
97	assessable	N	I-Premise
98	patients	N	I-Premise
99	with	N	I-Premise
100	3+	N	I-Premise
101	and	N	I-Premise
102	2+	N	I-Premise
103	HER2	N	I-Premise
104	overexpression	N	I-Premise
105	by	N	I-Premise
106	immunohistochemistry	N	I-Premise
107	(	N	I-Premise
108	IHC	N	I-Premise
109	)	N	I-Premise
110	were	N	I-Premise
111	35	N	I-Premise
112	%	N	I-Premise
113	(	N	I-Premise
114	95	N	I-Premise
115	%	N	I-Premise
116	CI	N	I-Premise
117	,	N	I-Premise
118	24.4	N	I-Premise
119	%	N	I-Premise
120	to	N	I-Premise
121	44.7	N	I-Premise
122	%	N	I-Premise
123	)	N	I-Premise
124	and	N	I-Premise
125	none	N	I-Premise
126	(	N	I-Premise
127	95	N	I-Premise
128	%	N	I-Premise
129	CI	N	I-Premise
130	,	N	I-Premise
131	0	N	I-Premise
132	%	N	I-Premise
133	to	N	I-Premise
134	15.5	N	I-Premise
135	%	N	I-Premise
136	)	N	I-Premise
137	,	N	I-Premise
138	respectively	N	I-Premise
139	.	N	I-Premise

140	The	N	I-Premise
141	clinical	N	I-Premise
142	benefit	N	I-Premise
143	rates	N	I-Premise
144	in	N	I-Premise
145	assessable	N	I-Premise
146	patients	N	I-Premise
147	with	N	I-Premise
148	3+	N	I-Premise
149	and	N	I-Premise
150	2+	N	I-Premise
151	HER2	N	I-Premise
152	overexpression	N	I-Premise
153	were	N	I-Premise
154	48	N	I-Premise
155	%	N	I-Premise
156	and	N	I-Premise
157	7	N	I-Premise
158	%	N	I-Premise
159	,	N	I-Premise
160	respectively	N	I-Premise
161	.	N	I-Premise

162	The	N	I-Premise
163	response	N	I-Premise
164	rates	N	I-Premise
165	in	N	I-Premise
166	108	N	I-Premise
167	assessable	N	I-Premise
168	patients	N	I-Premise
169	with	N	I-Premise
170	and	N	I-Premise
171	without	N	I-Premise
172	HER2	N	I-Premise
173	gene	N	I-Premise
174	amplification	N	I-Premise
175	by	N	I-Premise
176	fluorescence	N	I-Premise
177	in	N	I-Premise
178	situ	N	I-Premise
179	hybridization	N	I-Premise
180	(	N	I-Premise
181	FISH	N	I-Premise
182	)	N	I-Premise
183	analysis	N	I-Premise
184	were	N	I-Premise
185	34	N	I-Premise
186	%	N	I-Premise
187	(	N	I-Premise
188	95	N	I-Premise
189	%	N	I-Premise
190	CI	N	I-Premise
191	,	N	I-Premise
192	23.9	N	I-Premise
193	%	N	I-Premise
194	to	N	I-Premise
195	45.7	N	I-Premise
196	%	N	I-Premise
197	)	N	I-Premise
198	and	N	I-Premise
199	7	N	I-Premise
200	%	N	I-Premise
201	(	N	I-Premise
202	95	N	I-Premise
203	%	N	I-Premise
204	CI	N	I-Premise
205	,	N	I-Premise
206	0.8	N	I-Premise
207	%	N	I-Premise
208	to	N	I-Premise
209	22.8	N	I-Premise
210	%	N	I-Premise
211	)	N	I-Premise
212	,	N	I-Premise
213	respectively	N	I-Premise
214	.	N	I-Premise

215	Seventeen	N	I-Premise
216	(	N	I-Premise
217	57	N	I-Premise
218	%	N	I-Premise
219	)	N	I-Premise
220	of	N	I-Premise
221	30	N	I-Premise
222	patients	N	I-Premise
223	with	N	I-Premise
224	an	N	I-Premise
225	objective	N	I-Premise
226	response	N	I-Premise
227	and	N	I-Premise
228	22	N	I-Premise
229	(	N	I-Premise
230	51	N	I-Premise
231	%	N	I-Premise
232	)	N	I-Premise
233	of	N	I-Premise
234	43	N	I-Premise
235	patients	N	I-Premise
236	with	N	I-Premise
237	clinical	N	I-Premise
238	benefit	N	I-Premise
239	had	N	I-Premise
240	not	N	I-Premise
241	experienced	N	I-Premise
242	disease	N	I-Premise
243	progression	N	I-Premise
244	at	N	I-Premise
245	follow-up	N	I-Premise
246	at	N	I-Premise
247	12	N	I-Premise
248	months	N	I-Premise
249	or	N	I-Premise
250	later	N	I-Premise
251	.	N	I-Premise

252	The	N	I-Premise
253	most	N	I-Premise
254	common	N	I-Premise
255	treatment-related	N	I-Premise
256	adverse	N	I-Premise
257	events	N	I-Premise
258	were	N	I-Premise
259	chills	N	I-Premise
260	(	N	I-Premise
261	25	N	I-Premise
262	%	N	I-Premise
263	of	N	I-Premise
264	patients	N	I-Premise
265	)	N	I-Premise
266	,	N	I-Premise
267	asthenia	N	I-Premise
268	(	N	I-Premise
269	23	N	I-Premise
270	%	N	I-Premise
271	)	N	I-Premise
272	,	N	I-Premise
273	fever	N	I-Premise
274	(	N	I-Premise
275	22	N	I-Premise
276	%	N	I-Premise
277	)	N	I-Premise
278	,	N	I-Premise
279	pain	N	I-Premise
280	(	N	I-Premise
281	18	N	I-Premise
282	%	N	I-Premise
283	)	N	I-Premise
284	,	N	I-Premise
285	and	N	I-Premise
286	nausea	N	I-Premise
287	(	N	I-Premise
288	14	N	I-Premise
289	%	N	I-Premise
290	)	N	I-Premise
291	.	N	I-Premise

292	Cardiac	N	I-Premise
293	dysfunction	N	I-Premise
294	occurred	N	I-Premise
295	in	N	I-Premise
296	two	N	I-Premise
297	patients	N	I-Premise
298	(	N	I-Premise
299	2	N	I-Premise
300	%	N	I-Premise
301	)	N	I-Premise
302	;	N	I-Premise
303	both	N	I-Premise
304	had	N	I-Premise
305	histories	N	I-Premise
306	of	N	I-Premise
307	cardiac	N	I-Premise
308	disease	N	I-Premise
309	and	N	I-Premise
310	did	N	I-Premise
311	not	N	I-Premise
312	require	N	I-Premise
313	additional	N	I-Premise
314	intervention	N	I-Premise
315	after	N	I-Premise
316	discontinuation	N	I-Premise
317	of	N	I-Premise
318	trastuzumab	N	I-Premise
319	.	N	I-Premise

320	There	N	I-Claim
321	was	N	I-Claim
322	no	N	I-Claim
323	clear	N	I-Claim
324	evidence	N	I-Claim
325	of	N	I-Claim
326	a	N	I-Claim
327	dose-response	N	I-Claim
328	relationship	N	I-Claim
329	for	N	I-Claim
330	response	N	I-Claim
331	,	N	I-Claim
332	survival	N	I-Claim
333	,	N	I-Claim
334	or	N	I-Claim
335	adverse	N	I-Claim
336	events	N	I-Claim
337	.	N	I-Claim

338	Single-agent	N	I-Claim
339	trastuzumab	N	I-Claim
340	is	N	I-Claim
341	active	N	I-Claim
342	and	N	I-Claim
343	well	N	I-Claim
344	tolerated	N	I-Claim
345	as	N	I-Claim
346	first-line	N	I-Claim
347	treatment	N	I-Claim
348	of	N	I-Claim
349	women	N	I-Claim
350	with	N	I-Claim
351	metastatic	N	I-Claim
352	breast	N	I-Claim
353	cancer	N	I-Claim
354	with	N	I-Claim
355	HER2	N	I-Claim
356	3+	N	I-Claim
357	overexpression	N	I-Claim
358	by	N	I-Claim
359	IHC	N	I-Claim
360	or	N	I-Claim
361	gene	N	I-Claim
362	amplification	N	I-Claim
363	by	N	I-Claim
364	FISH	N	I-Claim
365	.	N	I-Claim

1	Older	N	I-Claim
2	patients	N	I-Claim
3	,	N	I-Claim
4	even	N	I-Claim
5	if	N	I-Claim
6	fit	N	I-Claim
7	,	N	I-Claim
8	are	N	I-Claim
9	often	N	I-Claim
10	considered	N	I-Claim
11	incapable	N	I-Claim
12	of	N	I-Claim
13	tolerating	N	I-Claim
14	platinum-based	N	I-Claim
15	systemic	N	I-Claim
16	therapy	N	I-Claim
17	.	N	I-Claim

18	We	N	O
19	performed	N	O
20	a	N	O
21	retrospective	N	O
22	analysis	N	O
23	of	N	O
24	Eastern	N	O
25	Cooperative	N	O
26	Oncology	N	O
27	Group	N	O
28	(	N	O
29	ECOG	N	O
30	)	N	O
31	5592	N	O
32	,	N	O
33	a	N	O
34	phase	N	O
35	III	N	O
36	randomized	N	O
37	trial	N	O
38	of	N	O
39	platinum-based	N	O
40	chemotherapy	N	O
41	regimens	N	O
42	for	N	O
43	non-small-cell	N	O
44	lung	N	O
45	cancer	N	O
46	(	N	O
47	NSCLC	N	O
48	)	N	O
49	,	N	O
50	and	N	O
51	compared	N	O
52	outcomes	N	O
53	in	N	O
54	enrollees	N	O
55	70	N	O
56	years	N	O
57	of	N	O
58	age	N	O
59	and	N	O
60	older	N	O
61	with	N	O
62	those	N	O
63	in	N	O
64	younger	N	O
65	patients	N	O
66	.	N	O

67	ECOG	N	O
68	carried	N	O
69	out	N	O
70	a	N	O
71	randomized	N	O
72	phase	N	O
73	III	N	O
74	trial	N	O
75	of	N	O
76	cisplatin	N	O
77	plus	N	O
78	either	N	O
79	etoposide	N	O
80	or	N	O
81	paclitaxel	N	O
82	in	N	O
83	chemotherapy-naÃ¯ve	N	O
84	NSCLC	N	O
85	patients	N	O
86	with	N	O
87	stages	N	O
88	III	N	O
89	(	N	O
90	B	N	O
91	)	N	O
92	or	N	O
93	IV	N	O
94	disease	N	O
95	.	N	O

96	Toxic	N	O
97	effects	N	O
98	,	N	O
99	response	N	O
100	rates	N	O
101	,	N	O
102	and	N	O
103	survival	N	O
104	rates	N	O
105	were	N	O
106	compared	N	O
107	between	N	O
108	age	N	O
109	groups	N	O
110	.	N	O

111	All	N	O
112	P	N	O
113	values	N	O
114	were	N	O
115	two-sided	N	O
116	.	N	O

117	A	N	O
118	total	N	O
119	of	N	O
120	574	N	O
121	patients	N	O
122	enrolled	N	O
123	from	N	O
124	August	N	O
125	1993	N	O
126	through	N	O
127	December	N	O
128	1994	N	O
129	were	N	O
130	evaluable	N	O
131	.	N	O

132	Eighty-six	N	O
133	(	N	O
134	15	N	O
135	%	N	O
136	)	N	O
137	were	N	O
138	70	N	O
139	years	N	O
140	old	N	O
141	or	N	O
142	older	N	O
143	.	N	O

144	Older	N	I-Premise
145	patients	N	I-Premise
146	had	N	I-Premise
147	a	N	I-Premise
148	higher	N	I-Premise
149	incidence	N	I-Premise
150	of	N	I-Premise
151	cardiovascular	N	I-Premise
152	(	N	I-Premise
153	P	N	I-Premise
154	=.009	N	I-Premise
155	)	N	I-Premise
156	and	N	I-Premise
157	respiratory	N	I-Premise
158	(	N	I-Premise
159	P	N	I-Premise
160	=.04	N	I-Premise
161	)	N	I-Premise
162	comorbidities	N	I-Premise
163	and	N	I-Premise
164	nonanalgesic	N	I-Premise
165	medication	N	I-Premise
166	use	N	I-Premise
167	(	N	I-Premise
168	P	N	I-Premise
169	=.02	N	I-Premise
170	)	N	I-Premise
171	.	N	I-Premise

172	Leukopenia	N	I-Premise
173	(	N	I-Premise
174	P	N	I-Premise
175	<	N	I-Premise
176	.001	N	I-Premise
177	)	N	I-Premise
178	and	N	I-Premise
179	neuropsychiatric	N	I-Premise
180	toxicity	N	I-Premise
181	(	N	I-Premise
182	P	N	I-Premise
183	=.002	N	I-Premise
184	)	N	I-Premise
185	were	N	I-Premise
186	more	N	I-Premise
187	common	N	I-Premise
188	in	N	I-Premise
189	elderly	N	I-Premise
190	men	N	I-Premise
191	than	N	I-Premise
192	in	N	I-Premise
193	younger	N	I-Premise
194	men	N	I-Premise
195	.	N	I-Premise

196	Elderly	N	I-Premise
197	women	N	I-Premise
198	lost	N	I-Premise
199	more	N	I-Premise
200	weight	N	I-Premise
201	than	N	I-Premise
202	younger	N	I-Premise
203	women	N	I-Premise
204	(	N	I-Premise
205	P	N	I-Premise
206	=.006	N	I-Premise
207	)	N	I-Premise
208	.	N	I-Premise

209	Other	N	I-Premise
210	toxic	N	I-Premise
211	effects	N	I-Premise
212	were	N	I-Premise
213	similar	N	I-Premise
214	in	N	I-Premise
215	older	N	I-Premise
216	and	N	I-Premise
217	younger	N	I-Premise
218	patients	N	I-Premise
219	.	N	I-Premise

220	The	N	I-Premise
221	proportions	N	I-Premise
222	with	N	I-Premise
223	clinical	N	I-Premise
224	partial	N	I-Premise
225	or	N	I-Premise
226	complete	N	I-Premise
227	response	N	I-Premise
228	(	N	I-Premise
229	21.5	N	I-Premise
230	%	N	I-Premise
231	versus	N	I-Premise
232	23.3	N	I-Premise
233	%	N	I-Premise
234	;	N	I-Premise
235	Fisher	N	I-Premise
236	's	N	I-Premise
237	exact	N	I-Premise
238	test	N	I-Premise
239	,	N	I-Premise
240	P	N	I-Premise
241	=.66	N	I-Premise
242	)	N	I-Premise
243	,	N	I-Premise
244	median	N	I-Premise
245	time	N	I-Premise
246	to	N	I-Premise
247	progression	N	I-Premise
248	(	N	I-Premise
249	4.37	N	I-Premise
250	versus	N	I-Premise
251	4.30	N	I-Premise
252	months	N	I-Premise
253	;	N	I-Premise
254	log-rank	N	I-Premise
255	test	N	I-Premise
256	,	N	I-Premise
257	P	N	I-Premise
258	=.29	N	I-Premise
259	)	N	I-Premise
260	,	N	I-Premise
261	and	N	I-Premise
262	survival	N	I-Premise
263	distribution	N	I-Premise
264	(	N	I-Premise
265	log-rank	N	I-Premise
266	test	N	I-Premise
267	,	N	I-Premise
268	P	N	I-Premise
269	=.29	N	I-Premise
270	;	N	I-Premise
271	median	N	I-Premise
272	survival	N	I-Premise
273	,	N	I-Premise
274	9.05	N	I-Premise
275	versus	N	I-Premise
276	8.53	N	I-Premise
277	months	N	I-Premise
278	;	N	I-Premise
279	1-year	N	I-Premise
280	survival	N	I-Premise
281	,	N	I-Premise
282	38	N	I-Premise
283	%	N	I-Premise
284	versus	N	I-Premise
285	29	N	I-Premise
286	%	N	I-Premise
287	;	N	I-Premise
288	and	N	I-Premise
289	2-year	N	I-Premise
290	survival	N	I-Premise
291	,	N	I-Premise
292	14	N	I-Premise
293	%	N	I-Premise
294	versus	N	I-Premise
295	12	N	I-Premise
296	%	N	I-Premise
297	)	N	I-Premise
298	were	N	I-Premise
299	similar	N	I-Premise
300	in	N	I-Premise
301	patients	N	I-Premise
302	younger	N	I-Premise
303	than	N	I-Premise
304	70	N	I-Premise
305	years	N	I-Premise
306	and	N	I-Premise
307	70	N	I-Premise
308	years	N	I-Premise
309	old	N	I-Premise
310	or	N	I-Premise
311	older	N	I-Premise
312	.	N	I-Premise

313	Baseline	N	I-Premise
314	quality-of-life	N	I-Premise
315	and	N	I-Premise
316	treatment-outcome	N	I-Premise
317	indices	N	I-Premise
318	were	N	I-Premise
319	similar	N	I-Premise
320	.	N	I-Premise

321	Equivalent	N	I-Premise
322	declines	N	I-Premise
323	over	N	I-Premise
324	time	N	I-Premise
325	in	N	I-Premise
326	functional	N	I-Premise
327	well-being	N	I-Premise
328	occurred	N	I-Premise
329	in	N	I-Premise
330	both	N	I-Premise
331	groups	N	I-Premise
332	.	N	I-Premise

333	Response	N	I-Claim
334	rate	N	I-Claim
335	,	N	I-Claim
336	toxicity	N	I-Claim
337	,	N	I-Claim
338	and	N	I-Claim
339	survival	N	I-Claim
340	in	N	I-Claim
341	fit	N	I-Claim
342	,	N	I-Claim
343	elderly	N	I-Claim
344	NSCLC	N	I-Claim
345	patients	N	I-Claim
346	receiving	N	I-Claim
347	platinum-based	N	I-Claim
348	treatment	N	I-Claim
349	appear	N	I-Claim
350	to	N	I-Claim
351	be	N	I-Claim
352	similar	N	I-Claim
353	to	N	I-Claim
354	those	N	I-Claim
355	in	N	I-Claim
356	younger	N	I-Claim
357	patients	N	I-Claim
358	,	N	I-Claim
359	although	N	I-Claim
360	patients	N	I-Claim
361	70	N	I-Claim
362	years	N	I-Claim
363	old	N	I-Claim
364	or	N	I-Claim
365	older	N	I-Claim
366	have	N	I-Claim
367	more	N	I-Claim
368	comorbidities	N	I-Claim
369	and	N	I-Claim
370	can	N	I-Claim
371	expect	N	I-Claim
372	more	N	I-Claim
373	leukopenia	N	I-Claim
374	and	N	I-Claim
375	neuropsychiatric	N	I-Claim
376	toxicity	N	I-Claim
377	.	N	I-Claim

378	Advanced	N	I-Claim
379	age	N	I-Claim
380	alone	N	I-Claim
381	should	N	I-Claim
382	not	N	I-Claim
383	preclude	N	I-Claim
384	appropriate	N	I-Claim
385	NSCLC	N	I-Claim
386	treatment	N	I-Claim
387	.	N	I-Claim

1	SIR-Spheres	N	O
2	are	N	O
3	radioactive	N	O
4	yttrium90	N	O
5	microspheres	N	O
6	(	N	O
7	SIR-Spheres	N	O
8	,	N	O
9	Sirtex	N	O
10	Medical	N	O
11	Limited	N	O
12	,	N	O
13	Australia	N	O
14	)	N	O
15	used	N	O
16	to	N	O
17	selectively	N	O
18	target	N	O
19	high	N	O
20	levels	N	O
21	of	N	O
22	ionising	N	O
23	radiation	N	O
24	to	N	O
25	tumors	N	O
26	within	N	O
27	the	N	O
28	liver	N	O
29	.	N	O

30	This	N	O
31	trial	N	O
32	was	N	O
33	designed	N	O
34	to	N	O
35	measure	N	O
36	any	N	O
37	increased	N	O
38	patient	N	O
39	benefit	N	O
40	by	N	O
41	adding	N	O
42	a	N	O
43	single	N	O
44	administration	N	O
45	of	N	O
46	SIR-Spheres	N	O
47	to	N	O
48	a	N	O
49	regimen	N	O
50	of	N	O
51	regional	N	O
52	hepatic	N	O
53	artery	N	O
54	chemotherapy	N	O
55	(	N	O
56	HAC	N	O
57	)	N	O
58	administered	N	O
59	as	N	O
60	a	N	O
61	12	N	O
62	day	N	O
63	infusion	N	O
64	of	N	O
65	floxuridine	N	O
66	and	N	O
67	repeated	N	O
68	at	N	O
69	monthly	N	O
70	intervals	N	O
71	,	N	O
72	vs.	N	O
73	the	N	O
74	same	N	O
75	chemotherapy	N	O
76	alone	N	O
77	.	N	O

78	A	N	O
79	phase	N	O
80	III	N	O
81	randomised	N	O
82	clinical	N	O
83	trial	N	O
84	entering	N	O
85	74	N	O
86	patients	N	O
87	was	N	O
88	undertaken	N	O
89	on	N	O
90	patients	N	O
91	with	N	O
92	bi-lobar	N	O
93	non-resectable	N	O
94	liver	N	O
95	metastases	N	O
96	from	N	O
97	primary	N	O
98	adenocarcinoma	N	O
99	of	N	O
100	the	N	O
101	large	N	O
102	bowel	N	O
103	.	N	O

104	Patient	N	O
105	benefit	N	O
106	criteria	N	O
107	assessed	N	O
108	in	N	O
109	the	N	O
110	trial	N	O
111	were	N	O
112	tumor	N	O
113	response	N	O
114	,	N	O
115	time	N	O
116	to	N	O
117	disease	N	O
118	progression	N	O
119	in	N	O
120	the	N	O
121	liver	N	O
122	,	N	O
123	overall	N	O
124	survival	N	O
125	,	N	O
126	quality	N	O
127	of	N	O
128	life	N	O
129	,	N	O
130	and	N	O
131	treatment	N	O
132	related	N	O
133	toxicity	N	O
134	.	N	O

135	Tumor	N	O
136	response	N	O
137	was	N	O
138	measured	N	O
139	by	N	O
140	serial	N	O
141	changes	N	O
142	in	N	O
143	both	N	O
144	cross-sectional	N	O
145	tumor	N	O
146	areas	N	O
147	and	N	O
148	total	N	O
149	tumor	N	O
150	volumes	N	O
151	,	N	O
152	provided	N	O
153	any	N	O
154	response	N	O
155	lasted	N	O
156	not	N	O
157	less	N	O
158	than	N	O
159	three	N	O
160	months	N	O
161	as	N	O
162	well	N	O
163	as	N	O
164	changes	N	O
165	in	N	O
166	serum	N	O
167	carcino-embryonic	N	O
168	antigen	N	O
169	(	N	O
170	CEA	N	O
171	)	N	O
172	.	N	O

173	The	N	I-Premise
174	partial	N	I-Premise
175	and	N	I-Premise
176	complete	N	I-Premise
177	response	N	I-Premise
178	rate	N	I-Premise
179	(	N	I-Premise
180	PR	N	I-Premise
181	+	N	I-Premise
182	CR	N	I-Premise
183	)	N	I-Premise
184	was	N	I-Premise
185	significantly	N	I-Premise
186	greater	N	I-Premise
187	for	N	I-Premise
188	patients	N	I-Premise
189	receiving	N	I-Premise
190	SIR-Spheres	N	I-Premise
191	when	N	I-Premise
192	measured	N	I-Premise
193	by	N	I-Premise
194	tumor	N	I-Premise
195	areas	N	I-Premise
196	(	N	I-Premise
197	44	N	I-Premise
198	%	N	I-Premise
199	)	N	I-Premise
200	vs.	N	I-Premise
201	17.6	N	I-Premise
202	%	N	I-Premise
203	,	N	I-Premise
204	P	N	I-Premise
205	=	N	I-Premise
206	0.01	N	I-Premise
207	)	N	I-Premise
208	tumor	N	I-Premise
209	volumes	N	I-Premise
210	(	N	I-Premise
211	50	N	I-Premise
212	%	N	I-Premise
213	vs.	N	I-Premise
214	24	N	I-Premise
215	%	N	I-Premise
216	,	N	I-Premise
217	P	N	I-Premise
218	=	N	I-Premise
219	0.03	N	I-Premise
220	)	N	I-Premise
221	and	N	I-Premise
222	CEA	N	I-Premise
223	(	N	I-Premise
224	72	N	I-Premise
225	%	N	I-Premise
226	vs.	N	I-Premise
227	47	N	I-Premise
228	%	N	I-Premise
229	,	N	I-Premise
230	P	N	I-Premise
231	=	N	I-Premise
232	0.004	N	I-Premise
233	)	N	I-Premise
234	.	N	I-Premise

235	The	N	I-Premise
236	median	N	I-Premise
237	time	N	I-Premise
238	to	N	I-Premise
239	disease	N	I-Premise
240	progression	N	I-Premise
241	in	N	I-Premise
242	the	N	I-Premise
243	liver	N	I-Premise
244	was	N	I-Premise
245	significantly	N	I-Premise
246	longer	N	I-Premise
247	for	N	I-Premise
248	patients	N	I-Premise
249	receiving	N	I-Premise
250	SIR-Spheres	N	I-Premise
251	in	N	I-Premise
252	comparison	N	I-Premise
253	to	N	I-Premise
254	patients	N	I-Premise
255	receiving	N	I-Premise
256	HAC	N	I-Premise
257	alone	N	I-Premise
258	when	N	I-Premise
259	measured	N	I-Premise
260	by	N	I-Premise
261	either	N	I-Premise
262	tumor	N	I-Premise
263	areas	N	I-Premise
264	(	N	I-Premise
265	9.7	N	I-Premise
266	vs.	N	I-Premise
267	15.9	N	I-Premise
268	months	N	I-Premise
269	,	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	0.001	N	I-Premise
273	)	N	I-Premise
274	,	N	I-Premise
275	tumor	N	I-Premise
276	volumes	N	I-Premise
277	(	N	I-Premise
278	7.6	N	I-Premise
279	vs.	N	I-Premise
280	12.0	N	I-Premise
281	months	N	I-Premise
282	,	N	I-Premise
283	P	N	I-Premise
284	=	N	I-Premise
285	0.04	N	I-Premise
286	)	N	I-Premise
287	or	N	I-Premise
288	CEA	N	I-Premise
289	(	N	I-Premise
290	5.7	N	I-Premise
291	vs.	N	I-Premise
292	6.7	N	I-Premise
293	months	N	I-Premise
294	,	N	I-Premise
295	P	N	I-Premise
296	=	N	I-Premise
297	0.06	N	I-Premise
298	)	N	I-Premise
299	.	N	I-Premise

300	The	N	I-Premise
301	one	N	I-Premise
302	,	N	I-Premise
303	two	N	I-Premise
304	,	N	I-Premise
305	three	N	I-Premise
306	and	N	I-Premise
307	five-year	N	I-Premise
308	survival	N	I-Premise
309	for	N	I-Premise
310	patients	N	I-Premise
311	receiving	N	I-Premise
312	SIR-Spheres	N	I-Premise
313	was	N	I-Premise
314	72	N	I-Premise
315	%	N	I-Premise
316	,	N	I-Premise
317	39	N	I-Premise
318	%	N	I-Premise
319	,	N	I-Premise
320	17	N	I-Premise
321	%	N	I-Premise
322	and	N	I-Premise
323	3.5	N	I-Premise
324	%	N	I-Premise
325	,	N	I-Premise
326	compared	N	I-Premise
327	to	N	I-Premise
328	68	N	I-Premise
329	%	N	I-Premise
330	,	N	I-Premise
331	29	N	I-Premise
332	%	N	I-Premise
333	,	N	I-Premise
334	6.5	N	I-Premise
335	%	N	I-Premise
336	and	N	I-Premise
337	0	N	I-Premise
338	%	N	I-Premise
339	for	N	I-Premise
340	HAC	N	I-Premise
341	alone	N	I-Premise
342	.	N	I-Premise

343	Cox	N	I-Premise
344	regression	N	I-Premise
345	analysis	N	I-Premise
346	suggests	N	I-Premise
347	an	N	I-Premise
348	improvement	N	I-Premise
349	in	N	I-Premise
350	survival	N	I-Premise
351	for	N	I-Premise
352	patients	N	I-Premise
353	treated	N	I-Premise
354	with	N	I-Premise
355	SIR-Spheres	N	I-Premise
356	who	N	I-Premise
357	survive	N	I-Premise
358	more	N	I-Premise
359	than	N	I-Premise
360	15	N	I-Premise
361	months	N	I-Premise
362	(	N	I-Premise
363	P	N	I-Premise
364	=	N	I-Premise
365	0.06	N	I-Premise
366	)	N	I-Premise
367	.	N	I-Premise

368	There	N	I-Premise
369	was	N	I-Premise
370	no	N	I-Premise
371	increase	N	I-Premise
372	in	N	I-Premise
373	grade	N	I-Premise
374	3-4	N	I-Premise
375	treatment	N	I-Premise
376	related	N	I-Premise
377	toxicity	N	I-Premise
378	and	N	I-Premise
379	no	N	I-Premise
380	loss	N	I-Premise
381	of	N	I-Premise
382	quality	N	I-Premise
383	of	N	I-Premise
384	life	N	I-Premise
385	for	N	I-Premise
386	patients	N	I-Premise
387	receiving	N	I-Premise
388	SIR-Spheres	N	I-Premise
389	in	N	I-Premise
390	comparison	N	I-Premise
391	to	N	I-Premise
392	patients	N	I-Premise
393	receiving	N	I-Premise
394	HAC	N	I-Premise
395	alone	N	I-Premise
396	.	N	I-Premise

397	The	N	I-Claim
398	combination	N	I-Claim
399	of	N	I-Claim
400	a	N	I-Claim
401	single	N	I-Claim
402	injection	N	I-Claim
403	of	N	I-Claim
404	SIR-Spheres	N	I-Claim
405	plus	N	I-Claim
406	HAC	N	I-Claim
407	is	N	I-Claim
408	substantially	N	I-Claim
409	more	N	I-Claim
410	effective	N	I-Claim
411	in	N	I-Claim
412	increasing	N	I-Claim
413	tumor	N	I-Claim
414	responses	N	I-Claim
415	and	N	I-Claim
416	progression	N	I-Claim
417	free	N	I-Claim
418	survival	N	I-Claim
419	than	N	I-Claim
420	the	N	I-Claim
421	same	N	I-Claim
422	regimen	N	I-Claim
423	of	N	I-Claim
424	HAC	N	I-Claim
425	alone	N	I-Claim
426	.	N	I-Claim

1	Phase	N	I-Claim
2	II	N	I-Claim
3	and	N	I-Claim
4	III	N	I-Claim
5	studies	N	I-Claim
6	have	N	I-Claim
7	shown	N	I-Claim
8	that	N	I-Claim
9	the	N	I-Claim
10	addition	N	I-Claim
11	of	N	I-Claim
12	interleukin-2	N	I-Claim
13	(	N	I-Claim
14	IL-2	N	I-Claim
15	)	N	I-Claim
16	and	N	I-Claim
17	interferon	N	I-Claim
18	alpha-2b	N	I-Claim
19	(	N	I-Claim
20	IFN	N	I-Claim
21	alpha-2b	N	I-Claim
22	)	N	I-Claim
23	in	N	I-Claim
24	multiagent	N	I-Claim
25	chemotherapy	N	I-Claim
26	(	N	I-Claim
27	CT	N	I-Claim
28	)	N	I-Claim
29	for	N	I-Claim
30	advanced	N	I-Claim
31	melanoma	N	I-Claim
32	increases	N	I-Claim
33	overall	N	I-Claim
34	response	N	I-Claim
35	(	N	I-Claim
36	OR	N	I-Claim
37	)	N	I-Claim
38	,	N	I-Claim
39	albeit	N	I-Claim
40	without	N	I-Claim
41	clear	N	I-Claim
42	evidence	N	I-Claim
43	of	N	I-Claim
44	an	N	I-Claim
45	improvement	N	I-Claim
46	in	N	I-Claim
47	overall	N	I-Claim
48	survival	N	I-Claim
49	(	N	I-Claim
50	OS	N	I-Claim
51	)	N	I-Claim
52	.	N	I-Claim

53	Treatment	N	I-Claim
54	with	N	I-Claim
55	high-dose	N	I-Claim
56	IL-2	N	I-Claim
57	can	N	I-Claim
58	cause	N	I-Claim
59	severe	N	I-Claim
60	toxicity	N	I-Claim
61	and	N	I-Claim
62	is	N	I-Claim
63	normally	N	I-Claim
64	administered	N	I-Claim
65	in	N	I-Claim
66	an	N	I-Claim
67	inpatient	N	I-Claim
68	setting	N	I-Claim
69	.	N	I-Claim

70	We	N	O
71	conducted	N	O
72	a	N	O
73	multicenter	N	O
74	prospective	N	O
75	randomized	N	O
76	clinical	N	O
77	trial	N	O
78	in	N	O
79	outpatients	N	O
80	with	N	O
81	metastatic	N	O
82	melanoma	N	O
83	to	N	O
84	compare	N	O
85	CT	N	O
86	with	N	O
87	biochemotherapy	N	O
88	(	N	O
89	bioCT	N	O
90	)	N	O
91	using	N	O
92	immunomodulant	N	O
93	doses	N	O
94	of	N	O
95	IL-2	N	O
96	and	N	O
97	IFN	N	O
98	alpha-2b	N	O
99	.	N	O

100	One	N	O
101	hundred	N	O
102	seventy-six	N	O
103	eligible	N	O
104	patients	N	O
105	with	N	O
106	advanced	N	O
107	melanoma	N	O
108	were	N	O
109	randomized	N	O
110	to	N	O
111	receive	N	O
112	CT	N	O
113	(	N	O
114	cisplatin	N	O
115	and	N	O
116	dacarbazine	N	O
117	with	N	O
118	or	N	O
119	without	N	O
120	carmustine	N	O
121	every	N	O
122	21	N	O
123	days	N	O
124	)	N	O
125	or	N	O
126	bioCT	N	O
127	comprising	N	O
128	the	N	O
129	same	N	O
130	CT	N	O
131	regimen	N	O
132	followed	N	O
133	by	N	O
134	low-dose	N	O
135	subcutaneous	N	O
136	IL-2	N	O
137	for	N	O
138	8	N	O
139	days	N	O
140	and	N	O
141	IFN	N	O
142	alpha-2b	N	O
143	three	N	O
144	times	N	O
145	a	N	O
146	week	N	O
147	,	N	O
148	both	N	O
149	for	N	O
150	six	N	O
151	cycles	N	O
152	.	N	O

153	At	N	I-Premise
154	a	N	I-Premise
155	median	N	I-Premise
156	follow-up	N	I-Premise
157	of	N	I-Premise
158	18	N	I-Premise
159	(	N	I-Premise
160	CT	N	I-Premise
161	)	N	I-Premise
162	and	N	I-Premise
163	16	N	I-Premise
164	(	N	I-Premise
165	bioCT	N	I-Premise
166	)	N	I-Premise
167	months	N	I-Premise
168	,	N	I-Premise
169	median	N	I-Premise
170	OS	N	I-Premise
171	was	N	I-Premise
172	9.5	N	I-Premise
173	versus	N	I-Premise
174	11.0	N	I-Premise
175	months	N	I-Premise
176	(	N	I-Premise
177	P	N	I-Premise
178	=.51	N	I-Premise
179	)	N	I-Premise
180	,	N	I-Premise
181	respectively	N	I-Premise
182	.	N	I-Premise

183	In	N	I-Premise
184	the	N	I-Premise
185	89	N	I-Premise
186	CT-arm	N	I-Premise
187	patients	N	I-Premise
188	,	N	I-Premise
189	18	N	I-Premise
190	ORs	N	I-Premise
191	(	N	I-Premise
192	20.2	N	I-Premise
193	%	N	I-Premise
194	)	N	I-Premise
195	(	N	I-Premise
196	three	N	I-Premise
197	complete	N	I-Premise
198	responders	N	I-Premise
199	[	N	I-Premise
200	CRs	N	I-Premise
201	]	N	I-Premise
202	and	N	I-Premise
203	15	N	I-Premise
204	partial	N	I-Premise
205	responders	N	I-Premise
206	[	N	I-Premise
207	PRs	N	I-Premise
208	]	N	I-Premise
209	)	N	I-Premise
210	were	N	I-Premise
211	observed	N	I-Premise
212	according	N	I-Premise
213	to	N	I-Premise
214	World	N	I-Premise
215	Health	N	I-Premise
216	Organization	N	I-Premise
217	criteria	N	I-Premise
218	.	N	I-Premise

219	In	N	I-Premise
220	the	N	I-Premise
221	87	N	I-Premise
222	bioCT-arm	N	I-Premise
223	patients	N	I-Premise
224	,	N	I-Premise
225	22	N	I-Premise
226	ORs	N	I-Premise
227	(	N	I-Premise
228	25.3	N	I-Premise
229	%	N	I-Premise
230	)	N	I-Premise
231	(	N	I-Premise
232	three	N	I-Premise
233	CRs	N	I-Premise
234	and	N	I-Premise
235	19	N	I-Premise
236	PRs	N	I-Premise
237	)	N	I-Premise
238	(	N	I-Premise
239	P	N	I-Premise
240	=.70	N	I-Premise
241	)	N	I-Premise
242	were	N	I-Premise
243	recorded	N	I-Premise
244	.	N	I-Premise

245	Treatment-related	N	I-Premise
246	toxicity	N	I-Premise
247	was	N	I-Premise
248	fairly	N	I-Premise
249	similar	N	I-Premise
250	in	N	I-Premise
251	both	N	I-Premise
252	arms	N	I-Premise
253	.	N	I-Premise

254	The	N	I-Claim
255	addition	N	I-Claim
256	of	N	I-Claim
257	low-dose	N	I-Claim
258	immunotherapy	N	I-Claim
259	did	N	I-Claim
260	not	N	I-Claim
261	produce	N	I-Claim
262	a	N	I-Claim
263	statistically	N	I-Claim
264	significant	N	I-Claim
265	advantage	N	I-Claim
266	in	N	I-Claim
267	OS	N	I-Claim
268	,	N	I-Claim
269	time	N	I-Claim
270	to	N	I-Claim
271	progression	N	I-Claim
272	,	N	I-Claim
273	or	N	I-Claim
274	OR	N	I-Claim
275	.	N	I-Claim

276	However	N	I-Claim
277	,	N	I-Claim
278	the	N	I-Claim
279	11-month	N	I-Claim
280	median	N	I-Claim
281	OS	N	I-Claim
282	in	N	I-Claim
283	the	N	I-Claim
284	bioCT	N	I-Claim
285	arm	N	I-Claim
286	does	N	I-Claim
287	not	N	I-Claim
288	differ	N	I-Claim
289	greatly	N	I-Claim
290	from	N	I-Claim
291	the	N	I-Claim
292	best	N	I-Claim
293	results	N	I-Claim
294	with	N	I-Claim
295	high-dose	N	I-Claim
296	IL-2-containing	N	I-Claim
297	regimens	N	I-Claim
298	reported	N	I-Claim
299	in	N	I-Claim
300	the	N	I-Claim
301	literature	N	I-Claim
302	.	N	I-Claim

303	Furthermore	N	O
304	,	N	O
305	our	N	I-Claim
306	treatment	N	I-Claim
307	schedule	N	I-Claim
308	was	N	I-Claim
309	carried	N	I-Claim
310	out	N	I-Claim
311	on	N	I-Claim
312	outpatients	N	I-Claim
313	and	N	I-Claim
314	had	N	I-Claim
315	an	N	I-Claim
316	acceptable	N	I-Claim
317	level	N	I-Claim
318	of	N	I-Claim
319	toxicity	N	I-Claim
320	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	epoetin	N	O
7	alfa	N	O
8	on	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	QOL	N	O
14	)	N	O
15	in	N	O
16	patients	N	O
17	with	N	O
18	solid	N	O
19	tumors	N	O
20	and	N	O
21	mild-to-moderate	N	O
22	anemia	N	O
23	receiving	N	O
24	platinum-based	N	O
25	chemotherapy	N	O
26	relative	N	O
27	to	N	O
28	population	N	O
29	norms	N	O
30	.	N	O

31	In	N	O
32	the	N	O
33	original	N	O
34	study	N	O
35	,	N	O
36	patients	N	O
37	(	N	O
38	n	N	O
39	=	N	O
40	316	N	O
41	)	N	O
42	with	N	O
43	hemoglobin	N	O
44	(	N	O
45	Hb	N	O
46	)	N	O
47	levels	N	O
48	<	N	O
49	or	N	O
50	=12.1	N	O
51	g/dl	N	O
52	were	N	O
53	randomized	N	O
54	2:1	N	O
55	to	N	O
56	receive	N	O
57	either	N	O
58	epoetin	N	O
59	alfa	N	O
60	at	N	O
61	a	N	O
62	dose	N	O
63	of	N	O
64	10,000	N	O
65	U	N	O
66	thrice	N	O
67	weekly	N	O
68	s.c.	N	O
69	or	N	O
70	best	N	O
71	supportive	N	O
72	care	N	O
73	(	N	O
74	BSC	N	O
75	)	N	O
76	to	N	O
77	compare	N	O
78	the	N	O
79	effects	N	O
80	on	N	O
81	transfusion	N	O
82	use	N	O
83	,	N	O
84	hematologic	N	O
85	response	N	O
86	,	N	O
87	and	N	O
88	QOL	N	O
89	(	N	O
90	measured	N	O
91	by	N	O
92	the	N	O
93	Functional	N	O
94	Assessment	N	O
95	of	N	O
96	Cancer	N	O
97	Therapy-Anemia	N	O
98	[	N	O
99	FACT-An	N	O
100	]	N	O
101	and	N	O
102	Cancer	N	O
103	Linear	N	O
104	Analogue	N	O
105	Scale	N	O
106	[	N	O
107	CLAS	N	O
108	]	N	O
109	)	N	O
110	.	N	O

111	The	N	O
112	QOL	N	O
113	data	N	O
114	from	N	O
115	this	N	O
116	previously	N	O
117	reported	N	O
118	trial	N	O
119	were	N	O
120	reanalyzed	N	O
121	here	N	O
122	relative	N	O
123	to	N	O
124	population	N	O
125	norms	N	O
126	.	N	O

127	Mean	N	O
128	baseline	N	O
129	QOL	N	O
130	scores	N	O
131	were	N	O
132	similar	N	O
133	between	N	O
134	groups	N	O
135	.	N	O

136	At	N	O
137	study	N	O
138	completion	N	O
139	,	N	O
140	mean	N	O
141	CLAS	N	O
142	,	N	O
143	FACT-An	N	O
144	,	N	O
145	FACT-An	N	O
146	Anemia	N	O
147	subscale	N	O
148	,	N	O
149	and	N	O
150	FACT-An	N	O
151	Fatigue	N	O
152	subscale	N	O
153	scores	N	O
154	were	N	O
155	significantly	N	O
156	higher	N	O
157	for	N	O
158	patients	N	O
159	given	N	O
160	epoetin	N	O
161	alfa	N	O
162	than	N	O
163	for	N	O
164	those	N	O
165	treated	N	O
166	with	N	O
167	BSC	N	O
168	.	N	O

169	Compared	N	O
170	with	N	O
171	population	N	O
172	norms	N	O
173	,	N	O
174	both	N	O
175	groups	N	O
176	had	N	O
177	impaired	N	O
178	QOL	N	O
179	at	N	O
180	baseline	N	O
181	.	N	O

182	Differences	N	I-Premise
183	in	N	I-Premise
184	mean	N	I-Premise
185	QOL	N	I-Premise
186	change	N	I-Premise
187	scores	N	I-Premise
188	from	N	I-Premise
189	baseline	N	I-Premise
190	to	N	I-Premise
191	study	N	I-Premise
192	end	N	I-Premise
193	for	N	I-Premise
194	epoetin	N	I-Premise
195	alfa	N	I-Premise
196	versus	N	I-Premise
197	BSC	N	I-Premise
198	were	N	I-Premise
199	3.17	N	I-Premise
200	points	N	I-Premise
201	for	N	I-Premise
202	the	N	I-Premise
203	FACT-General	N	I-Premise
204	Total	N	I-Premise
205	,	N	I-Premise
206	9.90	N	I-Premise
207	for	N	I-Premise
208	the	N	I-Premise
209	FACT-An	N	I-Premise
210	Fatigue	N	I-Premise
211	subscale	N	I-Premise
212	,	N	I-Premise
213	and	N	I-Premise
214	7.30	N	I-Premise
215	for	N	I-Premise
216	the	N	I-Premise
217	FACT-An	N	I-Premise
218	Anemia	N	I-Premise
219	subscale	N	I-Premise
220	.	N	I-Premise

221	This	N	I-Premise
222	was	N	I-Premise
223	equivalent	N	I-Premise
224	to	N	I-Premise
225	corrections	N	I-Premise
226	in	N	I-Premise
227	QOL	N	I-Premise
228	deficits	N	I-Premise
229	attributable	N	I-Premise
230	to	N	I-Premise
231	epoetin	N	I-Premise
232	alfa	N	I-Premise
233	of	N	I-Premise
234	97.3	N	I-Premise
235	%	N	I-Premise
236	,	N	I-Premise
237	40.7	N	I-Premise
238	%	N	I-Premise
239	,	N	I-Premise
240	and	N	I-Premise
241	38.0	N	I-Premise
242	%	N	I-Premise
243	for	N	I-Premise
244	the	N	I-Premise
245	FACT-General	N	I-Premise
246	Total	N	I-Premise
247	,	N	I-Premise
248	FACT-An	N	I-Premise
249	Fatigue	N	I-Premise
250	,	N	I-Premise
251	and	N	I-Premise
252	FACT-An	N	I-Premise
253	Anemia	N	I-Premise
254	subscale	N	I-Premise
255	scores	N	I-Premise
256	,	N	I-Premise
257	respectively	N	I-Premise
258	,	N	I-Premise
259	versus	N	I-Premise
260	BSC	N	I-Premise
261	.	N	I-Premise

262	A	N	I-Premise
263	somewhat	N	I-Premise
264	greater	N	I-Premise
265	QOL	N	I-Premise
266	benefit	N	I-Premise
267	was	N	I-Premise
268	observed	N	I-Premise
269	for	N	I-Premise
270	the	N	I-Premise
271	FACT-An	N	I-Premise
272	Fatigue	N	I-Premise
273	and	N	I-Premise
274	FACT-An	N	I-Premise
275	Anemia	N	I-Premise
276	subscales	N	I-Premise
277	in	N	I-Premise
278	the	N	I-Premise
279	subset	N	I-Premise
280	of	N	I-Premise
281	patients	N	I-Premise
282	with	N	I-Premise
283	baseline	N	I-Premise
284	Hb	N	I-Premise
285	levels	N	I-Premise
286	>	N	I-Premise
287	10.5	N	I-Premise
288	g/dl	N	I-Premise
289	.	N	I-Premise

290	Patients	N	I-Premise
291	in	N	I-Premise
292	this	N	I-Premise
293	study	N	I-Premise
294	had	N	I-Premise
295	impaired	N	I-Premise
296	QOL	N	I-Premise
297	compared	N	I-Premise
298	with	N	I-Premise
299	population	N	I-Premise
300	norms	N	I-Premise
301	.	N	I-Premise

302	Early	N	I-Claim
303	treatment	N	I-Claim
304	with	N	I-Claim
305	epoetin	N	I-Claim
306	alfa	N	I-Claim
307	to	N	I-Claim
308	correct	N	I-Claim
309	anemia	N	I-Claim
310	improved	N	I-Claim
311	QOL	N	I-Claim
312	in	N	I-Claim
313	a	N	I-Claim
314	statistically	N	I-Claim
315	significant	N	I-Claim
316	and	N	I-Claim
317	clinically	N	I-Claim
318	meaningful	N	I-Claim
319	way	N	I-Claim
320	,	N	I-Claim
321	and	N	I-Claim
322	improvements	N	I-Claim
323	were	N	I-Claim
324	greater	N	I-Claim
325	in	N	I-Claim
326	patients	N	I-Claim
327	with	N	I-Claim
328	baseline	N	I-Claim
329	Hb	N	I-Claim
330	levels	N	I-Claim
331	>	N	I-Claim
332	10.5	N	I-Claim
333	g/dl	N	I-Claim
334	.	N	I-Claim

1	This	N	O
2	analysis	N	O
3	of	N	O
4	the	N	O
5	results	N	O
6	of	N	O
7	a	N	O
8	randomized	N	O
9	,	N	O
10	controlled	N	O
11	trial	N	O
12	evaluating	N	O
13	the	N	O
14	effects	N	O
15	of	N	O
16	epoetin	N	O
17	alfa	N	O
18	(	N	O
19	EPO	N	O
20	)	N	O
21	therapy	N	O
22	on	N	O
23	transfusion	N	O
24	requirements	N	O
25	,	N	O
26	hemoglobin	N	O
27	(	N	O
28	Hb	N	O
29	)	N	O
30	,	N	O
31	and	N	O
32	quality	N	O
33	of	N	O
34	life	N	O
35	(	N	O
36	QOL	N	O
37	)	N	O
38	in	N	O
39	patients	N	O
40	with	N	O
41	cancer	N	O
42	receiving	N	O
43	platinum-based	N	O
44	chemotherapy	N	O
45	was	N	O
46	conducted	N	O
47	to	N	O
48	evaluate	N	O
49	the	N	O
50	effect	N	O
51	of	N	O
52	initial	N	O
53	Hb	N	O
54	level	N	O
55	on	N	O
56	study	N	O
57	outcomes	N	O
58	.	N	O

59	Patients	N	O
60	with	N	O
61	Hb	N	O
62	levels	N	O
63	<	N	O
64	or	N	O
65	=12.1	N	O
66	g/dl	N	O
67	were	N	O
68	randomized	N	O
69	2:1	N	O
70	to	N	O
71	receive	N	O
72	EPO	N	O
73	,	N	O
74	10,000	N	O
75	U	N	O
76	three	N	O
77	times	N	O
78	weekly	N	O
79	s.c.	N	O
80	or	N	O
81	best	N	O
82	supportive	N	O
83	care	N	O
84	(	N	O
85	BSC	N	O
86	)	N	O
87	until	N	O
88	4	N	O
89	weeks	N	O
90	after	N	O
91	their	N	O
92	last	N	O
93	chemotherapy	N	O
94	cycle	N	O
95	.	N	O

96	For	N	O
97	this	N	O
98	analysis	N	O
99	,	N	O
100	patients	N	O
101	were	N	O
102	stratified	N	O
103	by	N	O
104	baseline	N	O
105	Hb	N	O
106	level	N	O
107	(	N	O
108	<	N	O
109	or	N	O
110	=9.7	N	O
111	g/dl	N	O
112	,	N	O
113	>	N	O
114	9.7	N	O
115	g/dl	N	O
116	to	N	O
117	<	N	O
118	or	N	O
119	=10.5	N	O
120	g/dl	N	O
121	,	N	O
122	>	N	O
123	10.5	N	O
124	g/dl	N	O
125	to	N	O
126	<	N	O
127	or	N	O
128	=11.3	N	O
129	g/dl	N	O
130	,	N	O
131	and	N	O
132	>	N	O
133	11.3	N	O
134	g/dl	N	O
135	to	N	O
136	<	N	O
137	or	N	O
138	=12.1	N	O
139	g/dl	N	O
140	)	N	O
141	,	N	O
142	and	N	O
143	study	N	O
144	results	N	O
145	were	N	O
146	reanalyzed	N	O
147	.	N	O

148	Significantly	N	I-Premise
149	fewer	N	I-Premise
150	EPO	N	I-Premise
151	patients	N	I-Premise
152	than	N	I-Premise
153	BSC	N	I-Premise
154	patients	N	I-Premise
155	with	N	I-Premise
156	initial	N	I-Premise
157	Hb	N	I-Premise
158	levels	N	I-Premise
159	>	N	I-Premise
160	9.7	N	I-Premise
161	g/dl	N	I-Premise
162	to	N	I-Premise
163	<	N	I-Premise
164	or	N	I-Premise
165	=12.1	N	I-Premise
166	g/dl	N	I-Premise
167	required	N	I-Premise
168	transfusions	N	I-Premise
169	.	N	I-Premise

170	EPO	N	I-Premise
171	maintained	N	I-Premise
172	Hb	N	I-Premise
173	levels	N	I-Premise
174	throughout	N	I-Premise
175	the	N	I-Premise
176	study	N	I-Premise
177	for	N	I-Premise
178	patients	N	I-Premise
179	with	N	I-Premise
180	Hb	N	I-Premise
181	levels	N	I-Premise
182	>	N	I-Premise
183	11.3	N	I-Premise
184	g/dl	N	I-Premise
185	to	N	I-Premise
186	<	N	I-Premise
187	or	N	I-Premise
188	=12.1	N	I-Premise
189	g/dl	N	I-Premise
190	,	N	I-Premise
191	compared	N	I-Premise
192	with	N	I-Premise
193	a	N	I-Premise
194	decrease	N	I-Premise
195	with	N	I-Premise
196	BSC	N	I-Premise
197	.	N	I-Premise

198	For	N	I-Premise
199	patients	N	I-Premise
200	with	N	I-Premise
201	baseline	N	I-Premise
202	Hb	N	I-Premise
203	levels	N	I-Premise
204	>	N	I-Premise
205	10.5	N	I-Premise
206	g/dl	N	I-Premise
207	,	N	I-Premise
208	for	N	I-Premise
209	whom	N	I-Premise
210	the	N	I-Premise
211	mean	N	I-Premise
212	changes	N	I-Premise
213	from	N	I-Premise
214	baseline	N	I-Premise
215	to	N	I-Premise
216	last	N	I-Premise
217	assessment	N	I-Premise
218	were	N	I-Premise
219	measured	N	I-Premise
220	by	N	I-Premise
221	the	N	I-Premise
222	Cancer	N	I-Premise
223	Linear	N	I-Premise
224	Analogue	N	I-Premise
225	Scale	N	I-Premise
226	assessments	N	I-Premise
227	of	N	I-Premise
228	energy	N	I-Premise
229	and	N	I-Premise
230	overall	N	I-Premise
231	QOL	N	I-Premise
232	as	N	I-Premise
233	well	N	I-Premise
234	as	N	I-Premise
235	by	N	I-Premise
236	the	N	I-Premise
237	Functional	N	I-Premise
238	Assessment	N	I-Premise
239	of	N	I-Premise
240	Cancer	N	I-Premise
241	Therapy	N	I-Premise
242	(	N	I-Premise
243	FACT	N	I-Premise
244	)	N	I-Premise
245	-Fatigue	N	I-Premise
246	and	N	I-Premise
247	FACT-An	N	I-Premise
248	Anemia	N	I-Premise
249	subscale	N	I-Premise
250	,	N	I-Premise
251	QOL	N	I-Premise
252	scores	N	I-Premise
253	were	N	I-Premise
254	significantly	N	I-Premise
255	greater	N	I-Premise
256	with	N	I-Premise
257	EPO	N	I-Premise
258	than	N	I-Premise
259	with	N	I-Premise
260	BSC	N	I-Premise
261	.	N	I-Premise

262	QOL	N	I-Premise
263	declined	N	I-Premise
264	in	N	I-Premise
265	patients	N	I-Premise
266	receiving	N	I-Premise
267	BSC	N	I-Premise
268	,	N	I-Premise
269	and	N	O
270	the	N	I-Premise
271	mean	N	I-Premise
272	decreases	N	I-Premise
273	in	N	I-Premise
274	QOL	N	I-Premise
275	scores	N	I-Premise
276	were	N	I-Premise
277	greater	N	I-Premise
278	for	N	I-Premise
279	BSC	N	I-Premise
280	patients	N	I-Premise
281	with	N	I-Premise
282	baseline	N	I-Premise
283	Hb	N	I-Premise
284	levels	N	I-Premise
285	>	N	I-Premise
286	10.5	N	I-Premise
287	g/dl	N	I-Premise
288	,	N	I-Premise
289	compared	N	I-Premise
290	with	N	I-Premise
291	the	N	I-Premise
292	overall	N	I-Premise
293	BSC	N	I-Premise
294	group	N	I-Premise
295	.	N	I-Premise

296	In	N	I-Claim
297	patients	N	I-Claim
298	with	N	I-Claim
299	cancer	N	I-Claim
300	receiving	N	I-Claim
301	platinum-based	N	I-Claim
302	chemotherapy	N	I-Claim
303	and	N	I-Claim
304	with	N	I-Claim
305	baseline	N	I-Claim
306	Hb	N	I-Claim
307	levels	N	I-Claim
308	>	N	I-Claim
309	10.5	N	I-Claim
310	g/dl	N	I-Claim
311	,	N	I-Claim
312	early	N	I-Claim
313	intervention	N	I-Claim
314	with	N	I-Claim
315	EPO	N	I-Claim
316	reduces	N	I-Claim
317	transfusions	N	I-Claim
318	,	N	I-Claim
319	maintains	N	I-Claim
320	Hb	N	I-Claim
321	level	N	I-Claim
322	,	N	I-Claim
323	and	N	I-Claim
324	maintains	N	I-Claim
325	or	N	I-Claim
326	improves	N	I-Claim
327	QOL	N	I-Claim
328	.	N	I-Claim

329	This	N	I-Claim
330	study	N	I-Claim
331	supports	N	I-Claim
332	the	N	I-Claim
333	positive	N	I-Claim
334	effects	N	I-Claim
335	of	N	I-Claim
336	early	N	I-Claim
337	intervention	N	I-Claim
338	when	N	I-Claim
339	analyzed	N	I-Claim
340	according	N	I-Claim
341	to	N	I-Claim
342	initial	N	I-Claim
343	Hb	N	I-Claim
344	value	N	I-Claim
345	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	difference	N	O
5	of	N	O
6	efficacy	N	O
7	,	N	O
8	side-effects	N	O
9	and	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	in	N	O
14	advanced	N	O
15	non-small-cell	N	O
16	lung	N	O
17	cancer	N	O
18	(	N	O
19	NSCLC	N	O
20	)	N	O
21	patients	N	O
22	treated	N	O
23	with	N	O
24	oxaliplatin	N	O
25	plus	N	O
26	vinorelbine	N	O
27	or	N	O
28	cisplatin	N	O
29	plus	N	O
30	vinorelbine	N	O
31	.	N	O

32	Eligible	N	O
33	patients	N	O
34	were	N	O
35	randomly	N	O
36	assigned	N	O
37	to	N	O
38	NL	N	O
39	(	N	O
40	oxaliplatin	N	O
41	+	N	O
42	vinorelbine	N	O
43	)	N	O
44	group	N	O
45	and	N	O
46	NP	N	O
47	(	N	O
48	cisplatin	N	O
49	+	N	O
50	vinorelbine	N	O
51	)	N	O
52	group	N	O
53	in	N	O
54	a	N	O
55	2:1	N	O
56	ratio	N	O
57	.	N	O

58	In	N	O
59	the	N	O
60	NL	N	O
61	group	N	O
62	,	N	O
63	70	N	O
64	evaluable	N	O
65	cases	N	O
66	were	N	O
67	treated	N	O
68	with	N	O
69	oxaliplatin	N	O
70	130	N	O
71	mg/m	N	O
72	(	N	O
73	2	N	O
74	)	N	O
75	i.v	N	O
76	.	N	O

77	on	N	O
78	day	N	O
79	2	N	O
80	,	N	O
81	and	N	O
82	vinorelbine	N	O
83	25	N	O
84	mg/m	N	O
85	(	N	O
86	2	N	O
87	)	N	O
88	i.v	N	O
89	.	N	O

90	on	N	O
91	days	N	O
92	1	N	O
93	and	N	O
94	8	N	O
95	in	N	O
96	21	N	O
97	days	N	O
98	per	N	O
99	cycle	N	O
100	.	N	O

101	In	N	O
102	the	N	O
103	NP	N	O
104	group	N	O
105	,	N	O
106	32	N	O
107	evaluable	N	O
108	cases	N	O
109	were	N	O
110	treated	N	O
111	with	N	O
112	cisplatin	N	O
113	80	N	O
114	mg/m	N	O
115	(	N	O
116	2	N	O
117	)	N	O
118	i.v	N	O
119	.	N	O

120	divided	N	O
121	to	N	O
122	2	N	O
123	-	N	O
124	3	N	O
125	days	N	O
126	dosing	N	O
127	,	N	O
128	21	N	O
129	days	N	O
130	per	N	O
131	cycle	N	O
132	,	N	O
133	and	N	O
134	vinorelbine	N	O
135	administered	N	O
136	by	N	O
137	the	N	O
138	same	N	O
139	way	N	O
140	as	N	O
141	in	N	O
142	the	N	O
143	NL	N	O
144	group	N	O
145	.	N	O

146	The	N	O
147	response	N	O
148	rate	N	O
149	,	N	O
150	time	N	O
151	to	N	O
152	progression	N	O
153	(	N	O
154	TTP	N	O
155	)	N	O
156	,	N	O
157	one-year	N	O
158	survival	N	O
159	,	N	O
160	side-effects	N	O
161	and	N	O
162	the	N	O
163	quality	N	O
164	of	N	O
165	life	N	O
166	were	N	O
167	observed	N	O
168	.	N	O

169	The	N	I-Premise
170	response	N	I-Premise
171	rate	N	I-Premise
172	was	N	I-Premise
173	35.7	N	I-Premise
174	%	N	I-Premise
175	vs.	N	I-Premise
176	43.8	N	I-Premise
177	%	N	I-Premise
178	(	N	I-Premise
179	P	N	I-Premise
180	=	N	I-Premise
181	0.4	N	I-Premise
182	)	N	I-Premise
183	,	N	I-Premise
184	median	N	I-Premise
185	TTP	N	I-Premise
186	was	N	I-Premise
187	4.7	N	I-Premise
188	months	N	I-Premise
189	vs.	N	I-Premise
190	5.5	N	I-Premise
191	months	N	I-Premise
192	(	N	I-Premise
193	P	N	I-Premise
194	=	N	I-Premise
195	0.6	N	I-Premise
196	)	N	I-Premise
197	,	N	I-Premise
198	one-year	N	I-Premise
199	survival	N	I-Premise
200	rate	N	I-Premise
201	was	N	I-Premise
202	38.5	N	I-Premise
203	%	N	I-Premise
204	vs.	N	I-Premise
205	58.6	N	I-Premise
206	%	N	I-Premise
207	(	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	0.07	N	I-Premise
211	)	N	I-Premise
212	in	N	I-Premise
213	the	N	I-Premise
214	NL	N	I-Premise
215	and	N	I-Premise
216	NP	N	I-Premise
217	groups	N	I-Premise
218	,	N	I-Premise
219	respectively	N	I-Premise
220	.	N	I-Premise

221	Grade	N	I-Premise
222	I-II	N	I-Premise
223	neuro-sensory	N	I-Premise
224	toxicity	N	I-Premise
225	occurred	N	I-Premise
226	significantly	N	I-Premise
227	more	N	I-Premise
228	frequent	N	I-Premise
229	in	N	I-Premise
230	NL	N	I-Premise
231	group	N	I-Premise
232	than	N	I-Premise
233	in	N	I-Premise
234	NP	N	I-Premise
235	group	N	I-Premise
236	(	N	I-Premise
237	68.4	N	I-Premise
238	%	N	I-Premise
239	vs.	N	I-Premise
240	36.4	N	I-Premise
241	%	N	I-Premise
242	,	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	0.0017	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	However	N	I-Premise
249	,	N	I-Premise
250	Grade	N	I-Premise
251	I-II	N	I-Premise
252	granulocytopenia	N	I-Premise
253	was	N	I-Premise
254	significantly	N	I-Premise
255	less	N	I-Premise
256	occurred	N	I-Premise
257	in	N	I-Premise
258	NL	N	I-Premise
259	group	N	I-Premise
260	than	N	I-Premise
261	in	N	I-Premise
262	NP	N	I-Premise
263	group	N	I-Premise
264	(	N	I-Premise
265	49.4	N	I-Premise
266	%	N	I-Premise
267	vs.	N	I-Premise
268	70.6	N	I-Premise
269	%	N	I-Premise
270	,	N	I-Premise
271	P	N	I-Premise
272	=	N	I-Premise
273	0.037	N	I-Premise
274	)	N	I-Premise
275	.	N	I-Premise

276	There	N	I-Premise
277	was	N	I-Premise
278	no	N	I-Premise
279	statistically	N	I-Premise
280	difference	N	I-Premise
281	between	N	I-Premise
282	the	N	I-Premise
283	two	N	I-Premise
284	groups	N	I-Premise
285	regarding	N	I-Premise
286	quality	N	I-Premise
287	of	N	I-Premise
288	life	N	I-Premise
289	.	N	I-Premise

290	Due	N	I-Claim
291	to	N	I-Claim
292	good	N	I-Claim
293	efficacy	N	I-Claim
294	and	N	I-Claim
295	tolerability	N	I-Claim
296	,	N	I-Claim
297	the	N	I-Claim
298	NL	N	I-Claim
299	regimen	N	I-Claim
300	offered	N	I-Claim
301	a	N	I-Claim
302	new	N	I-Claim
303	candidate	N	I-Claim
304	for	N	I-Claim
305	treating	N	I-Claim
306	advanced	N	I-Claim
307	NSCLC	N	I-Claim
308	.	N	I-Claim

1	The	N	I-MajorClaim
2	impact	N	I-MajorClaim
3	of	N	I-MajorClaim
4	prolonged	N	I-MajorClaim
5	subclinical	N	I-MajorClaim
6	hyperthyroidism	N	I-MajorClaim
7	on	N	I-MajorClaim
8	quality	N	I-MajorClaim
9	of	N	I-MajorClaim
10	life	N	I-MajorClaim
11	is	N	I-MajorClaim
12	unclear	N	I-MajorClaim
13	.	N	I-MajorClaim

14	Therefore	N	O
15	,	N	O
16	we	N	O
17	evaluated	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	differentiated	N	O
25	thyroid	N	O
26	carcinoma	N	O
27	(	N	O
28	DTC	N	O
29	)	N	O
30	on	N	O
31	TSH-suppressive	N	O
32	thyroxine	N	O
33	therapy	N	O
34	as	N	O
35	a	N	O
36	model	N	O
37	for	N	O
38	subclinical	N	O
39	hyperthyroidism	N	O
40	and	N	O
41	we	N	O
42	investigated	N	O
43	whether	N	O
44	restoration	N	O
45	to	N	O
46	euthyroidism	N	O
47	affects	N	O
48	quality	N	O
49	of	N	O
50	life	N	O
51	.	N	O

52	We	N	O
53	performed	N	O
54	a	N	O
55	prospective	N	O
56	,	N	O
57	single-blinded	N	O
58	,	N	O
59	placebo-controlled	N	O
60	,	N	O
61	randomized	N	O
62	trial	N	O
63	of	N	O
64	6	N	O
65	months	N	O
66	'	N	O
67	duration	N	O
68	with	N	O
69	two	N	O
70	parallel	N	O
71	groups	N	O
72	.	N	O

73	Twenty-four	N	O
74	subjects	N	O
75	with	N	O
76	a	N	O
77	history	N	O
78	of	N	O
79	differentiated	N	O
80	thyroid	N	O
81	carcinoma	N	O
82	with	N	O
83	>	N	O
84	10	N	O
85	years	N	O
86	TSH-suppressive	N	O
87	therapy	N	O
88	with	N	O
89	L-thyroxine	N	O
90	completed	N	O
91	the	N	O
92	study	N	O
93	.	N	O

94	L-thyroxine	N	O
95	dose	N	O
96	was	N	O
97	replaced	N	O
98	by	N	O
99	study	N	O
100	medication	N	O
101	containing	N	O
102	L-thyroxine	N	O
103	or	N	O
104	L-thyroxine	N	O
105	plus	N	O
106	placebo	N	O
107	.	N	O

108	Medication	N	O
109	was	N	O
110	titrated	N	O
111	to	N	O
112	establish	N	O
113	continuation	N	O
114	of	N	O
115	TSH	N	O
116	suppression	N	O
117	(	N	O
118	low-TSH	N	O
119	group	N	O
120	)	N	O
121	and	N	O
122	euthyroidism	N	O
123	(	N	O
124	euthyroid	N	O
125	group	N	O
126	)	N	O
127	.	N	O

128	Both	N	O
129	groups	N	O
130	consisted	N	O
131	of	N	O
132	12	N	O
133	patients	N	O
134	.	N	O

135	We	N	O
136	evaluated	N	O
137	quality	N	O
138	of	N	O
139	life	N	O
140	using	N	O
141	five	N	O
142	validated	N	O
143	questionnaires	N	O
144	.	N	O

145	At	N	O
146	baseline	N	O
147	,	N	O
148	the	N	O
149	somatic	N	O
150	disorder	N	O
151	questionnaire	N	O
152	(	N	O
153	SDQ	N	O
154	)	N	O
155	indicated	N	O
156	more	N	O
157	somatic	N	O
158	dysfunction	N	O
159	in	N	O
160	patients	N	O
161	as	N	O
162	compared	N	O
163	with	N	O
164	reference	N	O
165	values	N	O
166	,	N	O
167	whereas	N	O
168	the	N	O
169	depression	N	O
170	score	N	O
171	(	N	O
172	HADS	N	O
173	)	N	O
174	revealed	N	O
175	a	N	O
176	better	N	O
177	score	N	O
178	than	N	O
179	the	N	O
180	reference	N	O
181	group	N	O
182	.	N	O

183	All	N	O
184	other	N	O
185	quality	N	O
186	of	N	O
187	life	N	O
188	parameters	N	O
189	were	N	O
190	normal	N	O
191	.	N	O

192	At	N	O
193	baseline	N	O
194	,	N	O
195	no	N	O
196	significant	N	O
197	differences	N	O
198	between	N	O
199	the	N	O
200	low-TSH	N	O
201	and	N	O
202	the	N	O
203	euthyroidism	N	O
204	groups	N	O
205	were	N	O
206	observed	N	O
207	.	N	O

208	After	N	I-Premise
209	6	N	I-Premise
210	months	N	I-Premise
211	,	N	I-Premise
212	none	N	I-Premise
213	of	N	I-Premise
214	the	N	I-Premise
215	quality	N	I-Premise
216	of	N	I-Premise
217	life	N	I-Premise
218	parameters	N	I-Premise
219	in	N	I-Premise
220	the	N	I-Premise
221	low-TSH	N	I-Premise
222	group	N	I-Premise
223	was	N	I-Premise
224	different	N	I-Premise
225	from	N	I-Premise
226	baseline	N	I-Premise
227	values	N	I-Premise
228	.	N	I-Premise

229	In	N	I-Premise
230	the	N	I-Premise
231	euthyroid	N	I-Premise
232	group	N	I-Premise
233	,	N	I-Premise
234	motivation	N	I-Premise
235	was	N	I-Premise
236	significantly	N	I-Premise
237	improved	N	I-Premise
238	(	N	I-Premise
239	Multidimensional	N	I-Premise
240	Fatigue	N	I-Premise
241	Index-20	N	I-Premise
242	,	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	0.003	N	I-Premise
246	)	N	I-Premise
247	,	N	I-Premise
248	although	N	I-Premise
249	this	N	I-Premise
250	parameter	N	I-Premise
251	did	N	I-Premise
252	not	N	I-Premise
253	differ	N	I-Premise
254	from	N	I-Premise
255	the	N	I-Premise
256	reference	N	I-Premise
257	group	N	I-Premise
258	at	N	I-Premise
259	baseline	N	I-Premise
260	.	N	I-Premise

261	A	N	I-Premise
262	probable	N	I-Premise
263	worsening	N	I-Premise
264	in	N	I-Premise
265	role	N	I-Premise
266	limitations	N	I-Premise
267	as	N	I-Premise
268	a	N	I-Premise
269	result	N	I-Premise
270	of	N	I-Premise
271	physical	N	I-Premise
272	problems	N	I-Premise
273	(	N	I-Premise
274	Short	N	I-Premise
275	Form-36	N	I-Premise
276	;	N	I-Premise
277	P	N	I-Premise
278	=	N	I-Premise
279	0.050	N	I-Premise
280	)	N	I-Premise
281	was	N	I-Premise
282	observed	N	I-Premise
283	.	N	I-Premise

284	No	N	I-Premise
285	improvement	N	I-Premise
286	in	N	I-Premise
287	the	N	I-Premise
288	SDQ	N	I-Premise
289	score	N	I-Premise
290	was	N	I-Premise
291	observed	N	I-Premise
292	.	N	I-Premise

293	In	N	I-Claim
294	summary	N	I-Claim
295	,	N	I-Claim
296	quality	N	I-Claim
297	of	N	I-Claim
298	life	N	I-Claim
299	in	N	I-Claim
300	patients	N	I-Claim
301	with	N	I-Claim
302	DTC	N	I-Claim
303	and	N	I-Claim
304	long-term	N	I-Claim
305	subclinical	N	I-Claim
306	hyperthyroidism	N	I-Claim
307	in	N	I-Claim
308	general	N	I-Claim
309	is	N	I-Claim
310	preserved	N	I-Claim
311	.	N	I-Claim

312	Restoration	N	I-Claim
313	of	N	I-Claim
314	euthyroidism	N	I-Claim
315	in	N	I-Claim
316	general	N	I-Claim
317	does	N	I-Claim
318	not	N	I-Claim
319	affect	N	I-Claim
320	quality	N	I-Claim
321	of	N	I-Claim
322	life	N	I-Claim
323	.	N	I-Claim

1	For	N	I-MajorClaim
2	patients	N	I-MajorClaim
3	with	N	I-MajorClaim
4	advanced	N	I-MajorClaim
5	gastric	N	I-MajorClaim
6	or	N	I-MajorClaim
7	gastroesophageal	N	I-MajorClaim
8	cancer	N	I-MajorClaim
9	(	N	I-MajorClaim
10	AGGEC	N	I-MajorClaim
11	)	N	I-MajorClaim
12	providing	N	I-MajorClaim
13	clinical	N	I-MajorClaim
14	benefit	N	I-MajorClaim
15	with	N	I-MajorClaim
16	improved	N	I-MajorClaim
17	palliation	N	I-MajorClaim
18	is	N	I-MajorClaim
19	highly	N	I-MajorClaim
20	desirable	N	I-MajorClaim
21	.	N	I-MajorClaim

22	However	N	O
23	,	N	O
24	a	N	O
25	prospective	N	O
26	evaluation	N	O
27	of	N	O
28	clinical	N	O
29	benefit	N	O
30	in	N	O
31	AGGEC	N	O
32	patients	N	O
33	has	N	O
34	never	N	O
35	before	N	O
36	been	N	O
37	reported	N	O
38	in	N	O
39	a	N	O
40	phase	N	O
41	III	N	O
42	setting	N	O
43	.	N	O

44	In	N	O
45	a	N	O
46	multinational	N	O
47	trial	N	O
48	(	N	O
49	V325	N	O
50	)	N	O
51	,	N	O
52	445	N	O
53	patients	N	O
54	were	N	O
55	randomly	N	O
56	assigned	N	O
57	and	N	O
58	treated	N	O
59	with	N	O
60	either	N	O
61	docetaxel	N	O
62	plus	N	O
63	cisplatin	N	O
64	and	N	O
65	fluorouracil	N	O
66	(	N	O
67	DCF	N	O
68	)	N	O
69	or	N	O
70	cisplatin	N	O
71	and	N	O
72	fluorouracil	N	O
73	(	N	O
74	CF	N	O
75	)	N	O
76	.	N	O

77	Clinical	N	O
78	benefit	N	O
79	was	N	O
80	prospectively	N	O
81	evaluated	N	O
82	in	N	O
83	this	N	O
84	trial	N	O
85	as	N	O
86	a	N	O
87	secondary	N	O
88	end	N	O
89	point	N	O
90	.	N	O

91	The	N	O
92	primary	N	O
93	measure	N	O
94	for	N	O
95	clinical	N	O
96	benefit	N	O
97	analysis	N	O
98	was	N	O
99	time	N	O
100	to	N	O
101	definitive	N	O
102	worsening	N	O
103	by	N	O
104	one	N	O
105	or	N	O
106	more	N	O
107	categories	N	O
108	of	N	O
109	Karnofsky	N	O
110	performance	N	O
111	status	N	O
112	(	N	O
113	KPS	N	O
114	)	N	O
115	.	N	O

116	Secondary	N	O
117	clinical	N	O
118	benefit	N	O
119	end	N	O
120	points	N	O
121	included	N	O
122	time	N	O
123	to	N	O
124	5	N	O
125	%	N	O
126	definitive	N	O
127	weight	N	O
128	loss	N	O
129	,	N	O
130	time	N	O
131	to	N	O
132	definitive	N	O
133	worsening	N	O
134	of	N	O
135	appetite	N	O
136	by	N	O
137	one	N	O
138	grade	N	O
139	,	N	O
140	pain-free	N	O
141	survival	N	O
142	(	N	O
143	defined	N	O
144	as	N	O
145	time	N	O
146	to	N	O
147	first	N	O
148	appearance	N	O
149	of	N	O
150	pain	N	O
151	)	N	O
152	,	N	O
153	and	N	O
154	time	N	O
155	to	N	O
156	first	N	O
157	cancer	N	O
158	pain-related	N	O
159	opioid	N	O
160	intake	N	O
161	.	N	O

162	Clinical	N	O
163	benefit	N	O
164	assessments	N	O
165	were	N	O
166	recorded	N	O
167	at	N	O
168	each	N	O
169	clinic	N	O
170	visit	N	O
171	.	N	O

172	Clinical	N	O
173	benefit	N	O
174	assessments	N	O
175	were	N	O
176	performed	N	O
177	in	N	O
178	more	N	O
179	than	N	O
180	75	N	O
181	%	N	O
182	of	N	O
183	patients	N	O
184	throughout	N	O
185	V325	N	O
186	.	N	O

187	DCF	N	I-Premise
188	significantly	N	I-Premise
189	prolonged	N	I-Premise
190	time	N	I-Premise
191	to	N	I-Premise
192	definitive	N	I-Premise
193	worsening	N	I-Premise
194	of	N	I-Premise
195	KPS	N	I-Premise
196	compared	N	I-Premise
197	with	N	I-Premise
198	CF	N	I-Premise
199	(	N	I-Premise
200	median	N	I-Premise
201	,	N	I-Premise
202	6.1	N	I-Premise
203	v	N	I-Premise
204	4.8	N	I-Premise
205	months	N	I-Premise
206	;	N	I-Premise
207	hazard	N	I-Premise
208	ratio	N	I-Premise
209	,	N	I-Premise
210	1.38	N	I-Premise
211	;	N	I-Premise
212	95	N	I-Premise
213	%	N	I-Premise
214	CI	N	I-Premise
215	,	N	I-Premise
216	1.08	N	I-Premise
217	to	N	I-Premise
218	1.76	N	I-Premise
219	;	N	I-Premise
220	log-rank	N	I-Premise
221	P	N	I-Premise
222	=	N	I-Premise
223	.009	N	I-Premise
224	)	N	I-Premise
225	.	N	I-Premise

226	Although	N	I-Premise
227	time	N	I-Premise
228	to	N	I-Premise
229	definitive	N	I-Premise
230	weight	N	I-Premise
231	loss	N	I-Premise
232	and	N	I-Premise
233	time	N	I-Premise
234	to	N	I-Premise
235	definitive	N	I-Premise
236	worsening	N	I-Premise
237	of	N	I-Premise
238	appetite	N	I-Premise
239	favored	N	I-Premise
240	DCF	N	I-Premise
241	,	N	I-Premise
242	the	N	I-Premise
243	results	N	I-Premise
244	were	N	I-Premise
245	not	N	I-Premise
246	statistically	N	I-Premise
247	significant	N	I-Premise
248	.	N	I-Premise

249	Pain-free	N	I-Premise
250	survival	N	I-Premise
251	and	N	I-Premise
252	time	N	I-Premise
253	to	N	I-Premise
254	first	N	I-Premise
255	cancer	N	I-Premise
256	pain-related	N	I-Premise
257	opioid	N	I-Premise
258	intake	N	I-Premise
259	were	N	I-Premise
260	comparable	N	I-Premise
261	.	N	I-Premise

262	To	N	O
263	our	N	O
264	knowledge	N	O
265	,	N	O
266	V325	N	O
267	is	N	O
268	the	N	O
269	first	N	O
270	phase	N	O
271	III	N	O
272	trial	N	O
273	to	N	O
274	report	N	O
275	clinical	N	O
276	benefit	N	O
277	in	N	O
278	AGGEC	N	O
279	patients	N	O
280	.	N	O

281	Clinical	N	O
282	benefit	N	O
283	was	N	O
284	assessed	N	O
285	beyond	N	O
286	protocol-specific	N	O
287	chemotherapy	N	O
288	.	N	O

289	The	N	I-Claim
290	addition	N	I-Claim
291	of	N	I-Claim
292	D	N	I-Claim
293	to	N	I-Claim
294	CF	N	I-Claim
295	not	N	I-Claim
296	only	N	I-Claim
297	significantly	N	I-Claim
298	improved	N	I-Claim
299	clinical	N	I-Claim
300	benefit	N	I-Claim
301	but	N	I-Claim
302	also	N	I-Claim
303	improved	N	I-Claim
304	quality	N	I-Claim
305	of	N	I-Claim
306	life	N	I-Claim
307	,	N	I-Claim
308	time	N	I-Claim
309	to	N	I-Claim
310	progression	N	I-Claim
311	,	N	I-Claim
312	and	N	I-Claim
313	overall	N	I-Claim
314	survival	N	I-Claim
315	compared	N	I-Claim
316	with	N	I-Claim
317	CF	N	I-Claim
318	.	N	I-Claim

1	Somatostatin	N	O
2	analogs	N	O
3	are	N	O
4	indicated	N	O
5	for	N	O
6	symptom	N	O
7	control	N	O
8	in	N	O
9	patients	N	O
10	with	N	O
11	gastroenteropancreatic	N	O
12	neuroendocrine	N	O
13	tumors	N	O
14	(	N	O
15	NETs	N	O
16	)	N	O
17	.	N	O

18	The	N	O
19	ability	N	O
20	of	N	O
21	somatostatin	N	O
22	analogs	N	O
23	to	N	O
24	control	N	O
25	the	N	O
26	growth	N	O
27	of	N	O
28	well-differentiated	N	O
29	metastatic	N	O
30	NETs	N	O
31	is	N	O
32	a	N	O
33	matter	N	O
34	of	N	O
35	debate	N	O
36	.	N	O

37	We	N	O
38	performed	N	O
39	a	N	O
40	placebo-controlled	N	O
41	,	N	O
42	double-blind	N	O
43	,	N	O
44	phase	N	O
45	IIIB	N	O
46	study	N	O
47	in	N	O
48	patients	N	O
49	with	N	O
50	well-differentiated	N	O
51	metastatic	N	O
52	midgut	N	O
53	NETs	N	O
54	.	N	O

55	The	N	O
56	hypothesis	N	O
57	was	N	O
58	that	N	O
59	octreotide	N	O
60	LAR	N	O
61	prolongs	N	O
62	time	N	O
63	to	N	O
64	tumor	N	O
65	progression	N	O
66	and	N	O
67	survival	N	O
68	.	N	O

69	Treatment-naive	N	O
70	patients	N	O
71	were	N	O
72	randomly	N	O
73	assigned	N	O
74	to	N	O
75	either	N	O
76	placebo	N	O
77	or	N	O
78	octreotide	N	O
79	LAR	N	O
80	30	N	O
81	mg	N	O
82	intramuscularly	N	O
83	in	N	O
84	monthly	N	O
85	intervals	N	O
86	until	N	O
87	tumor	N	O
88	progression	N	O
89	or	N	O
90	death	N	O
91	.	N	O

92	The	N	O
93	primary	N	O
94	efficacy	N	O
95	end	N	O
96	point	N	O
97	was	N	O
98	time	N	O
99	to	N	O
100	tumor	N	O
101	progression	N	O
102	.	N	O

103	Secondary	N	O
104	end	N	O
105	points	N	O
106	were	N	O
107	survival	N	O
108	time	N	O
109	and	N	O
110	tumor	N	O
111	response	N	O
112	.	N	O

113	This	N	O
114	report	N	O
115	is	N	O
116	based	N	O
117	on	N	O
118	67	N	O
119	tumor	N	O
120	progressions	N	O
121	and	N	O
122	16	N	O
123	observed	N	O
124	deaths	N	O
125	in	N	O
126	85	N	O
127	patients	N	O
128	at	N	O
129	the	N	O
130	time	N	O
131	of	N	O
132	the	N	O
133	planned	N	O
134	interim	N	O
135	analysis	N	O
136	.	N	O

137	Median	N	I-Premise
138	time	N	I-Premise
139	to	N	I-Premise
140	tumor	N	I-Premise
141	progression	N	I-Premise
142	in	N	I-Premise
143	the	N	I-Premise
144	octreotide	N	I-Premise
145	LAR	N	I-Premise
146	and	N	I-Premise
147	placebo	N	I-Premise
148	groups	N	I-Premise
149	was	N	I-Premise
150	14.3	N	I-Premise
151	and	N	I-Premise
152	6	N	I-Premise
153	months	N	I-Premise
154	,	N	I-Premise
155	respectively	N	I-Premise
156	(	N	I-Premise
157	hazard	N	I-Premise
158	ratio	N	I-Premise
159	[	N	I-Premise
160	HR	N	I-Premise
161	]	N	I-Premise
162	=	N	I-Premise
163	0.34	N	I-Premise
164	;	N	I-Premise
165	95	N	I-Premise
166	%	N	I-Premise
167	CI	N	I-Premise
168	,	N	I-Premise
169	0.20	N	I-Premise
170	to	N	I-Premise
171	0.59	N	I-Premise
172	;	N	I-Premise
173	P	N	I-Premise
174	=	N	I-Premise
175	.000072	N	I-Premise
176	)	N	I-Premise
177	.	N	I-Premise

178	After	N	I-Premise
179	6	N	I-Premise
180	months	N	I-Premise
181	of	N	I-Premise
182	treatment	N	I-Premise
183	,	N	I-Premise
184	stable	N	I-Premise
185	disease	N	I-Premise
186	was	N	I-Premise
187	observed	N	I-Premise
188	in	N	I-Premise
189	66.7	N	I-Premise
190	%	N	I-Premise
191	of	N	I-Premise
192	patients	N	I-Premise
193	in	N	I-Premise
194	the	N	I-Premise
195	octreotide	N	I-Premise
196	LAR	N	I-Premise
197	group	N	I-Premise
198	and	N	I-Premise
199	37.2	N	I-Premise
200	%	N	I-Premise
201	of	N	I-Premise
202	patients	N	I-Premise
203	in	N	I-Premise
204	the	N	I-Premise
205	placebo	N	I-Premise
206	group	N	I-Premise
207	.	N	I-Premise

208	Functionally	N	O
209	active	N	O
210	and	N	O
211	inactive	N	O
212	tumors	N	O
213	responded	N	O
214	similarly	N	O
215	.	N	O

216	The	N	I-Premise
217	most	N	I-Premise
218	favorable	N	I-Premise
219	effect	N	I-Premise
220	was	N	I-Premise
221	observed	N	I-Premise
222	in	N	I-Premise
223	patients	N	I-Premise
224	with	N	I-Premise
225	low	N	I-Premise
226	hepatic	N	I-Premise
227	tumor	N	I-Premise
228	load	N	I-Premise
229	and	N	I-Premise
230	resected	N	I-Premise
231	primary	N	I-Premise
232	tumor	N	I-Premise
233	.	N	I-Premise

234	Seven	N	I-Premise
235	and	N	I-Premise
236	nine	N	I-Premise
237	deaths	N	I-Premise
238	were	N	I-Premise
239	observed	N	I-Premise
240	in	N	I-Premise
241	the	N	I-Premise
242	octreotide	N	I-Premise
243	LAR	N	I-Premise
244	and	N	I-Premise
245	placebo	N	I-Premise
246	groups	N	I-Premise
247	,	N	I-Premise
248	respectively	N	I-Premise
249	.	N	I-Premise

250	The	N	I-Premise
251	HR	N	I-Premise
252	for	N	I-Premise
253	overall	N	I-Premise
254	survival	N	I-Premise
255	was	N	I-Premise
256	0.81	N	I-Premise
257	(	N	I-Premise
258	95	N	I-Premise
259	%	N	I-Premise
260	CI	N	I-Premise
261	,	N	I-Premise
262	0.30	N	I-Premise
263	to	N	I-Premise
264	2.18	N	I-Premise
265	)	N	I-Premise
266	.	N	I-Premise

267	Octreotide	N	I-Claim
268	LAR	N	I-Claim
269	significantly	N	I-Claim
270	lengthens	N	I-Claim
271	time	N	I-Claim
272	to	N	I-Claim
273	tumor	N	I-Claim
274	progression	N	I-Claim
275	compared	N	I-Claim
276	with	N	I-Claim
277	placebo	N	I-Claim
278	in	N	I-Claim
279	patients	N	I-Claim
280	with	N	I-Claim
281	functionally	N	I-Claim
282	active	N	I-Claim
283	and	N	I-Claim
284	inactive	N	I-Claim
285	metastatic	N	I-Claim
286	midgut	N	I-Claim
287	NETs	N	I-Claim
288	.	N	I-Claim

289	Because	N	I-Premise
290	of	N	I-Premise
291	the	N	I-Premise
292	low	N	I-Premise
293	number	N	I-Premise
294	of	N	I-Premise
295	observed	N	I-Premise
296	deaths	N	I-Premise
297	,	N	I-Premise
298	survival	N	I-Premise
299	analysis	N	I-Premise
300	was	N	I-Premise
301	not	N	I-Premise
302	confirmatory	N	I-Premise
303	.	N	I-Premise

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	combination	N	O
5	of	N	O
6	the	N	O
7	gastrin	N	O
8	antagonist	N	O
9	Z-360	N	O
10	and	N	O
11	gemcitabine	N	O
12	for	N	O
13	advanced	N	O
14	pancreatic	N	O
15	cancer	N	O
16	.	N	O

17	Previously	N	O
18	untreated	N	O
19	patients	N	O
20	with	N	O
21	PC	N	O
22	were	N	O
23	randomly	N	O
24	allocated	N	O
25	to	N	O
26	Z-360	N	O
27	120	N	O
28	mg	N	O
29	,	N	O
30	240	N	O
31	mg	N	O
32	or	N	O
33	placebo	N	O
34	.	N	O

35	Z-360/placebo	N	O
36	was	N	O
37	given	N	O
38	on	N	O
39	day	N	O
40	-3	N	O
41	and	N	O
42	gemcitabine	N	O
43	1000	N	O
44	mg/m	N	O
45	(	N	O
46	2	N	O
47	)	N	O
48	commenced	N	O
49	on	N	O
50	day	N	O
51	1	N	O
52	followed	N	O
53	by	N	O
54	Z-360	N	O
55	on	N	O
56	day	N	O
57	2	N	O
58	.	N	O

59	Thereafter	N	O
60	Z-360/placebo	N	O
61	was	N	O
62	given	N	O
63	twice	N	O
64	daily	N	O
65	concurrently	N	O
66	with	N	O
67	standard	N	O
68	dose	N	O
69	of	N	O
70	gemcitabine	N	O
71	.	N	O

72	Pharmacokinetics	N	O
73	for	N	O
74	both	N	O
75	drugs	N	O
76	was	N	O
77	measured	N	O
78	alone	N	O
79	and	N	O
80	in	N	O
81	combination	N	O
82	.	N	O

83	Toxicity	N	O
84	,	N	O
85	response	N	O
86	and	N	O
87	quality	N	O
88	of	N	O
89	life	N	O
90	were	N	O
91	also	N	O
92	recorded	N	O
93	.	N	O

94	Thirty-three	N	O
95	patients	N	O
96	with	N	O
97	a	N	O
98	median	N	O
99	age	N	O
100	of	N	O
101	62	N	O
102	years	N	O
103	were	N	O
104	randomised	N	O
105	of	N	O
106	which	N	O
107	six	N	O
108	had	N	O
109	locally	N	O
110	advanced	N	O
111	disease	N	O
112	and	N	O
113	26	N	O
114	had	N	O
115	metastatic	N	O
116	disease	N	O
117	.	N	O

118	Analysis	N	O
119	of	N	O
120	the	N	O
121	area	N	O
122	under	N	O
123	the	N	O
124	plasma	N	O
125	concentration	N	O
126	versus	N	O
127	time	N	O
128	curve	N	O
129	(	N	O
130	AUC	N	O
131	)	N	O
132	,	N	O
133	the	N	O
134	maximum	N	O
135	observed	N	O
136	concentration	N	O
137	(	N	O
138	Cmax	N	O
139	(	N	O
140	obs	N	O
141	)	N	O
142	)	N	O
143	and	N	O
144	the	N	O
145	time	N	O
146	of	N	O
147	the	N	O
148	maximum	N	O
149	observed	N	O
150	concentration	N	O
151	(	N	O
152	Tmax	N	O
153	(	N	O
154	obs	N	O
155	)	N	O
156	)	N	O
157	for	N	O
158	Z-360	N	O
159	,	N	O
160	gemcitabine	N	O
161	and	N	O
162	2,2-difluorodeoxyuridine	N	O
163	(	N	O
164	dFdU	N	O
165	)	N	O
166	,	N	O
167	could	N	O
168	not	N	O
169	exclude	N	O
170	an	N	O
171	effect	N	O
172	on	N	O
173	the	N	O
174	systemic	N	O
175	exposure	N	O
176	to	N	O
177	Z-360	N	O
178	,	N	O
179	gemcitabine	N	O
180	and	N	O
181	dFdU	N	O
182	when	N	O
183	co-administration	N	O
184	of	N	O
185	Z-360	N	O
186	and	N	O
187	gemcitabine	N	O
188	was	N	O
189	compared	N	O
190	with	N	O
191	single	N	O
192	agent	N	O
193	administration	N	O
194	.	N	O

195	The	N	I-Premise
196	most	N	I-Premise
197	commonly	N	I-Premise
198	reported	N	I-Premise
199	adverse	N	I-Premise
200	events	N	I-Premise
201	were	N	I-Premise
202	nausea	N	I-Premise
203	,	N	I-Premise
204	abdominal	N	I-Premise
205	pain	N	I-Premise
206	,	N	I-Premise
207	vomiting	N	I-Premise
208	and	N	I-Premise
209	fatigue	N	I-Premise
210	.	N	I-Premise

211	At	N	I-Premise
212	the	N	I-Premise
213	end	N	I-Premise
214	of	N	I-Premise
215	the	N	I-Premise
216	study	N	I-Premise
217	,	N	I-Premise
218	62.5	N	I-Premise
219	%	N	I-Premise
220	,	N	I-Premise
221	25	N	I-Premise
222	%	N	I-Premise
223	and	N	I-Premise
224	60	N	I-Premise
225	%	N	I-Premise
226	had	N	I-Premise
227	stable	N	I-Premise
228	disease	N	I-Premise
229	in	N	I-Premise
230	the	N	I-Premise
231	120	N	I-Premise
232	mg	N	I-Premise
233	,	N	I-Premise
234	240	N	I-Premise
235	mg	N	I-Premise
236	and	N	I-Premise
237	placebo	N	I-Premise
238	group	N	I-Premise
239	,	N	I-Premise
240	respectively	N	I-Premise
241	.	N	I-Premise

242	A	N	I-Premise
243	higher	N	I-Premise
244	proportion	N	I-Premise
245	of	N	I-Premise
246	patients	N	I-Premise
247	in	N	I-Premise
248	Z-360	N	I-Premise
249	groups	N	I-Premise
250	reported	N	I-Premise
251	improvement	N	I-Premise
252	in	N	I-Premise
253	pain	N	I-Premise
254	.	N	I-Premise

255	Z-360	N	I-Claim
256	is	N	I-Claim
257	safe	N	I-Claim
258	and	N	I-Claim
259	well	N	I-Claim
260	tolerated	N	I-Claim
261	when	N	I-Claim
262	combined	N	I-Claim
263	with	N	I-Claim
264	gemcitabine	N	I-Claim
265	.	N	I-Claim

266	A	N	O
267	Phase	N	O
268	III	N	O
269	trial	N	O
270	is	N	O
271	needed	N	O
272	to	N	O
273	determine	N	O
274	whether	N	O
275	the	N	O
276	combination	N	O
277	of	N	O
278	Z-360	N	O
279	and	N	O
280	gemcitabine	N	O
281	is	N	O
282	superior	N	O
283	to	N	O
284	gemcitabine	N	O
285	alone	N	O
286	in	N	O
287	advanced	N	O
288	PC	N	O
289	.	N	O

1	Restoring	N	O
2	sensory	N	O
3	innervation	N	O
4	may	N	O
5	be	N	O
6	a	N	O
7	useful	N	O
8	adjunct	N	O
9	in	N	O
10	free	N	O
11	flap	N	O
12	head	N	O
13	and	N	O
14	neck	N	O
15	reconstruction	N	O
16	but	N	O
17	,	N	O
18	as	N	O
19	yet	N	O
20	,	N	O
21	has	N	O
22	not	N	O
23	been	N	O
24	shown	N	O
25	to	N	O
26	improve	N	O
27	outcomes	N	O
28	of	N	O
29	breast	N	O
30	reconstruction	N	O
31	.	N	O

32	The	N	O
33	authors	N	O
34	'	N	O
35	previous	N	O
36	study	N	O
37	demonstrated	N	O
38	objectively	N	O
39	improved	N	O
40	sensation	N	O
41	in	N	O
42	a	N	O
43	group	N	O
44	of	N	O
45	innervated	N	O
46	transverse	N	O
47	rectus	N	O
48	abdominis	N	O
49	musculocutaneous	N	O
50	(	N	O
51	TRAM	N	O
52	)	N	O
53	flap	N	O
54	breast	N	O
55	reconstruction	N	O
56	patients	N	O
57	relative	N	O
58	to	N	O
59	noninnervated	N	O
60	flaps	N	O
61	.	N	O

62	This	N	O
63	study	N	O
64	compared	N	O
65	patient-rated	N	O
66	outcomes	N	O
67	of	N	O
68	free	N	O
69	TRAM	N	O
70	breast	N	O
71	reconstruction	N	O
72	in	N	O
73	innervated	N	O
74	versus	N	O
75	noninnervated	N	O
76	flaps	N	O
77	.	N	O

78	Twenty-seven	N	O
79	women	N	O
80	were	N	O
81	randomized	N	O
82	prospectively	N	O
83	to	N	O
84	undergo	N	O
85	either	N	O
86	innervated	N	O
87	or	N	O
88	noninnervated	N	O
89	free	N	O
90	TRAM	N	O
91	flap	N	O
92	breast	N	O
93	reconstruction	N	O
94	.	N	O

95	For	N	O
96	innervated	N	O
97	flaps	N	O
98	,	N	O
99	the	N	O
100	T10	N	O
101	intercostal	N	O
102	nerve	N	O
103	was	N	O
104	harvested	N	O
105	with	N	O
106	the	N	O
107	TRAM	N	O
108	flap	N	O
109	and	N	O
110	neurotized	N	O
111	to	N	O
112	the	N	O
113	T4	N	O
114	sensory	N	O
115	nerve	N	O
116	at	N	O
117	the	N	O
118	recipient	N	O
119	site	N	O
120	.	N	O

121	Three	N	O
122	validated	N	O
123	outcome	N	O
124	tools	N	O
125	were	N	O
126	administered	N	O
127	after	N	O
128	surgery	N	O
129	:	N	O
130	the	N	O
131	Medical	N	O
132	Outcomes	N	O
133	Study	N	O
134	36-Item	N	O
135	Short	N	O
136	Form	N	O
137	Health	N	O
138	Survey	N	O
139	,	N	O
140	the	N	O
141	Body	N	O
142	Image	N	O
143	after	N	O
144	Breast	N	O
145	Cancer	N	O
146	Questionnaire	N	O
147	,	N	O
148	and	N	O
149	the	N	O
150	Functional	N	O
151	Assessment	N	O
152	of	N	O
153	Cancer	N	O
154	Therapy-Breast	N	O
155	.	N	O

156	Results	N	I-Premise
157	were	N	I-Premise
158	correlated	N	I-Premise
159	with	N	I-Premise
160	previously	N	I-Premise
161	reported	N	I-Premise
162	objective	N	I-Premise
163	sensibility	N	I-Premise
164	outcomes	N	I-Premise
165	.	N	I-Premise

166	Eighteen	N	O
167	of	N	O
168	27	N	O
169	women	N	O
170	returned	N	O
171	their	N	O
172	questionnaires	N	O
173	a	N	O
174	mean	N	O
175	48	N	O
176	months	N	O
177	after	N	O
178	free	N	O
179	TRAM	N	O
180	flap	N	O
181	reconstruction	N	O
182	.	N	O

183	Demographic	N	O
184	analysis	N	O
185	revealed	N	O
186	no	N	O
187	significant	N	O
188	differences	N	O
189	in	N	O
190	patient	N	O
191	age	N	O
192	,	N	O
193	height	N	O
194	,	N	O
195	smoking	N	O
196	,	N	O
197	radiation	N	O
198	therapy	N	O
199	,	N	O
200	and	N	O
201	nipple-areola	N	O
202	complex	N	O
203	reconstruction	N	O
204	between	N	O
205	randomized	N	O
206	patient	N	O
207	groups	N	O
208	.	N	O

209	There	N	I-Premise
210	was	N	I-Premise
211	a	N	I-Premise
212	statistically	N	I-Premise
213	significant	N	I-Premise
214	improvement	N	I-Premise
215	in	N	I-Premise
216	all	N	I-Premise
217	three	N	I-Premise
218	measures	N	I-Premise
219	in	N	I-Premise
220	patients	N	I-Premise
221	who	N	I-Premise
222	were	N	I-Premise
223	randomized	N	I-Premise
224	to	N	I-Premise
225	receive	N	I-Premise
226	innervated	N	I-Premise
227	free	N	I-Premise
228	TRAM	N	I-Premise
229	flaps	N	I-Premise
230	compared	N	I-Premise
231	with	N	I-Premise
232	those	N	I-Premise
233	receiving	N	I-Premise
234	noninnervated	N	I-Premise
235	flaps	N	I-Premise
236	.	N	I-Premise

237	This	N	I-Claim
238	study	N	I-Claim
239	demonstrates	N	I-Claim
240	that	N	I-Claim
241	innervation	N	I-Claim
242	of	N	I-Claim
243	free	N	I-Claim
244	TRAM	N	I-Claim
245	flaps	N	I-Claim
246	used	N	I-Claim
247	for	N	I-Claim
248	breast	N	I-Claim
249	reconstruction	N	I-Claim
250	not	N	I-Claim
251	only	N	I-Claim
252	improves	N	I-Claim
253	sensibility	N	I-Claim
254	but	N	I-Claim
255	also	N	I-Claim
256	has	N	I-Claim
257	a	N	I-Claim
258	positive	N	I-Claim
259	effect	N	I-Claim
260	on	N	I-Claim
261	patient-rated	N	I-Claim
262	quality	N	I-Claim
263	of	N	I-Claim
264	life	N	I-Claim
265	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	toxicities	N	O
4	,	N	O
5	functional	N	O
6	outcomes	N	O
7	,	N	O
8	and	N	O
9	health-related	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	associated	N	O
14	with	N	O
15	concurrent	N	O
16	chemoradiation	N	O
17	therapy	N	O
18	(	N	O
19	CRT	N	O
20	)	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	head	N	O
25	and	N	O
26	neck	N	O
27	cancer	N	O
28	.	N	O

29	Prospective	N	O
30	and	N	O
31	retrospective	N	O
32	outcomes	N	O
33	study	N	O
34	.	N	O

35	Tertiary	N	O
36	care	N	O
37	institution	N	O
38	.	N	O

39	Participants	N	O
40	in	N	O
41	the	N	O
42	longitudinal	N	O
43	Outcomes	N	O
44	Assessment	N	O
45	Project	N	O
46	whose	N	O
47	head	N	O
48	and	N	O
49	neck	N	O
50	cancer	N	O
51	was	N	O
52	treated	N	O
53	with	N	O
54	CRT	N	O
55	between	N	O
56	February	N	O
57	1	N	O
58	,	N	O
59	2000	N	O
60	,	N	O
61	and	N	O
62	March	N	O
63	1	N	O
64	,	N	O
65	2007	N	O
66	(	N	O
67	n	N	O
68	=	N	O
69	104	N	O
70	)	N	O
71	.	N	O

72	Patients	N	O
73	prospectively	N	O
74	provided	N	O
75	functional	N	O
76	and	N	O
77	health-related	N	O
78	quality	N	O
79	of	N	O
80	life	N	O
81	information	N	O
82	,	N	O
83	including	N	O
84	data	N	O
85	from	N	O
86	the	N	O
87	1-year	N	O
88	and	N	O
89	most	N	O
90	current	N	O
91	follow-up	N	O
92	visits	N	O
93	.	N	O

94	Medical	N	O
95	records	N	O
96	were	N	O
97	reviewed	N	O
98	to	N	O
99	determine	N	O
100	toxicity	N	O
101	and	N	O
102	survival	N	O
103	rates	N	O
104	.	N	O

105	Well-defined	N	O
106	acute	N	O
107	and	N	O
108	late	N	O
109	toxicities	N	O
110	;	N	O
111	functional	N	O
112	outcomes	N	O
113	(	N	O
114	diet	N	O
115	,	N	O
116	dentition	N	O
117	,	N	O
118	tracheostomies	N	O
119	)	N	O
120	;	N	O
121	head	N	O
122	and	N	O
123	neck	N	O
124	cancer-specific	N	O
125	,	N	O
126	general	N	O
127	health	N	O
128	,	N	O
129	and	N	O
130	depression	N	O
131	outcomes	N	O
132	;	N	O
133	and	N	O
134	survival	N	O
135	rates	N	O
136	.	N	O

137	Most	N	O
138	patients	N	O
139	had	N	O
140	oropharyngeal	N	O
141	or	N	O
142	laryngeal	N	O
143	tumors	N	O
144	(	N	O
145	87.5	N	O
146	%	N	O
147	)	N	O
148	and	N	O
149	advanced-stage	N	O
150	disease	N	O
151	(	N	O
152	75.0	N	O
153	%	N	O
154	)	N	O
155	.	N	O

156	Approximately	N	I-Premise
157	one-half	N	I-Premise
158	had	N	I-Premise
159	hematologic	N	I-Premise
160	toxicities	N	I-Premise
161	and	N	I-Premise
162	toxicity-related	N	I-Premise
163	treatment	N	I-Premise
164	delays	N	I-Premise
165	.	N	I-Premise

166	Approximately	N	I-Premise
167	one-quarter	N	I-Premise
168	had	N	I-Premise
169	neurotoxicities	N	I-Premise
170	and/or	N	I-Premise
171	ototoxicites	N	I-Premise
172	,	N	I-Premise
173	moist	N	I-Premise
174	desquamation	N	I-Premise
175	,	N	I-Premise
176	pneumonia	N	I-Premise
177	,	N	I-Premise
178	nausea	N	I-Premise
179	and	N	I-Premise
180	vomiting	N	I-Premise
181	requiring	N	I-Premise
182	hospitalization	N	I-Premise
183	or	N	I-Premise
184	intravenous	N	I-Premise
185	fluids	N	I-Premise
186	,	N	I-Premise
187	dehydration	N	I-Premise
188	or	N	I-Premise
189	malnutrition	N	I-Premise
190	requiring	N	I-Premise
191	hospitalization	N	I-Premise
192	,	N	I-Premise
193	and	N	I-Premise
194	mild	N	I-Premise
195	or	N	I-Premise
196	moderate	N	I-Premise
197	fever	N	I-Premise
198	.	N	I-Premise

199	Although	N	I-Premise
200	patients	N	I-Premise
201	receiving	N	I-Premise
202	the	N	I-Premise
203	current	N	I-Premise
204	intensity-modulated	N	I-Premise
205	radiation	N	I-Premise
206	therapy	N	I-Premise
207	(	N	I-Premise
208	IMRT	N	I-Premise
209	)	N	I-Premise
210	protocol	N	I-Premise
211	using	N	I-Premise
212	the	N	I-Premise
213	Pinnacle	N	I-Premise
214	(	N	I-Premise
215	3	N	I-Premise
216	)	N	I-Premise
217	planning	N	I-Premise
218	system	N	I-Premise
219	had	N	I-Premise
220	more	N	I-Premise
221	toxicity-related	N	I-Premise
222	treatment	N	I-Premise
223	delays	N	I-Premise
224	,	N	I-Premise
225	they	N	I-Premise
226	had	N	I-Premise
227	fewer	N	I-Premise
228	toxicities	N	I-Premise
229	and	N	I-Premise
230	better	N	I-Premise
231	functional	N	I-Premise
232	and	N	I-Premise
233	health-related	N	I-Premise
234	quality	N	I-Premise
235	of	N	I-Premise
236	life	N	I-Premise
237	outcomes	N	I-Premise
238	compared	N	I-Premise
239	with	N	I-Premise
240	those	N	I-Premise
241	receiving	N	I-Premise
242	conventional	N	I-Premise
243	lateral	N	I-Premise
244	opposing-field	N	I-Premise
245	radiation	N	I-Premise
246	or	N	I-Premise
247	the	N	I-Premise
248	initial	N	I-Premise
249	IMRT	N	I-Premise
250	protocol	N	I-Premise
251	using	N	I-Premise
252	the	N	I-Premise
253	Best	N	I-Premise
254	nomos	N	I-Premise
255	PEACOCK	N	I-Premise
256	planning	N	I-Premise
257	system	N	I-Premise
258	.	N	I-Premise

259	Patients	N	I-Claim
260	receiving	N	I-Claim
261	CRT	N	I-Claim
262	experience	N	I-Claim
263	a	N	I-Claim
264	substantial	N	I-Claim
265	number	N	I-Claim
266	of	N	I-Claim
267	treatment-related	N	I-Claim
268	adverse	N	I-Claim
269	events	N	I-Claim
270	,	N	I-Claim
271	primarily	N	I-Claim
272	affecting	N	I-Claim
273	oropharyngeal	N	I-Claim
274	and	N	I-Claim
275	laryngeal	N	I-Claim
276	function	N	I-Claim
277	,	N	I-Claim
278	with	N	I-Claim
279	improvement	N	I-Claim
280	noted	N	I-Claim
281	for	N	I-Claim
282	the	N	I-Claim
283	current	N	I-Claim
284	IMRT	N	I-Claim
285	protocol	N	I-Claim
286	.	N	I-Claim

287	Improving	N	O
288	dental	N	O
289	prosthetic	N	O
290	rehabilitation	N	O
291	and	N	O
292	including	N	O
293	evaluations	N	O
294	with	N	O
295	speech	N	O
296	and	N	O
297	swallowing	N	O
298	pathologists	N	O
299	before	N	O
300	and	N	O
301	during	N	O
302	treatment	N	O
303	may	N	O
304	enhance	N	O
305	patient	N	O
306	outcomes	N	O
307	.	N	O

1	Despite	N	O
2	improvements	N	O
3	in	N	O
4	surgical	N	O
5	techniques	N	O
6	,	N	O
7	urinary	N	O
8	incontinence	N	O
9	(	N	O
10	UI	N	O
11	)	N	O
12	is	N	O
13	not	N	O
14	uncommon	N	O
15	after	N	O
16	radical	N	O
17	prostatectomy	N	O
18	(	N	O
19	RP	N	O
20	)	N	O
21	,	N	O
22	and	N	O
23	it	N	O
24	may	N	O
25	dramatically	N	O
26	worsen	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	(	N	O
31	QoL	N	O
32	)	N	O
33	.	N	O

34	To	N	O
35	determine	N	O
36	the	N	O
37	benefit	N	O
38	of	N	O
39	starting	N	O
40	pelvic	N	O
41	floor	N	O
42	muscle	N	O
43	exercise	N	O
44	(	N	O
45	PFME	N	O
46	)	N	O
47	30d	N	O
48	before	N	O
49	RP	N	O
50	and	N	O
51	of	N	O
52	continuing	N	O
53	PFME	N	O
54	postoperatively	N	O
55	for	N	O
56	early	N	O
57	recovery	N	O
58	of	N	O
59	continence	N	O
60	.	N	O

61	A	N	O
62	randomised	N	O
63	,	N	O
64	prospective	N	O
65	study	N	O
66	was	N	O
67	designed	N	O
68	.	N	O

69	Men	N	O
70	with	N	O
71	localised	N	O
72	prostate	N	O
73	cancer	N	O
74	(	N	O
75	PCa	N	O
76	)	N	O
77	who	N	O
78	underwent	N	O
79	an	N	O
80	open	N	O
81	radical	N	O
82	retropubic	N	O
83	prostatectomy	N	O
84	(	N	O
85	RRP	N	O
86	)	N	O
87	at	N	O
88	our	N	O
89	department	N	O
90	of	N	O
91	urology	N	O
92	were	N	O
93	included	N	O
94	.	N	O

95	Patients	N	O
96	were	N	O
97	randomised	N	O
98	to	N	O
99	start	N	O
100	PFME	N	O
101	preoperatively	N	O
102	and	N	O
103	continue	N	O
104	postoperatively	N	O
105	(	N	O
106	active	N	O
107	group	N	O
108	:	N	O
109	A	N	O
110	)	N	O
111	or	N	O
112	to	N	O
113	start	N	O
114	PFME	N	O
115	postoperatively	N	O
116	alone	N	O
117	(	N	O
118	control	N	O
119	group	N	O
120	:	N	O
121	B	N	O
122	)	N	O
123	.	N	O

124	The	N	O
125	primary	N	O
126	outcome	N	O
127	measure	N	O
128	was	N	O
129	self-reported	N	O
130	continence	N	O
131	after	N	O
132	surgery	N	O
133	.	N	O

134	Secondary	N	O
135	outcome	N	O
136	measures	N	O
137	were	N	O
138	assessed	N	O
139	by	N	O
140	degree	N	O
141	of	N	O
142	UI	N	O
143	based	N	O
144	on	N	O
145	a	N	O
146	24-h	N	O
147	pad	N	O
148	test	N	O
149	and	N	O
150	QoL	N	O
151	instruments	N	O
152	(	N	O
153	International	N	O
154	Continence	N	O
155	Society	N	O
156	[	N	O
157	ICS	N	O
158	]	N	O
159	male	N	O
160	short	N	O
161	form	N	O
162	[	N	O
163	SF	N	O
164	]	N	O
165	)	N	O
166	.	N	O

167	Of	N	O
168	143	N	O
169	men	N	O
170	evaluated	N	O
171	for	N	O
172	the	N	O
173	study	N	O
174	,	N	O
175	118	N	O
176	were	N	O
177	randomised	N	O
178	either	N	O
179	to	N	O
180	start	N	O
181	PFME	N	O
182	preoperatively	N	O
183	and	N	O
184	continue	N	O
185	postoperatively	N	O
186	(	N	O
187	group	N	O
188	A	N	O
189	;	N	O
190	n=59	N	O
191	)	N	O
192	or	N	O
193	to	N	O
194	start	N	O
195	postoperative	N	O
196	PFME	N	O
197	(	N	O
198	group	N	O
199	B	N	O
200	;	N	O
201	n=59	N	O
202	)	N	O
203	.	N	O

204	After	N	I-Premise
205	1	N	I-Premise
206	mo	N	I-Premise
207	,	N	I-Premise
208	44.1	N	I-Premise
209	%	N	I-Premise
210	(	N	I-Premise
211	26	N	I-Premise
212	of	N	I-Premise
213	59	N	I-Premise
214	)	N	I-Premise
215	of	N	I-Premise
216	patients	N	I-Premise
217	were	N	I-Premise
218	continent	N	I-Premise
219	in	N	I-Premise
220	group	N	I-Premise
221	A	N	I-Premise
222	,	N	I-Premise
223	while	N	I-Premise
224	20.3	N	I-Premise
225	%	N	I-Premise
226	(	N	I-Premise
227	12	N	I-Premise
228	of	N	I-Premise
229	59	N	I-Premise
230	)	N	I-Premise
231	were	N	I-Premise
232	continent	N	I-Premise
233	in	N	I-Premise
234	group	N	I-Premise
235	B	N	I-Premise
236	(	N	I-Premise
237	p=0.018	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	At	N	I-Premise
241	3	N	I-Premise
242	mo	N	I-Premise
243	,	N	I-Premise
244	59.3	N	I-Premise
245	%	N	I-Premise
246	(	N	I-Premise
247	35	N	I-Premise
248	of	N	I-Premise
249	59	N	I-Premise
250	)	N	I-Premise
251	and	N	I-Premise
252	37.3	N	I-Premise
253	%	N	I-Premise
254	(	N	I-Premise
255	22	N	I-Premise
256	of	N	I-Premise
257	59	N	I-Premise
258	)	N	I-Premise
259	patients	N	I-Premise
260	were	N	I-Premise
261	continent	N	I-Premise
262	in	N	I-Premise
263	group	N	I-Premise
264	A	N	I-Premise
265	and	N	I-Premise
266	group	N	I-Premise
267	B	N	I-Premise
268	,	N	I-Premise
269	respectively	N	I-Premise
270	(	N	I-Premise
271	p=0.028	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	The	N	I-Premise
275	ICS	N	I-Premise
276	male	N	I-Premise
277	SF	N	I-Premise
278	mean	N	I-Premise
279	score	N	I-Premise
280	showed	N	I-Premise
281	better	N	I-Premise
282	results	N	I-Premise
283	in	N	I-Premise
284	group	N	I-Premise
285	A	N	I-Premise
286	than	N	I-Premise
287	in	N	I-Premise
288	group	N	I-Premise
289	B	N	I-Premise
290	patients	N	I-Premise
291	at	N	I-Premise
292	both	N	I-Premise
293	1	N	I-Premise
294	mo	N	I-Premise
295	(	N	I-Premise
296	14.6	N	I-Premise
297	vs	N	I-Premise
298	18.3	N	I-Premise
299	)	N	I-Premise
300	and	N	I-Premise
301	3	N	I-Premise
302	mo	N	I-Premise
303	(	N	I-Premise
304	8.1	N	I-Premise
305	vs	N	I-Premise
306	12.2	N	I-Premise
307	)	N	I-Premise
308	after	N	I-Premise
309	RP	N	I-Premise
310	(	N	I-Premise
311	p=0.002	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	In	N	I-Premise
315	age-adjusted	N	I-Premise
316	logistic	N	I-Premise
317	regression	N	I-Premise
318	analyses	N	I-Premise
319	,	N	I-Premise
320	patients	N	I-Premise
321	who	N	I-Premise
322	performed	N	I-Premise
323	preoperative	N	I-Premise
324	PFME	N	I-Premise
325	had	N	I-Premise
326	a	N	I-Premise
327	0.41-fold	N	I-Premise
328	lower	N	I-Premise
329	risk	N	I-Premise
330	of	N	I-Premise
331	being	N	I-Premise
332	incontinent	N	I-Premise
333	1	N	I-Premise
334	mo	N	I-Premise
335	after	N	I-Premise
336	RP	N	I-Premise
337	and	N	I-Premise
338	a	N	I-Premise
339	0.38-fold	N	I-Premise
340	lower	N	I-Premise
341	risk	N	I-Premise
342	of	N	I-Premise
343	being	N	I-Premise
344	incontinent	N	I-Premise
345	3	N	I-Premise
346	mo	N	I-Premise
347	after	N	I-Premise
348	RP	N	I-Premise
349	(	N	I-Premise
350	pâ¤0.001	N	I-Premise
351	)	N	I-Premise
352	.	N	I-Premise

353	Preoperative	N	I-Claim
354	PFME	N	I-Claim
355	may	N	I-Claim
356	improve	N	I-Claim
357	early	N	I-Claim
358	continence	N	I-Claim
359	and	N	I-Claim
360	QoL	N	I-Claim
361	outcomes	N	I-Claim
362	after	N	I-Claim
363	RP	N	I-Claim
364	.	N	I-Claim

365	Further	N	I-Claim
366	studies	N	I-Claim
367	are	N	I-Claim
368	needed	N	I-Claim
369	to	N	I-Claim
370	corroborate	N	I-Claim
371	our	N	I-Claim
372	results	N	I-Claim
373	.	N	I-Claim

1	In	N	O
2	anorectal	N	O
3	cancer	N	O
4	patients	N	O
5	,	N	O
6	an	N	O
7	acute	N	O
8	side	N	O
9	effect	N	O
10	of	N	O
11	chemoradiotherapy	N	O
12	is	N	O
13	gastrointestinal	N	O
14	toxicity	N	O
15	,	N	O
16	which	N	O
17	often	N	O
18	impedes	N	O
19	treatment	N	O
20	delivery	N	O
21	.	N	O

22	Based	N	O
23	on	N	O
24	previous	N	O
25	trials	N	O
26	,	N	O
27	octreotide	N	O
28	acetate	N	O
29	is	N	O
30	widely	N	O
31	recommended	N	O
32	for	N	O
33	the	N	O
34	control	N	O
35	of	N	O
36	chemotherapy-induced	N	O
37	diarrhea	N	O
38	.	N	O

39	However	N	O
40	,	N	O
41	the	N	O
42	effectiveness	N	O
43	of	N	O
44	octreotide	N	O
45	in	N	O
46	preventing	N	O
47	or	N	O
48	controlling	N	O
49	radiation-	N	O
50	and	N	O
51	chemoradiation-induced	N	O
52	diarrhea	N	O
53	is	N	O
54	not	N	O
55	known	N	O
56	.	N	O

57	A	N	O
58	randomized	N	O
59	,	N	O
60	double-blinded	N	O
61	,	N	O
62	placebo-controlled	N	O
63	trial	N	O
64	was	N	O
65	designed	N	O
66	to	N	O
67	determine	N	O
68	the	N	O
69	efficacy	N	O
70	of	N	O
71	long-acting	N	O
72	octreotide	N	O
73	acetate	N	O
74	(	N	O
75	LAO	N	O
76	)	N	O
77	in	N	O
78	preventing	N	O
79	the	N	O
80	onset	N	O
81	of	N	O
82	acute	N	O
83	diarrhea	N	O
84	in	N	O
85	patients	N	O
86	undergoing	N	O
87	chemoradiation	N	O
88	therapy	N	O
89	for	N	O
90	rectal	N	O
91	or	N	O
92	anal	N	O
93	cancer	N	O
94	.	N	O

95	Between	N	O
96	4	N	O
97	and	N	O
98	7	N	O
99	days	N	O
100	before	N	O
101	the	N	O
102	start	N	O
103	of	N	O
104	radiation	N	O
105	therapy	N	O
106	,	N	O
107	patients	N	O
108	received	N	O
109	a	N	O
110	30-mg	N	O
111	dose	N	O
112	of	N	O
113	LAO	N	O
114	(	N	O
115	109	N	O
116	patients	N	O
117	)	N	O
118	or	N	O
119	placebo	N	O
120	(	N	O
121	106	N	O
122	patients	N	O
123	)	N	O
124	via	N	O
125	intramuscular	N	O
126	injection	N	O
127	.	N	O

128	A	N	O
129	second	N	O
130	dose	N	O
131	was	N	O
132	given	N	O
133	on	N	O
134	day	N	O
135	22	N	O
136	(	N	O
137	+/-3	N	O
138	days	N	O
139	)	N	O
140	of	N	O
141	radiation	N	O
142	treatment	N	O
143	.	N	O

144	A	N	O
145	total	N	O
146	of	N	O
147	215	N	O
148	patients	N	O
149	were	N	O
150	included	N	O
151	in	N	O
152	the	N	O
153	final	N	O
154	analysis	N	O
155	.	N	O

156	The	N	O
157	primary	N	O
158	endpoint	N	O
159	was	N	O
160	the	N	O
161	incidence	N	O
162	of	N	O
163	grade	N	O
164	2-4	N	O
165	acute	N	O
166	diarrhea	N	O
167	;	N	O
168	secondary	N	O
169	endpoints	N	O
170	included	N	O
171	treatment	N	O
172	compliance	N	O
173	,	N	O
174	medical	N	O
175	resource	N	O
176	utilization	N	O
177	,	N	O
178	patient-reported	N	O
179	bowel	N	O
180	function	N	O
181	,	N	O
182	and	N	O
183	quality	N	O
184	of	N	O
185	life	N	O
186	(	N	O
187	QoL	N	O
188	)	N	O
189	.	N	O

190	Statistical	N	O
191	tests	N	O
192	were	N	O
193	one-	N	O
194	or	N	O
195	two-sided	N	O
196	,	N	O
197	as	N	O
198	specified	N	O
199	.	N	O

200	After	N	I-Premise
201	a	N	I-Premise
202	median	N	I-Premise
203	follow-up	N	I-Premise
204	time	N	I-Premise
205	of	N	I-Premise
206	9.64	N	I-Premise
207	months	N	I-Premise
208	,	N	I-Premise
209	incidence	N	I-Premise
210	rates	N	I-Premise
211	of	N	I-Premise
212	grades	N	I-Premise
213	2-4	N	I-Premise
214	acute	N	I-Premise
215	diarrhea	N	I-Premise
216	were	N	I-Premise
217	similar	N	I-Premise
218	in	N	I-Premise
219	both	N	I-Premise
220	groups	N	I-Premise
221	(	N	I-Premise
222	49	N	I-Premise
223	%	N	I-Premise
224	placebo	N	I-Premise
225	vs	N	I-Premise
226	44	N	I-Premise
227	%	N	I-Premise
228	LAO	N	I-Premise
229	;	N	I-Premise
230	P	N	I-Premise
231	=	N	I-Premise
232	.21	N	I-Premise
233	)	N	I-Premise
234	.	N	I-Premise

235	No	N	I-Premise
236	statistically	N	I-Premise
237	significant	N	I-Premise
238	treatment	N	I-Premise
239	differences	N	I-Premise
240	in	N	I-Premise
241	chemotherapy	N	I-Premise
242	or	N	I-Premise
243	radiation	N	I-Premise
244	delivery	N	I-Premise
245	,	N	I-Premise
246	medical	N	I-Premise
247	resource	N	I-Premise
248	utilization	N	I-Premise
249	,	N	I-Premise
250	patient-reported	N	I-Premise
251	bowel	N	I-Premise
252	function	N	I-Premise
253	,	N	I-Premise
254	or	N	I-Premise
255	QoL	N	I-Premise
256	were	N	I-Premise
257	observed	N	I-Premise
258	.	N	I-Premise

259	In	N	I-Claim
260	this	N	I-Claim
261	study	N	I-Claim
262	,	N	I-Claim
263	the	N	I-Claim
264	prophylactic	N	I-Claim
265	use	N	I-Claim
266	of	N	I-Claim
267	LAO	N	I-Claim
268	did	N	I-Claim
269	not	N	I-Claim
270	prevent	N	I-Claim
271	the	N	I-Claim
272	incidence	N	I-Claim
273	or	N	I-Claim
274	reduce	N	I-Claim
275	the	N	I-Claim
276	severity	N	I-Claim
277	of	N	I-Claim
278	diarrhea	N	I-Claim
279	and	N	I-Claim
280	had	N	I-Claim
281	no	N	I-Claim
282	notable	N	I-Claim
283	impact	N	I-Claim
284	on	N	I-Claim
285	patient-reported	N	I-Claim
286	bowel	N	I-Claim
287	function	N	I-Claim
288	or	N	I-Claim
289	QoL	N	I-Claim
290	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	vinflunine	N	O
4	(	N	O
5	VFL	N	O
6	)	N	O
7	to	N	O
8	docetaxel	N	O
9	in	N	O
10	patients	N	O
11	with	N	O
12	stage	N	O
13	IIIB/IV	N	O
14	non-small-cell	N	O
15	lung	N	O
16	cancer	N	O
17	(	N	O
18	NSCLC	N	O
19	)	N	O
20	who	N	O
21	have	N	O
22	experienced	N	O
23	treatment	N	O
24	failure	N	O
25	with	N	O
26	first-line	N	O
27	platinum-based	N	O
28	chemotherapy	N	O
29	.	N	O

30	Randomized	N	O
31	,	N	O
32	multicenter	N	O
33	,	N	O
34	phase	N	O
35	III	N	O
36	study	N	O
37	,	N	O
38	551	N	O
39	patients	N	O
40	received	N	O
41	either	N	O
42	vinflunine	N	O
43	320	N	O
44	mg/m	N	O
45	(	N	O
46	2	N	O
47	)	N	O
48	or	N	O
49	docetaxel	N	O
50	75	N	O
51	mg/m	N	O
52	(	N	O
53	2	N	O
54	)	N	O
55	every	N	O
56	21	N	O
57	days	N	O
58	until	N	O
59	disease	N	O
60	progression	N	O
61	or	N	O
62	serious	N	O
63	toxicity	N	O
64	.	N	O

65	The	N	O
66	primary	N	O
67	end	N	O
68	point	N	O
69	was	N	O
70	progression-free	N	O
71	survival	N	O
72	(	N	O
73	PFS	N	O
74	)	N	O
75	.	N	O

76	The	N	O
77	noninferiority	N	O
78	analysis	N	O
79	was	N	O
80	based	N	O
81	on	N	O
82	a	N	O
83	10	N	O
84	%	N	O
85	difference	N	O
86	(	N	O
87	types	N	O
88	I/II	N	O
89	error	N	O
90	rates	N	O
91	:	N	O
92	5	N	O
93	%	N	O
94	/20	N	O
95	%	N	O
96	)	N	O
97	.	N	O

98	Secondary	N	O
99	end	N	O
100	points	N	O
101	included	N	O
102	response	N	O
103	rate	N	O
104	(	N	O
105	ORR	N	O
106	)	N	O
107	,	N	O
108	response	N	O
109	duration	N	O
110	,	N	O
111	overall	N	O
112	survival	N	O
113	(	N	O
114	OS	N	O
115	)	N	O
116	,	N	O
117	clinical	N	O
118	benefit	N	O
119	,	N	O
120	quality	N	O
121	of	N	O
122	life	N	O
123	(	N	O
124	QOL	N	O
125	)	N	O
126	,	N	O
127	and	N	O
128	safety	N	O
129	.	N	O

130	Median	N	I-Premise
131	PFS	N	I-Premise
132	was	N	I-Premise
133	2.3	N	I-Premise
134	months	N	I-Premise
135	for	N	I-Premise
136	each	N	I-Premise
137	arm	N	I-Premise
138	(	N	I-Premise
139	HR	N	I-Premise
140	,	N	I-Premise
141	1.004	N	I-Premise
142	;	N	I-Premise
143	95	N	I-Premise
144	%	N	I-Premise
145	CI	N	I-Premise
146	,	N	I-Premise
147	0.841	N	I-Premise
148	to	N	I-Premise
149	1.199	N	I-Premise
150	)	N	I-Premise
151	.	N	I-Premise

152	ORR	N	I-Premise
153	,	N	I-Premise
154	stable	N	I-Premise
155	disease	N	I-Premise
156	,	N	I-Premise
157	median	N	I-Premise
158	OS	N	I-Premise
159	,	N	I-Premise
160	were	N	I-Premise
161	4.4	N	I-Premise
162	%	N	I-Premise
163	versus	N	I-Premise
164	5.5	N	I-Premise
165	%	N	I-Premise
166	,	N	I-Premise
167	36.0	N	I-Premise
168	%	N	I-Premise
169	versus	N	I-Premise
170	39.6	N	I-Premise
171	%	N	I-Premise
172	,	N	I-Premise
173	6.7	N	I-Premise
174	versus	N	I-Premise
175	7.2	N	I-Premise
176	months	N	I-Premise
177	(	N	I-Premise
178	HR	N	I-Premise
179	,	N	I-Premise
180	0.973	N	I-Premise
181	;	N	I-Premise
182	95	N	I-Premise
183	%	N	I-Premise
184	CI	N	I-Premise
185	,	N	I-Premise
186	0.805	N	I-Premise
187	to	N	I-Premise
188	1.176	N	I-Premise
189	)	N	I-Premise
190	,	N	I-Premise
191	respectively	N	I-Premise
192	.	N	I-Premise

193	No	N	I-Premise
194	significant	N	I-Premise
195	difference	N	I-Premise
196	in	N	I-Premise
197	patient	N	I-Premise
198	benefit	N	I-Premise
199	and	N	I-Premise
200	QOL	N	I-Premise
201	(	N	I-Premise
202	Functional	N	I-Premise
203	Assessment	N	I-Premise
204	of	N	I-Premise
205	Cancer	N	I-Premise
206	Therapy-Lung	N	I-Premise
207	)	N	I-Premise
208	.	N	I-Premise

209	No	N	I-Premise
210	unexpected	N	I-Premise
211	adverse	N	I-Premise
212	events	N	I-Premise
213	were	N	I-Premise
214	observed	N	I-Premise
215	.	N	I-Premise

216	Grade	N	I-Premise
217	higher	N	I-Premise
218	than	N	I-Premise
219	0	N	I-Premise
220	(	N	I-Premise
221	vinflunine	N	I-Premise
222	v	N	I-Premise
223	docetaxel	N	I-Premise
224	)	N	I-Premise
225	anemia	N	I-Premise
226	(	N	I-Premise
227	82.1	N	I-Premise
228	%	N	I-Premise
229	v	N	I-Premise
230	79.8	N	I-Premise
231	%	N	I-Premise
232	)	N	I-Premise
233	,	N	I-Premise
234	neutropenia	N	I-Premise
235	(	N	I-Premise
236	49.3	N	I-Premise
237	v	N	I-Premise
238	39.02	N	I-Premise
239	%	N	I-Premise
240	)	N	I-Premise
241	,	N	I-Premise
242	thrombocytopenia	N	I-Premise
243	(	N	I-Premise
244	30.6	N	I-Premise
245	%	N	I-Premise
246	v	N	I-Premise
247	14.3	N	I-Premise
248	%	N	I-Premise
249	)	N	I-Premise
250	,	N	I-Premise
251	febrile	N	I-Premise
252	neutropenia	N	I-Premise
253	(	N	I-Premise
254	3.3	N	I-Premise
255	%	N	I-Premise
256	v	N	I-Premise
257	4.7	N	I-Premise
258	%	N	I-Premise
259	)	N	I-Premise
260	,	N	I-Premise
261	constipation	N	I-Premise
262	(	N	I-Premise
263	39.2	N	I-Premise
264	%	N	I-Premise
265	v	N	I-Premise
266	11.7	N	I-Premise
267	%	N	I-Premise
268	)	N	I-Premise
269	,	N	I-Premise
270	fatigue	N	I-Premise
271	(	N	I-Premise
272	36.6	N	I-Premise
273	%	N	I-Premise
274	v	N	I-Premise
275	33.9	N	I-Premise
276	%	N	I-Premise
277	)	N	I-Premise
278	,	N	I-Premise
279	injection	N	I-Premise
280	site	N	I-Premise
281	reaction	N	I-Premise
282	(	N	I-Premise
283	31.9	N	I-Premise
284	%	N	I-Premise
285	v	N	I-Premise
286	0.7	N	I-Premise
287	%	N	I-Premise
288	)	N	I-Premise
289	,	N	I-Premise
290	nausea	N	I-Premise
291	(	N	I-Premise
292	26.7	N	I-Premise
293	%	N	I-Premise
294	v	N	I-Premise
295	23.7	N	I-Premise
296	%	N	I-Premise
297	)	N	I-Premise
298	,	N	I-Premise
299	vomiting	N	I-Premise
300	(	N	I-Premise
301	23.8	N	I-Premise
302	%	N	I-Premise
303	v	N	I-Premise
304	14.2	N	I-Premise
305	%	N	I-Premise
306	)	N	I-Premise
307	,	N	I-Premise
308	alopecia	N	I-Premise
309	(	N	I-Premise
310	19.8	N	I-Premise
311	%	N	I-Premise
312	v	N	I-Premise
313	35.4	N	I-Premise
314	%	N	I-Premise
315	)	N	I-Premise
316	,	N	I-Premise
317	stomatis	N	I-Premise
318	(	N	I-Premise
319	19.4	N	I-Premise
320	%	N	I-Premise
321	v	N	I-Premise
322	12.4	N	I-Premise
323	%	N	I-Premise
324	)	N	I-Premise
325	,	N	I-Premise
326	abdominal	N	I-Premise
327	pain	N	I-Premise
328	(	N	I-Premise
329	20.1	N	I-Premise
330	%	N	I-Premise
331	v	N	I-Premise
332	3.6	N	I-Premise
333	%	N	I-Premise
334	)	N	I-Premise
335	,	N	I-Premise
336	myalgia	N	I-Premise
337	(	N	I-Premise
338	14.7	N	I-Premise
339	%	N	I-Premise
340	v	N	I-Premise
341	6.6	N	I-Premise
342	%	N	I-Premise
343	)	N	I-Premise
344	,	N	I-Premise
345	peripheral	N	I-Premise
346	neuropathy	N	I-Premise
347	(	N	I-Premise
348	10.7	N	I-Premise
349	%	N	I-Premise
350	v	N	I-Premise
351	15.0	N	I-Premise
352	%	N	I-Premise
353	)	N	I-Premise
354	,	N	I-Premise
355	arthralgia	N	I-Premise
356	(	N	I-Premise
357	7.0	N	I-Premise
358	%	N	I-Premise
359	v	N	I-Premise
360	7.7	N	I-Premise
361	%	N	I-Premise
362	)	N	I-Premise
363	,	N	I-Premise
364	diarrhea	N	I-Premise
365	(	N	I-Premise
366	6.2	N	I-Premise
367	%	N	I-Premise
368	v	N	I-Premise
369	12.4	N	I-Premise
370	%	N	I-Premise
371	)	N	I-Premise
372	,	N	I-Premise
373	edema	N	I-Premise
374	(	N	I-Premise
375	1.5	N	I-Premise
376	%	N	I-Premise
377	v	N	I-Premise
378	5.4	N	I-Premise
379	%	N	I-Premise
380	)	N	I-Premise
381	,	N	I-Premise
382	and	N	I-Premise
383	nail	N	I-Premise
384	disorders	N	I-Premise
385	(	N	I-Premise
386	1.1	N	I-Premise
387	%	N	I-Premise
388	v	N	I-Premise
389	5	N	I-Premise
390	;	N	I-Premise
391	1	N	I-Premise
392	%	N	I-Premise
393	)	N	I-Premise
394	were	N	I-Premise
395	observed	N	I-Premise
396	.	N	I-Premise

397	This	N	I-Claim
398	noninferiority	N	I-Claim
399	phase	N	I-Claim
400	III	N	I-Claim
401	study	N	I-Claim
402	showed	N	I-Claim
403	similar	N	I-Claim
404	efficacy	N	I-Claim
405	end	N	I-Claim
406	points	N	I-Claim
407	for	N	I-Claim
408	vinflunine	N	I-Claim
409	and	N	I-Claim
410	docetaxel	N	I-Claim
411	.	N	I-Claim

412	Despite	N	I-Claim
413	higher	N	I-Claim
414	rates	N	I-Claim
415	of	N	I-Claim
416	some	N	I-Claim
417	adverse	N	I-Claim
418	effects	N	I-Claim
419	(	N	I-Claim
420	anemia	N	I-Claim
421	,	N	I-Claim
422	abdominal	N	I-Claim
423	pain	N	I-Claim
424	,	N	I-Claim
425	constipation	N	I-Claim
426	,	N	I-Claim
427	fatigue	N	I-Claim
428	)	N	I-Claim
429	the	N	I-Claim
430	overall	N	I-Claim
431	toxicity	N	I-Claim
432	profile	N	I-Claim
433	of	N	I-Claim
434	vinflunine	N	I-Claim
435	was	N	I-Claim
436	manageable	N	I-Claim
437	.	N	I-Claim

438	Therefore	N	O
439	,	N	O
440	VFL	N	I-MajorClaim
441	may	N	I-MajorClaim
442	be	N	I-MajorClaim
443	another	N	I-MajorClaim
444	option	N	I-MajorClaim
445	in	N	I-MajorClaim
446	the	N	I-MajorClaim
447	second-line	N	I-MajorClaim
448	treatment	N	I-MajorClaim
449	of	N	I-MajorClaim
450	patients	N	I-MajorClaim
451	with	N	I-MajorClaim
452	advanced	N	I-MajorClaim
453	NSCLC	N	I-MajorClaim
454	.	N	I-MajorClaim

1	A	N	O
2	significant	N	O
3	proportion	N	O
4	of	N	O
5	patients	N	O
6	develop	N	O
7	urinary	N	O
8	incontinence	N	O
9	early	N	O
10	after	N	O
11	radical	N	O
12	prostatectomy	N	O
13	.	N	O

14	Posterior	N	O
15	reconstruction	N	O
16	of	N	O
17	supporting	N	O
18	tissues	N	O
19	has	N	O
20	been	N	O
21	found	N	O
22	to	N	O
23	reduce	N	O
24	incontinence	N	O
25	in	N	O
26	open	N	O
27	and	N	O
28	conventional	N	O
29	laparoscopic	N	O
30	prostatectomy	N	O
31	series	N	O
32	.	N	O

33	To	N	O
34	investigate	N	O
35	whether	N	O
36	our	N	O
37	version	N	O
38	of	N	O
39	a	N	O
40	posterior	N	O
41	musculofascial	N	O
42	reconstruction	N	O
43	will	N	O
44	reduce	N	O
45	early	N	O
46	incontinence	N	O
47	and	N	O
48	have	N	O
49	a	N	O
50	beneficial	N	O
51	effect	N	O
52	on	N	O
53	patients	N	O
54	'	N	O
55	quality	N	O
56	of	N	O
57	life	N	O
58	(	N	O
59	QoL	N	O
60	)	N	O
61	.	N	O

62	One	N	O
63	hundred	N	O
64	seven	N	O
65	consecutive	N	O
66	patients	N	O
67	undergoing	N	O
68	primary	N	O
69	robot-assisted	N	O
70	radical	N	O
71	laparoscopic	N	O
72	prostatectomy	N	O
73	(	N	O
74	RALP	N	O
75	)	N	O
76	performed	N	O
77	by	N	O
78	a	N	O
79	single	N	O
80	surgeon	N	O
81	at	N	O
82	one	N	O
83	tertiary	N	O
84	referral	N	O
85	oncology	N	O
86	institution	N	O
87	were	N	O
88	alternately	N	O
89	assigned	N	O
90	(	N	O
91	not	N	O
92	randomised	N	O
93	)	N	O
94	to	N	O
95	intervention	N	O
96	(	N	O
97	n=53	N	O
98	)	N	O
99	or	N	O
100	control	N	O
101	groups	N	O
102	(	N	O
103	n=54	N	O
104	)	N	O
105	.	N	O

106	RALP	N	O
107	with	N	O
108	median	N	O
109	fibrous	N	O
110	raphe	N	O
111	reconstruction	N	O
112	(	N	O
113	MFRR	N	O
114	)	N	O
115	followed	N	O
116	by	N	O
117	formation	N	O
118	of	N	O
119	the	N	O
120	urethrovesical	N	O
121	anastomosis	N	O
122	(	N	O
123	intervention	N	O
124	group	N	O
125	)	N	O
126	versus	N	O
127	standard	N	O
128	anastomosis	N	O
129	without	N	O
130	posterior	N	O
131	reconstruction	N	O
132	(	N	O
133	control	N	O
134	group	N	O
135	)	N	O
136	.	N	O

137	Measurements	N	O
138	included	N	O
139	incontinence	N	O
140	at	N	O
141	baseline	N	O
142	and	N	O
143	3-mo	N	O
144	intervals	N	O
145	;	N	O
146	QoL	N	O
147	as	N	O
148	measured	N	O
149	by	N	O
150	a	N	O
151	simple	N	O
152	questionnaire	N	O
153	,	N	O
154	the	N	O
155	European	N	O
156	Organisation	N	O
157	for	N	O
158	Research	N	O
159	and	N	O
160	Treatment	N	O
161	of	N	O
162	Cancer	N	O
163	(	N	O
164	EORTC	N	O
165	)	N	O
166	Quality	N	O
167	of	N	O
168	Life-Core	N	O
169	30	N	O
170	(	N	O
171	QLQ-C30	N	O
172	)	N	O
173	,	N	O
174	and	N	O
175	Prostate	N	O
176	Cancer	N	O
177	Module	N	O
178	(	N	O
179	PR25	N	O
180	)	N	O
181	questionnaires	N	O
182	preoperatively	N	O
183	and	N	O
184	at	N	O
185	6	N	O
186	mo	N	O
187	postprocedure	N	O
188	;	N	O
189	tumour	N	O
190	characteristics	N	O
191	;	N	O
192	operative	N	O
193	time	N	O
194	;	N	O
195	fascial	N	O
196	preservation	N	O
197	score	N	O
198	;	N	O
199	duration	N	O
200	of	N	O
201	catheterisation	N	O
202	;	N	O
203	and	N	O
204	anastomotic	N	O
205	leakage	N	O
206	on	N	O
207	cystogram	N	O
208	.	N	O

209	For	N	I-Premise
210	intervention	N	I-Premise
211	and	N	I-Premise
212	control	N	I-Premise
213	groups	N	I-Premise
214	respectively	N	I-Premise
215	,	N	I-Premise
216	mean	N	I-Premise
217	catheter	N	I-Premise
218	duration	N	I-Premise
219	was	N	I-Premise
220	11.74	N	I-Premise
221	d	N	I-Premise
222	and	N	I-Premise
223	12.74	N	I-Premise
224	d	N	I-Premise
225	(	N	I-Premise
226	p=0.451	N	I-Premise
227	)	N	I-Premise
228	;	N	I-Premise
229	leakage	N	I-Premise
230	on	N	I-Premise
231	cystogram	N	I-Premise
232	was	N	I-Premise
233	present	N	I-Premise
234	in	N	I-Premise
235	six	N	I-Premise
236	and	N	I-Premise
237	eight	N	I-Premise
238	cases	N	I-Premise
239	(	N	I-Premise
240	p=0.28	N	I-Premise
241	)	N	I-Premise
242	;	N	I-Premise
243	and	N	I-Premise
244	incontinence	N	I-Premise
245	(	N	I-Premise
246	any	N	I-Premise
247	involuntary	N	I-Premise
248	urine	N	I-Premise
249	loss	N	I-Premise
250	)	N	I-Premise
251	at	N	I-Premise
252	3	N	I-Premise
253	mo	N	I-Premise
254	was	N	I-Premise
255	75	N	I-Premise
256	%	N	I-Premise
257	and	N	I-Premise
258	69	N	I-Premise
259	%	N	I-Premise
260	(	N	I-Premise
261	p=0.391	N	I-Premise
262	)	N	I-Premise
263	and	N	I-Premise
264	at	N	I-Premise
265	6	N	I-Premise
266	mo	N	I-Premise
267	was	N	I-Premise
268	51	N	I-Premise
269	%	N	I-Premise
270	and	N	I-Premise
271	43	N	I-Premise
272	%	N	I-Premise
273	(	N	I-Premise
274	p=0.686	N	I-Premise
275	)	N	I-Premise
276	.	N	I-Premise

277	Urinary	N	I-Premise
278	retention	N	I-Premise
279	occurred	N	I-Premise
280	only	N	I-Premise
281	in	N	I-Premise
282	one	N	I-Premise
283	case	N	I-Premise
284	(	N	I-Premise
285	control	N	I-Premise
286	group	N	I-Premise
287	)	N	I-Premise
288	.	N	I-Premise

289	The	N	I-Premise
290	percentage	N	I-Premise
291	of	N	I-Premise
292	cases	N	I-Premise
293	returning	N	I-Premise
294	to	N	I-Premise
295	baseline	N	I-Premise
296	in	N	I-Premise
297	all	N	I-Premise
298	QoL	N	I-Premise
299	domains	N	I-Premise
300	(	N	I-Premise
301	except	N	I-Premise
302	insomnia	N	I-Premise
303	)	N	I-Premise
304	was	N	I-Premise
305	similar	N	I-Premise
306	at	N	I-Premise
307	6	N	I-Premise
308	mo	N	I-Premise
309	between	N	I-Premise
310	the	N	I-Premise
311	two	N	I-Premise
312	groups	N	I-Premise
313	.	N	I-Premise

314	Short	N	I-Premise
315	follow-up	N	I-Premise
316	,	N	I-Premise
317	lack	N	I-Premise
318	of	N	I-Premise
319	blinding	N	I-Premise
320	,	N	I-Premise
321	and	N	I-Premise
322	probable	N	I-Premise
323	small	N	I-Premise
324	differences	N	I-Premise
325	in	N	I-Premise
326	our	N	I-Premise
327	method	N	I-Premise
328	of	N	I-Premise
329	MFRR	N	I-Premise
330	performed	N	I-Premise
331	compared	N	I-Premise
332	with	N	I-Premise
333	other	N	I-Premise
334	studies	N	I-Premise
335	were	N	I-Premise
336	identified	N	I-Premise
337	as	N	I-Premise
338	significant	N	I-Premise
339	limitations	N	I-Premise
340	.	N	I-Premise

341	No	N	I-Premise
342	significant	N	I-Premise
343	difference	N	I-Premise
344	in	N	I-Premise
345	any	N	I-Premise
346	of	N	I-Premise
347	the	N	I-Premise
348	analysed	N	I-Premise
349	outcome	N	I-Premise
350	measures	N	I-Premise
351	was	N	I-Premise
352	observed	N	I-Premise
353	.	N	I-Premise

354	Posterior	N	I-Claim
355	reconstruction	N	I-Claim
356	of	N	I-Claim
357	the	N	I-Claim
358	musculofascial	N	I-Claim
359	complex	N	I-Claim
360	does	N	I-Claim
361	not	N	I-Claim
362	appear	N	I-Claim
363	to	N	I-Claim
364	improve	N	I-Claim
365	early	N	I-Claim
366	urinary	N	I-Claim
367	incontinence	N	I-Claim
368	after	N	I-Claim
369	RALP	N	I-Claim
370	.	N	I-Claim

1	The	N	O
2	role	N	O
3	of	N	O
4	chemotherapy	N	O
5	for	N	O
6	advanced	N	O
7	NSCLC	N	O
8	patients	N	O
9	and	N	O
10	ECOG	N	O
11	PS2	N	O
12	remains	N	O
13	controversial	N	O
14	.	N	O

15	We	N	O
16	evaluated	N	O
17	4	N	O
18	doses	N	O
19	of	N	O
20	3-weekly	N	O
21	docetaxel	N	O
22	to	N	O
23	identify	N	O
24	a	N	O
25	less	N	O
26	toxic	N	O
27	,	N	O
28	clinically	N	O
29	effective	N	O
30	dose	N	O
31	.	N	O

32	Seventy-three	N	O
33	patients	N	O
34	with	N	O
35	stage	N	O
36	III	N	O
37	(	N	O
38	22	N	O
39	%	N	O
40	)	N	O
41	(	N	O
42	unsuitable	N	O
43	for	N	O
44	radical	N	O
45	surgery/radiotherapy	N	O
46	)	N	O
47	and	N	O
48	IV	N	O
49	(	N	O
50	78	N	O
51	%	N	O
52	)	N	O
53	NSCLC	N	O
54	were	N	O
55	randomized	N	O
56	to	N	O
57	receive	N	O
58	4	N	O
59	doses	N	O
60	of	N	O
61	3-weekly	N	O
62	docetaxel	N	O
63	,	N	O
64	for	N	O
65	4	N	O
66	cycles	N	O
67	:	N	O
68	arm	N	O
69	(	N	O
70	A	N	O
71	)	N	O
72	40	N	O
73	mg/m	N	O
74	(	N	O
75	2	N	O
76	)	N	O
77	(	N	O
78	n=17	N	O
79	)	N	O
80	,	N	O
81	arm	N	O
82	(	N	O
83	B	N	O
84	)	N	O
85	50	N	O
86	mg/m	N	O
87	(	N	O
88	2	N	O
89	)	N	O
90	(	N	O
91	n=17	N	O
92	)	N	O
93	,	N	O
94	arm	N	O
95	(	N	O
96	C	N	O
97	)	N	O
98	60	N	O
99	mg/m	N	O
100	(	N	O
101	2	N	O
102	)	N	O
103	(	N	O
104	n=19	N	O
105	)	N	O
106	,	N	O
107	arm	N	O
108	(	N	O
109	D	N	O
110	)	N	O
111	50	N	O
112	mg/m	N	O
113	(	N	O
114	2	N	O
115	)	N	O
116	escalated	N	O
117	by	N	O
118	10	N	O
119	mg/m	N	O
120	(	N	O
121	2	N	O
122	)	N	O
123	to	N	O
124	a	N	O
125	maximum	N	O
126	of	N	O
127	70	N	O
128	mg/m	N	O
129	(	N	O
130	2	N	O
131	)	N	O
132	(	N	O
133	n=19	N	O
134	)	N	O
135	.	N	O

136	Primary	N	O
137	endpoints	N	O
138	:	N	O
139	maximum	N	O
140	tolerated	N	O
141	dose	N	O
142	,	N	O
143	RR	N	O
144	,	N	O
145	duration	N	O
146	of	N	O
147	response	N	O
148	,	N	O
149	symptom	N	O
150	improvement	N	O
151	,	N	O
152	toxicity	N	O
153	and	N	O
154	QoL	N	O
155	.	N	O

156	Secondary	N	O
157	endpoint	N	O
158	:	N	O
159	overall	N	O
160	survival	N	O
161	(	N	O
162	OS	N	O
163	)	N	O
164	.	N	O

165	Patients	N	O
166	and	N	O
167	disease	N	O
168	characteristics	N	O
169	were	N	O
170	well	N	O
171	balanced	N	O
172	.	N	O

173	Median	N	O
174	age	N	O
175	was	N	O
176	67	N	O
177	(	N	O
178	range	N	O
179	45-81	N	O
180	)	N	O
181	,	N	O
182	there	N	O
183	were	N	O
184	32	N	O
185	male	N	O
186	and	N	O
187	41	N	O
188	female	N	O
189	,	N	O
190	histology	N	O
191	subtype	N	O
192	:	N	O
193	squamous/adenocarcinoma/mixed/NOS=42	N	O
194	%	N	O
195	/49	N	O
196	%	N	O
197	/4	N	O
198	%	N	O
199	/5	N	O
200	%	N	O
201	.	N	O

202	Seven	N	O
203	patients	N	O
204	did	N	O
205	not	N	O
206	receive	N	O
207	any	N	O
208	treatment	N	O
209	because	N	O
210	of	N	O
211	deterioration	N	O
212	in	N	O
213	PS	N	O
214	or	N	O
215	death	N	O
216	.	N	O

217	50	N	O
218	%	N	O
219	of	N	O
220	patients	N	O
221	in	N	O
222	arm	N	O
223	D	N	O
224	,	N	O
225	who	N	O
226	received	N	O
227	more	N	O
228	than	N	O
229	one	N	O
230	cycle	N	O
231	,	N	O
232	received	N	O
233	dose	N	O
234	escalation	N	O
235	.	N	O

236	There	N	I-Premise
237	was	N	I-Premise
238	no	N	I-Premise
239	statistical	N	I-Premise
240	difference	N	I-Premise
241	in	N	I-Premise
242	the	N	I-Premise
243	number	N	I-Premise
244	of	N	I-Premise
245	cycles	N	I-Premise
246	administered	N	I-Premise
247	(	N	I-Premise
248	arms	N	I-Premise
249	A	N	I-Premise
250	,	N	I-Premise
251	B	N	I-Premise
252	and	N	I-Premise
253	D	N	I-Premise
254	:	N	I-Premise
255	median	N	I-Premise
256	2	N	I-Premise
257	cycles	N	I-Premise
258	and	N	I-Premise
259	arm	N	I-Premise
260	C	N	I-Premise
261	:	N	I-Premise
262	median	N	I-Premise
263	3	N	I-Premise
264	cycles	N	I-Premise
265	)	N	I-Premise
266	and	N	I-Premise
267	no	N	I-Premise
268	difference	N	I-Premise
269	in	N	I-Premise
270	RR	N	I-Premise
271	:	N	I-Premise
272	arm	N	I-Premise
273	A=6	N	I-Premise
274	%	N	I-Premise
275	,	N	I-Premise
276	arm	N	I-Premise
277	B=6	N	I-Premise
278	%	N	I-Premise
279	,	N	I-Premise
280	arm	N	I-Premise
281	C=10	N	I-Premise
282	%	N	I-Premise
283	,	N	I-Premise
284	and	N	I-Premise
285	arm	N	I-Premise
286	D=0	N	I-Premise
287	%	N	I-Premise
288	.	N	I-Premise

289	There	N	I-Premise
290	was	N	I-Premise
291	no	N	I-Premise
292	statistically	N	I-Premise
293	significant	N	I-Premise
294	difference	N	I-Premise
295	in	N	I-Premise
296	grade	N	I-Premise
297	3/4	N	I-Premise
298	neutropenia	N	I-Premise
299	and	N	I-Premise
300	thrombocytopenia	N	I-Premise
301	between	N	I-Premise
302	the	N	I-Premise
303	four	N	I-Premise
304	arms	N	I-Premise
305	.	N	I-Premise

306	No	N	I-Premise
307	difference	N	I-Premise
308	was	N	I-Premise
309	observed	N	I-Premise
310	in	N	I-Premise
311	hospitalization	N	I-Premise
312	rate	N	I-Premise
313	,	N	I-Premise
314	blood	N	I-Premise
315	transfusions	N	I-Premise
316	,	N	I-Premise
317	antibiotics	N	I-Premise
318	administration	N	I-Premise
319	and	N	I-Premise
320	non-haematological	N	I-Premise
321	toxicity	N	I-Premise
322	.	N	I-Premise

323	QoL	N	O
324	:	N	O
325	no	N	O
326	difference	N	O
327	in	N	O
328	total	N	O
329	scores	N	O
330	between	N	O
331	baseline	N	O
332	and	N	O
333	cycles	N	O
334	1-4	N	O
335	.	N	O

336	There	N	I-Premise
337	was	N	I-Premise
338	a	N	I-Premise
339	significant	N	I-Premise
340	decrease	N	I-Premise
341	in	N	I-Premise
342	pain	N	I-Premise
343	scores	N	I-Premise
344	from	N	I-Premise
345	baseline	N	I-Premise
346	to	N	I-Premise
347	post	N	I-Premise
348	cycles	N	I-Premise
349	2	N	I-Premise
350	and	N	I-Premise
351	3	N	I-Premise
352	(	N	I-Premise
353	p=0.025	N	I-Premise
354	and	N	I-Premise
355	p=0.002	N	I-Premise
356	,	N	I-Premise
357	respectively	N	I-Premise
358	)	N	I-Premise
359	.	N	I-Premise

360	There	N	I-Premise
361	was	N	I-Premise
362	no	N	I-Premise
363	difference	N	I-Premise
364	in	N	I-Premise
365	OS	N	I-Premise
366	(	N	I-Premise
367	p=0.992	N	I-Premise
368	)	N	I-Premise
369	.	N	I-Premise

370	Median	N	I-Premise
371	survival	N	I-Premise
372	and	N	I-Premise
373	6-month	N	I-Premise
374	survival	N	I-Premise
375	were	N	I-Premise
376	61	N	I-Premise
377	,	N	I-Premise
378	86	N	I-Premise
379	,	N	I-Premise
380	88	N	I-Premise
381	and	N	I-Premise
382	97	N	I-Premise
383	days	N	I-Premise
384	and	N	I-Premise
385	29	N	I-Premise
386	%	N	I-Premise
387	,	N	I-Premise
388	33	N	I-Premise
389	%	N	I-Premise
390	,	N	I-Premise
391	21	N	I-Premise
392	%	N	I-Premise
393	and	N	I-Premise
394	26	N	I-Premise
395	%	N	I-Premise
396	for	N	I-Premise
397	arms	N	I-Premise
398	A	N	I-Premise
399	,	N	I-Premise
400	B	N	I-Premise
401	,	N	I-Premise
402	C	N	I-Premise
403	,	N	I-Premise
404	and	N	I-Premise
405	D	N	I-Premise
406	,	N	I-Premise
407	respectively	N	I-Premise
408	.	N	I-Premise

409	Clinical	N	I-Claim
410	efficacy	N	I-Claim
411	of	N	I-Claim
412	docetaxel	N	I-Claim
413	was	N	I-Claim
414	observed	N	I-Claim
415	at	N	I-Claim
416	all	N	I-Claim
417	dose	N	I-Claim
418	levels	N	I-Claim
419	.	N	I-Claim

420	Higher	N	I-Claim
421	dose	N	I-Claim
422	levels	N	I-Claim
423	were	N	I-Claim
424	not	N	I-Claim
425	associated	N	I-Claim
426	with	N	I-Claim
427	increased	N	I-Claim
428	toxicities	N	I-Claim
429	,	N	I-Claim
430	use	N	I-Claim
431	of	N	I-Claim
432	IV	N	I-Claim
433	antibiotics	N	I-Claim
434	or	N	I-Claim
435	hospitalization	N	I-Claim
436	rates	N	I-Claim
437	.	N	I-Claim

438	However	N	O
439	,	N	O
440	the	N	I-Premise
441	median	N	I-Premise
442	survival	N	I-Premise
443	observed	N	I-Premise
444	is	N	I-Premise
445	shorter	N	I-Premise
446	than	N	I-Premise
447	historical	N	I-Premise
448	data	N	I-Premise
449	and	N	I-Premise
450	do	N	I-Premise
451	not	N	I-Premise
452	support	N	I-Premise
453	further	N	I-Premise
454	evaluation	N	I-Premise
455	of	N	I-Premise
456	these	N	I-Premise
457	doses	N	I-Premise
458	of	N	I-Premise
459	single	N	I-Premise
460	agent	N	I-Premise
461	docetaxel	N	I-Premise
462	in	N	I-Premise
463	this	N	I-Premise
464	population	N	I-Premise
465	.	N	I-Premise

1	To	N	O
2	assess	N	O
3	whether	N	O
4	omission	N	O
5	of	N	O
6	post-operative	N	O
7	radiotherapy	N	O
8	(	N	O
9	RT	N	O
10	)	N	O
11	in	N	O
12	women	N	O
13	with	N	O
14	'low-risk	N	O
15	'	N	O
16	axillary	N	O
17	node-negative	N	O
18	breast	N	O
19	cancer	N	O
20	[	N	O
21	tumour	N	O
22	size	N	O
23	of	N	O
24	less	N	O
25	than	N	O
26	5	N	O
27	cm	N	O
28	(	N	O
29	T0-2	N	O
30	)	N	O
31	although	N	O
32	the	N	O
33	eligibility	N	O
34	criteria	N	O
35	further	N	O
36	reduce	N	O
37	the	N	O
38	eligible	N	O
39	size	N	O
40	to	N	O
41	a	N	O
42	maximum	N	O
43	of	N	O
44	3	N	O
45	cm	N	O
46	]	N	O
47	treated	N	O
48	by	N	O
49	breast-conserving	N	O
50	surgery	N	O
51	and	N	O
52	endocrine	N	O
53	therapy	N	O
54	improves	N	O
55	quality	N	O
56	of	N	O
57	life	N	O
58	and	N	O
59	is	N	O
60	more	N	O
61	cost-effective	N	O
62	.	N	O

63	A	N	O
64	randomised	N	O
65	controlled	N	O
66	clinical	N	O
67	trial	N	O
68	,	N	O
69	using	N	O
70	a	N	O
71	method	N	O
72	of	N	O
73	minimisation	N	O
74	balanced	N	O
75	by	N	O
76	centre	N	O
77	,	N	O
78	grade	N	O
79	of	N	O
80	cancer	N	O
81	,	N	O
82	age	N	O
83	,	N	O
84	lymphovascular	N	O
85	invasion	N	O
86	and	N	O
87	preoperative	N	O
88	endocrine	N	O
89	therapy	N	O
90	was	N	O
91	performed	N	O
92	.	N	O

93	Breast	N	O
94	cancer	N	O
95	clinics	N	O
96	in	N	O
97	cancer	N	O
98	centres	N	O
99	in	N	O
100	the	N	O
101	UK	N	O
102	.	N	O

103	Patients	N	O
104	aged	N	O
105	â¥	N	O
106	65	N	O
107	years	N	O
108	were	N	O
109	eligible	N	O
110	provided	N	O
111	that	N	O
112	their	N	O
113	breast	N	O
114	cancers	N	O
115	were	N	O
116	considered	N	O
117	to	N	O
118	be	N	O
119	at	N	O
120	low	N	O
121	risk	N	O
122	of	N	O
123	local	N	O
124	recurrence	N	O
125	,	N	O
126	they	N	O
127	were	N	O
128	suitable	N	O
129	for	N	O
130	breast	N	O
131	conservation	N	O
132	surgery	N	O
133	,	N	O
134	they	N	O
135	were	N	O
136	receiving	N	O
137	endocrine	N	O
138	therapy	N	O
139	and	N	O
140	they	N	O
141	were	N	O
142	willing	N	O
143	and	N	O
144	able	N	O
145	to	N	O
146	give	N	O
147	informed	N	O
148	consent	N	O
149	.	N	O

150	The	N	O
151	standard	N	O
152	treatment	N	O
153	of	N	O
154	post-operative	N	O
155	whole	N	O
156	breast	N	O
157	irradiation	N	O
158	or	N	O
159	the	N	O
160	omission	N	O
161	of	N	O
162	RT	N	O
163	.	N	O

164	Quality	N	O
165	of	N	O
166	life	N	O
167	was	N	O
168	the	N	O
169	primary	N	O
170	outcome	N	O
171	measure	N	O
172	,	N	O
173	together	N	O
174	with	N	O
175	anxiety	N	O
176	and	N	O
177	depression	N	O
178	and	N	O
179	cost-effectiveness	N	O
180	.	N	O

181	Secondary	N	O
182	outcome	N	O
183	measures	N	O
184	were	N	O
185	recurrence	N	O
186	rates	N	O
187	and	N	O
188	survival	N	O
189	,	N	O
190	and	N	O
191	treatment-related	N	O
192	morbidity	N	O
193	.	N	O

194	The	N	O
195	principal	N	O
196	method	N	O
197	of	N	O
198	data	N	O
199	collection	N	O
200	was	N	O
201	by	N	O
202	questionnaire	N	O
203	,	N	O
204	completed	N	O
205	at	N	O
206	home	N	O
207	with	N	O
208	a	N	O
209	research	N	O
210	nurse	N	O
211	on	N	O
212	four	N	O
213	occasions	N	O
214	over	N	O
215	15	N	O
216	months	N	O
217	,	N	O
218	then	N	O
219	by	N	O
220	postal	N	O
221	questionnaire	N	O
222	at	N	O
223	3	N	O
224	and	N	O
225	5	N	O
226	years	N	O
227	after	N	O
228	surgery	N	O
229	.	N	O

230	The	N	O
231	hypothesised	N	O
232	improvement	N	O
233	in	N	O
234	overall	N	O
235	quality	N	O
236	of	N	O
237	life	N	O
238	with	N	O
239	the	N	O
240	omission	N	O
241	of	N	O
242	RT	N	O
243	was	N	O
244	not	N	O
245	seen	N	O
246	in	N	O
247	the	N	O
248	summary	N	O
249	domains	N	O
250	of	N	O
251	the	N	O
252	European	N	O
253	Organisation	N	O
254	for	N	O
255	Research	N	O
256	in	N	O
257	the	N	O
258	Treatment	N	O
259	of	N	O
260	Cancer	N	O
261	(	N	O
262	EORTC	N	O
263	)	N	O
264	scales	N	O
265	.	N	O

266	Some	N	O
267	differences	N	O
268	were	N	O
269	apparent	N	O
270	within	N	O
271	subscales	N	O
272	of	N	O
273	the	N	O
274	EORTC	N	O
275	questionnaires	N	O
276	,	N	O
277	and	N	O
278	insights	N	O
279	into	N	O
280	the	N	O
281	impact	N	O
282	of	N	O
283	treatment	N	O
284	were	N	O
285	also	N	O
286	provided	N	O
287	by	N	O
288	the	N	O
289	qualitative	N	O
290	data	N	O
291	obtained	N	O
292	by	N	O
293	open-ended	N	O
294	questions	N	O
295	added	N	O
296	by	N	O
297	the	N	O
298	trial	N	O
299	team	N	O
300	.	N	O

301	Differences	N	O
302	were	N	O
303	most	N	O
304	apparent	N	O
305	shortly	N	O
306	after	N	O
307	the	N	O
308	time	N	O
309	of	N	O
310	completion	N	O
311	of	N	O
312	RT	N	O
313	.	N	O

314	RT	N	I-Premise
315	was	N	I-Premise
316	then	N	I-Premise
317	associated	N	I-Premise
318	with	N	I-Premise
319	increased	N	I-Premise
320	breast	N	I-Premise
321	symptoms	N	I-Premise
322	and	N	I-Premise
323	with	N	I-Premise
324	greater	N	I-Premise
325	(	N	I-Premise
326	self-reported	N	I-Premise
327	)	N	I-Premise
328	fatigue	N	I-Premise
329	,	N	I-Premise
330	but	N	I-Premise
331	with	N	I-Premise
332	lower	N	I-Premise
333	levels	N	I-Premise
334	of	N	I-Premise
335	insomnia	N	I-Premise
336	and	N	I-Premise
337	endocrine	N	I-Premise
338	side	N	I-Premise
339	effects	N	I-Premise
340	.	N	I-Premise

341	These	N	I-Premise
342	statistically	N	I-Premise
343	significant	N	I-Premise
344	differences	N	I-Premise
345	in	N	I-Premise
346	breast	N	I-Premise
347	symptoms	N	I-Premise
348	persisted	N	I-Premise
349	for	N	I-Premise
350	up	N	I-Premise
351	to	N	I-Premise
352	5	N	I-Premise
353	years	N	I-Premise
354	after	N	I-Premise
355	RT	N	I-Premise
356	[	N	I-Premise
357	mean	N	I-Premise
358	difference	N	I-Premise
359	,	N	I-Premise
360	RT	N	I-Premise
361	was	N	I-Premise
362	5.27	N	I-Premise
363	units	N	I-Premise
364	greater	N	I-Premise
365	than	N	I-Premise
366	no	N	I-Premise
367	RT	N	I-Premise
368	,	N	I-Premise
369	95	N	I-Premise
370	%	N	I-Premise
371	confidence	N	I-Premise
372	interval	N	I-Premise
373	(	N	I-Premise
374	CI	N	I-Premise
375	)	N	I-Premise
376	of	N	I-Premise
377	1.46	N	I-Premise
378	to	N	I-Premise
379	9.07	N	I-Premise
380	]	N	I-Premise
381	,	N	I-Premise
382	with	N	I-Premise
383	similar	N	I-Premise
384	,	N	I-Premise
385	though	N	I-Premise
386	non-significant	N	I-Premise
387	,	N	I-Premise
388	trends	N	I-Premise
389	in	N	I-Premise
390	insomnia	N	I-Premise
391	.	N	I-Premise

392	No	N	I-Premise
393	significant	N	I-Premise
394	difference	N	I-Premise
395	was	N	I-Premise
396	found	N	I-Premise
397	in	N	I-Premise
398	the	N	I-Premise
399	overall	N	I-Premise
400	quality	N	I-Premise
401	of	N	I-Premise
402	life	N	I-Premise
403	measure	N	I-Premise
404	,	N	I-Premise
405	with	N	I-Premise
406	the	N	I-Premise
407	no	N	I-Premise
408	RT	N	I-Premise
409	group	N	I-Premise
410	having	N	I-Premise
411	0.36	N	I-Premise
412	units	N	I-Premise
413	greater	N	I-Premise
414	quality	N	I-Premise
415	of	N	I-Premise
416	life	N	I-Premise
417	than	N	I-Premise
418	the	N	I-Premise
419	RT	N	I-Premise
420	group	N	I-Premise
421	(	N	I-Premise
422	95	N	I-Premise
423	%	N	I-Premise
424	CI	N	I-Premise
425	-5.09	N	I-Premise
426	to	N	I-Premise
427	5.81	N	I-Premise
428	)	N	I-Premise
429	.	N	I-Premise

430	Breast	N	I-Claim
431	RT	N	I-Claim
432	is	N	I-Claim
433	tolerated	N	I-Claim
434	well	N	I-Claim
435	by	N	I-Claim
436	most	N	I-Claim
437	older	N	I-Claim
438	breast	N	I-Claim
439	cancer	N	I-Claim
440	patients	N	I-Claim
441	without	N	I-Claim
442	impairing	N	I-Claim
443	their	N	I-Claim
444	overall	N	I-Claim
445	health-related	N	I-Claim
446	quality	N	I-Claim
447	of	N	I-Claim
448	life	N	I-Claim
449	(	N	I-Claim
450	HRQoL	N	I-Claim
451	)	N	I-Claim
452	.	N	I-Claim

453	Although	N	O
454	HRQoL	N	O
455	should	N	O
456	always	N	O
457	be	N	O
458	taken	N	O
459	into	N	O
460	account	N	O
461	when	N	O
462	determining	N	O
463	treatment	N	O
464	,	N	O
465	our	N	I-Claim
466	results	N	I-Claim
467	show	N	I-Claim
468	that	N	I-Claim
469	the	N	I-Claim
470	addition	N	I-Claim
471	of	N	I-Claim
472	RT	N	I-Claim
473	does	N	I-Claim
474	not	N	I-Claim
475	impair	N	I-Claim
476	overall	N	I-Claim
477	quality	N	I-Claim
478	of	N	I-Claim
479	life	N	I-Claim
480	.	N	I-Claim

481	Further	N	I-Claim
482	economic	N	I-Claim
483	modelling	N	I-Claim
484	on	N	I-Claim
485	the	N	I-Claim
486	longer-term	N	I-Claim
487	costs	N	I-Claim
488	and	N	I-Claim
489	consequences	N	I-Claim
490	of	N	I-Claim
491	omitting	N	I-Claim
492	RT	N	I-Claim
493	is	N	I-Claim
494	required	N	I-Claim
495	.	N	I-Claim

1	Evaluation	N	O
2	of	N	O
3	health-related	N	O
4	quality-of-life	N	O
5	(	N	O
6	HRQoL	N	O
7	)	N	O
8	and	N	O
9	symptom	N	O
10	improvement	N	O
11	were	N	O
12	preplanned	N	O
13	secondary	N	O
14	objectives	N	O
15	for	N	O
16	the	N	O
17	overall	N	O
18	population	N	O
19	and	N	O
20	posthoc	N	O
21	analyses	N	O
22	for	N	O
23	epidermal	N	O
24	growth	N	O
25	factor	N	O
26	receptor	N	O
27	(	N	O
28	EGFR	N	O
29	)	N	O
30	mutation-positive/negative	N	O
31	subgroups	N	O
32	in	N	O
33	IPASS	N	O
34	.	N	O

35	HRQoL	N	O
36	was	N	O
37	assessed	N	O
38	using	N	O
39	the	N	O
40	Functional	N	O
41	Assessment	N	O
42	of	N	O
43	Cancer	N	O
44	Therapy-Lung	N	O
45	(	N	O
46	FACT-L	N	O
47	)	N	O
48	and	N	O
49	Trial	N	O
50	Outcome	N	O
51	Index	N	O
52	(	N	O
53	TOI	N	O
54	)	N	O
55	;	N	O
56	symptom	N	O
57	improvement	N	O
58	by	N	O
59	the	N	O
60	Lung	N	O
61	Cancer	N	O
62	Subscale	N	O
63	(	N	O
64	LCS	N	O
65	)	N	O
66	.	N	O

67	Improvements	N	O
68	defined	N	O
69	as	N	O
70	:	N	O
71	6	N	O
72	or	N	O
73	more	N	O
74	(	N	O
75	FACT-L	N	O
76	;	N	O
77	TOI	N	O
78	)	N	O
79	,	N	O
80	2	N	O
81	or	N	O
82	more	N	O
83	(	N	O
84	LCS	N	O
85	)	N	O
86	points	N	O
87	increase	N	O
88	maintained	N	O
89	for	N	O
90	21	N	O
91	or	N	O
92	more	N	O
93	days	N	O
94	.	N	O

95	Overall	N	O
96	(	N	O
97	n	N	O
98	=	N	O
99	1151/1217	N	O
100	evaluable	N	O
101	)	N	O
102	,	N	O
103	HRQoL	N	O
104	improvement	N	O
105	rates	N	O
106	were	N	O
107	significantly	N	O
108	greater	N	O
109	with	N	O
110	gefitinib	N	O
111	versus	N	O
112	carboplatin/paclitaxel	N	O
113	;	N	O
114	symptom	N	O
115	improvement	N	O
116	rates	N	O
117	were	N	O
118	similar	N	O
119	for	N	O
120	both	N	O
121	treatments	N	O
122	.	N	O

123	Significantly	N	I-Premise
124	more	N	I-Premise
125	patients	N	I-Premise
126	recorded	N	I-Premise
127	improvements	N	I-Premise
128	in	N	I-Premise
129	HRQoL	N	I-Premise
130	and	N	I-Premise
131	symptoms	N	I-Premise
132	with	N	I-Premise
133	gefitinib	N	I-Premise
134	in	N	I-Premise
135	the	N	I-Premise
136	EGFR	N	I-Premise
137	mutation-positive	N	I-Premise
138	subgroup	N	I-Premise
139	(	N	I-Premise
140	n	N	I-Premise
141	=	N	I-Premise
142	259	N	I-Premise
143	;	N	I-Premise
144	FACT-L	N	I-Premise
145	70.2	N	I-Premise
146	%	N	I-Premise
147	versus	N	I-Premise
148	44.5	N	I-Premise
149	%	N	I-Premise
150	;	N	I-Premise
151	odds	N	I-Premise
152	ratio	N	I-Premise
153	,	N	I-Premise
154	3.01	N	I-Premise
155	[	N	I-Premise
156	95	N	I-Premise
157	%	N	I-Premise
158	confidence	N	I-Premise
159	interval	N	I-Premise
160	,	N	I-Premise
161	1.79-5.07	N	I-Premise
162	]	N	I-Premise
163	;	N	I-Premise
164	p	N	I-Premise
165	<	N	I-Premise
166	0.001	N	I-Premise
167	;	N	I-Premise
168	TOI	N	I-Premise
169	70.2	N	I-Premise
170	%	N	I-Premise
171	versus	N	I-Premise
172	38.3	N	I-Premise
173	%	N	I-Premise
174	;	N	I-Premise
175	3.96	N	I-Premise
176	[	N	I-Premise
177	2.33-6.71	N	I-Premise
178	]	N	I-Premise
179	;	N	I-Premise
180	p	N	I-Premise
181	<	N	I-Premise
182	0.001	N	I-Premise
183	;	N	I-Premise
184	LCS	N	I-Premise
185	75.6	N	I-Premise
186	%	N	I-Premise
187	versus	N	I-Premise
188	53.9	N	I-Premise
189	%	N	I-Premise
190	;	N	I-Premise
191	2.70	N	I-Premise
192	[	N	I-Premise
193	1.58-4.62	N	I-Premise
194	]	N	I-Premise
195	;	N	I-Premise
196	p	N	I-Premise
197	<	N	I-Premise
198	0.001	N	I-Premise
199	)	N	I-Premise
200	,	N	I-Premise
201	and	N	I-Premise
202	with	N	I-Premise
203	carboplatin/paclitaxel	N	I-Premise
204	in	N	I-Premise
205	the	N	I-Premise
206	EGFR	N	I-Premise
207	mutation-negative	N	I-Premise
208	subgroup	N	I-Premise
209	(	N	I-Premise
210	n	N	I-Premise
211	=	N	I-Premise
212	169	N	I-Premise
213	;	N	I-Premise
214	FACT-L	N	I-Premise
215	14.6	N	I-Premise
216	%	N	I-Premise
217	versus	N	I-Premise
218	36.3	N	I-Premise
219	%	N	I-Premise
220	;	N	I-Premise
221	odds	N	I-Premise
222	ratio	N	I-Premise
223	,	N	I-Premise
224	0.31	N	I-Premise
225	[	N	I-Premise
226	0.15-0.65	N	I-Premise
227	]	N	I-Premise
228	;	N	I-Premise
229	p	N	I-Premise
230	=	N	I-Premise
231	0.002	N	I-Premise
232	;	N	I-Premise
233	TOI	N	I-Premise
234	12.4	N	I-Premise
235	%	N	I-Premise
236	versus	N	I-Premise
237	28.8	N	I-Premise
238	%	N	I-Premise
239	;	N	I-Premise
240	0.35	N	I-Premise
241	[	N	I-Premise
242	0.16-0.79	N	I-Premise
243	]	N	I-Premise
244	;	N	I-Premise
245	p	N	I-Premise
246	=	N	I-Premise
247	0.011	N	I-Premise
248	;	N	I-Premise
249	LCS	N	I-Premise
250	20.2	N	I-Premise
251	%	N	I-Premise
252	versus	N	I-Premise
253	47.5	N	I-Premise
254	%	N	I-Premise
255	;	N	I-Premise
256	0.28	N	I-Premise
257	[	N	I-Premise
258	0.14-0.55	N	I-Premise
259	]	N	I-Premise
260	;	N	I-Premise
261	p	N	I-Premise
262	<	N	I-Premise
263	0.001	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	Median	N	I-Premise
267	time-to-worsening	N	I-Premise
268	(	N	I-Premise
269	months	N	I-Premise
270	)	N	I-Premise
271	FACT-L	N	I-Premise
272	score	N	I-Premise
273	was	N	I-Premise
274	longer	N	I-Premise
275	with	N	I-Premise
276	gefitinib	N	I-Premise
277	versus	N	I-Premise
278	carboplatin/paclitaxel	N	I-Premise
279	for	N	I-Premise
280	the	N	I-Premise
281	overall	N	I-Premise
282	population	N	I-Premise
283	(	N	I-Premise
284	8.3	N	I-Premise
285	versus	N	I-Premise
286	2.5	N	I-Premise
287	)	N	I-Premise
288	and	N	I-Premise
289	EGFR	N	I-Premise
290	mutation-positive	N	I-Premise
291	subgroup	N	I-Premise
292	(	N	I-Premise
293	15.6	N	I-Premise
294	versus	N	I-Premise
295	3.0	N	I-Premise
296	)	N	I-Premise
297	,	N	I-Premise
298	and	N	I-Premise
299	similar	N	I-Premise
300	for	N	I-Premise
301	both	N	I-Premise
302	treatments	N	I-Premise
303	in	N	I-Premise
304	the	N	I-Premise
305	EGFR	N	I-Premise
306	mutation-negative	N	I-Premise
307	subgroup	N	I-Premise
308	(	N	I-Premise
309	1.4	N	I-Premise
310	versus	N	I-Premise
311	1.4	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	Median	N	I-Premise
315	time-to-improvement	N	I-Premise
316	with	N	I-Premise
317	gefitinib	N	I-Premise
318	was	N	I-Premise
319	8	N	I-Premise
320	days	N	I-Premise
321	in	N	I-Premise
322	patients	N	I-Premise
323	with	N	I-Premise
324	EGFR	N	I-Premise
325	mutation-positive	N	I-Premise
326	tumors	N	I-Premise
327	who	N	I-Premise
328	improved	N	I-Premise
329	.	N	I-Premise

330	HRQoL	N	I-Claim
331	and	N	I-Claim
332	symptom	N	I-Claim
333	endpoints	N	I-Claim
334	were	N	I-Claim
335	consistent	N	I-Claim
336	with	N	I-Claim
337	efficacy	N	I-Claim
338	outcomes	N	I-Claim
339	in	N	I-Claim
340	IPASS	N	I-Claim
341	and	N	I-Claim
342	favored	N	I-Claim
343	gefitinib	N	I-Claim
344	in	N	I-Claim
345	patients	N	I-Claim
346	with	N	I-Claim
347	EGFR	N	I-Claim
348	mutation-positive	N	I-Claim
349	tumors	N	I-Claim
350	and	N	I-Claim
351	carboplatin/paclitaxel	N	I-Claim
352	in	N	I-Claim
353	patients	N	I-Claim
354	with	N	I-Claim
355	EGFR	N	I-Claim
356	mutation-negative	N	I-Claim
357	tumors	N	I-Claim
358	.	N	I-Claim

1	To	N	O
2	observe	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	Chinese	N	O
7	medicine	N	O
8	(	N	O
9	CM	N	O
10	)	N	O
11	comprehensive	N	O
12	regimen	N	O
13	as	N	O
14	the	N	O
15	maintenance	N	O
16	therapy	N	O
17	(	N	O
18	MT	N	O
19	)	N	O
20	on	N	O
21	time	N	O
22	to	N	O
23	progression	N	O
24	(	N	O
25	TTP	N	O
26	)	N	O
27	and	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	(	N	O
32	QOL	N	O
33	)	N	O
34	of	N	O
35	patients	N	O
36	with	N	O
37	advanced	N	O
38	non-small-cell	N	O
39	lung	N	O
40	cancer	N	O
41	(	N	O
42	NSCLC	N	O
43	)	N	O
44	.	N	O

45	The	N	O
46	study	N	O
47	was	N	O
48	a	N	O
49	prospective	N	O
50	,	N	O
51	randomized	N	O
52	and	N	O
53	controlled	N	O
54	clinical	N	O
55	trial	N	O
56	.	N	O

57	Fifty	N	O
58	non-progressive	N	O
59	patients	N	O
60	with	N	O
61	advanced	N	O
62	NSCLC	N	O
63	who	N	O
64	responded	N	O
65	to	N	O
66	first-line	N	O
67	therapy	N	O
68	were	N	O
69	randomized	N	O
70	into	N	O
71	the	N	O
72	test	N	O
73	group	N	O
74	(	N	O
75	25	N	O
76	cases	N	O
77	,	N	O
78	treated	N	O
79	with	N	O
80	CM	N	O
81	comprehensive	N	O
82	regimen	N	O
83	:	N	O
84	intravenous	N	O
85	dripping	N	O
86	of	N	O
87	Chinese	N	O
88	herbal	N	O
89	preparation	N	O
90	,	N	O
91	oral	N	O
92	administration	N	O
93	of	N	O
94	Chinese	N	O
95	herbal	N	O
96	decoction	N	O
97	,	N	O
98	and	N	O
99	point	N	O
100	application	N	O
101	)	N	O
102	and	N	O
103	the	N	O
104	control	N	O
105	group	N	O
106	[	N	O
107	25	N	O
108	cases	N	O
109	,	N	O
110	treated	N	O
111	with	N	O
112	one	N	O
113	of	N	O
114	three	N	O
115	single-agent	N	O
116	maintenance	N	O
117	chemotherapy	N	O
118	regimens	N	O
119	:	N	O
120	pemetrexed	N	O
121	(	N	O
122	500	N	O
123	mg/m2	N	O
124	,	N	O
125	day	N	O
126	1	N	O
127	)	N	O
128	,	N	O
129	docetaxel	N	O
130	(	N	O
131	75	N	O
132	mg/m2	N	O
133	,	N	O
134	day	N	O
135	1	N	O
136	)	N	O
137	,	N	O
138	and	N	O
139	gemcitabine	N	O
140	(	N	O
141	1000	N	O
142	mg/mi	N	O
143	,	N	O
144	day	N	O
145	1	N	O
146	and	N	O
147	day	N	O
148	8	N	O
149	)	N	O
150	in	N	O
151	the	N	O
152	ratio	N	O
153	of	N	O
154	1:1	N	O
155	]	N	O
156	.	N	O

157	Each	N	O
158	cycle	N	O
159	consisted	N	O
160	of	N	O
161	21	N	O
162	days	N	O
163	.	N	O

164	Cycles	N	O
165	were	N	O
166	repeated	N	O
167	until	N	O
168	the	N	O
169	disease	N	O
170	progressed	N	O
171	,	N	O
172	or	N	O
173	intolerable	N	O
174	toxic	N	O
175	or	N	O
176	adverse	N	O
177	reaction	N	O
178	occurred	N	O
179	,	N	O
180	or	N	O
181	patients	N	O
182	refused	N	O
183	to	N	O
184	continue	N	O
185	the	N	O
186	treatment	N	O
187	.	N	O

188	The	N	O
189	primary	N	O
190	end	N	O
191	point	N	O
192	was	N	O
193	TTP	N	O
194	and	N	O
195	the	N	O
196	secondary	N	O
197	end	N	O
198	point	N	O
199	was	N	O
200	QOL	N	O
201	.	N	O

202	QOL	N	O
203	was	N	O
204	evaluated	N	O
205	using	N	O
206	the	N	O
207	European	N	O
208	Organization	N	O
209	for	N	O
210	Research	N	O
211	and	N	O
212	Treatment	N	O
213	of	N	O
214	Cancer	N	O
215	quality-of-life	N	O
216	questionnaire	N	O
217	QLQ-LC43	N	O
218	(	N	O
219	EORTC	N	O
220	QLQ-LC43	N	O
221	)	N	O
222	.	N	O

223	TTP	N	O
224	of	N	O
225	fifty	N	O
226	patients	N	O
227	and	N	O
228	QOL	N	O
229	of	N	O
230	43	N	O
231	patients	N	O
232	had	N	O
233	been	N	O
234	statistically	N	O
235	analyzed	N	O
236	.	N	O

237	(	N	O
238	1	N	O
239	)	N	O
240	The	N	I-Premise
241	TTP	N	I-Premise
242	in	N	I-Premise
243	the	N	I-Premise
244	test	N	I-Premise
245	group	N	I-Premise
246	was	N	I-Premise
247	prolonged	N	I-Premise
248	for	N	I-Premise
249	23	N	I-Premise
250	days	N	I-Premise
251	when	N	I-Premise
252	compared	N	I-Premise
253	with	N	I-Premise
254	that	N	I-Premise
255	of	N	I-Premise
256	the	N	I-Premise
257	control	N	I-Premise
258	group	N	I-Premise
259	,	N	I-Premise
260	with	N	I-Premise
261	insignificant	N	I-Premise
262	difference	N	I-Premise
263	(	N	I-Premise
264	87	N	I-Premise
265	days	N	I-Premise
266	vs	N	I-Premise
267	64	N	I-Premise
268	days	N	I-Premise
269	,	N	I-Premise
270	P=0.063	N	I-Premise
271	)	N	I-Premise
272	.	N	I-Premise

273	(	N	O
274	2	N	O
275	)	N	O
276	The	N	I-Premise
277	scores	N	I-Premise
278	of	N	I-Premise
279	domains	N	I-Premise
280	in	N	I-Premise
281	EORTC	N	I-Premise
282	QLQ-LC43	N	I-Premise
283	were	N	I-Premise
284	statistically	N	I-Premise
285	significantly	N	I-Premise
286	better	N	I-Premise
287	in	N	I-Premise
288	the	N	I-Premise
289	test	N	I-Premise
290	group	N	I-Premise
291	than	N	I-Premise
292	in	N	I-Premise
293	the	N	I-Premise
294	control	N	I-Premise
295	group	N	I-Premise
296	(	N	I-Premise
297	P	N	I-Premise
298	<	N	I-Premise
299	0.05	N	I-Premise
300	)	N	I-Premise
301	except	N	I-Premise
302	cognitive	N	I-Premise
303	and	N	I-Premise
304	social	N	I-Premise
305	functions	N	I-Premise
306	,	N	I-Premise
307	the	N	I-Premise
308	symptoms	N	I-Premise
309	of	N	I-Premise
310	dysphagia	N	I-Premise
311	and	N	I-Premise
312	pain	N	I-Premise
313	in	N	I-Premise
314	other	N	I-Premise
315	parts	N	I-Premise
316	.	N	I-Premise

317	(	N	O
318	1	N	O
319	)	N	O
320	The	N	I-Claim
321	CM	N	I-Claim
322	comprehensive	N	I-Claim
323	regimen	N	I-Claim
324	as	N	I-Claim
325	MT	N	I-Claim
326	had	N	I-Claim
327	equivalent	N	I-Claim
328	efficacy	N	I-Claim
329	on	N	I-Claim
330	TTP	N	I-Claim
331	when	N	I-Claim
332	compared	N	I-Claim
333	with	N	I-Claim
334	single-agent	N	I-Claim
335	maintenance	N	I-Claim
336	chemotherapy	N	I-Claim
337	regimen	N	I-Claim
338	.	N	I-Claim

339	It	N	I-Claim
340	was	N	I-Claim
341	advantageous	N	I-Claim
342	over	N	I-Claim
343	improving	N	I-Claim
344	the	N	I-Claim
345	QOL	N	I-Claim
346	.	N	I-Claim

347	(	N	O
348	2	N	O
349	)	N	O
350	It	N	I-Claim
351	is	N	I-Claim
352	necessary	N	I-Claim
353	to	N	I-Claim
354	enlarge	N	I-Claim
355	the	N	I-Claim
356	sample	N	I-Claim
357	size	N	I-Claim
358	to	N	I-Claim
359	further	N	I-Claim
360	confirm	N	I-Claim
361	the	N	I-Claim
362	therapeutic	N	I-Claim
363	efficacy	N	I-Claim
364	of	N	I-Claim
365	CM	N	I-Claim
366	comprehensive	N	I-Claim
367	regimen	N	I-Claim
368	as	N	I-Claim
369	MT	N	I-Claim
370	in	N	I-Claim
371	treatment	N	I-Claim
372	of	N	I-Claim
373	patients	N	I-Claim
374	with	N	I-Claim
375	advanced	N	I-Claim
376	NSCLC	N	I-Claim
377	.	N	I-Claim

1	Implant-based	N	O
2	reconstruction	N	O
3	is	N	O
4	performed	N	O
5	in	N	O
6	the	N	O
7	majority	N	O
8	of	N	O
9	women	N	O
10	offered	N	O
11	primary	N	O
12	reconstruction	N	O
13	for	N	O
14	breast	N	O
15	cancer	N	O
16	.	N	O

17	Two	N	O
18	different	N	O
19	expander	N	O
20	implants	N	O
21	were	N	O
22	compared	N	O
23	prospectively	N	O
24	.	N	O

25	The	N	O
26	primary	N	O
27	endpoint	N	O
28	was	N	O
29	the	N	O
30	number	N	O
31	of	N	O
32	operations	N	O
33	needed	N	O
34	in	N	O
35	each	N	O
36	group	N	O
37	to	N	O
38	obtain	N	O
39	patient	N	O
40	satisfaction	N	O
41	.	N	O

42	Secondary	N	O
43	endpoints	N	O
44	were	N	O
45	evaluation	N	O
46	of	N	O
47	breast	N	O
48	volume	N	O
49	and	N	O
50	shape	N	O
51	and	N	O
52	aspects	N	O
53	of	N	O
54	quality	N	O
55	of	N	O
56	life	N	O
57	.	N	O

58	Seventy	N	O
59	consecutive	N	O
60	breast	N	O
61	cancer	N	O
62	patients	N	O
63	were	N	O
64	randomized	N	O
65	to	N	O
66	either	N	O
67	a	N	O
68	one-stage	N	O
69	reconstruction	N	O
70	with	N	O
71	a	N	O
72	round	N	O
73	permanent	N	O
74	expander	N	O
75	implant	N	O
76	(	N	O
77	Becker	N	O
78	25	N	O
79	;	N	O
80	n=35	N	O
81	)	N	O
82	or	N	O
83	a	N	O
84	two-stage	N	O
85	reconstruction	N	O
86	with	N	O
87	a	N	O
88	crescent-shaped	N	O
89	expander	N	O
90	(	N	O
91	LV	N	O
92	133	N	O
93	;	N	O
94	n=35	N	O
95	)	N	O
96	,	N	O
97	later	N	O
98	replaced	N	O
99	by	N	O
100	a	N	O
101	form-stable	N	O
102	anatomical	N	O
103	implant	N	O
104	.	N	O

105	Thirty	N	O
106	patients	N	O
107	had	N	O
108	to	N	O
109	be	N	O
110	excluded	N	O
111	and	N	O
112	40	N	O
113	patients	N	O
114	,	N	O
115	20	N	O
116	in	N	O
117	each	N	O
118	group	N	O
119	,	N	O
120	were	N	O
121	evaluated	N	O
122	.	N	O

123	The	N	O
124	median	N	O
125	follow-up	N	O
126	for	N	O
127	both	N	O
128	groups	N	O
129	was	N	O
130	3.5	N	O
131	years	N	O
132	(	N	O
133	range	N	O
134	,	N	O
135	1.5	N	O
136	to	N	O
137	5	N	O
138	years	N	O
139	)	N	O
140	.	N	O

141	Plastic	N	O
142	cups	N	O
143	,	N	O
144	plastic	N	O
145	casts	N	O
146	,	N	O
147	and	N	O
148	two	N	O
149	-and	N	O
150	three-dimensional	N	O
151	scanning	N	O
152	techniques	N	O
153	were	N	O
154	used	N	O
155	for	N	O
156	objective	N	O
157	assessment	N	O
158	of	N	O
159	breast	N	O
160	volume	N	O
161	and	N	O
162	shape	N	O
163	.	N	O

164	The	N	O
165	aesthetic	N	O
166	outcome	N	O
167	was	N	O
168	evaluated	N	O
169	by	N	O
170	a	N	O
171	panel	N	O
172	of	N	O
173	experts	N	O
174	and	N	O
175	lay	N	O
176	people	N	O
177	,	N	O
178	and	N	O
179	by	N	O
180	the	N	O
181	patients	N	O
182	.	N	O

183	Quality	N	O
184	of	N	O
185	life	N	O
186	was	N	O
187	evaluated	N	O
188	with	N	O
189	a	N	O
190	validated	N	O
191	questionnaire	N	O
192	(	N	O
193	36-Item	N	O
194	Short	N	O
195	Form	N	O
196	Health	N	O
197	Survey	N	O
198	)	N	O
199	.	N	O

200	Of	N	I-Premise
201	the	N	I-Premise
202	patients	N	I-Premise
203	in	N	I-Premise
204	the	N	I-Premise
205	one-stage	N	I-Premise
206	group	N	I-Premise
207	,	N	I-Premise
208	70	N	I-Premise
209	percent	N	I-Premise
210	had	N	I-Premise
211	revision	N	I-Premise
212	surgery	N	I-Premise
213	,	N	I-Premise
214	mostly	N	I-Premise
215	because	N	I-Premise
216	of	N	I-Premise
217	upper	N	I-Premise
218	pole	N	I-Premise
219	fullness	N	I-Premise
220	and	N	I-Premise
221	poor	N	I-Premise
222	ptosis	N	I-Premise
223	.	N	I-Premise

224	These	N	O
225	findings	N	O
226	agreed	N	O
227	with	N	O
228	the	N	O
229	data	N	O
230	from	N	O
231	the	N	O
232	two-dimensional	N	O
233	scanning	N	O
234	and	N	O
235	from	N	O
236	the	N	O
237	expert	N	O
238	panel	N	O
239	and	N	O
240	the	N	O
241	patients	N	O
242	'	N	O
243	subjective	N	O
244	judgment	N	O
245	.	N	O

246	Quality	N	I-Premise
247	of	N	I-Premise
248	life	N	I-Premise
249	was	N	I-Premise
250	similar	N	I-Premise
251	in	N	I-Premise
252	the	N	I-Premise
253	two	N	I-Premise
254	groups	N	I-Premise
255	.	N	I-Premise

256	The	N	I-Claim
257	permanent	N	I-Claim
258	expander	N	I-Claim
259	method	N	I-Claim
260	failed	N	I-Claim
261	significantly	N	I-Claim
262	as	N	I-Claim
263	a	N	I-Claim
264	one-stage	N	I-Claim
265	procedure	N	I-Claim
266	.	N	I-Claim

267	The	N	I-Claim
268	crescent	N	I-Claim
269	two-stage	N	I-Claim
270	method	N	I-Claim
271	gave	N	I-Claim
272	the	N	I-Claim
273	most	N	I-Claim
274	acceptable	N	I-Claim
275	results	N	I-Claim
276	both	N	I-Claim
277	objectively	N	I-Claim
278	and	N	I-Claim
279	subjectively	N	I-Claim
280	.	N	I-Claim

1	Intermittent	N	O
2	dosing	N	O
3	may	N	O
4	reduce	N	O
5	the	N	O
6	adverse	N	O
7	events	N	O
8	(	N	O
9	AEs	N	O
10	)	N	O
11	of	N	O
12	androgen-deprivation	N	O
13	therapy	N	O
14	(	N	O
15	ADT	N	O
16	)	N	O
17	.	N	O

18	To	N	O
19	compare	N	O
20	intermittent	N	O
21	androgen	N	O
22	deprivation	N	O
23	(	N	O
24	IAD	N	O
25	)	N	O
26	and	N	O
27	continuous	N	O
28	androgen	N	O
29	deprivation	N	O
30	(	N	O
31	CAD	N	O
32	)	N	O
33	with	N	O
34	regard	N	O
35	to	N	O
36	health-related	N	O
37	quality	N	O
38	of	N	O
39	life	N	O
40	(	N	O
41	QoL	N	O
42	)	N	O
43	.	N	O

44	A	N	O
45	total	N	O
46	of	N	O
47	852	N	O
48	men	N	O
49	with	N	O
50	advanced	N	O
51	prostate	N	O
52	cancer	N	O
53	(	N	O
54	PCa	N	O
55	)	N	O
56	were	N	O
57	enrolled	N	O
58	to	N	O
59	receive	N	O
60	goserelin	N	O
61	acetate	N	O
62	3.6	N	O
63	mg	N	O
64	every	N	O
65	28	N	O
66	d	N	O
67	for	N	O
68	24	N	O
69	wk	N	O
70	.	N	O

71	A	N	O
72	total	N	O
73	of	N	O
74	554	N	O
75	patients	N	O
76	whose	N	O
77	prostate-specific	N	O
78	antigen	N	O
79	(	N	O
80	PSA	N	O
81	)	N	O
82	decreased	N	O
83	to	N	O
84	<	N	O
85	10	N	O
86	ng/ml	N	O
87	or	N	O
88	by	N	O
89	â¥50	N	O
90	%	N	O
91	(	N	O
92	<	N	O
93	20	N	O
94	ng/ml	N	O
95	at	N	O
96	baseline	N	O
97	)	N	O
98	were	N	O
99	randomised	N	O
100	to	N	O
101	IAD	N	O
102	or	N	O
103	CAD	N	O
104	.	N	O

105	In	N	O
106	the	N	O
107	IAD	N	O
108	arm	N	O
109	,	N	O
110	ADT	N	O
111	was	N	O
112	resumed	N	O
113	for	N	O
114	at	N	O
115	least	N	O
116	24	N	O
117	wk	N	O
118	whenever	N	O
119	PSA	N	O
120	increased	N	O
121	>	N	O
122	20	N	O
123	ng/ml	N	O
124	or	N	O
125	above	N	O
126	baseline	N	O
127	.	N	O

128	QoL	N	O
129	was	N	O
130	monitored	N	O
131	with	N	O
132	a	N	O
133	validated	N	O
134	Cleary	N	O
135	30-item	N	O
136	questionnaire	N	O
137	and	N	O
138	analysed	N	O
139	by	N	O
140	the	N	O
141	Mann-Whitney	N	O
142	U	N	O
143	test	N	O
144	,	N	O
145	0.5	N	O
146	standard	N	O
147	deviation	N	O
148	rule	N	O
149	,	N	O
150	and	N	O
151	repeated	N	O
152	measures	N	O
153	analysis	N	O
154	of	N	O
155	variance	N	O
156	.	N	O

157	AEs	N	O
158	and	N	O
159	adverse	N	O
160	drug	N	O
161	reactions	N	O
162	(	N	O
163	ADRs	N	O
164	)	N	O
165	were	N	O
166	analysed	N	O
167	by	N	O
168	the	N	O
169	chi-square	N	O
170	test	N	O
171	.	N	O

172	Median	N	O
173	follow-up	N	O
174	was	N	O
175	65	N	O
176	mo	N	O
177	.	N	O

178	Significant	N	I-Premise
179	differences	N	I-Premise
180	in	N	I-Premise
181	QoL	N	I-Premise
182	emerged	N	I-Premise
183	in	N	I-Premise
184	activity	N	I-Premise
185	limitation	N	I-Premise
186	,	N	I-Premise
187	physical	N	I-Premise
188	capacity	N	I-Premise
189	,	N	I-Premise
190	and	N	I-Premise
191	sexual	N	I-Premise
192	functioning	N	I-Premise
193	,	N	I-Premise
194	favouring	N	I-Premise
195	IAD	N	I-Premise
196	.	N	I-Premise

197	No	N	I-Premise
198	significant	N	I-Premise
199	differences	N	I-Premise
200	emerged	N	I-Premise
201	in	N	I-Premise
202	the	N	I-Premise
203	prevalence	N	I-Premise
204	of	N	I-Premise
205	AEs	N	I-Premise
206	:	N	I-Premise
207	87	N	I-Premise
208	patients	N	I-Premise
209	in	N	I-Premise
210	the	N	I-Premise
211	IAD	N	I-Premise
212	arm	N	I-Premise
213	(	N	I-Premise
214	31.8	N	I-Premise
215	%	N	I-Premise
216	)	N	I-Premise
217	and	N	I-Premise
218	95	N	I-Premise
219	in	N	I-Premise
220	the	N	I-Premise
221	CAD	N	I-Premise
222	arm	N	I-Premise
223	(	N	I-Premise
224	33.9	N	I-Premise
225	%	N	I-Premise
226	)	N	I-Premise
227	had	N	I-Premise
228	cardiovascular	N	I-Premise
229	(	N	I-Premise
230	CV	N	I-Premise
231	)	N	I-Premise
232	AEs	N	I-Premise
233	(	N	I-Premise
234	p=0.59	N	I-Premise
235	)	N	I-Premise
236	,	N	I-Premise
237	with	N	I-Premise
238	25	N	I-Premise
239	(	N	I-Premise
240	9.1	N	I-Premise
241	%	N	I-Premise
242	)	N	I-Premise
243	and	N	I-Premise
244	29	N	I-Premise
245	(	N	I-Premise
246	10.4	N	I-Premise
247	%	N	I-Premise
248	)	N	I-Premise
249	withdrawn	N	I-Premise
250	(	N	I-Premise
251	p=0.62	N	I-Premise
252	)	N	I-Premise
253	,	N	I-Premise
254	and	N	I-Premise
255	21	N	I-Premise
256	(	N	I-Premise
257	7.7	N	I-Premise
258	%	N	I-Premise
259	)	N	I-Premise
260	and	N	I-Premise
261	24	N	I-Premise
262	(	N	I-Premise
263	8.6	N	I-Premise
264	%	N	I-Premise
265	)	N	I-Premise
266	dying	N	I-Premise
267	because	N	I-Premise
268	of	N	I-Premise
269	a	N	I-Premise
270	CV	N	I-Premise
271	event	N	I-Premise
272	(	N	I-Premise
273	p=0.70	N	I-Premise
274	)	N	I-Premise
275	,	N	I-Premise
276	respectively	N	I-Premise
277	;	N	I-Premise
278	bone	N	I-Premise
279	fractures	N	I-Premise
280	occurred	N	I-Premise
281	in	N	I-Premise
282	19	N	I-Premise
283	(	N	I-Premise
284	6.9	N	I-Premise
285	%	N	I-Premise
286	)	N	I-Premise
287	and	N	I-Premise
288	15	N	I-Premise
289	(	N	I-Premise
290	5.4	N	I-Premise
291	%	N	I-Premise
292	)	N	I-Premise
293	patients	N	I-Premise
294	(	N	I-Premise
295	p=0.44	N	I-Premise
296	)	N	I-Premise
297	,	N	I-Premise
298	respectively	N	I-Premise
299	.	N	I-Premise

300	Hot	N	I-Premise
301	flushes	N	I-Premise
302	or	N	I-Premise
303	night	N	I-Premise
304	sweats	N	I-Premise
305	were	N	I-Premise
306	the	N	I-Premise
307	most	N	I-Premise
308	common	N	I-Premise
309	ADRs	N	I-Premise
310	(	N	I-Premise
311	47.1	N	I-Premise
312	%	N	I-Premise
313	vs	N	I-Premise
314	50.4	N	I-Premise
315	%	N	I-Premise
316	;	N	I-Premise
317	p=0.44	N	I-Premise
318	)	N	I-Premise
319	.	N	I-Premise

320	Erectile	N	I-Premise
321	dysfunction	N	I-Premise
322	(	N	I-Premise
323	15.7	N	I-Premise
324	%	N	I-Premise
325	vs	N	I-Premise
326	7.9	N	I-Premise
327	%	N	I-Premise
328	;	N	I-Premise
329	p=0.042	N	I-Premise
330	)	N	I-Premise
331	and	N	I-Premise
332	depressed	N	I-Premise
333	mood	N	I-Premise
334	(	N	I-Premise
335	2.2	N	I-Premise
336	vs	N	I-Premise
337	0	N	I-Premise
338	%	N	I-Premise
339	;	N	I-Premise
340	p=0.032	N	I-Premise
341	)	N	I-Premise
342	were	N	I-Premise
343	more	N	I-Premise
344	common	N	I-Premise
345	in	N	I-Premise
346	the	N	I-Premise
347	IAD	N	I-Premise
348	arm	N	I-Premise
349	.	N	I-Premise

350	IAD	N	I-Claim
351	showed	N	I-Claim
352	benefits	N	I-Claim
353	in	N	I-Claim
354	the	N	I-Claim
355	treatment	N	I-Claim
356	of	N	I-Claim
357	advanced	N	I-Claim
358	PCa	N	I-Claim
359	with	N	I-Claim
360	respect	N	I-Claim
361	to	N	I-Claim
362	QoL	N	I-Claim
363	.	N	I-Claim

364	The	N	I-Claim
365	prevalence	N	I-Claim
366	of	N	I-Claim
367	AEs	N	I-Claim
368	was	N	I-Claim
369	not	N	I-Claim
370	significantly	N	I-Claim
371	lower	N	I-Claim
372	with	N	I-Claim
373	IAD	N	I-Claim
374	.	N	I-Claim

1	Patients	N	O
2	who	N	O
3	develop	N	O
4	castration-resistant	N	O
5	prostate	N	O
6	cancer	N	O
7	(	N	O
8	CRPCa	N	O
9	)	N	O
10	typically	N	O
11	continue	N	O
12	on	N	O
13	androgen	N	O
14	deprivation	N	O
15	therapy	N	O
16	(	N	O
17	ADT	N	O
18	)	N	O
19	.	N	O

20	Whether	N	O
21	these	N	O
22	patients	N	O
23	need	N	O
24	to	N	O
25	remain	N	O
26	on	N	O
27	ADT	N	O
28	has	N	O
29	not	N	O
30	been	N	O
31	well	N	O
32	studied	N	O
33	.	N	O

34	We	N	O
35	conducted	N	O
36	a	N	O
37	multicenter	N	O
38	randomized	N	O
39	trial	N	O
40	to	N	O
41	compare	N	O
42	an	N	O
43	intermittent	N	O
44	versus	N	O
45	continuous	N	O
46	approach	N	O
47	to	N	O
48	ADT	N	O
49	in	N	O
50	CRPCa	N	O
51	patients	N	O
52	.	N	O

53	Overall	N	O
54	survival	N	O
55	,	N	O
56	health-related	N	O
57	quality	N	O
58	of	N	O
59	life	N	O
60	(	N	O
61	QOL	N	O
62	)	N	O
63	,	N	O
64	and	N	O
65	cost	N	O
66	were	N	O
67	the	N	O
68	main	N	O
69	endpoints	N	O
70	.	N	O

71	CRPCa	N	O
72	patients	N	O
73	were	N	O
74	randomized	N	O
75	2:1	N	O
76	to	N	O
77	intermittent	N	O
78	or	N	O
79	continuous	N	O
80	luteinizing	N	O
81	hormone-releasing	N	O
82	hormone	N	O
83	agonists	N	O
84	(	N	O
85	LHRHa	N	O
86	)	N	O
87	.	N	O

88	Patients	N	O
89	were	N	O
90	followed	N	O
91	with	N	O
92	clinical	N	O
93	assessments	N	O
94	,	N	O
95	laboratory	N	O
96	investigations	N	O
97	,	N	O
98	and	N	O
99	QOL	N	O
100	questionnaires	N	O
101	(	N	O
102	EORTC	N	O
103	QLQ-C30	N	O
104	or	N	O
105	PROSQOLI	N	O
106	)	N	O
107	every	N	O
108	2	N	O
109	months	N	O
110	.	N	O

111	If	N	O
112	the	N	O
113	serum	N	O
114	testosterone	N	O
115	rose	N	O
116	above	N	O
117	castrate	N	O
118	levels	N	O
119	(	N	O
120	1.75	N	O
121	nmol/L	N	O
122	)	N	O
123	,	N	O
124	LHRHa	N	O
125	were	N	O
126	reinitiated	N	O
127	.	N	O

128	The	N	O
129	study	N	O
130	was	N	O
131	designed	N	O
132	to	N	O
133	close	N	O
134	if	N	O
135	>	N	O
136	50	N	O
137	%	N	O
138	of	N	O
139	patients	N	O
140	needed	N	O
141	to	N	O
142	restart	N	O
143	ADT	N	O
144	in	N	O
145	the	N	O
146	intermittent	N	O
147	arm	N	O
148	.	N	O

149	Thirty-one	N	O
150	patients	N	O
151	were	N	O
152	followed	N	O
153	with	N	O
154	a	N	O
155	median	N	O
156	follow-up	N	O
157	of	N	O
158	26.8	N	O
159	months-18	N	O
160	in	N	O
161	the	N	O
162	intermittent	N	O
163	arm	N	O
164	and	N	O
165	13	N	O
166	in	N	O
167	the	N	O
168	continuous	N	O
169	.	N	O

170	Twelve	N	O
171	of	N	O
172	18	N	O
173	patients	N	O
174	on	N	O
175	the	N	O
176	intermittent	N	O
177	arm	N	O
178	were	N	O
179	reinitiated	N	O
180	on	N	O
181	LHRHa	N	O
182	at	N	O
183	a	N	O
184	median	N	O
185	time	N	O
186	of	N	O
187	17.9	N	O
188	months	N	O
189	.	N	O

190	There	N	I-Premise
191	was	N	I-Premise
192	no	N	I-Premise
193	difference	N	I-Premise
194	in	N	I-Premise
195	overall	N	I-Premise
196	or	N	I-Premise
197	cancer-specific	N	I-Premise
198	survival	N	I-Premise
199	between	N	I-Premise
200	the	N	I-Premise
201	2	N	I-Premise
202	arms	N	I-Premise
203	.	N	I-Premise

204	There	N	I-Premise
205	was	N	I-Premise
206	no	N	I-Premise
207	statistically	N	I-Premise
208	significant	N	I-Premise
209	difference	N	I-Premise
210	in	N	I-Premise
211	QOL	N	I-Premise
212	between	N	I-Premise
213	the	N	I-Premise
214	2	N	I-Premise
215	arms	N	I-Premise
216	at	N	I-Premise
217	0	N	I-Premise
218	and	N	I-Premise
219	12	N	I-Premise
220	months	N	I-Premise
221	.	N	I-Premise

222	The	N	I-Premise
223	total	N	I-Premise
224	mean	N	I-Premise
225	costs	N	I-Premise
226	at	N	I-Premise
227	24	N	I-Premise
228	months	N	I-Premise
229	were	N	I-Premise
230	significantly	N	I-Premise
231	lower	N	I-Premise
232	in	N	I-Premise
233	the	N	I-Premise
234	intermittent	N	I-Premise
235	arm	N	I-Premise
236	(	N	I-Premise
237	$	N	I-Premise
238	3135	N	I-Premise
239	vs.	N	I-Premise
240	$	N	I-Premise
241	8253	N	I-Premise
242	Canadian	N	I-Premise
243	dollars	N	I-Premise
244	,	N	I-Premise
245	P=0.0167	N	I-Premise
246	)	N	I-Premise
247	compared	N	I-Premise
248	with	N	I-Premise
249	the	N	I-Premise
250	continuous	N	I-Premise
251	.	N	I-Premise

252	The	N	I-Premise
253	main	N	I-Premise
254	limitation	N	I-Premise
255	of	N	I-Premise
256	this	N	I-Premise
257	study	N	I-Premise
258	is	N	I-Premise
259	the	N	I-Premise
260	small	N	I-Premise
261	sample	N	I-Premise
262	size	N	I-Premise
263	.	N	I-Premise

264	We	N	I-Claim
265	have	N	I-Claim
266	observed	N	I-Claim
267	that	N	I-Claim
268	intermittent	N	I-Claim
269	ADT	N	I-Claim
270	in	N	I-Claim
271	patients	N	I-Claim
272	with	N	I-Claim
273	CRPCa	N	I-Claim
274	,	N	I-Claim
275	using	N	I-Claim
276	a	N	I-Claim
277	testosterone	N	I-Claim
278	of	N	I-Claim
279	>	N	I-Claim
280	1.75	N	I-Claim
281	ngmol/L	N	I-Claim
282	as	N	I-Claim
283	a	N	I-Claim
284	trigger	N	I-Claim
285	to	N	I-Claim
286	reinitiate	N	I-Claim
287	LHRHa	N	I-Claim
288	,	N	I-Claim
289	results	N	I-Claim
290	in	N	I-Claim
291	a	N	I-Claim
292	substantial	N	I-Claim
293	cost	N	I-Claim
294	savings	N	I-Claim
295	with	N	I-Claim
296	no	N	I-Claim
297	negative	N	I-Claim
298	impact	N	I-Claim
299	on	N	I-Claim
300	oncologic	N	I-Claim
301	and	N	I-Claim
302	QOL	N	I-Claim
303	outcomes	N	I-Claim
304	.	N	I-Claim

1	Most	N	O
2	patients	N	O
3	with	N	O
4	glioblastoma	N	O
5	are	N	O
6	older	N	O
7	than	N	O
8	60	N	O
9	years	N	O
10	,	N	O
11	but	N	O
12	treatment	N	O
13	guidelines	N	O
14	are	N	O
15	based	N	O
16	on	N	O
17	trials	N	O
18	in	N	O
19	patients	N	O
20	aged	N	O
21	only	N	O
22	up	N	O
23	to	N	O
24	70	N	O
25	years	N	O
26	.	N	O

27	We	N	O
28	did	N	O
29	a	N	O
30	randomised	N	O
31	trial	N	O
32	to	N	O
33	assess	N	O
34	the	N	O
35	optimum	N	O
36	palliative	N	O
37	treatment	N	O
38	in	N	O
39	patients	N	O
40	aged	N	O
41	60	N	O
42	years	N	O
43	and	N	O
44	older	N	O
45	with	N	O
46	glioblastoma	N	O
47	.	N	O

48	Patients	N	O
49	with	N	O
50	newly	N	O
51	diagnosed	N	O
52	glioblastoma	N	O
53	were	N	O
54	recruited	N	O
55	from	N	O
56	Austria	N	O
57	,	N	O
58	Denmark	N	O
59	,	N	O
60	France	N	O
61	,	N	O
62	Norway	N	O
63	,	N	O
64	Sweden	N	O
65	,	N	O
66	Switzerland	N	O
67	,	N	O
68	and	N	O
69	Turkey	N	O
70	.	N	O

71	They	N	O
72	were	N	O
73	assigned	N	O
74	by	N	O
75	a	N	O
76	computer-generated	N	O
77	randomisation	N	O
78	schedule	N	O
79	,	N	O
80	stratified	N	O
81	by	N	O
82	centre	N	O
83	,	N	O
84	to	N	O
85	receive	N	O
86	temozolomide	N	O
87	(	N	O
88	200	N	O
89	mg/m	N	O
90	(	N	O
91	2	N	O
92	)	N	O
93	on	N	O
94	days	N	O
95	1-5	N	O
96	of	N	O
97	every	N	O
98	28	N	O
99	days	N	O
100	for	N	O
101	up	N	O
102	to	N	O
103	six	N	O
104	cycles	N	O
105	)	N	O
106	,	N	O
107	hypofractionated	N	O
108	radiotherapy	N	O
109	(	N	O
110	34Â·0	N	O
111	Gy	N	O
112	administered	N	O
113	in	N	O
114	3Â·4	N	O
115	Gy	N	O
116	fractions	N	O
117	over	N	O
118	2	N	O
119	weeks	N	O
120	)	N	O
121	,	N	O
122	or	N	O
123	standard	N	O
124	radiotherapy	N	O
125	(	N	O
126	60Â·0	N	O
127	Gy	N	O
128	administered	N	O
129	in	N	O
130	2Â·0	N	O
131	Gy	N	O
132	fractions	N	O
133	over	N	O
134	6	N	O
135	weeks	N	O
136	)	N	O
137	.	N	O

138	Patients	N	O
139	and	N	O
140	study	N	O
141	staff	N	O
142	were	N	O
143	aware	N	O
144	of	N	O
145	treatment	N	O
146	assignment	N	O
147	.	N	O

148	The	N	O
149	primary	N	O
150	endpoint	N	O
151	was	N	O
152	overall	N	O
153	survival	N	O
154	.	N	O

155	Analyses	N	O
156	were	N	O
157	done	N	O
158	by	N	O
159	intention	N	O
160	to	N	O
161	treat	N	O
162	.	N	O

163	This	N	O
164	trial	N	O
165	is	N	O
166	registered	N	O
167	,	N	O
168	number	N	O
169	ISRCTN81470623	N	O
170	.	N	O

171	342	N	O
172	patients	N	O
173	were	N	O
174	enrolled	N	O
175	,	N	O
176	of	N	O
177	whom	N	O
178	291	N	O
179	were	N	O
180	randomised	N	O
181	across	N	O
182	three	N	O
183	treatment	N	O
184	groups	N	O
185	(	N	O
186	temozolomide	N	O
187	n=93	N	O
188	,	N	O
189	hypofractionated	N	O
190	radiotherapy	N	O
191	n=98	N	O
192	,	N	O
193	standard	N	O
194	radiotherapy	N	O
195	n=100	N	O
196	)	N	O
197	and	N	O
198	51	N	O
199	of	N	O
200	whom	N	O
201	were	N	O
202	randomised	N	O
203	across	N	O
204	only	N	O
205	two	N	O
206	groups	N	O
207	(	N	O
208	temozolomide	N	O
209	n=26	N	O
210	,	N	O
211	hypofractionated	N	O
212	radiotherapy	N	O
213	n=25	N	O
214	)	N	O
215	.	N	O

216	In	N	I-Premise
217	the	N	I-Premise
218	three-group	N	I-Premise
219	randomisation	N	I-Premise
220	,	N	I-Premise
221	in	N	I-Premise
222	comparison	N	I-Premise
223	with	N	I-Premise
224	standard	N	I-Premise
225	radiotherapy	N	I-Premise
226	,	N	I-Premise
227	median	N	I-Premise
228	overall	N	I-Premise
229	survival	N	I-Premise
230	was	N	I-Premise
231	significantly	N	I-Premise
232	longer	N	I-Premise
233	with	N	I-Premise
234	temozolomide	N	I-Premise
235	(	N	I-Premise
236	8Â·3	N	I-Premise
237	months	N	I-Premise
238	[	N	I-Premise
239	95	N	I-Premise
240	%	N	I-Premise
241	CI	N	I-Premise
242	7Â·1-9Â·5	N	I-Premise
243	;	N	I-Premise
244	n=93	N	I-Premise
245	]	N	I-Premise
246	vs	N	I-Premise
247	6Â·0	N	I-Premise
248	months	N	I-Premise
249	[	N	I-Premise
250	95	N	I-Premise
251	%	N	I-Premise
252	CI	N	I-Premise
253	5Â·1-6Â·8	N	I-Premise
254	;	N	I-Premise
255	n=100	N	I-Premise
256	]	N	I-Premise
257	,	N	I-Premise
258	hazard	N	I-Premise
259	ratio	N	I-Premise
260	[	N	I-Premise
261	HR	N	I-Premise
262	]	N	I-Premise
263	0Â·70	N	I-Premise
264	;	N	I-Premise
265	95	N	I-Premise
266	%	N	I-Premise
267	CI	N	I-Premise
268	0Â·52-0Â·93	N	I-Premise
269	,	N	I-Premise
270	p=0Â·01	N	I-Premise
271	)	N	I-Premise
272	,	N	I-Premise
273	but	N	I-Premise
274	not	N	I-Premise
275	with	N	I-Premise
276	hypofractionated	N	I-Premise
277	radiotherapy	N	I-Premise
278	(	N	I-Premise
279	7Â·5	N	I-Premise
280	months	N	I-Premise
281	[	N	I-Premise
282	6Â·5-8Â·6	N	I-Premise
283	;	N	I-Premise
284	n=98	N	I-Premise
285	]	N	I-Premise
286	,	N	I-Premise
287	HR	N	I-Premise
288	0Â·85	N	I-Premise
289	[	N	I-Premise
290	0Â·64-1Â·12	N	I-Premise
291	]	N	I-Premise
292	,	N	I-Premise
293	p=0Â·24	N	I-Premise
294	)	N	I-Premise
295	.	N	I-Premise

296	For	N	I-Premise
297	all	N	I-Premise
298	patients	N	I-Premise
299	who	N	I-Premise
300	received	N	I-Premise
301	temozolomide	N	I-Premise
302	or	N	I-Premise
303	hypofractionated	N	I-Premise
304	radiotherapy	N	I-Premise
305	(	N	I-Premise
306	n=242	N	I-Premise
307	)	N	I-Premise
308	overall	N	I-Premise
309	survival	N	I-Premise
310	was	N	I-Premise
311	similar	N	I-Premise
312	(	N	I-Premise
313	8Â·4	N	I-Premise
314	months	N	I-Premise
315	[	N	I-Premise
316	7Â·3-9Â·4	N	I-Premise
317	;	N	I-Premise
318	n=119	N	I-Premise
319	]	N	I-Premise
320	vs	N	I-Premise
321	7Â·4	N	I-Premise
322	months	N	I-Premise
323	[	N	I-Premise
324	6Â·4-8Â·4	N	I-Premise
325	;	N	I-Premise
326	n=123	N	I-Premise
327	]	N	I-Premise
328	;	N	I-Premise
329	HR	N	I-Premise
330	0Â·82	N	I-Premise
331	,	N	I-Premise
332	95	N	I-Premise
333	%	N	I-Premise
334	CI	N	I-Premise
335	0Â·63-1Â·06	N	I-Premise
336	;	N	I-Premise
337	p=0Â·12	N	I-Premise
338	)	N	I-Premise
339	.	N	I-Premise

340	For	N	I-Premise
341	age	N	I-Premise
342	older	N	I-Premise
343	than	N	I-Premise
344	70	N	I-Premise
345	years	N	I-Premise
346	,	N	I-Premise
347	survival	N	I-Premise
348	was	N	I-Premise
349	better	N	I-Premise
350	with	N	I-Premise
351	temozolomide	N	I-Premise
352	and	N	I-Premise
353	with	N	I-Premise
354	hypofractionated	N	I-Premise
355	radiotherapy	N	I-Premise
356	than	N	I-Premise
357	with	N	I-Premise
358	standard	N	I-Premise
359	radiotherapy	N	I-Premise
360	(	N	I-Premise
361	HR	N	I-Premise
362	for	N	I-Premise
363	temozolomide	N	I-Premise
364	vs	N	I-Premise
365	standard	N	I-Premise
366	radiotherapy	N	I-Premise
367	0Â·35	N	I-Premise
368	[	N	I-Premise
369	0Â·21-0Â·56	N	I-Premise
370	]	N	I-Premise
371	,	N	I-Premise
372	p	N	I-Premise
373	<	N	I-Premise
374	0Â·0001	N	I-Premise
375	;	N	I-Premise
376	HR	N	I-Premise
377	for	N	I-Premise
378	hypofractionated	N	I-Premise
379	vs	N	I-Premise
380	standard	N	I-Premise
381	radiotherapy	N	I-Premise
382	0Â·59	N	I-Premise
383	[	N	I-Premise
384	95	N	I-Premise
385	%	N	I-Premise
386	CI	N	I-Premise
387	0Â·37-0Â·93	N	I-Premise
388	]	N	I-Premise
389	,	N	I-Premise
390	p=0Â·02	N	I-Premise
391	)	N	I-Premise
392	.	N	I-Premise

393	Patients	N	I-Premise
394	treated	N	I-Premise
395	with	N	I-Premise
396	temozolomide	N	I-Premise
397	who	N	I-Premise
398	had	N	I-Premise
399	tumour	N	I-Premise
400	MGMT	N	I-Premise
401	promoter	N	I-Premise
402	methylation	N	I-Premise
403	had	N	I-Premise
404	significantly	N	I-Premise
405	longer	N	I-Premise
406	survival	N	I-Premise
407	than	N	I-Premise
408	those	N	I-Premise
409	without	N	I-Premise
410	MGMT	N	I-Premise
411	promoter	N	I-Premise
412	methylation	N	I-Premise
413	(	N	I-Premise
414	9Â·7	N	I-Premise
415	months	N	I-Premise
416	[	N	I-Premise
417	95	N	I-Premise
418	%	N	I-Premise
419	CI	N	I-Premise
420	8Â·0-11Â·4	N	I-Premise
421	]	N	I-Premise
422	vs	N	I-Premise
423	6Â·8	N	I-Premise
424	months	N	I-Premise
425	[	N	I-Premise
426	5Â·9-7Â·7	N	I-Premise
427	]	N	I-Premise
428	;	N	I-Premise
429	HR	N	I-Premise
430	0Â·56	N	I-Premise
431	[	N	I-Premise
432	95	N	I-Premise
433	%	N	I-Premise
434	CI	N	I-Premise
435	0Â·34-0Â·93	N	I-Premise
436	]	N	I-Premise
437	,	N	I-Premise
438	p=0Â·02	N	I-Premise
439	)	N	I-Premise
440	,	N	I-Premise
441	but	N	I-Premise
442	no	N	I-Premise
443	difference	N	I-Premise
444	was	N	I-Premise
445	noted	N	I-Premise
446	between	N	I-Premise
447	those	N	I-Premise
448	with	N	I-Premise
449	methylated	N	I-Premise
450	and	N	I-Premise
451	unmethylated	N	I-Premise
452	MGMT	N	I-Premise
453	promoter	N	I-Premise
454	treated	N	I-Premise
455	with	N	I-Premise
456	radiotherapy	N	I-Premise
457	(	N	I-Premise
458	HR	N	I-Premise
459	0Â·97	N	I-Premise
460	[	N	I-Premise
461	95	N	I-Premise
462	%	N	I-Premise
463	CI	N	I-Premise
464	0Â·69-1Â·38	N	I-Premise
465	]	N	I-Premise
466	;	N	I-Premise
467	p=0Â·81	N	I-Premise
468	)	N	I-Premise
469	.	N	I-Premise

470	As	N	O
471	expected	N	O
472	,	N	O
473	the	N	I-Premise
474	most	N	I-Premise
475	common	N	I-Premise
476	grade	N	I-Premise
477	3-4	N	I-Premise
478	adverse	N	I-Premise
479	events	N	I-Premise
480	in	N	I-Premise
481	the	N	I-Premise
482	temozolomide	N	I-Premise
483	group	N	I-Premise
484	were	N	I-Premise
485	neutropenia	N	I-Premise
486	(	N	I-Premise
487	n=12	N	I-Premise
488	)	N	I-Premise
489	and	N	I-Premise
490	thrombocytopenia	N	I-Premise
491	(	N	I-Premise
492	n=18	N	I-Premise
493	)	N	I-Premise
494	.	N	I-Premise

495	Grade	N	I-Premise
496	3-5	N	I-Premise
497	infections	N	I-Premise
498	in	N	I-Premise
499	all	N	I-Premise
500	randomisation	N	I-Premise
501	groups	N	I-Premise
502	were	N	I-Premise
503	reported	N	I-Premise
504	in	N	I-Premise
505	18	N	I-Premise
506	patients	N	I-Premise
507	.	N	I-Premise

508	Two	N	I-Premise
509	patients	N	I-Premise
510	had	N	I-Premise
511	fatal	N	I-Premise
512	infections	N	I-Premise
513	(	N	I-Premise
514	one	N	I-Premise
515	in	N	I-Premise
516	the	N	I-Premise
517	temozolomide	N	I-Premise
518	group	N	I-Premise
519	and	N	I-Premise
520	one	N	I-Premise
521	in	N	I-Premise
522	the	N	I-Premise
523	standard	N	I-Premise
524	radiotherapy	N	I-Premise
525	group	N	I-Premise
526	)	N	I-Premise
527	and	N	I-Premise
528	one	N	I-Premise
529	in	N	I-Premise
530	the	N	I-Premise
531	temozolomide	N	I-Premise
532	group	N	I-Premise
533	with	N	I-Premise
534	grade	N	I-Premise
535	2	N	I-Premise
536	thrombocytopenia	N	I-Premise
537	died	N	I-Premise
538	from	N	I-Premise
539	complications	N	I-Premise
540	after	N	I-Premise
541	surgery	N	I-Premise
542	for	N	I-Premise
543	a	N	I-Premise
544	gastrointestinal	N	I-Premise
545	bleed	N	I-Premise
546	.	N	I-Premise

547	Standard	N	I-Claim
548	radiotherapy	N	I-Claim
549	was	N	I-Claim
550	associated	N	I-Claim
551	with	N	I-Claim
552	poor	N	I-Claim
553	outcomes	N	I-Claim
554	,	N	I-Claim
555	especially	N	I-Claim
556	in	N	I-Claim
557	patients	N	I-Claim
558	older	N	I-Claim
559	than	N	I-Claim
560	70	N	I-Claim
561	years	N	I-Claim
562	.	N	I-Claim

563	Both	N	I-Claim
564	temozolomide	N	I-Claim
565	and	N	I-Claim
566	hypofractionated	N	I-Claim
567	radiotherapy	N	I-Claim
568	should	N	I-Claim
569	be	N	I-Claim
570	considered	N	I-Claim
571	as	N	I-Claim
572	standard	N	I-Claim
573	treatment	N	I-Claim
574	options	N	I-Claim
575	in	N	I-Claim
576	elderly	N	I-Claim
577	patients	N	I-Claim
578	with	N	I-Claim
579	glioblastoma	N	I-Claim
580	.	N	I-Claim

581	MGMT	N	I-Claim
582	promoter	N	I-Claim
583	methylation	N	I-Claim
584	status	N	I-Claim
585	might	N	I-Claim
586	be	N	I-Claim
587	a	N	I-Claim
588	useful	N	I-Claim
589	predictive	N	I-Claim
590	marker	N	I-Claim
591	for	N	I-Claim
592	benefit	N	I-Claim
593	from	N	I-Claim
594	temozolomide	N	I-Claim
595	.	N	I-Claim

1	This	N	O
2	randomised	N	O
3	,	N	O
4	placebo-controlled	N	O
5	single-blind	N	O
6	trial	N	O
7	investigated	N	O
8	the	N	O
9	safety	N	O
10	and	N	O
11	efficacy	N	O
12	of	N	O
13	SAMITALÂ®	N	O
14	,	N	O
15	a	N	O
16	formulation	N	O
17	of	N	O
18	highly	N	O
19	standardised	N	O
20	botanical	N	O
21	extracts	N	O
22	,	N	O
23	in	N	O
24	the	N	O
25	treatment	N	O
26	of	N	O
27	chemo/radiotherapy-induced	N	O
28	oral	N	O
29	mucositis	N	O
30	(	N	O
31	OM	N	O
32	)	N	O
33	in	N	O
34	patients	N	O
35	with	N	O
36	head	N	O
37	and	N	O
38	neck	N	O
39	cancer	N	O
40	.	N	O

41	Patients	N	O
42	received	N	O
43	SAMITALÂ®	N	O
44	or	N	O
45	placebo	N	O
46	four	N	O
47	times	N	O
48	daily	N	O
49	for	N	O
50	up	N	O
51	to	N	O
52	50	N	O
53	days	N	O
54	during	N	O
55	scheduled	N	O
56	chemo/radiotherapy	N	O
57	.	N	O

58	Severity	N	O
59	of	N	O
60	OM	N	O
61	was	N	O
62	monitored	N	O
63	according	N	O
64	to	N	O
65	a	N	O
66	modified	N	O
67	WHO	N	O
68	severity	N	O
69	scale	N	O
70	,	N	O
71	and	N	O
72	pain	N	O
73	and	N	O
74	quality-of-life	N	O
75	assessments	N	O
76	were	N	O
77	based	N	O
78	on	N	O
79	the	N	O
80	effect	N	O
81	of	N	O
82	symptoms	N	O
83	of	N	O
84	OM	N	O
85	on	N	O
86	relevant	N	O
87	daily	N	O
88	activities	N	O
89	,	N	O
90	according	N	O
91	to	N	O
92	a	N	O
93	visual	N	O
94	analogue	N	O
95	scale	N	O
96	.	N	O

97	Mean	N	I-Premise
98	scores	N	I-Premise
99	for	N	I-Premise
100	the	N	I-Premise
101	severity	N	I-Premise
102	of	N	I-Premise
103	OM	N	I-Premise
104	were	N	I-Premise
105	significantly	N	I-Premise
106	(	N	I-Premise
107	p	N	I-Premise
108	<	N	I-Premise
109	0.05	N	I-Premise
110	versus	N	I-Premise
111	baseline	N	I-Premise
112	)	N	I-Premise
113	reduced	N	I-Premise
114	from	N	I-Premise
115	day	N	I-Premise
116	31	N	I-Premise
117	until	N	I-Premise
118	the	N	I-Premise
119	end	N	I-Premise
120	of	N	I-Premise
121	treatment	N	I-Premise
122	in	N	I-Premise
123	patients	N	I-Premise
124	treated	N	I-Premise
125	with	N	I-Premise
126	SAMITALÂ®	N	I-Premise
127	(	N	I-Premise
128	n	N	I-Premise
129	=	N	I-Premise
130	20	N	I-Premise
131	)	N	I-Premise
132	.	N	I-Premise

133	No	N	I-Premise
134	significant	N	I-Premise
135	improvement	N	I-Premise
136	was	N	I-Premise
137	observed	N	I-Premise
138	in	N	I-Premise
139	the	N	I-Premise
140	placebo	N	I-Premise
141	group	N	I-Premise
142	(	N	I-Premise
143	n	N	I-Premise
144	=	N	I-Premise
145	10	N	I-Premise
146	)	N	I-Premise
147	.	N	I-Premise

148	Pain	N	I-Premise
149	reduction	N	I-Premise
150	was	N	I-Premise
151	significant	N	I-Premise
152	from	N	I-Premise
153	day	N	I-Premise
154	4	N	I-Premise
155	till	N	I-Premise
156	end	N	I-Premise
157	of	N	I-Premise
158	treatment	N	I-Premise
159	with	N	I-Premise
160	SAMITALÂ®	N	I-Premise
161	and	N	I-Premise
162	from	N	I-Premise
163	days	N	I-Premise
164	7	N	I-Premise
165	to	N	I-Premise
166	21	N	I-Premise
167	in	N	I-Premise
168	placebo	N	I-Premise
169	patients	N	I-Premise
170	.	N	I-Premise

171	SAMITALÂ®	N	I-Premise
172	also	N	I-Premise
173	significantly	N	I-Premise
174	improved	N	I-Premise
175	quality	N	I-Premise
176	of	N	I-Premise
177	life	N	I-Premise
178	,	N	I-Premise
179	as	N	I-Premise
180	shown	N	I-Premise
181	by	N	I-Premise
182	improvements	N	I-Premise
183	in	N	I-Premise
184	scores	N	I-Premise
185	for	N	I-Premise
186	relevant	N	I-Premise
187	daily	N	I-Premise
188	activities	N	I-Premise
189	including	N	I-Premise
190	eating	N	I-Premise
191	,	N	I-Premise
192	drinking	N	I-Premise
193	and	N	I-Premise
194	sleeping	N	I-Premise
195	.	N	I-Premise

196	All	N	O
197	SAMITALÂ®	N	O
198	patients	N	O
199	completed	N	O
200	the	N	O
201	treatment	N	O
202	period	N	O
203	,	N	O
204	but	N	O
205	no	N	O
206	placebo	N	O
207	recipients	N	O
208	completed	N	O
209	treatment	N	O
210	.	N	O

211	No	N	I-Premise
212	severe	N	I-Premise
213	adverse	N	I-Premise
214	events	N	I-Premise
215	were	N	I-Premise
216	observed	N	I-Premise
217	with	N	I-Premise
218	SAMITALÂ®	N	I-Premise
219	,	N	I-Premise
220	and	N	I-Premise
221	systemic	N	I-Premise
222	absorption	N	I-Premise
223	of	N	I-Premise
224	relevant	N	I-Premise
225	active	N	I-Premise
226	ingredients	N	I-Premise
227	was	N	I-Premise
228	undetectable	N	I-Premise
229	.	N	I-Premise

230	SAMITALÂ®	N	I-Claim
231	significantly	N	I-Claim
232	decreased	N	I-Claim
233	the	N	I-Claim
234	severity	N	I-Claim
235	of	N	I-Claim
236	chemo/radiotherapy-induced	N	I-Claim
237	OM	N	I-Claim
238	in	N	I-Claim
239	patients	N	I-Claim
240	with	N	I-Claim
241	head	N	I-Claim
242	and	N	I-Claim
243	neck	N	I-Claim
244	cancer	N	I-Claim
245	,	N	I-Claim
246	with	N	I-Claim
247	no	N	I-Claim
248	treatment-related	N	I-Claim
249	adverse	N	I-Claim
250	events	N	I-Claim
251	.	N	I-Claim

252	Pain	N	I-Claim
253	relief	N	I-Claim
254	lasted	N	I-Claim
255	through	N	I-Claim
256	the	N	I-Claim
257	treatment	N	I-Claim
258	period	N	I-Claim
259	,	N	I-Claim
260	and	N	I-Claim
261	improvements	N	I-Claim
262	in	N	I-Claim
263	quality	N	I-Claim
264	of	N	I-Claim
265	life	N	I-Claim
266	were	N	I-Claim
267	reflected	N	I-Claim
268	by	N	I-Claim
269	the	N	I-Claim
270	significant	N	I-Claim
271	benefits	N	I-Claim
272	of	N	I-Claim
273	SAMITALÂ®	N	I-Claim
274	on	N	I-Claim
275	activities	N	I-Claim
276	like	N	I-Claim
277	drinking	N	I-Claim
278	,	N	I-Claim
279	eating	N	I-Claim
280	and	N	I-Claim
281	speaking	N	I-Claim
282	.	N	I-Claim

1	We	N	O
2	investigated	N	O
3	the	N	O
4	influence	N	O
5	of	N	O
6	bladder	N	O
7	neck	N	O
8	preservation	N	O
9	on	N	O
10	urinary	N	O
11	continence	N	O
12	,	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	and	N	O
17	surgical	N	O
18	margins	N	O
19	after	N	O
20	radical	N	O
21	prostatectomy	N	O
22	.	N	O

23	A	N	O
24	total	N	O
25	of	N	O
26	208	N	O
27	men	N	O
28	who	N	O
29	presented	N	O
30	for	N	O
31	radical	N	O
32	prostatectomy	N	O
33	were	N	O
34	randomized	N	O
35	to	N	O
36	complete	N	O
37	bladder	N	O
38	neck	N	O
39	preservation	N	O
40	with	N	O
41	subsequent	N	O
42	urethro-urethral	N	O
43	anastomosis	N	O
44	or	N	O
45	to	N	O
46	no	N	O
47	preservation	N	O
48	as	N	O
49	controls	N	O
50	.	N	O

51	Patients	N	O
52	with	N	O
53	failed	N	O
54	bladder	N	O
55	neck	N	O
56	preservation	N	O
57	were	N	O
58	not	N	O
59	included	N	O
60	in	N	O
61	study	N	O
62	.	N	O

63	We	N	O
64	documented	N	O
65	objective	N	O
66	continence	N	O
67	by	N	O
68	the	N	O
69	24-hour	N	O
70	pad	N	O
71	test	N	O
72	,	N	O
73	social	N	O
74	continence	N	O
75	by	N	O
76	the	N	O
77	number	N	O
78	of	N	O
79	pads	N	O
80	per	N	O
81	day	N	O
82	and	N	O
83	quality	N	O
84	of	N	O
85	life	N	O
86	outcomes	N	O
87	by	N	O
88	the	N	O
89	validated	N	O
90	Incontinence	N	O
91	Quality	N	O
92	of	N	O
93	Life	N	O
94	questionnaire	N	O
95	in	N	O
96	a	N	O
97	single	N	O
98	blind	N	O
99	setting	N	O
100	.	N	O

101	Cancer	N	O
102	resection	N	O
103	was	N	O
104	assessed	N	O
105	by	N	O
106	surgical	N	O
107	margin	N	O
108	status	N	O
109	.	N	O

110	At	N	I-Premise
111	0	N	I-Premise
112	,	N	I-Premise
113	3	N	I-Premise
114	,	N	I-Premise
115	6	N	I-Premise
116	and	N	I-Premise
117	12	N	I-Premise
118	months	N	I-Premise
119	mean	N	I-Premise
120	urine	N	I-Premise
121	loss	N	I-Premise
122	in	N	I-Premise
123	the	N	I-Premise
124	control	N	I-Premise
125	vs	N	I-Premise
126	the	N	I-Premise
127	bladder	N	I-Premise
128	neck	N	I-Premise
129	preservation	N	I-Premise
130	group	N	I-Premise
131	was	N	I-Premise
132	713.3	N	I-Premise
133	vs	N	I-Premise
134	237.0	N	I-Premise
135	,	N	I-Premise
136	49.6	N	I-Premise
137	vs	N	I-Premise
138	15.6	N	I-Premise
139	,	N	I-Premise
140	44.4	N	I-Premise
141	vs	N	I-Premise
142	5.5	N	I-Premise
143	and	N	I-Premise
144	25.4	N	I-Premise
145	vs	N	I-Premise
146	3.1	N	I-Premise
147	gm	N	I-Premise
148	,	N	I-Premise
149	respectively	N	I-Premise
150	(	N	I-Premise
151	each	N	I-Premise
152	p	N	I-Premise
153	<	N	I-Premise
154	0.001	N	I-Premise
155	)	N	I-Premise
156	.	N	I-Premise

157	At	N	I-Premise
158	3	N	I-Premise
159	,	N	I-Premise
160	6	N	I-Premise
161	and	N	I-Premise
162	12	N	I-Premise
163	months	N	I-Premise
164	in	N	I-Premise
165	the	N	I-Premise
166	control	N	I-Premise
167	vs	N	I-Premise
168	the	N	I-Premise
169	preservation	N	I-Premise
170	group	N	I-Premise
171	the	N	I-Premise
172	social	N	I-Premise
173	continence	N	I-Premise
174	rate	N	I-Premise
175	was	N	I-Premise
176	55.3	N	I-Premise
177	%	N	I-Premise
178	vs	N	I-Premise
179	84.2	N	I-Premise
180	%	N	I-Premise
181	(	N	I-Premise
182	p	N	I-Premise
183	<	N	I-Premise
184	0.001	N	I-Premise
185	)	N	I-Premise
186	,	N	I-Premise
187	74.8	N	I-Premise
188	%	N	I-Premise
189	vs	N	I-Premise
190	89.5	N	I-Premise
191	%	N	I-Premise
192	(	N	I-Premise
193	p	N	I-Premise
194	=	N	I-Premise
195	0.05	N	I-Premise
196	)	N	I-Premise
197	and	N	I-Premise
198	81.4	N	I-Premise
199	%	N	I-Premise
200	vs	N	I-Premise
201	94.7	N	I-Premise
202	%	N	I-Premise
203	(	N	I-Premise
204	p	N	I-Premise
205	=	N	I-Premise
206	0.027	N	I-Premise
207	)	N	I-Premise
208	,	N	I-Premise
209	and	N	I-Premise
210	the	N	I-Premise
211	quality	N	I-Premise
212	of	N	I-Premise
213	life	N	I-Premise
214	score	N	I-Premise
215	was	N	I-Premise
216	80.4	N	I-Premise
217	vs	N	I-Premise
218	90.3	N	I-Premise
219	(	N	I-Premise
220	p	N	I-Premise
221	<	N	I-Premise
222	0.001	N	I-Premise
223	)	N	I-Premise
224	,	N	I-Premise
225	85.4	N	I-Premise
226	vs	N	I-Premise
227	91.7	N	I-Premise
228	(	N	I-Premise
229	p	N	I-Premise
230	=	N	I-Premise
231	0.016	N	I-Premise
232	)	N	I-Premise
233	and	N	I-Premise
234	86.0	N	I-Premise
235	vs	N	I-Premise
236	93.8	N	I-Premise
237	(	N	I-Premise
238	p	N	I-Premise
239	=	N	I-Premise
240	0.001	N	I-Premise
241	)	N	I-Premise
242	,	N	I-Premise
243	respectively	N	I-Premise
244	.	N	I-Premise

245	We	N	I-Premise
246	noted	N	I-Premise
247	significantly	N	I-Premise
248	less	N	I-Premise
249	urine	N	I-Premise
250	loss	N	I-Premise
251	,	N	I-Premise
252	higher	N	I-Premise
253	objective	N	I-Premise
254	and	N	I-Premise
255	social	N	I-Premise
256	continence	N	I-Premise
257	rates	N	I-Premise
258	,	N	I-Premise
259	and	N	I-Premise
260	higher	N	I-Premise
261	quality	N	I-Premise
262	of	N	I-Premise
263	life	N	I-Premise
264	scores	N	I-Premise
265	after	N	I-Premise
266	complete	N	I-Premise
267	bladder	N	I-Premise
268	neck	N	I-Premise
269	preservation	N	I-Premise
270	at	N	I-Premise
271	all	N	I-Premise
272	followup	N	I-Premise
273	points	N	I-Premise
274	.	N	I-Premise

275	On	N	O
276	multiple	N	O
277	logistic	N	O
278	regression	N	O
279	analysis	N	O
280	complete	N	O
281	bladder	N	O
282	neck	N	O
283	preservation	N	O
284	was	N	O
285	an	N	O
286	independent	N	O
287	positive	N	O
288	predictor	N	O
289	of	N	O
290	continence	N	O
291	.	N	O

292	No	N	I-Premise
293	significant	N	I-Premise
294	difference	N	I-Premise
295	was	N	I-Premise
296	found	N	I-Premise
297	in	N	I-Premise
298	surgical	N	I-Premise
299	margin	N	I-Premise
300	status	N	I-Premise
301	between	N	I-Premise
302	the	N	I-Premise
303	control	N	I-Premise
304	and	N	I-Premise
305	bladder	N	I-Premise
306	neck	N	I-Premise
307	preservation	N	I-Premise
308	groups	N	I-Premise
309	(	N	I-Premise
310	12.5	N	I-Premise
311	%	N	I-Premise
312	vs	N	I-Premise
313	14.7	N	I-Premise
314	%	N	I-Premise
315	,	N	I-Premise
316	p	N	I-Premise
317	=	N	I-Premise
318	0.65	N	I-Premise
319	)	N	I-Premise
320	.	N	I-Premise

321	In	N	I-Claim
322	what	N	I-Claim
323	is	N	I-Claim
324	to	N	I-Claim
325	our	N	I-Claim
326	knowledge	N	I-Claim
327	the	N	I-Claim
328	first	N	I-Claim
329	prospective	N	I-Claim
330	,	N	I-Claim
331	randomized	N	I-Claim
332	,	N	I-Claim
333	controlled	N	I-Claim
334	,	N	I-Claim
335	single	N	I-Claim
336	blind	N	I-Claim
337	trial	N	I-Claim
338	complete	N	I-Claim
339	bladder	N	I-Claim
340	neck	N	I-Claim
341	preservation	N	I-Claim
342	during	N	I-Claim
343	radical	N	I-Claim
344	prostatectomy	N	I-Claim
345	was	N	I-Claim
346	associated	N	I-Claim
347	with	N	I-Claim
348	a	N	I-Claim
349	significantly	N	I-Claim
350	higher	N	I-Claim
351	urinary	N	I-Claim
352	continence	N	I-Claim
353	rate	N	I-Claim
354	and	N	I-Claim
355	increased	N	I-Claim
356	patient	N	I-Claim
357	satisfaction	N	I-Claim
358	without	N	I-Claim
359	compromising	N	I-Claim
360	resection	N	I-Claim
361	margins	N	I-Claim
362	.	N	I-Claim

1	Docetaxel	N	O
2	administered	N	O
3	every	N	O
4	3	N	O
5	weeks	N	O
6	is	N	O
7	a	N	O
8	standard	N	O
9	treatment	N	O
10	for	N	O
11	castration-resistant	N	O
12	advanced	N	O
13	prostate	N	O
14	cancer	N	O
15	.	N	O

16	We	N	O
17	hypothesised	N	O
18	that	N	O
19	2-weekly	N	O
20	administration	N	O
21	of	N	O
22	docetaxel	N	O
23	would	N	O
24	be	N	O
25	better	N	O
26	tolerated	N	O
27	than	N	O
28	3-weekly	N	O
29	docetaxel	N	O
30	in	N	O
31	patients	N	O
32	with	N	O
33	castration-resistant	N	O
34	advanced	N	O
35	prostate	N	O
36	cancer	N	O
37	,	N	O
38	and	N	O
39	did	N	O
40	a	N	O
41	prospective	N	O
42	,	N	O
43	multicentre	N	O
44	,	N	O
45	randomised	N	O
46	,	N	O
47	phase	N	O
48	3	N	O
49	study	N	O
50	to	N	O
51	compare	N	O
52	efficacy	N	O
53	and	N	O
54	safety	N	O
55	.	N	O

56	Eligible	N	O
57	patients	N	O
58	had	N	O
59	advanced	N	O
60	prostate	N	O
61	cancer	N	O
62	(	N	O
63	metastasis	N	O
64	,	N	O
65	a	N	O
66	prostate-specific-antigen	N	O
67	test	N	O
68	result	N	O
69	of	N	O
70	more	N	O
71	than	N	O
72	10Â·0	N	O
73	ng/mL	N	O
74	,	N	O
75	and	N	O
76	WHO	N	O
77	performance	N	O
78	status	N	O
79	score	N	O
80	of	N	O
81	0-2	N	O
82	)	N	O
83	,	N	O
84	had	N	O
85	received	N	O
86	no	N	O
87	chemotherapy	N	O
88	(	N	O
89	except	N	O
90	with	N	O
91	estramustine	N	O
92	)	N	O
93	,	N	O
94	had	N	O
95	undergone	N	O
96	surgical	N	O
97	or	N	O
98	chemical	N	O
99	castration	N	O
100	,	N	O
101	and	N	O
102	had	N	O
103	been	N	O
104	referred	N	O
105	to	N	O
106	a	N	O
107	treatment	N	O
108	centre	N	O
109	in	N	O
110	Finland	N	O
111	,	N	O
112	Ireland	N	O
113	,	N	O
114	or	N	O
115	Sweden	N	O
116	.	N	O

117	Enrolment	N	O
118	and	N	O
119	treatment	N	O
120	were	N	O
121	done	N	O
122	between	N	O
123	March	N	O
124	1	N	O
125	,	N	O
126	2004	N	O
127	,	N	O
128	and	N	O
129	May	N	O
130	31	N	O
131	,	N	O
132	2009	N	O
133	.	N	O

134	Randomisation	N	O
135	was	N	O
136	done	N	O
137	centrally	N	O
138	and	N	O
139	stratified	N	O
140	by	N	O
141	centre	N	O
142	and	N	O
143	WHO	N	O
144	performance	N	O
145	status	N	O
146	score	N	O
147	of	N	O
148	0-1	N	O
149	vs	N	O
150	2	N	O
151	.	N	O

152	Patients	N	O
153	were	N	O
154	assigned	N	O
155	75	N	O
156	mg/m	N	O
157	(	N	O
158	2	N	O
159	)	N	O
160	docetaxel	N	O
161	intravenously	N	O
162	on	N	O
163	day	N	O
164	1	N	O
165	of	N	O
166	a	N	O
167	3-week	N	O
168	cycle	N	O
169	,	N	O
170	or	N	O
171	50	N	O
172	mg/m	N	O
173	(	N	O
174	2	N	O
175	)	N	O
176	docetaxel	N	O
177	intravenously	N	O
178	on	N	O
179	days	N	O
180	1	N	O
181	and	N	O
182	15	N	O
183	of	N	O
184	a	N	O
185	4-week	N	O
186	cycle	N	O
187	.	N	O

188	10	N	O
189	mg	N	O
190	oral	N	O
191	prednisolone	N	O
192	was	N	O
193	administered	N	O
194	daily	N	O
195	to	N	O
196	all	N	O
197	patients	N	O
198	.	N	O

199	The	N	O
200	primary	N	O
201	endpoint	N	O
202	was	N	O
203	time	N	O
204	to	N	O
205	treatment	N	O
206	failure	N	O
207	(	N	O
208	TTTF	N	O
209	)	N	O
210	.	N	O

211	We	N	O
212	assessed	N	O
213	data	N	O
214	in	N	O
215	the	N	O
216	per-protocol	N	O
217	population	N	O
218	.	N	O

219	177	N	O
220	patients	N	O
221	were	N	O
222	randomly	N	O
223	assigned	N	O
224	to	N	O
225	the	N	O
226	2-weekly	N	O
227	docetaxel	N	O
228	group	N	O
229	and	N	O
230	184	N	O
231	to	N	O
232	the	N	O
233	3-weekly	N	O
234	group	N	O
235	.	N	O

236	170	N	O
237	patients	N	O
238	in	N	O
239	the	N	O
240	2-weekly	N	O
241	group	N	O
242	and	N	O
243	176	N	O
244	in	N	O
245	the	N	O
246	3-weekly	N	O
247	group	N	O
248	were	N	O
249	included	N	O
250	in	N	O
251	the	N	O
252	analysis	N	O
253	.	N	O

254	The	N	I-Premise
255	2-weekly	N	I-Premise
256	administration	N	I-Premise
257	was	N	I-Premise
258	associated	N	I-Premise
259	with	N	I-Premise
260	significantly	N	I-Premise
261	longer	N	I-Premise
262	TTTF	N	I-Premise
263	than	N	I-Premise
264	was	N	I-Premise
265	3-weekly	N	I-Premise
266	administration	N	I-Premise
267	(	N	I-Premise
268	5Â·6	N	I-Premise
269	months	N	I-Premise
270	,	N	I-Premise
271	95	N	I-Premise
272	%	N	I-Premise
273	CI	N	I-Premise
274	5Â·0-6Â·2	N	I-Premise
275	vs	N	I-Premise
276	4Â·9	N	I-Premise
277	months	N	I-Premise
278	,	N	I-Premise
279	4Â·5-5Â·4	N	I-Premise
280	;	N	I-Premise
281	hazard	N	I-Premise
282	ratio	N	I-Premise
283	1Â·3	N	I-Premise
284	,	N	I-Premise
285	95	N	I-Premise
286	%	N	I-Premise
287	CI	N	I-Premise
288	1Â·1-1Â·6	N	I-Premise
289	,	N	I-Premise
290	p=0Â·014	N	I-Premise
291	)	N	I-Premise
292	.	N	I-Premise

293	Grade	N	I-Premise
294	3-4	N	I-Premise
295	adverse	N	I-Premise
296	events	N	I-Premise
297	occurred	N	I-Premise
298	more	N	I-Premise
299	frequently	N	I-Premise
300	in	N	I-Premise
301	the	N	I-Premise
302	3-weekly	N	I-Premise
303	than	N	I-Premise
304	in	N	I-Premise
305	the	N	I-Premise
306	2-weekly	N	I-Premise
307	administration	N	I-Premise
308	group	N	I-Premise
309	,	N	I-Premise
310	including	N	I-Premise
311	neutropenia	N	I-Premise
312	(	N	I-Premise
313	93	N	I-Premise
314	[	N	I-Premise
315	53	N	I-Premise
316	%	N	I-Premise
317	]	N	I-Premise
318	vs	N	I-Premise
319	61	N	I-Premise
320	[	N	I-Premise
321	36	N	I-Premise
322	%	N	I-Premise
323	]	N	I-Premise
324	)	N	I-Premise
325	,	N	I-Premise
326	leucopenia	N	I-Premise
327	(	N	I-Premise
328	51	N	I-Premise
329	[	N	I-Premise
330	29	N	I-Premise
331	%	N	I-Premise
332	]	N	I-Premise
333	vs	N	I-Premise
334	22	N	I-Premise
335	[	N	I-Premise
336	13	N	I-Premise
337	%	N	I-Premise
338	]	N	I-Premise
339	)	N	I-Premise
340	,	N	I-Premise
341	and	N	I-Premise
342	febrile	N	I-Premise
343	neutropenia	N	I-Premise
344	(	N	I-Premise
345	25	N	I-Premise
346	[	N	I-Premise
347	14	N	I-Premise
348	%	N	I-Premise
349	]	N	I-Premise
350	vs	N	I-Premise
351	six	N	I-Premise
352	[	N	I-Premise
353	4	N	I-Premise
354	%	N	I-Premise
355	]	N	I-Premise
356	)	N	I-Premise
357	.	N	I-Premise

358	Neutropenic	N	I-Premise
359	infections	N	I-Premise
360	were	N	I-Premise
361	reported	N	I-Premise
362	more	N	I-Premise
363	frequently	N	I-Premise
364	in	N	I-Premise
365	patients	N	I-Premise
366	who	N	I-Premise
367	received	N	I-Premise
368	docetaxel	N	I-Premise
369	every	N	I-Premise
370	3	N	I-Premise
371	weeks	N	I-Premise
372	(	N	I-Premise
373	43	N	I-Premise
374	[	N	I-Premise
375	24	N	I-Premise
376	%	N	I-Premise
377	]	N	I-Premise
378	vs	N	I-Premise
379	11	N	I-Premise
380	[	N	I-Premise
381	6	N	I-Premise
382	%	N	I-Premise
383	]	N	I-Premise
384	,	N	I-Premise
385	p=0Â·002	N	I-Premise
386	)	N	I-Premise
387	.	N	I-Premise

388	Administration	N	I-Claim
389	of	N	I-Claim
390	docetaxel	N	I-Claim
391	every	N	I-Claim
392	2	N	I-Claim
393	weeks	N	I-Claim
394	seems	N	I-Claim
395	to	N	I-Claim
396	be	N	I-Claim
397	well	N	I-Claim
398	tolerated	N	I-Claim
399	in	N	I-Claim
400	patients	N	I-Claim
401	with	N	I-Claim
402	castration-resistant	N	I-Claim
403	advanced	N	I-Claim
404	prostate	N	I-Claim
405	cancer	N	I-Claim
406	and	N	I-Claim
407	could	N	I-Claim
408	be	N	I-Claim
409	a	N	I-Claim
410	useful	N	I-Claim
411	option	N	I-Claim
412	when	N	I-Claim
413	3-weekly	N	I-Claim
414	single-dose	N	I-Claim
415	administration	N	I-Claim
416	is	N	I-Claim
417	unlikely	N	I-Claim
418	to	N	I-Claim
419	be	N	I-Claim
420	tolerated	N	I-Claim
421	.	N	I-Claim

1	In	N	O
2	the	N	O
3	Gynecologic	N	O
4	Cancer	N	O
5	Intergroup	N	O
6	International	N	O
7	Collaboration	N	O
8	on	N	O
9	Ovarian	N	O
10	Neoplasms	N	O
11	7	N	O
12	(	N	O
13	ICON7	N	O
14	)	N	O
15	trial	N	O
16	,	N	O
17	bevacizumab	N	O
18	improved	N	O
19	progression-free	N	O
20	survival	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	ovarian	N	O
25	cancer	N	O
26	when	N	O
27	used	N	O
28	in	N	O
29	combination	N	O
30	with	N	O
31	first-line	N	O
32	chemotherapy	N	O
33	and	N	O
34	as	N	O
35	a	N	O
36	single-drug	N	O
37	continuation	N	O
38	treatment	N	O
39	for	N	O
40	18	N	O
41	cycles	N	O
42	.	N	O

43	In	N	O
44	a	N	O
45	preliminary	N	O
46	analysis	N	O
47	of	N	O
48	a	N	O
49	high-risk	N	O
50	subset	N	O
51	of	N	O
52	patients	N	O
53	,	N	O
54	there	N	O
55	was	N	O
56	also	N	O
57	an	N	O
58	improvement	N	O
59	in	N	O
60	overall	N	O
61	survival	N	O
62	.	N	O

63	This	N	O
64	study	N	O
65	aims	N	O
66	to	N	O
67	describe	N	O
68	the	N	O
69	health-related	N	O
70	quality-of-life	N	O
71	(	N	O
72	QoL	N	O
73	)	N	O
74	outcomes	N	O
75	from	N	O
76	ICON7	N	O
77	.	N	O

78	ICON7	N	O
79	is	N	O
80	a	N	O
81	randomised	N	O
82	,	N	O
83	multicentre	N	O
84	,	N	O
85	open-label	N	O
86	phase	N	O
87	3	N	O
88	trial	N	O
89	.	N	O

90	Between	N	O
91	Dec	N	O
92	18	N	O
93	,	N	O
94	2006	N	O
95	,	N	O
96	and	N	O
97	Feb	N	O
98	16	N	O
99	,	N	O
100	2009	N	O
101	,	N	O
102	after	N	O
103	a	N	O
104	surgical	N	O
105	procedure	N	O
106	aiming	N	O
107	to	N	O
108	debulk	N	O
109	the	N	O
110	disease	N	O
111	,	N	O
112	women	N	O
113	with	N	O
114	International	N	O
115	Federation	N	O
116	of	N	O
117	Gynecology	N	O
118	and	N	O
119	Obstetrics	N	O
120	(	N	O
121	FIGO	N	O
122	)	N	O
123	high-risk	N	O
124	stage	N	O
125	I-IV	N	O
126	epithelial	N	O
127	ovarian	N	O
128	cancer	N	O
129	were	N	O
130	randomly	N	O
131	allocated	N	O
132	(	N	O
133	1:1	N	O
134	)	N	O
135	by	N	O
136	computer	N	O
137	program	N	O
138	and	N	O
139	block	N	O
140	randomisation	N	O
141	to	N	O
142	receive	N	O
143	either	N	O
144	six	N	O
145	cycles	N	O
146	of	N	O
147	standard	N	O
148	chemotherapy	N	O
149	(	N	O
150	total	N	O
151	18	N	O
152	weeks	N	O
153	)	N	O
154	with	N	O
155	carboplatin	N	O
156	(	N	O
157	area	N	O
158	under	N	O
159	the	N	O
160	curve	N	O
161	5	N	O
162	or	N	O
163	6	N	O
164	)	N	O
165	and	N	O
166	paclitaxel	N	O
167	(	N	O
168	175	N	O
169	mg/m	N	O
170	(	N	O
171	2	N	O
172	)	N	O
173	)	N	O
174	alone	N	O
175	or	N	O
176	with	N	O
177	bevacizumab	N	O
178	(	N	O
179	7Â·5	N	O
180	mg/kg	N	O
181	)	N	O
182	given	N	O
183	intravenously	N	O
184	with	N	O
185	chemotherapy	N	O
186	and	N	O
187	continued	N	O
188	as	N	O
189	a	N	O
190	single	N	O
191	drug	N	O
192	thereafter	N	O
193	(	N	O
194	total	N	O
195	54	N	O
196	weeks	N	O
197	)	N	O
198	.	N	O

199	The	N	O
200	primary	N	O
201	QoL	N	O
202	endpoint	N	O
203	was	N	O
204	global	N	O
205	QoL	N	O
206	from	N	O
207	the	N	O
208	European	N	O
209	Organisation	N	O
210	for	N	O
211	Research	N	O
212	and	N	O
213	Treatment	N	O
214	of	N	O
215	Cancer	N	O
216	quality-of-life	N	O
217	questionnaire-core	N	O
218	30	N	O
219	at	N	O
220	week	N	O
221	54	N	O
222	,	N	O
223	analysed	N	O
224	by	N	O
225	ANOVA	N	O
226	and	N	O
227	adjusted	N	O
228	for	N	O
229	baseline	N	O
230	score	N	O
231	.	N	O

232	Analyses	N	O
233	were	N	O
234	by	N	O
235	intention	N	O
236	to	N	O
237	treat	N	O
238	.	N	O

239	The	N	O
240	ICON7	N	O
241	trial	N	O
242	has	N	O
243	completed	N	O
244	recruitment	N	O
245	and	N	O
246	remains	N	O
247	in	N	O
248	follow-up	N	O
249	.	N	O

250	This	N	O
251	study	N	O
252	is	N	O
253	registered	N	O
254	,	N	O
255	number	N	O
256	ISRCTN91273375	N	O
257	.	N	O

258	764	N	O
259	women	N	O
260	were	N	O
261	randomly	N	O
262	assigned	N	O
263	to	N	O
264	the	N	O
265	standard	N	O
266	chemotherapy	N	O
267	group	N	O
268	and	N	O
269	764	N	O
270	to	N	O
271	the	N	O
272	bevacizumab	N	O
273	group	N	O
274	.	N	O

275	At	N	O
276	baseline	N	O
277	,	N	O
278	684	N	O
279	(	N	O
280	90	N	O
281	%	N	O
282	)	N	O
283	of	N	O
284	women	N	O
285	in	N	O
286	the	N	O
287	standard	N	O
288	chemotherapy	N	O
289	group	N	O
290	and	N	O
291	691	N	O
292	(	N	O
293	90	N	O
294	%	N	O
295	)	N	O
296	of	N	O
297	those	N	O
298	in	N	O
299	the	N	O
300	bevacizumab	N	O
301	group	N	O
302	had	N	O
303	completed	N	O
304	QoL	N	O
305	questionnaires	N	O
306	.	N	O

307	At	N	O
308	week	N	O
309	54	N	O
310	,	N	O
311	502	N	O
312	(	N	O
313	66	N	O
314	%	N	O
315	)	N	O
316	women	N	O
317	in	N	O
318	the	N	O
319	bevacizumab	N	O
320	group	N	O
321	and	N	O
322	388	N	O
323	(	N	O
324	51	N	O
325	%	N	O
326	)	N	O
327	women	N	O
328	in	N	O
329	the	N	O
330	standard	N	O
331	chemotherapy	N	O
332	group	N	O
333	provided	N	O
334	QoL	N	O
335	data	N	O
336	.	N	O

337	Overall	N	I-Premise
338	,	N	I-Premise
339	the	N	I-Premise
340	mean	N	I-Premise
341	global	N	I-Premise
342	QoL	N	I-Premise
343	score	N	I-Premise
344	improved	N	I-Premise
345	during	N	I-Premise
346	chemotherapy	N	I-Premise
347	by	N	I-Premise
348	7Â·2	N	I-Premise
349	points	N	I-Premise
350	(	N	I-Premise
351	SD	N	I-Premise
352	24Â·4	N	I-Premise
353	)	N	I-Premise
354	when	N	I-Premise
355	analysed	N	I-Premise
356	for	N	I-Premise
357	all	N	I-Premise
358	women	N	I-Premise
359	with	N	I-Premise
360	data	N	I-Premise
361	at	N	I-Premise
362	baseline	N	I-Premise
363	and	N	I-Premise
364	week	N	I-Premise
365	18	N	I-Premise
366	.	N	I-Premise

367	The	N	I-Premise
368	mean	N	I-Premise
369	global	N	I-Premise
370	QoL	N	I-Premise
371	score	N	I-Premise
372	at	N	I-Premise
373	54	N	I-Premise
374	weeks	N	I-Premise
375	was	N	I-Premise
376	higher	N	I-Premise
377	in	N	I-Premise
378	the	N	I-Premise
379	standard	N	I-Premise
380	chemotherapy	N	I-Premise
381	group	N	I-Premise
382	than	N	I-Premise
383	in	N	I-Premise
384	the	N	I-Premise
385	bevacizumab	N	I-Premise
386	group	N	I-Premise
387	(	N	I-Premise
388	76Â·1	N	I-Premise
389	[	N	I-Premise
390	SD	N	I-Premise
391	18Â·2	N	I-Premise
392	]	N	I-Premise
393	vs	N	I-Premise
394	69Â·7	N	I-Premise
395	[	N	I-Premise
396	19Â·1	N	I-Premise
397	]	N	I-Premise
398	points	N	I-Premise
399	;	N	I-Premise
400	difference	N	I-Premise
401	6Â·4	N	I-Premise
402	points	N	I-Premise
403	,	N	I-Premise
404	95	N	I-Premise
405	%	N	I-Premise
406	CI	N	I-Premise
407	3Â·7-9Â·0	N	I-Premise
408	,	N	I-Premise
409	p	N	I-Premise
410	<	N	I-Premise
411	0Â·0001	N	I-Premise
412	)	N	I-Premise
413	.	N	I-Premise

414	Bevacizumab	N	I-Claim
415	continuation	N	I-Claim
416	treatment	N	I-Claim
417	seems	N	I-Claim
418	to	N	I-Claim
419	be	N	I-Claim
420	associated	N	I-Claim
421	with	N	I-Claim
422	a	N	I-Claim
423	small	N	I-Claim
424	but	N	I-Claim
425	clinically	N	I-Claim
426	significant	N	I-Claim
427	decrement	N	I-Claim
428	in	N	I-Claim
429	QoL	N	I-Claim
430	compared	N	I-Claim
431	with	N	I-Claim
432	standard	N	I-Claim
433	treatment	N	I-Claim
434	for	N	I-Claim
435	women	N	I-Claim
436	with	N	I-Claim
437	ovarian	N	I-Claim
438	cancer	N	I-Claim
439	.	N	I-Claim

440	The	N	O
441	trade-off	N	O
442	between	N	O
443	the	N	O
444	prolongation	N	O
445	of	N	O
446	progression-free	N	O
447	survival	N	O
448	and	N	O
449	the	N	O
450	quality	N	O
451	of	N	O
452	that	N	O
453	period	N	O
454	of	N	O
455	time	N	O
456	needs	N	O
457	to	N	O
458	be	N	O
459	considered	N	O
460	in	N	O
461	clinical	N	O
462	practice	N	O
463	when	N	O
464	making	N	O
465	treatment	N	O
466	decisions	N	O
467	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	(	N	O
5	QoL	N	O
6	)	N	O
7	after	N	O
8	breast	N	O
9	cancer	N	O
10	is	N	O
11	nowadays	N	O
12	a	N	O
13	major	N	O
14	challenge	N	O
15	.	N	O

16	Complementary	N	O
17	interventions	N	O
18	are	N	O
19	necessary	N	O
20	because	N	O
21	of	N	O
22	frequent	N	O
23	depression	N	O
24	symptoms	N	O
25	after	N	O
26	treatment	N	O
27	and	N	O
28	also	N	O
29	to	N	O
30	favour	N	O
31	return	N	O
32	to	N	O
33	activity	N	O
34	.	N	O

35	Besides	N	O
36	,	N	O
37	radio-chemotherapy	N	O
38	has	N	O
39	side-effects	N	O
40	like	N	O
41	weight	N	O
42	gain	N	O
43	and	N	O
44	fatigue	N	O
45	.	N	O

46	Several	N	O
47	strategies	N	O
48	including	N	O
49	group	N	O
50	behavioural-educational	N	O
51	interventions	N	O
52	,	N	O
53	physical	N	O
54	training	N	O
55	and/or	N	O
56	dietary	N	O
57	education	N	O
58	,	N	O
59	have	N	O
60	been	N	O
61	tested	N	O
62	to	N	O
63	answer	N	O
64	these	N	O
65	difficulties	N	O
66	with	N	O
67	moderate	N	O
68	success	N	O
69	in	N	O
70	the	N	O
71	long	N	O
72	run	N	O
73	.	N	O

74	Two	N	O
75	hundred	N	O
76	and	N	O
77	fifty-one	N	O
78	non-metastatic	N	O
79	patients	N	O
80	were	N	O
81	accrued	N	O
82	after	N	O
83	chemotherapy	N	O
84	in	N	O
85	a	N	O
86	prospective	N	O
87	randomised	N	O
88	multicenter	N	O
89	trial	N	O
90	between	N	O
91	2008	N	O
92	and	N	O
93	2010	N	O
94	,	N	O
95	testing	N	O
96	a	N	O
97	2-week	N	O
98	intervention	N	O
99	in	N	O
100	SPA	N	O
101	centres	N	O
102	.	N	O

103	Intervention	N	O
104	comprised	N	O
105	group	N	O
106	physical	N	O
107	training	N	O
108	,	N	O
109	dietary	N	O
110	education	N	O
111	and	N	O
112	physiotherapy	N	O
113	.	N	O

114	Selected	N	O
115	patients	N	O
116	were	N	O
117	in	N	O
118	complete	N	O
119	remission	N	O
120	.	N	O

121	QoL	N	O
122	was	N	O
123	evaluated	N	O
124	with	N	O
125	SF36	N	O
126	questionnaire	N	O
127	,	N	O
128	anxiety	N	O
129	and	N	O
130	depression	N	O
131	with	N	O
132	the	N	O
133	hospital	N	O
134	anxiety	N	O
135	and	N	O
136	depression	N	O
137	(	N	O
138	HAD	N	O
139	)	N	O
140	one	N	O
141	.	N	O

142	Anthropometric	N	O
143	measures	N	O
144	and	N	O
145	QoL	N	O
146	evaluations	N	O
147	were	N	O
148	obtained	N	O
149	before	N	O
150	randomisation	N	O
151	and	N	O
152	every	N	O
153	6	N	O
154	months	N	O
155	during	N	O
156	3	N	O
157	years	N	O
158	.	N	O

159	Two	N	O
160	hundred	N	O
161	and	N	O
162	twenty	N	O
163	patients	N	O
164	were	N	O
165	evaluable	N	O
166	at	N	O
167	1	N	O
168	year	N	O
169	.	N	O

170	Intervention	N	I-Premise
171	increased	N	I-Premise
172	SF36	N	I-Premise
173	score	N	I-Premise
174	by	N	I-Premise
175	9.5	N	I-Premise
176	points	N	I-Premise
177	(	N	I-Premise
178	p=0.000006	N	I-Premise
179	)	N	I-Premise
180	,	N	I-Premise
181	4.6	N	I-Premise
182	(	N	I-Premise
183	p=0.032	N	I-Premise
184	)	N	I-Premise
185	and	N	I-Premise
186	6.2	N	I-Premise
187	(	N	I-Premise
188	p=0.028	N	I-Premise
189	)	N	I-Premise
190	respectively	N	I-Premise
191	at	N	I-Premise
192	6	N	I-Premise
193	,	N	I-Premise
194	12	N	I-Premise
195	and	N	I-Premise
196	24	N	I-Premise
197	months	N	I-Premise
198	.	N	I-Premise

199	Effect	N	I-Premise
200	size	N	I-Premise
201	(	N	I-Premise
202	ES	N	I-Premise
203	)	N	I-Premise
204	was	N	I-Premise
205	0.63	N	I-Premise
206	[	N	I-Premise
207	0.37	N	I-Premise
208	;	N	I-Premise
209	0.90	N	I-Premise
210	]	N	I-Premise
211	,	N	I-Premise
212	0.29	N	I-Premise
213	[	N	I-Premise
214	0.03	N	I-Premise
215	;	N	I-Premise
216	0.55	N	I-Premise
217	]	N	I-Premise
218	and	N	I-Premise
219	0.41	N	I-Premise
220	[	N	I-Premise
221	0.04	N	I-Premise
222	;	N	I-Premise
223	0.78	N	I-Premise
224	]	N	I-Premise
225	.	N	I-Premise

226	Anxiety	N	I-Premise
227	score	N	I-Premise
228	was	N	I-Premise
229	shortly	N	I-Premise
230	minored	N	I-Premise
231	by	N	I-Premise
232	intervention	N	I-Premise
233	(	N	I-Premise
234	6-month	N	I-Premise
235	ES=-0.24	N	I-Premise
236	[	N	I-Premise
237	-0.42	N	I-Premise
238	;	N	I-Premise
239	-0.05	N	I-Premise
240	]	N	I-Premise
241	)	N	I-Premise
242	and	N	I-Premise
243	depression	N	I-Premise
244	score	N	I-Premise
245	more	N	I-Premise
246	durably	N	I-Premise
247	:	N	I-Premise
248	ES=-0.45	N	I-Premise
249	[	N	I-Premise
250	-0.72	N	I-Premise
251	;	N	I-Premise
252	-0.18	N	I-Premise
253	]	N	I-Premise
254	,	N	I-Premise
255	-0.34	N	I-Premise
256	[	N	I-Premise
257	-061	N	I-Premise
258	;	N	I-Premise
259	-0.08	N	I-Premise
260	]	N	I-Premise
261	,	N	I-Premise
262	and	N	I-Premise
263	-0.26	N	I-Premise
264	[	N	I-Premise
265	-0.63	N	I-Premise
266	;	N	I-Premise
267	0.11	N	I-Premise
268	]	N	I-Premise
269	at	N	I-Premise
270	6	N	I-Premise
271	,	N	I-Premise
272	12	N	I-Premise
273	and	N	I-Premise
274	24	N	I-Premise
275	months	N	I-Premise
276	.	N	I-Premise

277	This	N	I-Claim
278	2-week	N	I-Claim
279	group	N	I-Claim
280	intervention	N	I-Claim
281	seemed	N	I-Claim
282	to	N	I-Claim
283	durably	N	I-Claim
284	influence	N	I-Claim
285	QoL	N	I-Claim
286	of	N	I-Claim
287	breast	N	I-Claim
288	cancer	N	I-Claim
289	patients	N	I-Claim
290	treated	N	I-Claim
291	by	N	I-Claim
292	chemotherapy	N	I-Claim
293	.	N	I-Claim

294	Differences	N	I-Claim
295	,	N	I-Claim
296	smaller	N	I-Claim
297	at	N	I-Claim
298	12	N	I-Claim
299	months	N	I-Claim
300	than	N	I-Claim
301	at	N	I-Claim
302	six	N	I-Claim
303	,	N	I-Claim
304	suggest	N	I-Claim
305	that	N	I-Claim
306	a	N	I-Claim
307	second	N	I-Claim
308	but	N	I-Claim
309	shorter	N	I-Claim
310	intervention	N	I-Claim
311	could	N	I-Claim
312	help	N	I-Claim
313	maintain	N	I-Claim
314	the	N	I-Claim
315	6-month	N	I-Claim
316	benefits	N	I-Claim
317	.	N	I-Claim

1	The	N	O
2	addition	N	O
3	of	N	O
4	mTOR	N	O
5	inhibitor	N	O
6	everolimus	N	O
7	(	N	O
8	EVE	N	O
9	)	N	O
10	to	N	O
11	exemestane	N	O
12	(	N	O
13	EXE	N	O
14	)	N	O
15	was	N	O
16	evaluated	N	O
17	in	N	O
18	an	N	O
19	international	N	O
20	,	N	O
21	phase	N	O
22	3	N	O
23	study	N	O
24	(	N	O
25	BOLERO-2	N	O
26	)	N	O
27	in	N	O
28	patients	N	O
29	with	N	O
30	hormone-receptor-positive	N	O
31	(	N	O
32	HR	N	O
33	(	N	O
34	+	N	O
35	)	N	O
36	)	N	O
37	breast	N	O
38	cancer	N	O
39	refractory	N	O
40	to	N	O
41	letrozole	N	O
42	or	N	O
43	anastrozole	N	O
44	.	N	O

45	The	N	O
46	safety	N	O
47	and	N	O
48	efficacy	N	O
49	of	N	O
50	anticancer	N	O
51	treatments	N	O
52	may	N	O
53	be	N	O
54	influenced	N	O
55	by	N	O
56	ethnicity	N	O
57	(	N	O
58	Sekine	N	O
59	et	N	O
60	al	N	O
61	.	N	O

62	in	N	O
63	Br	N	O
64	J	N	O
65	Cancer	N	O
66	99:1757-62	N	O
67	,	N	O
68	2008	N	O
69	)	N	O
70	.	N	O

71	Safety	N	O
72	and	N	O
73	efficacy	N	O
74	results	N	O
75	from	N	O
76	Asian	N	O
77	versus	N	O
78	non-Asian	N	O
79	patients	N	O
80	in	N	O
81	BOLERO-2	N	O
82	are	N	O
83	reported	N	O
84	.	N	O

85	Patients	N	O
86	were	N	O
87	randomized	N	O
88	(	N	O
89	2:1	N	O
90	)	N	O
91	to	N	O
92	10	N	O
93	mg/day	N	O
94	EVE	N	O
95	+	N	O
96	EXE	N	O
97	or	N	O
98	placebo	N	O
99	(	N	O
100	PBO	N	O
101	)	N	O
102	+	N	O
103	EXE	N	O
104	.	N	O

105	Primary	N	O
106	endpoint	N	O
107	was	N	O
108	progression-free	N	O
109	survival	N	O
110	(	N	O
111	PFS	N	O
112	)	N	O
113	.	N	O

114	Secondary	N	O
115	endpoints	N	O
116	included	N	O
117	overall	N	O
118	survival	N	O
119	,	N	O
120	response	N	O
121	rate	N	O
122	,	N	O
123	clinical	N	O
124	benefit	N	O
125	rate	N	O
126	,	N	O
127	and	N	O
128	safety	N	O
129	.	N	O

130	Of	N	O
131	143	N	O
132	Asian	N	O
133	patients	N	O
134	,	N	O
135	98	N	O
136	received	N	O
137	EVE	N	O
138	+	N	O
139	EXE	N	O
140	and	N	O
141	45	N	O
142	received	N	O
143	PBO	N	O
144	+	N	O
145	EXE	N	O
146	.	N	O

147	Treatment	N	I-Premise
148	with	N	I-Premise
149	EVE	N	I-Premise
150	+	N	I-Premise
151	EXE	N	I-Premise
152	significantly	N	I-Premise
153	improved	N	I-Premise
154	median	N	I-Premise
155	PFS	N	I-Premise
156	versus	N	I-Premise
157	PBO	N	I-Premise
158	+	N	I-Premise
159	EXE	N	I-Premise
160	among	N	I-Premise
161	Asian	N	I-Premise
162	patients	N	I-Premise
163	by	N	I-Premise
164	38	N	I-Premise
165	%	N	I-Premise
166	(	N	I-Premise
167	HR	N	I-Premise
168	=	N	I-Premise
169	0.62	N	I-Premise
170	;	N	I-Premise
171	95	N	I-Premise
172	%	N	I-Premise
173	CI	N	I-Premise
174	,	N	I-Premise
175	0.41-0.94	N	I-Premise
176	)	N	I-Premise
177	.	N	I-Premise

178	Median	N	I-Premise
179	PFS	N	I-Premise
180	was	N	I-Premise
181	also	N	I-Premise
182	improved	N	I-Premise
183	among	N	I-Premise
184	non-Asian	N	I-Premise
185	patients	N	I-Premise
186	by	N	I-Premise
187	59	N	I-Premise
188	%	N	I-Premise
189	(	N	I-Premise
190	HR	N	I-Premise
191	=	N	I-Premise
192	0.41	N	I-Premise
193	;	N	I-Premise
194	95	N	I-Premise
195	%	N	I-Premise
196	CI	N	I-Premise
197	,	N	I-Premise
198	0.33-0.50	N	I-Premise
199	)	N	I-Premise
200	.	N	I-Premise

201	Median	N	I-Premise
202	PFS	N	I-Premise
203	duration	N	I-Premise
204	among	N	I-Premise
205	EVE-treated	N	I-Premise
206	Asian	N	I-Premise
207	patients	N	I-Premise
208	was	N	I-Premise
209	8.48	N	I-Premise
210	versus	N	I-Premise
211	4.14	N	I-Premise
212	months	N	I-Premise
213	for	N	I-Premise
214	PBO	N	I-Premise
215	+	N	I-Premise
216	EXE	N	I-Premise
217	,	N	I-Premise
218	and	N	I-Premise
219	7.33	N	I-Premise
220	versus	N	I-Premise
221	2.83	N	I-Premise
222	months	N	I-Premise
223	,	N	I-Premise
224	respectively	N	I-Premise
225	,	N	I-Premise
226	in	N	I-Premise
227	non-Asian	N	I-Premise
228	patients	N	I-Premise
229	.	N	I-Premise

230	The	N	I-Premise
231	most	N	I-Premise
232	common	N	I-Premise
233	grade	N	I-Premise
234	3/4	N	I-Premise
235	adverse	N	I-Premise
236	events	N	I-Premise
237	(	N	I-Premise
238	stomatitis	N	I-Premise
239	,	N	I-Premise
240	anemia	N	I-Premise
241	,	N	I-Premise
242	elevated	N	I-Premise
243	liver	N	I-Premise
244	enzymes	N	I-Premise
245	,	N	I-Premise
246	hyperglycemia	N	I-Premise
247	,	N	I-Premise
248	and	N	I-Premise
249	dyspnea	N	I-Premise
250	)	N	I-Premise
251	occurred	N	I-Premise
252	at	N	I-Premise
253	similar	N	I-Premise
254	frequencies	N	I-Premise
255	in	N	I-Premise
256	Asian	N	I-Premise
257	and	N	I-Premise
258	non-Asian	N	I-Premise
259	patients	N	I-Premise
260	.	N	I-Premise

261	Grade	N	I-Premise
262	1/2	N	I-Premise
263	interstitial	N	I-Premise
264	lung	N	I-Premise
265	disease	N	I-Premise
266	occurred	N	I-Premise
267	more	N	I-Premise
268	frequently	N	I-Premise
269	in	N	I-Premise
270	Asian	N	I-Premise
271	patients	N	I-Premise
272	.	N	I-Premise

273	Quality	N	I-Premise
274	of	N	I-Premise
275	life	N	I-Premise
276	was	N	I-Premise
277	similar	N	I-Premise
278	between	N	I-Premise
279	treatment	N	I-Premise
280	arms	N	I-Premise
281	in	N	I-Premise
282	Asian	N	I-Premise
283	patients	N	I-Premise
284	.	N	I-Premise

285	Adding	N	I-Claim
286	EVE	N	I-Claim
287	to	N	I-Claim
288	EXE	N	I-Claim
289	provided	N	I-Claim
290	substantial	N	I-Claim
291	clinical	N	I-Claim
292	benefit	N	I-Claim
293	in	N	I-Claim
294	both	N	I-Claim
295	Asian	N	I-Claim
296	and	N	I-Claim
297	non-Asian	N	I-Claim
298	patients	N	I-Claim
299	with	N	I-Claim
300	similar	N	I-Claim
301	safety	N	I-Claim
302	profiles	N	I-Claim
303	.	N	I-Claim

304	This	N	I-Claim
305	combination	N	I-Claim
306	represents	N	I-Claim
307	an	N	I-Claim
308	improvement	N	I-Claim
309	in	N	I-Claim
310	the	N	I-Claim
311	management	N	I-Claim
312	of	N	I-Claim
313	postmenopausal	N	I-Claim
314	women	N	I-Claim
315	with	N	I-Claim
316	HR	N	I-Claim
317	(	N	I-Claim
318	+	N	I-Claim
319	)	N	I-Claim
320	/HER2	N	I-Claim
321	(	N	I-Claim
322	-	N	I-Claim
323	)	N	I-Claim
324	advanced	N	I-Claim
325	breast	N	I-Claim
326	cancer	N	I-Claim
327	progressing	N	I-Claim
328	on	N	I-Claim
329	nonsteroidal	N	I-Claim
330	aromatase	N	I-Claim
331	inhibitors	N	I-Claim
332	,	N	I-Claim
333	regardless	N	I-Claim
334	of	N	I-Claim
335	ethnicity	N	I-Claim
336	.	N	I-Claim

1	Bacillus	N	I-MajorClaim
2	Calmette-GuÃ©rin	N	I-MajorClaim
3	and	N	I-MajorClaim
4	intravesical	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	represent	N	I-MajorClaim
7	viable	N	I-MajorClaim
8	adjuvant	N	I-MajorClaim
9	options	N	I-MajorClaim
10	for	N	I-MajorClaim
11	intermediate	N	I-MajorClaim
12	risk	N	I-MajorClaim
13	nonmuscle	N	I-MajorClaim
14	invasive	N	I-MajorClaim
15	bladder	N	I-MajorClaim
16	cancer	N	I-MajorClaim
17	.	N	I-MajorClaim

18	Although	N	O
19	bacillus	N	O
20	Calmette-GuÃ©rin	N	O
21	is	N	O
22	perceived	N	O
23	as	N	O
24	less	N	O
25	tolerable	N	O
26	than	N	O
27	intravesical	N	O
28	chemotherapy	N	O
29	,	N	O
30	to	N	O
31	our	N	O
32	knowledge	N	O
33	no	N	O
34	comparative	N	O
35	studies	N	O
36	have	N	O
37	addressed	N	O
38	quality	N	O
39	of	N	O
40	life	N	O
41	issues	N	O
42	.	N	O

43	We	N	O
44	compared	N	O
45	the	N	O
46	quality	N	O
47	of	N	O
48	life	N	O
49	of	N	O
50	patients	N	O
51	with	N	O
52	nonmuscle	N	O
53	invasive	N	O
54	bladder	N	O
55	cancer	N	O
56	who	N	O
57	received	N	O
58	adjuvant	N	O
59	intravesical	N	O
60	gemcitabine	N	O
61	or	N	O
62	1/3	N	O
63	dose	N	O
64	bacillus	N	O
65	Calmette-GuÃ©rin	N	O
66	.	N	O

67	Our	N	O
68	multicenter	N	O
69	,	N	O
70	prospective	N	O
71	,	N	O
72	randomized	N	O
73	,	N	O
74	phase	N	O
75	II	N	O
76	study	N	O
77	included	N	O
78	120	N	O
79	patients	N	O
80	with	N	O
81	intermediate	N	O
82	risk	N	O
83	nonmuscle	N	O
84	invasive	N	O
85	bladder	N	O
86	cancer	N	O
87	.	N	O

88	Of	N	O
89	these	N	O
90	patients	N	O
91	88	N	O
92	remained	N	O
93	assessable	N	O
94	at	N	O
95	1-year	N	O
96	followup	N	O
97	.	N	O

98	Only	N	O
99	1	N	O
100	patient	N	O
101	was	N	O
102	withdrawn	N	O
103	because	N	O
104	of	N	O
105	adverse	N	O
106	events	N	O
107	.	N	O

108	Overall	N	O
109	61	N	O
110	patients	N	O
111	received	N	O
112	2,000	N	O
113	mg/50	N	O
114	cc	N	O
115	gemcitabine	N	O
116	weekly	N	O
117	for	N	O
118	6	N	O
119	weeks	N	O
120	(	N	O
121	maintenance	N	O
122	monthly	N	O
123	for	N	O
124	1	N	O
125	year	N	O
126	)	N	O
127	while	N	O
128	59	N	O
129	received	N	O
130	1/3	N	O
131	dose	N	O
132	bacillus	N	O
133	Calmette-GuÃ©rin	N	O
134	Connaught	N	O
135	weekly	N	O
136	for	N	O
137	6	N	O
138	weeks	N	O
139	(	N	O
140	maintenance	N	O
141	3	N	O
142	weekly	N	O
143	instillations	N	O
144	at	N	O
145	3	N	O
146	,	N	O
147	6	N	O
148	and	N	O
149	12	N	O
150	months	N	O
151	)	N	O
152	.	N	O

153	Quality	N	O
154	of	N	O
155	life	N	O
156	was	N	O
157	measured	N	O
158	by	N	O
159	the	N	O
160	EORTC	N	O
161	QLQ-C30	N	O
162	(	N	O
163	European	N	O
164	Organization	N	O
165	for	N	O
166	the	N	O
167	Research	N	O
168	and	N	O
169	Treatment	N	O
170	of	N	O
171	Cancer	N	O
172	Quality	N	O
173	of	N	O
174	Life	N	O
175	Questionnaire	N	O
176	Core	N	O
177	30	N	O
178	version	N	O
179	3.0	N	O
180	)	N	O
181	and	N	O
182	QLQ-BLS24	N	O
183	(	N	O
184	Quality	N	O
185	of	N	O
186	Life	N	O
187	Superficial	N	O
188	Bladder	N	O
189	Cancer-Specific	N	O
190	24	N	O
191	)	N	O
192	questionnaires	N	O
193	.	N	O

194	Group	N	O
195	differences	N	O
196	were	N	O
197	calculated	N	O
198	using	N	O
199	ANOVA	N	O
200	(	N	O
201	ANOVA/MANOVA	N	O
202	)	N	O
203	.	N	O

204	Treatment	N	I-Premise
205	was	N	I-Premise
206	well	N	I-Premise
207	tolerated	N	I-Premise
208	in	N	I-Premise
209	both	N	I-Premise
210	groups	N	I-Premise
211	,	N	I-Premise
212	although	N	I-Premise
213	local	N	I-Premise
214	and	N	I-Premise
215	systemic	N	I-Premise
216	side	N	I-Premise
217	effects	N	I-Premise
218	were	N	I-Premise
219	more	N	I-Premise
220	frequently	N	I-Premise
221	reported	N	I-Premise
222	in	N	I-Premise
223	the	N	I-Premise
224	bacillus	N	I-Premise
225	Calmette-GuÃ©rin	N	I-Premise
226	arm	N	I-Premise
227	.	N	I-Premise

228	Multivariate	N	I-Premise
229	analyses	N	I-Premise
230	showed	N	I-Premise
231	no	N	I-Premise
232	significant	N	I-Premise
233	differences	N	I-Premise
234	between	N	I-Premise
235	the	N	I-Premise
236	2	N	I-Premise
237	groups	N	I-Premise
238	in	N	I-Premise
239	all	N	I-Premise
240	quality	N	I-Premise
241	of	N	I-Premise
242	life	N	I-Premise
243	dimensions	N	I-Premise
244	.	N	I-Premise

245	No	N	I-Premise
246	significant	N	I-Premise
247	changes	N	I-Premise
248	over	N	I-Premise
249	time	N	I-Premise
250	in	N	I-Premise
251	quality	N	I-Premise
252	of	N	I-Premise
253	life	N	I-Premise
254	domains	N	I-Premise
255	were	N	I-Premise
256	detected	N	I-Premise
257	for	N	I-Premise
258	patients	N	I-Premise
259	on	N	I-Premise
260	bacillus	N	I-Premise
261	Calmette-GuÃ©rin	N	I-Premise
262	and	N	I-Premise
263	gemcitabine	N	I-Premise
264	except	N	I-Premise
265	for	N	I-Premise
266	physical	N	I-Premise
267	functioning	N	I-Premise
268	,	N	I-Premise
269	which	N	I-Premise
270	decreased	N	I-Premise
271	significantly	N	I-Premise
272	in	N	I-Premise
273	both	N	I-Premise
274	groups	N	I-Premise
275	(	N	I-Premise
276	p	N	I-Premise
277	=	N	I-Premise
278	0.002	N	I-Premise
279	)	N	I-Premise
280	.	N	I-Premise

281	No	N	I-Premise
282	significant	N	I-Premise
283	differences	N	I-Premise
284	were	N	I-Premise
285	detected	N	I-Premise
286	in	N	I-Premise
287	terms	N	I-Premise
288	of	N	I-Premise
289	recurrence	N	I-Premise
290	and	N	I-Premise
291	progression	N	I-Premise
292	between	N	I-Premise
293	the	N	I-Premise
294	2	N	I-Premise
295	groups	N	I-Premise
296	at	N	I-Premise
297	1-year	N	I-Premise
298	followup	N	I-Premise
299	.	N	I-Premise

300	While	N	O
301	a	N	I-Claim
302	higher	N	I-Claim
303	rate	N	I-Claim
304	of	N	I-Claim
305	side	N	I-Claim
306	effects	N	I-Claim
307	,	N	I-Claim
308	albeit	N	I-Claim
309	mild	N	I-Claim
310	to	N	I-Claim
311	moderate	N	I-Claim
312	,	N	I-Claim
313	was	N	I-Claim
314	detected	N	I-Claim
315	with	N	I-Claim
316	1/3	N	I-Claim
317	dose	N	I-Claim
318	bacillus	N	I-Claim
319	Calmette-GuÃ©rin	N	I-Claim
320	compared	N	I-Claim
321	to	N	I-Claim
322	gemcitabine	N	I-Claim
323	,	N	I-Claim
324	our	N	I-Claim
325	study	N	I-Claim
326	failed	N	I-Claim
327	to	N	I-Claim
328	show	N	I-Claim
329	significant	N	I-Claim
330	differences	N	I-Claim
331	between	N	I-Claim
332	the	N	I-Claim
333	2	N	I-Claim
334	drugs	N	I-Claim
335	in	N	I-Claim
336	terms	N	I-Claim
337	of	N	I-Claim
338	quality	N	I-Claim
339	of	N	I-Claim
340	life	N	I-Claim
341	.	N	I-Claim

1	Although	N	O
2	chemotherapy-induced	N	O
3	cognitive	N	O
4	impairment	N	O
5	is	N	O
6	common	N	O
7	among	N	O
8	breast	N	O
9	cancer	N	O
10	patients	N	O
11	,	N	O
12	evidence	N	O
13	for	N	O
14	effective	N	O
15	interventions	N	O
16	addressing	N	O
17	cognitive	N	O
18	deficits	N	O
19	is	N	O
20	limited	N	O
21	.	N	O

22	This	N	O
23	randomized	N	O
24	controlled	N	O
25	trial	N	O
26	examined	N	O
27	the	N	O
28	feasibility	N	O
29	and	N	O
30	preliminary	N	O
31	efficacy	N	O
32	of	N	O
33	a	N	O
34	Tibetan	N	O
35	Sound	N	O
36	Meditation	N	O
37	(	N	O
38	TSM	N	O
39	)	N	O
40	program	N	O
41	to	N	O
42	improve	N	O
43	cognitive	N	O
44	function	N	O
45	and	N	O
46	quality	N	O
47	of	N	O
48	life	N	O
49	in	N	O
50	breast	N	O
51	cancer	N	O
52	patients	N	O
53	.	N	O

54	Forty-seven	N	O
55	breast	N	O
56	cancer	N	O
57	patients	N	O
58	(	N	O
59	mean	N	O
60	age	N	O
61	56.3	N	O
62	years	N	O
63	)	N	O
64	,	N	O
65	who	N	O
66	were	N	O
67	staged	N	O
68	I-III	N	O
69	at	N	O
70	diagnosis	N	O
71	,	N	O
72	6-60	N	O
73	months	N	O
74	post-chemotherapy	N	O
75	,	N	O
76	and	N	O
77	reported	N	O
78	cognitive	N	O
79	impairment	N	O
80	at	N	O
81	study	N	O
82	entry	N	O
83	were	N	O
84	recruited	N	O
85	.	N	O

86	Participants	N	O
87	were	N	O
88	randomized	N	O
89	to	N	O
90	either	N	O
91	two	N	O
92	weekly	N	O
93	TSM	N	O
94	sessions	N	O
95	for	N	O
96	6	N	O
97	weeks	N	O
98	or	N	O
99	a	N	O
100	wait	N	O
101	list	N	O
102	control	N	O
103	group	N	O
104	.	N	O

105	Neuropsychological	N	O
106	assessments	N	O
107	were	N	O
108	completed	N	O
109	at	N	O
110	baseline	N	O
111	and	N	O
112	1	N	O
113	month	N	O
114	post-treatment	N	O
115	.	N	O

116	Self-report	N	O
117	measures	N	O
118	of	N	O
119	cognitive	N	O
120	function	N	O
121	(	N	O
122	Functional	N	O
123	Assessment	N	O
124	of	N	O
125	Cancer	N	O
126	Therapy	N	O
127	(	N	O
128	FACT	N	O
129	)	N	O
130	-Cog	N	O
131	)	N	O
132	,	N	O
133	quality	N	O
134	of	N	O
135	life	N	O
136	(	N	O
137	SF-36	N	O
138	)	N	O
139	,	N	O
140	depressive	N	O
141	symptoms	N	O
142	(	N	O
143	Center	N	O
144	for	N	O
145	Epidemiologic	N	O
146	Studies	N	O
147	Depression	N	O
148	Scale	N	O
149	)	N	O
150	,	N	O
151	sleep	N	O
152	disturbance	N	O
153	(	N	O
154	Pittsburgh	N	O
155	Sleep	N	O
156	Quality	N	O
157	Index	N	O
158	)	N	O
159	,	N	O
160	fatigue	N	O
161	(	N	O
162	Brief	N	O
163	Fatigue	N	O
164	Inventory	N	O
165	)	N	O
166	,	N	O
167	and	N	O
168	spirituality	N	O
169	(	N	O
170	FACT-Sp	N	O
171	)	N	O
172	were	N	O
173	completed	N	O
174	at	N	O
175	baseline	N	O
176	,	N	O
177	the	N	O
178	end	N	O
179	of	N	O
180	treatment	N	O
181	,	N	O
182	and	N	O
183	1	N	O
184	month	N	O
185	later	N	O
186	.	N	O

187	Relative	N	I-Premise
188	to	N	I-Premise
189	the	N	I-Premise
190	control	N	I-Premise
191	group	N	I-Premise
192	,	N	I-Premise
193	women	N	I-Premise
194	in	N	I-Premise
195	the	N	I-Premise
196	TSM	N	I-Premise
197	group	N	I-Premise
198	performed	N	I-Premise
199	better	N	I-Premise
200	on	N	I-Premise
201	the	N	I-Premise
202	verbal	N	I-Premise
203	memory	N	I-Premise
204	test	N	I-Premise
205	(	N	I-Premise
206	Rey	N	I-Premise
207	Auditory	N	I-Premise
208	Verbal	N	I-Premise
209	Learning	N	I-Premise
210	Test	N	I-Premise
211	trial	N	I-Premise
212	1	N	I-Premise
213	)	N	I-Premise
214	(	N	I-Premise
215	p	N	I-Premise
216	=	N	I-Premise
217	0.06	N	I-Premise
218	)	N	I-Premise
219	and	N	I-Premise
220	the	N	I-Premise
221	short-term	N	I-Premise
222	memory	N	I-Premise
223	and	N	I-Premise
224	processing	N	I-Premise
225	speed	N	I-Premise
226	task	N	I-Premise
227	(	N	I-Premise
228	Digit	N	I-Premise
229	Symbol	N	I-Premise
230	)	N	I-Premise
231	(	N	I-Premise
232	p	N	I-Premise
233	=	N	I-Premise
234	0.09	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	reported	N	I-Premise
238	improved	N	I-Premise
239	cognitive	N	I-Premise
240	function	N	I-Premise
241	(	N	I-Premise
242	p	N	I-Premise
243	=	N	I-Premise
244	0.06	N	I-Premise
245	)	N	I-Premise
246	,	N	I-Premise
247	cognitive	N	I-Premise
248	abilities	N	I-Premise
249	(	N	I-Premise
250	p	N	I-Premise
251	=	N	I-Premise
252	0.08	N	I-Premise
253	)	N	I-Premise
254	,	N	I-Premise
255	mental	N	I-Premise
256	health	N	I-Premise
257	(	N	I-Premise
258	p	N	I-Premise
259	=	N	I-Premise
260	0.04	N	I-Premise
261	)	N	I-Premise
262	,	N	I-Premise
263	and	N	I-Premise
264	spirituality	N	I-Premise
265	(	N	I-Premise
266	p	N	I-Premise
267	=	N	I-Premise
268	0.05	N	I-Premise
269	)	N	I-Premise
270	at	N	I-Premise
271	the	N	I-Premise
272	end	N	I-Premise
273	of	N	I-Premise
274	treatment	N	I-Premise
275	but	N	I-Premise
276	not	N	I-Premise
277	1	N	I-Premise
278	month	N	I-Premise
279	later	N	I-Premise
280	.	N	I-Premise

281	This	N	I-Claim
282	randomized	N	I-Claim
283	controlled	N	I-Claim
284	trial	N	I-Claim
285	revealed	N	I-Claim
286	that	N	I-Claim
287	TSM	N	I-Claim
288	program	N	I-Claim
289	appears	N	I-Claim
290	to	N	I-Claim
291	be	N	I-Claim
292	a	N	I-Claim
293	feasible	N	I-Claim
294	and	N	I-Claim
295	acceptable	N	I-Claim
296	intervention	N	I-Claim
297	and	N	I-Claim
298	may	N	I-Claim
299	be	N	I-Claim
300	associated	N	I-Claim
301	with	N	I-Claim
302	short-term	N	I-Claim
303	improvements	N	I-Claim
304	in	N	I-Claim
305	objective	N	I-Claim
306	and	N	I-Claim
307	subjective	N	I-Claim
308	cognitive	N	I-Claim
309	function	N	I-Claim
310	as	N	I-Claim
311	well	N	I-Claim
312	as	N	I-Claim
313	mental	N	I-Claim
314	health	N	I-Claim
315	and	N	I-Claim
316	spirituality	N	I-Claim
317	in	N	I-Claim
318	breast	N	I-Claim
319	cancer	N	I-Claim
320	patients	N	I-Claim
321	.	N	I-Claim

1	Restorative	N	O
2	proctocolectomy	N	O
3	with	N	O
4	ileal	N	O
5	pouch-anal	N	O
6	anastomosis	N	O
7	(	N	O
8	IPAA	N	O
9	)	N	O
10	is	N	O
11	the	N	O
12	standard	N	O
13	surgical	N	O
14	procedure	N	O
15	for	N	O
16	ulcerative	N	O
17	colitis	N	O
18	(	N	O
19	UC	N	O
20	)	N	O
21	and	N	O
22	familial	N	O
23	adenomatous	N	O
24	polyposis	N	O
25	(	N	O
26	FAP	N	O
27	)	N	O
28	.	N	O

29	While	N	O
30	minimal	N	O
31	invasive	N	O
32	techniques	N	O
33	have	N	O
34	been	N	O
35	applied	N	O
36	increasingly	N	O
37	,	N	O
38	clear	N	O
39	evidence	N	O
40	of	N	O
41	superiority	N	O
42	for	N	O
43	laparoscopic	N	O
44	pouch	N	O
45	procedures	N	O
46	is	N	O
47	not	N	O
48	yet	N	O
49	available	N	O
50	.	N	O

51	The	N	O
52	aim	N	O
53	of	N	O
54	the	N	O
55	LapConPouch	N	O
56	Trial	N	O
57	was	N	O
58	to	N	O
59	compare	N	O
60	the	N	O
61	effectiveness	N	O
62	of	N	O
63	laparoscopic	N	O
64	(	N	O
65	LAP	N	O
66	)	N	O
67	versus	N	O
68	conventional	N	O
69	(	N	O
70	CON	N	O
71	)	N	O
72	ileoanal	N	O
73	pouch	N	O
74	procedure	N	O
75	in	N	O
76	patients	N	O
77	undergoing	N	O
78	elective	N	O
79	restorative	N	O
80	proctocolectomy	N	O
81	.	N	O

82	The	N	O
83	trial	N	O
84	was	N	O
85	designed	N	O
86	as	N	O
87	a	N	O
88	single-centre	N	O
89	,	N	O
90	pre-operatively	N	O
91	randomized	N	O
92	,	N	O
93	controlled	N	O
94	trial	N	O
95	using	N	O
96	a	N	O
97	two-group	N	O
98	parallel	N	O
99	superiority	N	O
100	design	N	O
101	.	N	O

102	Eligible	N	O
103	for	N	O
104	participation	N	O
105	were	N	O
106	patients	N	O
107	scheduled	N	O
108	for	N	O
109	restorative	N	O
110	proctocolectomy	N	O
111	either	N	O
112	for	N	O
113	FAP	N	O
114	or	N	O
115	for	N	O
116	UC	N	O
117	.	N	O

118	Patients	N	O
119	and	N	O
120	outcome	N	O
121	assessors	N	O
122	were	N	O
123	blinded	N	O
124	to	N	O
125	group	N	O
126	assignment	N	O
127	.	N	O

128	The	N	O
129	primary	N	O
130	endpoint	N	O
131	was	N	O
132	defined	N	O
133	as	N	O
134	the	N	O
135	amount	N	O
136	of	N	O
137	blood	N	O
138	loss	N	O
139	.	N	O

140	Statistical	N	O
141	analyses	N	O
142	were	N	O
143	explorative	N	O
144	since	N	O
145	the	N	O
146	trial	N	O
147	had	N	O
148	to	N	O
149	be	N	O
150	stopped	N	O
151	prematurely	N	O
152	.	N	O

153	A	N	O
154	total	N	O
155	of	N	O
156	42	N	O
157	patients	N	O
158	(	N	O
159	21	N	O
160	LAP	N	O
161	(	N	O
162	50.0	N	O
163	%	N	O
164	)	N	O
165	;	N	O
166	21	N	O
167	CON	N	O
168	(	N	O
169	50.0	N	O
170	%	N	O
171	)	N	O
172	)	N	O
173	were	N	O
174	randomized	N	O
175	.	N	O

176	The	N	I-Premise
177	trial	N	I-Premise
178	had	N	I-Premise
179	to	N	I-Premise
180	be	N	I-Premise
181	stopped	N	I-Premise
182	prematurely	N	I-Premise
183	due	N	I-Premise
184	to	N	I-Premise
185	insufficient	N	I-Premise
186	patient	N	I-Premise
187	recruitment	N	I-Premise
188	.	N	I-Premise

189	There	N	I-Premise
190	was	N	I-Premise
191	no	N	I-Premise
192	difference	N	I-Premise
193	in	N	I-Premise
194	the	N	I-Premise
195	amount	N	I-Premise
196	of	N	I-Premise
197	blood	N	I-Premise
198	loss	N	I-Premise
199	between	N	I-Premise
200	both	N	I-Premise
201	groups	N	I-Premise
202	:	N	I-Premise
203	LAP	N	I-Premise
204	261.5	N	I-Premise
205	Â±	N	I-Premise
206	195.4	N	I-Premise
207	ml	N	I-Premise
208	,	N	I-Premise
209	CON	N	I-Premise
210	228.1	N	I-Premise
211	Â±	N	I-Premise
212	119.5	N	I-Premise
213	ml	N	I-Premise
214	.	N	I-Premise

215	Secondary	N	O
216	endpoints	N	O
217	differ	N	O
218	in	N	O
219	both	N	O
220	groups	N	O
221	.	N	O

222	Laparoscopic	N	I-Claim
223	surgery	N	I-Claim
224	was	N	I-Claim
225	superior	N	I-Claim
226	regarding	N	I-Claim
227	the	N	I-Claim
228	length	N	I-Claim
229	of	N	I-Claim
230	skin	N	I-Claim
231	incision	N	I-Claim
232	;	N	I-Claim
233	in	N	O
234	contrast	N	O
235	,	N	O
236	the	N	I-Claim
237	conventional	N	I-Claim
238	approach	N	I-Claim
239	was	N	I-Claim
240	superior	N	I-Claim
241	in	N	I-Claim
242	duration	N	I-Claim
243	of	N	I-Claim
244	operation	N	I-Claim
245	.	N	I-Claim

246	There	N	I-Premise
247	were	N	I-Premise
248	no	N	I-Premise
249	discrepancies	N	I-Premise
250	in	N	I-Premise
251	length	N	I-Premise
252	of	N	I-Premise
253	hospital	N	I-Premise
254	stay	N	I-Premise
255	,	N	I-Premise
256	postoperative	N	I-Premise
257	pain	N	I-Premise
258	,	N	I-Premise
259	bowel	N	I-Premise
260	function	N	I-Premise
261	,	N	I-Premise
262	and	N	I-Premise
263	quality	N	I-Premise
264	of	N	I-Premise
265	life	N	I-Premise
266	between	N	I-Premise
267	both	N	I-Premise
268	approaches	N	I-Premise
269	.	N	I-Premise

270	The	N	O
271	conversion	N	O
272	rate	N	O
273	from	N	O
274	LAP	N	O
275	to	N	O
276	CON	N	O
277	approach	N	O
278	was	N	O
279	23.8	N	O
280	%	N	O
281	.	N	O

282	There	N	I-Claim
283	was	N	I-Claim
284	no	N	I-Claim
285	difference	N	I-Claim
286	with	N	I-Claim
287	respect	N	I-Claim
288	to	N	I-Claim
289	blood	N	I-Claim
290	loss	N	I-Claim
291	between	N	I-Claim
292	the	N	I-Claim
293	LAP	N	I-Claim
294	and	N	I-Claim
295	the	N	I-Claim
296	CON	N	I-Claim
297	group	N	I-Claim
298	.	N	I-Claim

299	The	N	I-Claim
300	LAP	N	I-Claim
301	approach	N	I-Claim
302	is	N	I-Claim
303	feasible	N	I-Claim
304	for	N	I-Claim
305	restorative	N	I-Claim
306	proctocolectomy	N	I-Claim
307	,	N	I-Claim
308	and	N	I-Claim
309	IPAA	N	I-Claim
310	seems	N	I-Claim
311	at	N	I-Claim
312	least	N	I-Claim
313	as	N	I-Claim
314	safe	N	I-Claim
315	as	N	I-Claim
316	CON	N	I-Claim
317	surgery	N	I-Claim
318	.	N	I-Claim

319	The	N	O
320	most	N	O
321	obvious	N	O
322	advantage	N	O
323	of	N	O
324	the	N	O
325	minimal	N	O
326	invasive	N	O
327	technique	N	O
328	is	N	O
329	the	N	O
330	improved	N	O
331	cosmesis	N	O
332	.	N	O

1	Colorectal	N	O
2	cancer	N	O
3	survivors	N	O
4	are	N	O
5	at	N	O
6	risk	N	O
7	for	N	O
8	poor	N	O
9	health	N	O
10	outcomes	N	O
11	because	N	O
12	of	N	O
13	unhealthy	N	O
14	lifestyles	N	O
15	,	N	O
16	but	N	O
17	few	N	O
18	studies	N	O
19	have	N	O
20	developed	N	O
21	translatable	N	O
22	health	N	O
23	behavior	N	O
24	change	N	O
25	interventions	N	O
26	.	N	O

27	This	N	O
28	study	N	O
29	aimed	N	O
30	to	N	O
31	determine	N	O
32	the	N	O
33	effects	N	O
34	of	N	O
35	a	N	O
36	telephone-delivered	N	O
37	multiple	N	O
38	health	N	O
39	behavior	N	O
40	change	N	O
41	intervention	N	O
42	(	N	O
43	CanChange	N	O
44	)	N	O
45	on	N	O
46	health	N	O
47	and	N	O
48	behavioral	N	O
49	outcomes	N	O
50	among	N	O
51	colorectal	N	O
52	cancer	N	O
53	survivors	N	O
54	.	N	O

55	In	N	O
56	this	N	O
57	two-group	N	O
58	randomized	N	O
59	controlled	N	O
60	trial	N	O
61	,	N	O
62	410	N	O
63	colorectal	N	O
64	cancer	N	O
65	survivors	N	O
66	were	N	O
67	randomly	N	O
68	assigned	N	O
69	to	N	O
70	the	N	O
71	health	N	O
72	coaching	N	O
73	intervention	N	O
74	(	N	O
75	11	N	O
76	theory-based	N	O
77	telephone-delivered	N	O
78	health	N	O
79	coaching	N	O
80	sessions	N	O
81	delivered	N	O
82	over	N	O
83	6	N	O
84	months	N	O
85	focusing	N	O
86	on	N	O
87	physical	N	O
88	activity	N	O
89	,	N	O
90	weight	N	O
91	management	N	O
92	,	N	O
93	dietary	N	O
94	habits	N	O
95	,	N	O
96	alcohol	N	O
97	,	N	O
98	and	N	O
99	smoking	N	O
100	)	N	O
101	or	N	O
102	usual	N	O
103	care	N	O
104	.	N	O

105	Assessment	N	O
106	of	N	O
107	primary	N	O
108	(	N	O
109	ie	N	O
110	,	N	O
111	physical	N	O
112	activity	N	O
113	[	N	O
114	Godin	N	O
115	Leisure	N	O
116	Time	N	O
117	Index	N	O
118	]	N	O
119	,	N	O
120	health-related	N	O
121	quality	N	O
122	of	N	O
123	life	N	O
124	[	N	O
125	HRQoL	N	O
126	;	N	O
127	Short	N	O
128	Form-36	N	O
129	]	N	O
130	,	N	O
131	and	N	O
132	cancer-related	N	O
133	fatigue	N	O
134	[	N	O
135	Functional	N	O
136	Assessment	N	O
137	of	N	O
138	Chronic	N	O
139	Illness	N	O
140	Therapy	N	O
141	Fatigue	N	O
142	Scale	N	O
143	]	N	O
144	)	N	O
145	and	N	O
146	secondary	N	O
147	outcomes	N	O
148	(	N	O
149	ie	N	O
150	,	N	O
151	body	N	O
152	mass	N	O
153	index	N	O
154	[	N	O
155	kg/m	N	O
156	(	N	O
157	2	N	O
158	)	N	O
159	]	N	O
160	,	N	O
161	diet	N	O
162	and	N	O
163	alcohol	N	O
164	intake	N	O
165	[	N	O
166	Food	N	O
167	Frequency	N	O
168	Questionnaire	N	O
169	]	N	O
170	,	N	O
171	and	N	O
172	smoking	N	O
173	)	N	O
174	were	N	O
175	conducted	N	O
176	at	N	O
177	baseline	N	O
178	and	N	O
179	6	N	O
180	and	N	O
181	12	N	O
182	months	N	O
183	.	N	O

184	At	N	I-Premise
185	12	N	I-Premise
186	months	N	I-Premise
187	,	N	I-Premise
188	significant	N	I-Premise
189	intervention	N	I-Premise
190	effects	N	I-Premise
191	were	N	I-Premise
192	observed	N	I-Premise
193	for	N	I-Premise
194	moderate	N	I-Premise
195	physical	N	I-Premise
196	activity	N	I-Premise
197	(	N	I-Premise
198	28.5	N	I-Premise
199	minutes	N	I-Premise
200	;	N	I-Premise
201	P	N	I-Premise
202	=	N	I-Premise
203	.003	N	I-Premise
204	)	N	I-Premise
205	,	N	I-Premise
206	body	N	I-Premise
207	mass	N	I-Premise
208	index	N	I-Premise
209	(	N	I-Premise
210	-0.9	N	I-Premise
211	kg/m	N	I-Premise
212	(	N	I-Premise
213	2	N	I-Premise
214	)	N	I-Premise
215	;	N	I-Premise
216	P	N	I-Premise
217	=	N	I-Premise
218	.001	N	I-Premise
219	)	N	I-Premise
220	,	N	I-Premise
221	energy	N	I-Premise
222	from	N	I-Premise
223	total	N	I-Premise
224	fat	N	I-Premise
225	(	N	I-Premise
226	-7.0	N	I-Premise
227	%	N	I-Premise
228	;	N	I-Premise
229	P	N	I-Premise
230	=	N	I-Premise
231	.006	N	I-Premise
232	)	N	I-Premise
233	,	N	I-Premise
234	and	N	I-Premise
235	energy	N	I-Premise
236	from	N	I-Premise
237	saturated	N	I-Premise
238	fat	N	I-Premise
239	(	N	I-Premise
240	-2.8	N	I-Premise
241	%	N	I-Premise
242	;	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	.016	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	A	N	I-Premise
249	significant	N	I-Premise
250	intervention	N	I-Premise
251	effect	N	I-Premise
252	was	N	I-Premise
253	reported	N	I-Premise
254	for	N	I-Premise
255	vegetable	N	I-Premise
256	intake	N	I-Premise
257	(	N	I-Premise
258	0.4	N	I-Premise
259	servings	N	I-Premise
260	per	N	I-Premise
261	day	N	I-Premise
262	;	N	I-Premise
263	P	N	I-Premise
264	=	N	I-Premise
265	.001	N	I-Premise
266	)	N	I-Premise
267	at	N	I-Premise
268	6	N	I-Premise
269	months	N	I-Premise
270	.	N	I-Premise

271	No	N	I-Premise
272	significant	N	I-Premise
273	group	N	I-Premise
274	differences	N	I-Premise
275	were	N	I-Premise
276	found	N	I-Premise
277	at	N	I-Premise
278	6	N	I-Premise
279	or	N	I-Premise
280	12	N	I-Premise
281	months	N	I-Premise
282	for	N	I-Premise
283	HRQoL	N	I-Premise
284	,	N	I-Premise
285	cancer-related	N	I-Premise
286	fatigue	N	I-Premise
287	,	N	I-Premise
288	fruit	N	I-Premise
289	,	N	I-Premise
290	fiber	N	I-Premise
291	,	N	I-Premise
292	or	N	I-Premise
293	alcohol	N	I-Premise
294	intake	N	I-Premise
295	,	N	I-Premise
296	or	N	I-Premise
297	smoking	N	I-Premise
298	.	N	I-Premise

299	The	N	I-Claim
300	CanChange	N	I-Claim
301	intervention	N	I-Claim
302	was	N	I-Claim
303	effective	N	I-Claim
304	for	N	I-Claim
305	improving	N	I-Claim
306	physical	N	I-Claim
307	activity	N	I-Claim
308	,	N	I-Claim
309	dietary	N	I-Claim
310	habits	N	I-Claim
311	,	N	I-Claim
312	and	N	I-Claim
313	body	N	I-Claim
314	mass	N	I-Claim
315	index	N	I-Claim
316	in	N	I-Claim
317	colorectal	N	I-Claim
318	cancer	N	I-Claim
319	survivors	N	I-Claim
320	.	N	I-Claim

321	The	N	O
322	intervention	N	O
323	is	N	O
324	translatable	N	O
325	through	N	O
326	existing	N	O
327	telephone	N	O
328	cancer	N	O
329	support	N	O
330	and	N	O
331	information	N	O
332	services	N	O
333	in	N	O
334	Australia	N	O
335	and	N	O
336	other	N	O
337	countries	N	O
338	.	N	O

1	Enhanced	N	O
2	recovery	N	O
3	programmes	N	O
4	(	N	O
5	ERPs	N	O
6	)	N	O
7	have	N	O
8	been	N	O
9	shown	N	O
10	to	N	O
11	reduce	N	O
12	length	N	O
13	of	N	O
14	hospital	N	O
15	stay	N	O
16	(	N	O
17	LOS	N	O
18	)	N	O
19	and	N	O
20	complications	N	O
21	in	N	O
22	colorectal	N	O
23	surgery	N	O
24	.	N	O

25	Whether	N	O
26	ERPs	N	O
27	have	N	O
28	the	N	O
29	same	N	O
30	benefits	N	O
31	in	N	O
32	open	N	O
33	liver	N	O
34	resection	N	O
35	surgery	N	O
36	is	N	O
37	unclear	N	O
38	,	N	O
39	and	N	O
40	randomized	N	O
41	clinical	N	O
42	trials	N	O
43	are	N	O
44	lacking	N	O
45	.	N	O

46	Consecutive	N	O
47	patients	N	O
48	scheduled	N	O
49	for	N	O
50	open	N	O
51	liver	N	O
52	resection	N	O
53	were	N	O
54	randomized	N	O
55	to	N	O
56	an	N	O
57	ERP	N	O
58	group	N	O
59	or	N	O
60	standard	N	O
61	care	N	O
62	.	N	O

63	Primary	N	O
64	endpoints	N	O
65	were	N	O
66	time	N	O
67	until	N	O
68	medically	N	O
69	fit	N	O
70	for	N	O
71	discharge	N	O
72	(	N	O
73	MFD	N	O
74	)	N	O
75	and	N	O
76	LOS	N	O
77	.	N	O

78	Secondary	N	O
79	endpoints	N	O
80	were	N	O
81	postoperative	N	O
82	morbidity	N	O
83	,	N	O
84	pain	N	O
85	scores	N	O
86	,	N	O
87	readmission	N	O
88	rate	N	O
89	,	N	O
90	mortality	N	O
91	,	N	O
92	quality	N	O
93	of	N	O
94	life	N	O
95	(	N	O
96	QoL	N	O
97	)	N	O
98	and	N	O
99	patient	N	O
100	satisfaction	N	O
101	.	N	O

102	ERP	N	O
103	elements	N	O
104	included	N	O
105	greater	N	O
106	preoperative	N	O
107	education	N	O
108	,	N	O
109	preoperative	N	O
110	oral	N	O
111	carbohydrate	N	O
112	loading	N	O
113	,	N	O
114	postoperative	N	O
115	goal-directed	N	O
116	fluid	N	O
117	therapy	N	O
118	,	N	O
119	early	N	O
120	mobilization	N	O
121	and	N	O
122	physiotherapy	N	O
123	.	N	O

124	Both	N	O
125	groups	N	O
126	received	N	O
127	standardized	N	O
128	anaesthesia	N	O
129	with	N	O
130	epidural	N	O
131	analgesia	N	O
132	.	N	O

133	The	N	O
134	analysis	N	O
135	included	N	O
136	46	N	O
137	patients	N	O
138	in	N	O
139	the	N	O
140	ERP	N	O
141	group	N	O
142	and	N	O
143	45	N	O
144	in	N	O
145	the	N	O
146	standard	N	O
147	care	N	O
148	group	N	O
149	.	N	O

150	Median	N	I-Premise
151	MFD	N	I-Premise
152	time	N	I-Premise
153	was	N	I-Premise
154	reduced	N	I-Premise
155	in	N	I-Premise
156	the	N	I-Premise
157	ERP	N	I-Premise
158	group	N	I-Premise
159	(	N	I-Premise
160	3	N	I-Premise
161	days	N	I-Premise
162	versus	N	I-Premise
163	6	N	I-Premise
164	days	N	I-Premise
165	with	N	I-Premise
166	standard	N	I-Premise
167	care	N	I-Premise
168	;	N	I-Premise
169	P	N	I-Premise
170	<	N	I-Premise
171	0Â·001	N	I-Premise
172	)	N	I-Premise
173	,	N	I-Premise
174	as	N	I-Premise
175	was	N	I-Premise
176	LOS	N	I-Premise
177	(	N	I-Premise
178	4	N	I-Premise
179	days	N	I-Premise
180	versus	N	I-Premise
181	7	N	I-Premise
182	days	N	I-Premise
183	;	N	I-Premise
184	P	N	I-Premise
185	<	N	I-Premise
186	0Â·001	N	I-Premise
187	)	N	I-Premise
188	.	N	I-Premise

189	The	N	I-Premise
190	ERP	N	I-Premise
191	significantly	N	I-Premise
192	reduced	N	I-Premise
193	the	N	I-Premise
194	rate	N	I-Premise
195	of	N	I-Premise
196	medical	N	I-Premise
197	complications	N	I-Premise
198	(	N	I-Premise
199	7	N	I-Premise
200	versus	N	I-Premise
201	27	N	I-Premise
202	per	N	I-Premise
203	cent	N	I-Premise
204	;	N	I-Premise
205	P	N	I-Premise
206	=	N	I-Premise
207	0Â·020	N	I-Premise
208	)	N	I-Premise
209	,	N	I-Premise
210	but	N	I-Premise
211	not	N	I-Premise
212	surgical	N	I-Premise
213	complications	N	I-Premise
214	(	N	I-Premise
215	15	N	I-Premise
216	versus	N	I-Premise
217	11	N	I-Premise
218	per	N	I-Premise
219	cent	N	I-Premise
220	;	N	I-Premise
221	P	N	I-Premise
222	=	N	I-Premise
223	0Â·612	N	I-Premise
224	)	N	I-Premise
225	,	N	I-Premise
226	readmissions	N	I-Premise
227	(	N	I-Premise
228	4	N	I-Premise
229	versus	N	I-Premise
230	0	N	I-Premise
231	per	N	I-Premise
232	cent	N	I-Premise
233	;	N	I-Premise
234	P	N	I-Premise
235	=	N	I-Premise
236	0Â·153	N	I-Premise
237	)	N	I-Premise
238	or	N	I-Premise
239	mortality	N	I-Premise
240	(	N	I-Premise
241	both	N	I-Premise
242	2	N	I-Premise
243	per	N	I-Premise
244	cent	N	I-Premise
245	;	N	I-Premise
246	P	N	I-Premise
247	=	N	I-Premise
248	0Â·987	N	I-Premise
249	)	N	I-Premise
250	.	N	I-Premise

251	QoL	N	I-Premise
252	over	N	I-Premise
253	28	N	I-Premise
254	days	N	I-Premise
255	was	N	I-Premise
256	significantly	N	I-Premise
257	better	N	I-Premise
258	in	N	I-Premise
259	the	N	I-Premise
260	ERP	N	I-Premise
261	group	N	I-Premise
262	(	N	I-Premise
263	P	N	I-Premise
264	=	N	I-Premise
265	0Â·002	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	There	N	I-Premise
269	was	N	I-Premise
270	no	N	I-Premise
271	difference	N	I-Premise
272	in	N	I-Premise
273	patient	N	I-Premise
274	satisfaction	N	I-Premise
275	.	N	I-Premise

276	ERPs	N	I-Claim
277	for	N	I-Claim
278	open	N	I-Claim
279	liver	N	I-Claim
280	resection	N	I-Claim
281	surgery	N	I-Claim
282	are	N	I-Claim
283	safe	N	I-Claim
284	and	N	I-Claim
285	effective	N	I-Claim
286	.	N	I-Claim

287	Patients	N	I-Claim
288	treated	N	I-Claim
289	in	N	I-Claim
290	the	N	I-Claim
291	ERP	N	I-Claim
292	recovered	N	I-Claim
293	faster	N	I-Claim
294	,	N	I-Claim
295	were	N	I-Claim
296	discharged	N	I-Claim
297	sooner	N	I-Claim
298	,	N	I-Claim
299	and	N	I-Claim
300	had	N	I-Claim
301	fewer	N	I-Claim
302	medical-related	N	I-Claim
303	complications	N	I-Claim
304	and	N	I-Claim
305	improved	N	I-Claim
306	QoL	N	I-Claim
307	.	N	I-Claim

1	To	N	O
2	analyze	N	O
3	the	N	O
4	clinical	N	O
5	course	N	O
6	,	N	O
7	treatment	N	O
8	,	N	O
9	complications	N	O
10	,	N	O
11	outcome	N	O
12	,	N	O
13	and	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	(	N	O
18	QOL	N	O
19	)	N	O
20	in	N	O
21	patients	N	O
22	with	N	O
23	perineal/perianal	N	O
24	rhabdomyosarcoma	N	O
25	(	N	O
26	PRMS	N	O
27	)	N	O
28	treated	N	O
29	within	N	O
30	the	N	O
31	CWS-86	N	O
32	,	N	O
33	-91	N	O
34	,	N	O
35	-96	N	O
36	,	N	O
37	and	N	O
38	-2002P	N	O
39	trials	N	O
40	.	N	O

41	Although	N	O
42	multiple	N	O
43	international	N	O
44	study	N	O
45	trials	N	O
46	exist	N	O
47	for	N	O
48	the	N	O
49	treatment	N	O
50	of	N	O
51	rhabdomyosarcoma	N	O
52	,	N	O
53	only	N	O
54	very	N	O
55	limited	N	O
56	information	N	O
57	is	N	O
58	given	N	O
59	on	N	O
60	treatment	N	O
61	,	N	O
62	outcome	N	O
63	,	N	O
64	and	N	O
65	QOL	N	O
66	in	N	O
67	PRMS	N	O
68	.	N	O

69	A	N	O
70	total	N	O
71	of	N	O
72	35	N	O
73	patients	N	O
74	suffering	N	O
75	from	N	O
76	PRMS	N	O
77	were	N	O
78	treated	N	O
79	with	N	O
80	neoadjuvant	N	O
81	chemotherapy	N	O
82	.	N	O

83	Local	N	O
84	therapy	N	O
85	with	N	O
86	radiation	N	O
87	and/or	N	O
88	surgery	N	O
89	was	N	O
90	performed	N	O
91	,	N	O
92	followed	N	O
93	by	N	O
94	adjuvant	N	O
95	chemotherapy	N	O
96	.	N	O

97	Functional	N	O
98	long-term	N	O
99	follow-up	N	O
100	was	N	O
101	evaluated	N	O
102	by	N	O
103	a	N	O
104	gastrointestinal/QOL	N	O
105	survey	N	O
106	.	N	O

107	Thirty-two	N	O
108	patients	N	O
109	were	N	O
110	evaluated	N	O
111	(	N	O
112	exclusion	N	O
113	n	N	O
114	=	N	O
115	3	N	O
116	)	N	O
117	.	N	O

118	Eight	N	O
119	patients	N	O
120	had	N	O
121	embryonal	N	O
122	histology	N	O
123	,	N	O
124	and	N	O
125	24	N	O
126	patients	N	O
127	had	N	O
128	alveolar	N	O
129	histology	N	O
130	.	N	O

131	The	N	O
132	median	N	O
133	age	N	O
134	was	N	O
135	108	N	O
136	months	N	O
137	(	N	O
138	median	N	O
139	follow-up	N	O
140	:	N	O
141	5.8	N	O
142	years	N	O
143	)	N	O
144	.	N	O

145	The	N	O
146	5-year	N	O
147	overall	N	O
148	survival	N	O
149	was	N	O
150	47	N	O
151	%	N	O
152	(	N	O
153	95	N	O
154	%	N	O
155	confidence	N	O
156	interval	N	O
157	:	N	O
158	29-64	N	O
159	)	N	O
160	.	N	O

161	Sixteen	N	O
162	IRS	N	O
163	(	N	O
164	Intergroup	N	O
165	Rhabdomyosarcoma	N	O
166	Study	N	O
167	)	N	O
168	III	N	O
169	and	N	O
170	IV	N	O
171	patients	N	O
172	had	N	O
173	locoregional	N	O
174	lymph	N	O
175	node	N	O
176	involvement	N	O
177	at	N	O
178	diagnosis	N	O
179	.	N	O

180	Seven	N	O
181	patients	N	O
182	were	N	O
183	treated	N	O
184	with	N	O
185	chemotherapy/surgery	N	O
186	alone	N	O
187	[	N	O
188	5-year	N	O
189	event-free	N	O
190	survival	N	O
191	(	N	O
192	EFS	N	O
193	)	N	O
194	:	N	O
195	85.7	N	O
196	%	N	O
197	]	N	O
198	.	N	O

199	Eleven	N	O
200	patients	N	O
201	received	N	O
202	only	N	O
203	radiochemotherapy	N	O
204	(	N	O
205	5-year	N	O
206	EFS	N	O
207	:	N	O
208	27.3	N	O
209	%	N	O
210	)	N	O
211	.	N	O

212	Combined	N	O
213	radiochemotherapy/surgery	N	O
214	was	N	O
215	used	N	O
216	in	N	O
217	12	N	O
218	patients	N	O
219	(	N	O
220	5-year	N	O
221	EFS	N	O
222	:	N	O
223	63.6	N	O
224	%	N	O
225	)	N	O
226	.	N	O

227	Two	N	O
228	patients	N	O
229	were	N	O
230	treated	N	O
231	only	N	O
232	with	N	O
233	chemotherapy	N	O
234	and	N	O
235	they	N	O
236	died	N	O
237	.	N	O

238	Patients	N	I-Premise
239	with	N	I-Premise
240	embryonal	N	I-Premise
241	histology	N	I-Premise
242	had	N	I-Premise
243	a	N	I-Premise
244	significantly	N	I-Premise
245	better	N	I-Premise
246	5-year	N	I-Premise
247	EFS	N	I-Premise
248	(	N	I-Premise
249	87.5	N	I-Premise
250	%	N	I-Premise
251	)	N	I-Premise
252	than	N	I-Premise
253	patients	N	I-Premise
254	with	N	I-Premise
255	alveolar	N	I-Premise
256	histology	N	I-Premise
257	(	N	I-Premise
258	39.1	N	I-Premise
259	%	N	I-Premise
260	;	N	I-Premise
261	P	N	I-Premise
262	=	N	I-Premise
263	0.013	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	Some	N	I-Premise
267	patients	N	I-Premise
268	reported	N	I-Premise
269	symptoms	N	I-Premise
270	of	N	I-Premise
271	fecal	N	I-Premise
272	incontinence	N	I-Premise
273	.	N	I-Premise

274	The	N	I-Premise
275	median	N	I-Premise
276	Wexner	N	I-Premise
277	fecal	N	I-Premise
278	incontinence	N	I-Premise
279	score	N	I-Premise
280	was	N	I-Premise
281	9	N	I-Premise
282	(	N	I-Premise
283	possible	N	I-Premise
284	range	N	I-Premise
285	:	N	I-Premise
286	0-20	N	I-Premise
287	)	N	I-Premise
288	,	N	I-Premise
289	and	N	I-Premise
290	the	N	I-Premise
291	median	N	I-Premise
292	QOL	N	I-Premise
293	score	N	I-Premise
294	was	N	I-Premise
295	90.5	N	I-Premise
296	(	N	I-Premise
297	applicable	N	I-Premise
298	range	N	I-Premise
299	:	N	I-Premise
300	0-144	N	I-Premise
301	)	N	I-Premise
302	.	N	I-Premise

303	The	N	I-Claim
304	outcome	N	I-Claim
305	of	N	I-Claim
306	these	N	I-Claim
307	patients	N	I-Claim
308	remains	N	I-Claim
309	unsatisfactory	N	I-Claim
310	.	N	I-Claim

311	Prognostic	N	I-Premise
312	factors	N	I-Premise
313	for	N	I-Premise
314	a	N	I-Premise
315	favorable	N	I-Premise
316	outcome	N	I-Premise
317	are	N	I-Premise
318	tumor	N	I-Premise
319	size	N	I-Premise
320	of	N	I-Premise
321	smaller	N	I-Premise
322	than	N	I-Premise
323	5	N	I-Premise
324	cm	N	I-Premise
325	,	N	I-Premise
326	negative	N	I-Premise
327	locoregional	N	I-Premise
328	lymph	N	I-Premise
329	nodes	N	I-Premise
330	,	N	I-Premise
331	age	N	I-Premise
332	less	N	I-Premise
333	than	N	I-Premise
334	10	N	I-Premise
335	years	N	I-Premise
336	,	N	I-Premise
337	low	N	I-Premise
338	IRS	N	I-Premise
339	group	N	I-Premise
340	,	N	I-Premise
341	and	N	I-Premise
342	embryonal	N	I-Premise
343	histology	N	I-Premise
344	.	N	I-Premise

345	Fecal	N	I-Claim
346	incontinence	N	I-Claim
347	seems	N	I-Claim
348	to	N	I-Claim
349	be	N	I-Claim
350	a	N	I-Claim
351	problem	N	I-Claim
352	.	N	I-Claim

1	Menopausal	N	O
2	hormone	N	O
3	therapy	N	O
4	continues	N	O
5	in	N	O
6	clinical	N	O
7	use	N	O
8	but	N	O
9	questions	N	O
10	remain	N	O
11	regarding	N	O
12	its	N	O
13	risks	N	O
14	and	N	O
15	benefits	N	O
16	for	N	O
17	chronic	N	O
18	disease	N	O
19	prevention	N	O
20	.	N	O

21	To	N	O
22	report	N	O
23	a	N	O
24	comprehensive	N	O
25	,	N	O
26	integrated	N	O
27	overview	N	O
28	of	N	O
29	findings	N	O
30	from	N	O
31	the	N	O
32	2	N	O
33	Women	N	O
34	's	N	O
35	Health	N	O
36	Initiative	N	O
37	(	N	O
38	WHI	N	O
39	)	N	O
40	hormone	N	O
41	therapy	N	O
42	trials	N	O
43	with	N	O
44	extended	N	O
45	postintervention	N	O
46	follow-up	N	O
47	.	N	O

48	A	N	O
49	total	N	O
50	of	N	O
51	27,347	N	O
52	postmenopausal	N	O
53	women	N	O
54	aged	N	O
55	50	N	O
56	to	N	O
57	79	N	O
58	years	N	O
59	were	N	O
60	enrolled	N	O
61	at	N	O
62	40	N	O
63	US	N	O
64	centers	N	O
65	.	N	O

66	Women	N	O
67	with	N	O
68	an	N	O
69	intact	N	O
70	uterus	N	O
71	received	N	O
72	conjugated	N	O
73	equine	N	O
74	estrogens	N	O
75	(	N	O
76	CEE	N	O
77	;	N	O
78	0.625	N	O
79	mg/d	N	O
80	)	N	O
81	plus	N	O
82	medroxyprogesterone	N	O
83	acetate	N	O
84	(	N	O
85	MPA	N	O
86	;	N	O
87	2.5	N	O
88	mg/d	N	O
89	)	N	O
90	(	N	O
91	n	N	O
92	=	N	O
93	8506	N	O
94	)	N	O
95	or	N	O
96	placebo	N	O
97	(	N	O
98	n	N	O
99	=	N	O
100	8102	N	O
101	)	N	O
102	.	N	O

103	Women	N	O
104	with	N	O
105	prior	N	O
106	hysterectomy	N	O
107	received	N	O
108	CEE	N	O
109	alone	N	O
110	(	N	O
111	0.625	N	O
112	mg/d	N	O
113	)	N	O
114	(	N	O
115	n	N	O
116	=	N	O
117	5310	N	O
118	)	N	O
119	or	N	O
120	placebo	N	O
121	(	N	O
122	n	N	O
123	=	N	O
124	5429	N	O
125	)	N	O
126	.	N	O

127	The	N	O
128	intervention	N	O
129	lasted	N	O
130	a	N	O
131	median	N	O
132	of	N	O
133	5.6	N	O
134	years	N	O
135	in	N	O
136	CEE	N	O
137	plus	N	O
138	MPA	N	O
139	trial	N	O
140	and	N	O
141	7.2	N	O
142	years	N	O
143	in	N	O
144	CEE	N	O
145	alone	N	O
146	trial	N	O
147	with	N	O
148	13	N	O
149	years	N	O
150	of	N	O
151	cumulative	N	O
152	follow-up	N	O
153	until	N	O
154	September	N	O
155	30	N	O
156	,	N	O
157	2010	N	O
158	.	N	O

159	Primary	N	O
160	efficacy	N	O
161	and	N	O
162	safety	N	O
163	outcomes	N	O
164	were	N	O
165	coronary	N	O
166	heart	N	O
167	disease	N	O
168	(	N	O
169	CHD	N	O
170	)	N	O
171	and	N	O
172	invasive	N	O
173	breast	N	O
174	cancer	N	O
175	,	N	O
176	respectively	N	O
177	.	N	O

178	A	N	O
179	global	N	O
180	index	N	O
181	also	N	O
182	included	N	O
183	stroke	N	O
184	,	N	O
185	pulmonary	N	O
186	embolism	N	O
187	,	N	O
188	colorectal	N	O
189	cancer	N	O
190	,	N	O
191	endometrial	N	O
192	cancer	N	O
193	,	N	O
194	hip	N	O
195	fracture	N	O
196	,	N	O
197	and	N	O
198	death	N	O
199	.	N	O

200	During	N	I-Premise
201	the	N	I-Premise
202	CEE	N	I-Premise
203	plus	N	I-Premise
204	MPA	N	I-Premise
205	intervention	N	I-Premise
206	phase	N	I-Premise
207	,	N	I-Premise
208	the	N	I-Premise
209	numbers	N	I-Premise
210	of	N	I-Premise
211	CHD	N	I-Premise
212	cases	N	I-Premise
213	were	N	I-Premise
214	196	N	I-Premise
215	for	N	I-Premise
216	CEE	N	I-Premise
217	plus	N	I-Premise
218	MPA	N	I-Premise
219	vs	N	I-Premise
220	159	N	I-Premise
221	for	N	I-Premise
222	placebo	N	I-Premise
223	(	N	I-Premise
224	hazard	N	I-Premise
225	ratio	N	I-Premise
226	[	N	I-Premise
227	HR	N	I-Premise
228	]	N	I-Premise
229	,	N	I-Premise
230	1.18	N	I-Premise
231	;	N	I-Premise
232	95	N	I-Premise
233	%	N	I-Premise
234	CI	N	I-Premise
235	,	N	I-Premise
236	0.95-1.45	N	I-Premise
237	)	N	I-Premise
238	and	N	I-Premise
239	206	N	I-Premise
240	vs	N	I-Premise
241	155	N	I-Premise
242	,	N	I-Premise
243	respectively	N	I-Premise
244	,	N	I-Premise
245	for	N	I-Premise
246	invasive	N	I-Premise
247	breast	N	I-Premise
248	cancer	N	I-Premise
249	(	N	I-Premise
250	HR	N	I-Premise
251	,	N	I-Premise
252	1.24	N	I-Premise
253	;	N	I-Premise
254	95	N	I-Premise
255	%	N	I-Premise
256	CI	N	I-Premise
257	,	N	I-Premise
258	1.01-1.53	N	I-Premise
259	)	N	I-Premise
260	.	N	I-Premise

261	Other	N	I-Premise
262	risks	N	I-Premise
263	included	N	I-Premise
264	increased	N	I-Premise
265	stroke	N	I-Premise
266	,	N	I-Premise
267	pulmonary	N	I-Premise
268	embolism	N	I-Premise
269	,	N	I-Premise
270	dementia	N	I-Premise
271	(	N	I-Premise
272	in	N	I-Premise
273	women	N	I-Premise
274	aged	N	I-Premise
275	â¥65	N	I-Premise
276	years	N	I-Premise
277	)	N	I-Premise
278	,	N	I-Premise
279	gallbladder	N	I-Premise
280	disease	N	I-Premise
281	,	N	I-Premise
282	and	N	I-Premise
283	urinary	N	I-Premise
284	incontinence	N	I-Premise
285	;	N	I-Premise
286	benefits	N	I-Premise
287	included	N	I-Premise
288	decreased	N	I-Premise
289	hip	N	I-Premise
290	fractures	N	I-Premise
291	,	N	I-Premise
292	diabetes	N	I-Premise
293	,	N	I-Premise
294	and	N	I-Premise
295	vasomotor	N	I-Premise
296	symptoms	N	I-Premise
297	.	N	I-Premise

298	Most	N	I-Premise
299	risks	N	I-Premise
300	and	N	I-Premise
301	benefits	N	I-Premise
302	dissipated	N	I-Premise
303	postintervention	N	I-Premise
304	,	N	I-Premise
305	although	N	I-Premise
306	some	N	I-Premise
307	elevation	N	I-Premise
308	in	N	I-Premise
309	breast	N	I-Premise
310	cancer	N	I-Premise
311	risk	N	I-Premise
312	persisted	N	I-Premise
313	during	N	I-Premise
314	cumulative	N	I-Premise
315	follow-up	N	I-Premise
316	(	N	I-Premise
317	434	N	I-Premise
318	cases	N	I-Premise
319	for	N	I-Premise
320	CEE	N	I-Premise
321	plus	N	I-Premise
322	MPA	N	I-Premise
323	vs	N	I-Premise
324	323	N	I-Premise
325	for	N	I-Premise
326	placebo	N	I-Premise
327	;	N	I-Premise
328	HR	N	I-Premise
329	,	N	I-Premise
330	1.28	N	I-Premise
331	[	N	I-Premise
332	95	N	I-Premise
333	%	N	I-Premise
334	CI	N	I-Premise
335	,	N	I-Premise
336	1.11-1.48	N	I-Premise
337	]	N	I-Premise
338	)	N	I-Premise
339	.	N	I-Premise

340	The	N	I-Premise
341	risks	N	I-Premise
342	and	N	I-Premise
343	benefits	N	I-Premise
344	were	N	I-Premise
345	more	N	I-Premise
346	balanced	N	I-Premise
347	during	N	I-Premise
348	the	N	I-Premise
349	CEE	N	I-Premise
350	alone	N	I-Premise
351	intervention	N	I-Premise
352	with	N	I-Premise
353	204	N	I-Premise
354	CHD	N	I-Premise
355	cases	N	I-Premise
356	for	N	I-Premise
357	CEE	N	I-Premise
358	alone	N	I-Premise
359	vs	N	I-Premise
360	222	N	I-Premise
361	cases	N	I-Premise
362	for	N	I-Premise
363	placebo	N	I-Premise
364	(	N	I-Premise
365	HR	N	I-Premise
366	,	N	I-Premise
367	0.94	N	I-Premise
368	;	N	I-Premise
369	95	N	I-Premise
370	%	N	I-Premise
371	CI	N	I-Premise
372	,	N	I-Premise
373	0.78-1.14	N	I-Premise
374	)	N	I-Premise
375	and	N	I-Premise
376	104	N	I-Premise
377	vs	N	I-Premise
378	135	N	I-Premise
379	,	N	I-Premise
380	respectively	N	I-Premise
381	,	N	I-Premise
382	for	N	I-Premise
383	invasive	N	I-Premise
384	breast	N	I-Premise
385	cancer	N	I-Premise
386	(	N	I-Premise
387	HR	N	I-Premise
388	,	N	I-Premise
389	0.79	N	I-Premise
390	;	N	I-Premise
391	95	N	I-Premise
392	%	N	I-Premise
393	CI	N	I-Premise
394	,	N	I-Premise
395	0.61-1.02	N	I-Premise
396	)	N	I-Premise
397	;	N	I-Premise
398	cumulatively	N	I-Premise
399	,	N	I-Premise
400	there	N	I-Premise
401	were	N	I-Premise
402	168	N	I-Premise
403	vs	N	I-Premise
404	216	N	I-Premise
405	,	N	I-Premise
406	respectively	N	I-Premise
407	,	N	I-Premise
408	cases	N	I-Premise
409	of	N	I-Premise
410	breast	N	I-Premise
411	cancer	N	I-Premise
412	diagnosed	N	I-Premise
413	(	N	I-Premise
414	HR	N	I-Premise
415	,	N	I-Premise
416	0.79	N	I-Premise
417	;	N	I-Premise
418	95	N	I-Premise
419	%	N	I-Premise
420	CI	N	I-Premise
421	,	N	I-Premise
422	0.65-0.97	N	I-Premise
423	)	N	I-Premise
424	.	N	I-Premise

425	Results	N	O
426	for	N	O
427	other	N	O
428	outcomes	N	O
429	were	N	O
430	similar	N	O
431	to	N	O
432	CEE	N	O
433	plus	N	O
434	MPA	N	O
435	.	N	O

436	Neither	N	O
437	regimen	N	O
438	affected	N	O
439	all-cause	N	O
440	mortality	N	O
441	.	N	O

442	For	N	I-Premise
443	CEE	N	I-Premise
444	alone	N	I-Premise
445	,	N	I-Premise
446	younger	N	I-Premise
447	women	N	I-Premise
448	(	N	I-Premise
449	aged	N	I-Premise
450	50-59	N	I-Premise
451	years	N	I-Premise
452	)	N	I-Premise
453	had	N	I-Premise
454	more	N	I-Premise
455	favorable	N	I-Premise
456	results	N	I-Premise
457	for	N	I-Premise
458	all-cause	N	I-Premise
459	mortality	N	I-Premise
460	,	N	I-Premise
461	myocardial	N	I-Premise
462	infarction	N	I-Premise
463	,	N	I-Premise
464	and	N	I-Premise
465	the	N	I-Premise
466	global	N	I-Premise
467	index	N	I-Premise
468	(	N	I-Premise
469	nominal	N	I-Premise
470	P	N	I-Premise
471	<	N	I-Premise
472	.05	N	I-Premise
473	for	N	I-Premise
474	trend	N	I-Premise
475	by	N	I-Premise
476	age	N	I-Premise
477	)	N	I-Premise
478	.	N	I-Premise

479	Absolute	N	I-Premise
480	risks	N	I-Premise
481	of	N	I-Premise
482	adverse	N	I-Premise
483	events	N	I-Premise
484	(	N	I-Premise
485	measured	N	I-Premise
486	by	N	I-Premise
487	the	N	I-Premise
488	global	N	I-Premise
489	index	N	I-Premise
490	)	N	I-Premise
491	per	N	I-Premise
492	10,000	N	I-Premise
493	women	N	I-Premise
494	annually	N	I-Premise
495	taking	N	I-Premise
496	CEE	N	I-Premise
497	plus	N	I-Premise
498	MPA	N	I-Premise
499	ranged	N	I-Premise
500	from	N	I-Premise
501	12	N	I-Premise
502	excess	N	I-Premise
503	cases	N	I-Premise
504	for	N	I-Premise
505	ages	N	I-Premise
506	of	N	I-Premise
507	50-59	N	I-Premise
508	years	N	I-Premise
509	to	N	I-Premise
510	38	N	I-Premise
511	for	N	I-Premise
512	ages	N	I-Premise
513	of	N	I-Premise
514	70-79	N	I-Premise
515	years	N	I-Premise
516	;	N	I-Premise
517	for	N	I-Premise
518	women	N	I-Premise
519	taking	N	I-Premise
520	CEE	N	I-Premise
521	alone	N	I-Premise
522	,	N	I-Premise
523	from	N	I-Premise
524	19	N	I-Premise
525	fewer	N	I-Premise
526	cases	N	I-Premise
527	for	N	I-Premise
528	ages	N	I-Premise
529	of	N	I-Premise
530	50-59	N	I-Premise
531	years	N	I-Premise
532	to	N	I-Premise
533	51	N	I-Premise
534	excess	N	I-Premise
535	cases	N	I-Premise
536	for	N	I-Premise
537	ages	N	I-Premise
538	of	N	I-Premise
539	70-79	N	I-Premise
540	years	N	I-Premise
541	.	N	I-Premise

542	Quality-of-life	N	O
543	outcomes	N	O
544	had	N	O
545	mixed	N	O
546	results	N	O
547	in	N	O
548	both	N	O
549	trials	N	O
550	.	N	O

551	Menopausal	N	I-Claim
552	hormone	N	I-Claim
553	therapy	N	I-Claim
554	has	N	I-Claim
555	a	N	I-Claim
556	complex	N	I-Claim
557	pattern	N	I-Claim
558	of	N	I-Claim
559	risks	N	I-Claim
560	and	N	I-Claim
561	benefits	N	I-Claim
562	.	N	I-Claim

563	Findings	N	I-Claim
564	from	N	I-Claim
565	the	N	I-Claim
566	intervention	N	I-Claim
567	and	N	I-Claim
568	extended	N	I-Claim
569	postintervention	N	I-Claim
570	follow-up	N	I-Claim
571	of	N	I-Claim
572	the	N	I-Claim
573	2	N	I-Claim
574	WHI	N	I-Claim
575	hormone	N	I-Claim
576	therapy	N	I-Claim
577	trials	N	I-Claim
578	do	N	I-Claim
579	not	N	I-Claim
580	support	N	I-Claim
581	use	N	I-Claim
582	of	N	I-Claim
583	this	N	I-Claim
584	therapy	N	I-Claim
585	for	N	I-Claim
586	chronic	N	I-Claim
587	disease	N	I-Claim
588	prevention	N	I-Claim
589	,	N	I-Claim
590	although	N	I-Claim
591	it	N	I-Claim
592	is	N	I-Claim
593	appropriate	N	I-Claim
594	for	N	I-Claim
595	symptom	N	I-Claim
596	management	N	I-Claim
597	in	N	I-Claim
598	some	N	I-Claim
599	women	N	I-Claim
600	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	the	N	O
7	Chinese	N	O
8	medicine	N	O
9	(	N	O
10	CM	N	O
11	)	N	O
12	five-element	N	O
13	music	N	O
14	on	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	for	N	O
19	senior	N	O
20	and	N	O
21	non-senior	N	O
22	advanced	N	O
23	cancer	N	O
24	patients	N	O
25	.	N	O

26	With	N	O
27	a	N	O
28	randomized	N	O
29	controlled	N	O
30	trial	N	O
31	,	N	O
32	170	N	O
33	advanced	N	O
34	cancer	N	O
35	patients	N	O
36	were	N	O
37	randomly	N	O
38	assigned	N	O
39	to	N	O
40	three	N	O
41	groups	N	O
42	:	N	O
43	the	N	O
44	CM	N	O
45	five-element	N	O
46	music	N	O
47	group	N	O
48	(	N	O
49	68	N	O
50	patients	N	O
51	)	N	O
52	,	N	O
53	the	N	O
54	Western	N	O
55	music	N	O
56	therapy	N	O
57	group	N	O
58	(	N	O
59	68	N	O
60	cases	N	O
61	)	N	O
62	,	N	O
63	and	N	O
64	the	N	O
65	no	N	O
66	music	N	O
67	therapy	N	O
68	group	N	O
69	(	N	O
70	34	N	O
71	cases	N	O
72	)	N	O
73	.	N	O

74	All	N	O
75	patients	N	O
76	of	N	O
77	70	N	O
78	years	N	O
79	old	N	O
80	or	N	O
81	older	N	O
82	were	N	O
83	considered	N	O
84	seniors	N	O
85	and	N	O
86	the	N	O
87	remaining	N	O
88	patients	N	O
89	younger	N	O
90	than	N	O
91	70	N	O
92	years	N	O
93	were	N	O
94	considered	N	O
95	nonseniors	N	O
96	.	N	O

97	Patients	N	O
98	in	N	O
99	the	N	O
100	CM	N	O
101	five-element	N	O
102	music	N	O
103	group	N	O
104	listened	N	O
105	to	N	O
106	CM	N	O
107	five-element	N	O
108	music	N	O
109	,	N	O
110	the	N	O
111	patients	N	O
112	in	N	O
113	the	N	O
114	Western	N	O
115	music	N	O
116	group	N	O
117	listened	N	O
118	to	N	O
119	Western	N	O
120	music	N	O
121	,	N	O
122	and	N	O
123	the	N	O
124	patients	N	O
125	in	N	O
126	the	N	O
127	no	N	O
128	music	N	O
129	group	N	O
130	did	N	O
131	not	N	O
132	listen	N	O
133	to	N	O
134	music	N	O
135	.	N	O

136	A	N	O
137	course	N	O
138	of	N	O
139	treatment	N	O
140	was	N	O
141	3	N	O
142	weeks	N	O
143	,	N	O
144	with	N	O
145	30	N	O
146	min	N	O
147	each	N	O
148	day	N	O
149	,	N	O
150	5	N	O
151	days	N	O
152	a	N	O
153	week	N	O
154	.	N	O

155	The	N	O
156	Hospice	N	O
157	Quality	N	O
158	of	N	O
159	Life	N	O
160	Index-Revised	N	O
161	(	N	O
162	HQOLI-R	N	O
163	)	N	O
164	and	N	O
165	Karnofsky	N	O
166	performance	N	O
167	score	N	O
168	(	N	O
169	KPS	N	O
170	)	N	O
171	were	N	O
172	measured	N	O
173	in	N	O
174	the	N	O
175	three	N	O
176	groups	N	O
177	before	N	O
178	and	N	O
179	after	N	O
180	treatment	N	O
181	.	N	O

182	The	N	O
183	symptom	N	O
184	diary	N	O
185	score	N	O
186	was	N	O
187	measured	N	O
188	in	N	O
189	the	N	O
190	three	N	O
191	groups	N	O
192	every	N	O
193	3	N	O
194	days	N	O
195	,	N	O
196	7	N	O
197	times	N	O
198	in	N	O
199	total	N	O
200	.	N	O

201	CM	N	I-Premise
202	five-element	N	I-Premise
203	music	N	I-Premise
204	group	N	I-Premise
205	showed	N	I-Premise
206	a	N	I-Premise
207	significant	N	I-Premise
208	difference	N	I-Premise
209	of	N	I-Premise
210	HQOLI-R	N	I-Premise
211	,	N	I-Premise
212	KPS	N	I-Premise
213	and	N	I-Premise
214	symptom	N	I-Premise
215	diary	N	I-Premise
216	score	N	I-Premise
217	with	N	I-Premise
218	other	N	I-Premise
219	groups	N	I-Premise
220	(	N	I-Premise
221	all	N	I-Premise
222	P	N	I-Premise
223	<	N	I-Premise
224	0.01	N	I-Premise
225	)	N	I-Premise
226	.	N	I-Premise

227	There	N	I-Premise
228	were	N	I-Premise
229	significant	N	I-Premise
230	differences	N	I-Premise
231	of	N	I-Premise
232	HQOLI-R	N	I-Premise
233	,	N	I-Premise
234	symptom	N	I-Premise
235	diary	N	I-Premise
236	score	N	I-Premise
237	,	N	I-Premise
238	and	N	I-Premise
239	KPS	N	I-Premise
240	after	N	I-Premise
241	treatment	N	I-Premise
242	in	N	I-Premise
243	CM	N	I-Premise
244	five-element	N	I-Premise
245	music	N	I-Premise
246	group	N	I-Premise
247	and	N	I-Premise
248	other	N	I-Premise
249	groups	N	I-Premise
250	in	N	I-Premise
251	the	N	I-Premise
252	non-senior	N	I-Premise
253	subgroup	N	I-Premise
254	(	N	I-Premise
255	P	N	I-Premise
256	<	N	I-Premise
257	0.05	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	Additionally	N	O
261	,	N	O
262	there	N	I-Premise
263	were	N	I-Premise
264	significant	N	I-Premise
265	differences	N	I-Premise
266	in	N	I-Premise
267	HQOLI-R	N	I-Premise
268	and	N	I-Premise
269	KPS	N	I-Premise
270	after	N	I-Premise
271	treatment	N	I-Premise
272	among	N	I-Premise
273	the	N	I-Premise
274	three	N	I-Premise
275	groups	N	I-Premise
276	in	N	I-Premise
277	the	N	I-Premise
278	senior	N	I-Premise
279	subgroup	N	I-Premise
280	(	N	I-Premise
281	P	N	I-Premise
282	<	N	I-Premise
283	0.05	N	I-Premise
284	)	N	I-Premise
285	.	N	I-Premise

286	CM	N	I-Claim
287	five-element	N	I-Claim
288	music	N	I-Claim
289	therapy	N	I-Claim
290	could	N	I-Claim
291	improve	N	I-Claim
292	the	N	I-Claim
293	quality	N	I-Claim
294	of	N	I-Claim
295	life	N	I-Claim
296	and	N	I-Claim
297	KPS	N	I-Claim
298	for	N	I-Claim
299	senior	N	I-Claim
300	and	N	I-Claim
301	non	N	I-Claim
302	senior	N	I-Claim
303	advanced	N	I-Claim
304	cancer	N	I-Claim
305	patients	N	I-Claim
306	,	N	I-Claim
307	and	N	I-Claim
308	it	N	I-Claim
309	could	N	I-Claim
310	improve	N	I-Claim
311	subjective	N	I-Claim
312	symptoms	N	I-Claim
313	for	N	I-Claim
314	non-senior	N	I-Claim
315	advanced	N	I-Claim
316	cancer	N	I-Claim
317	patients	N	I-Claim
318	.	N	I-Claim

1	Mediating	N	O
2	mechanisms	N	O
3	of	N	O
4	a	N	O
5	12-week	N	O
6	group-based	N	O
7	exercise	N	O
8	intervention	N	O
9	on	N	O
10	cancer	N	O
11	survivors	N	O
12	'	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	(	N	O
17	QoL	N	O
18	)	N	O
19	were	N	O
20	examined	N	O
21	to	N	O
22	inform	N	O
23	future	N	O
24	exercise	N	O
25	intervention	N	O
26	development	N	O
27	.	N	O

28	Two	N	O
29	hundred	N	O
30	nine	N	O
31	cancer	N	O
32	survivors	N	O
33	â¥	N	O
34	3	N	O
35	months	N	O
36	posttreatment	N	O
37	(	N	O
38	57	N	O
39	%	N	O
40	breast	N	O
41	cancer	N	O
42	)	N	O
43	aged	N	O
44	49.5	N	O
45	(	N	O
46	Â±	N	O
47	10.4	N	O
48	)	N	O
49	years	N	O
50	were	N	O
51	assigned	N	O
52	to	N	O
53	physical	N	O
54	exercise	N	O
55	(	N	O
56	n	N	O
57	=	N	O
58	147	N	O
59	)	N	O
60	or	N	O
61	wait-list	N	O
62	control	N	O
63	(	N	O
64	n	N	O
65	=	N	O
66	62	N	O
67	)	N	O
68	.	N	O

69	QoL	N	O
70	,	N	O
71	fatigue	N	O
72	,	N	O
73	emotional	N	O
74	distress	N	O
75	,	N	O
76	physical	N	O
77	activity	N	O
78	,	N	O
79	general	N	O
80	self-efficacy	N	O
81	and	N	O
82	mastery	N	O
83	were	N	O
84	assessed	N	O
85	at	N	O
86	baseline	N	O
87	and	N	O
88	post-intervention	N	O
89	using	N	O
90	questionnaires	N	O
91	.	N	O

92	Path	N	O
93	analysis	N	O
94	was	N	O
95	conducted	N	O
96	using	N	O
97	Mplus	N	O
98	to	N	O
99	explore	N	O
100	whether	N	O
101	improved	N	O
102	physical	N	O
103	activity	N	O
104	,	N	O
105	general	N	O
106	self-efficacy	N	O
107	and	N	O
108	mastery	N	O
109	mediated	N	O
110	the	N	O
111	effects	N	O
112	of	N	O
113	exercise	N	O
114	on	N	O
115	fatigue	N	O
116	and	N	O
117	distress	N	O
118	and	N	O
119	consequently	N	O
120	QoL	N	O
121	.	N	O

122	The	N	I-Premise
123	intervention	N	I-Premise
124	was	N	I-Premise
125	associated	N	I-Premise
126	with	N	I-Premise
127	increased	N	I-Premise
128	physical	N	I-Premise
129	activity	N	I-Premise
130	(	N	I-Premise
131	Î²	N	I-Premise
132	=	N	I-Premise
133	0.46	N	I-Premise
134	,	N	I-Premise
135	95	N	I-Premise
136	%	N	I-Premise
137	confidence	N	I-Premise
138	interval	N	I-Premise
139	(	N	I-Premise
140	CI	N	I-Premise
141	)	N	I-Premise
142	=	N	I-Premise
143	0.14	N	I-Premise
144	;	N	I-Premise
145	0.59	N	I-Premise
146	)	N	I-Premise
147	,	N	I-Premise
148	general	N	I-Premise
149	self-efficacy	N	I-Premise
150	(	N	I-Premise
151	Î²	N	I-Premise
152	=	N	I-Premise
153	2.41	N	I-Premise
154	,	N	I-Premise
155	95	N	I-Premise
156	%	N	I-Premise
157	CI	N	I-Premise
158	=	N	I-Premise
159	0.35	N	I-Premise
160	;	N	I-Premise
161	4.73	N	I-Premise
162	)	N	I-Premise
163	,	N	I-Premise
164	and	N	I-Premise
165	mastery	N	I-Premise
166	(	N	I-Premise
167	Î²	N	I-Premise
168	=	N	I-Premise
169	1.75	N	I-Premise
170	,	N	I-Premise
171	95	N	I-Premise
172	%	N	I-Premise
173	CI	N	I-Premise
174	=	N	I-Premise
175	0.36	N	I-Premise
176	;	N	I-Premise
177	2.78	N	I-Premise
178	)	N	I-Premise
179	.	N	I-Premise

180	Further	N	O
181	,	N	O
182	the	N	I-Premise
183	intervention	N	I-Premise
184	had	N	I-Premise
185	both	N	I-Premise
186	a	N	I-Premise
187	direct	N	I-Premise
188	effect	N	I-Premise
189	on	N	I-Premise
190	fatigue	N	I-Premise
191	(	N	I-Premise
192	Î²	N	I-Premise
193	=	N	I-Premise
194	-1.09	N	I-Premise
195	,	N	I-Premise
196	95	N	I-Premise
197	%	N	I-Premise
198	CI	N	I-Premise
199	=	N	I-Premise
200	-2.12	N	I-Premise
201	;	N	I-Premise
202	0.01	N	I-Premise
203	)	N	I-Premise
204	,	N	I-Premise
205	and	N	I-Premise
206	an	N	I-Premise
207	indirect	N	I-Premise
208	effect	N	I-Premise
209	(	N	I-Premise
210	Î²	N	I-Premise
211	=	N	I-Premise
212	-0.54	N	I-Premise
213	,	N	I-Premise
214	95	N	I-Premise
215	%	N	I-Premise
216	CI	N	I-Premise
217	=	N	I-Premise
218	-1.00	N	I-Premise
219	;	N	I-Premise
220	-0.21	N	I-Premise
221	)	N	I-Premise
222	via	N	I-Premise
223	physical	N	I-Premise
224	activity	N	I-Premise
225	(	N	I-Premise
226	Î²	N	I-Premise
227	=	N	I-Premise
228	-0.29	N	I-Premise
229	,	N	I-Premise
230	95	N	I-Premise
231	%	N	I-Premise
232	CI	N	I-Premise
233	=	N	I-Premise
234	-0.64	N	I-Premise
235	;	N	I-Premise
236	-0.07	N	I-Premise
237	)	N	I-Premise
238	and	N	I-Premise
239	general	N	I-Premise
240	self-efficacy	N	I-Premise
241	(	N	I-Premise
242	Î²	N	I-Premise
243	=	N	I-Premise
244	-0.25	N	I-Premise
245	,	N	I-Premise
246	95	N	I-Premise
247	%	N	I-Premise
248	CI	N	I-Premise
249	=	N	I-Premise
250	-0.61	N	I-Premise
251	;	N	I-Premise
252	-0.05	N	I-Premise
253	)	N	I-Premise
254	.	N	I-Premise

255	The	N	I-Premise
256	intervention	N	I-Premise
257	had	N	I-Premise
258	a	N	I-Premise
259	borderline	N	I-Premise
260	significant	N	I-Premise
261	direct	N	I-Premise
262	effect	N	I-Premise
263	on	N	I-Premise
264	reduced	N	I-Premise
265	distress	N	I-Premise
266	(	N	I-Premise
267	Î²	N	I-Premise
268	=	N	I-Premise
269	-1.32	N	I-Premise
270	,	N	I-Premise
271	95	N	I-Premise
272	%	N	I-Premise
273	CI	N	I-Premise
274	=	N	I-Premise
275	-2.68	N	I-Premise
276	;	N	I-Premise
277	0.11	N	I-Premise
278	)	N	I-Premise
279	,	N	I-Premise
280	and	N	I-Premise
281	a	N	I-Premise
282	significant	N	I-Premise
283	indirect	N	I-Premise
284	effect	N	I-Premise
285	via	N	I-Premise
286	increased	N	I-Premise
287	general	N	I-Premise
288	self-efficacy	N	I-Premise
289	and	N	I-Premise
290	mastery	N	I-Premise
291	(	N	I-Premise
292	Î²	N	I-Premise
293	=	N	I-Premise
294	-1.06	N	I-Premise
295	,	N	I-Premise
296	95	N	I-Premise
297	%	N	I-Premise
298	CI	N	I-Premise
299	=	N	I-Premise
300	-1.89	N	I-Premise
301	;	N	I-Premise
302	-0.38	N	I-Premise
303	)	N	I-Premise
304	.	N	I-Premise

305	Reductions	N	I-Premise
306	in	N	I-Premise
307	fatigue	N	I-Premise
308	(	N	I-Premise
309	Î²	N	I-Premise
310	=	N	I-Premise
311	-1.33	N	I-Premise
312	,	N	I-Premise
313	95	N	I-Premise
314	%	N	I-Premise
315	CI	N	I-Premise
316	=-1.85	N	I-Premise
317	;	N	I-Premise
318	-0.83	N	I-Premise
319	)	N	I-Premise
320	and	N	I-Premise
321	distress	N	I-Premise
322	(	N	I-Premise
323	Î²	N	I-Premise
324	=	N	I-Premise
325	-0.86	N	I-Premise
326	,	N	I-Premise
327	95	N	I-Premise
328	%	N	I-Premise
329	CI	N	I-Premise
330	=	N	I-Premise
331	-1.25	N	I-Premise
332	;	N	I-Premise
333	-0.52	N	I-Premise
334	)	N	I-Premise
335	were	N	I-Premise
336	associated	N	I-Premise
337	with	N	I-Premise
338	improved	N	I-Premise
339	QoL	N	I-Premise
340	.	N	I-Premise

341	Further	N	O
342	,	N	O
343	increased	N	I-Premise
344	physical	N	I-Premise
345	activity	N	I-Premise
346	was	N	I-Premise
347	directly	N	I-Premise
348	associated	N	I-Premise
349	with	N	I-Premise
350	improved	N	I-Premise
351	QoL	N	I-Premise
352	(	N	I-Premise
353	Î²	N	I-Premise
354	=	N	I-Premise
355	3.37	N	I-Premise
356	,	N	I-Premise
357	95	N	I-Premise
358	%	N	I-Premise
359	CI	N	I-Premise
360	=	N	I-Premise
361	1.01	N	I-Premise
362	;	N	I-Premise
363	5.54	N	I-Premise
364	)	N	I-Premise
365	.	N	I-Premise

366	The	N	I-Claim
367	beneficial	N	I-Claim
368	effect	N	I-Claim
369	of	N	I-Claim
370	group-based	N	I-Claim
371	physical	N	I-Claim
372	exercise	N	I-Claim
373	on	N	I-Claim
374	QoL	N	I-Claim
375	was	N	I-Claim
376	mediated	N	I-Claim
377	by	N	I-Claim
378	increased	N	I-Claim
379	physical	N	I-Claim
380	activity	N	I-Claim
381	,	N	I-Claim
382	general	N	I-Claim
383	self-efficacy	N	I-Claim
384	and	N	I-Claim
385	mastery	N	I-Claim
386	,	N	I-Claim
387	and	N	I-Claim
388	subsequent	N	I-Claim
389	reductions	N	I-Claim
390	in	N	I-Claim
391	fatigue	N	I-Claim
392	and	N	I-Claim
393	distress	N	I-Claim
394	.	N	I-Claim

395	In	N	I-Claim
396	addition	N	I-Claim
397	to	N	I-Claim
398	physical	N	I-Claim
399	activity	N	I-Claim
400	,	N	I-Claim
401	future	N	I-Claim
402	interventions	N	I-Claim
403	should	N	I-Claim
404	target	N	I-Claim
405	self-efficacy	N	I-Claim
406	and	N	I-Claim
407	mastery	N	I-Claim
408	.	N	I-Claim

409	This	N	I-Claim
410	may	N	I-Claim
411	lead	N	I-Claim
412	to	N	I-Claim
413	reduced	N	I-Claim
414	distress	N	I-Claim
415	and	N	I-Claim
416	fatigue	N	I-Claim
417	,	N	I-Claim
418	and	N	I-Claim
419	consequently	N	I-Claim
420	improved	N	I-Claim
421	QoL	N	I-Claim
422	of	N	I-Claim
423	cancer	N	I-Claim
424	survivors	N	I-Claim
425	.	N	I-Claim

1	The	N	I-MajorClaim
2	extent	N	I-MajorClaim
3	to	N	I-MajorClaim
4	which	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	may	N	I-MajorClaim
7	relieve	N	I-MajorClaim
8	tumour-related	N	I-MajorClaim
9	symptoms	N	I-MajorClaim
10	,	N	I-MajorClaim
11	improve	N	I-MajorClaim
12	quality	N	I-MajorClaim
13	of	N	I-MajorClaim
14	life	N	I-MajorClaim
15	and	N	I-MajorClaim
16	prolong	N	I-MajorClaim
17	survival	N	I-MajorClaim
18	in	N	I-MajorClaim
19	patients	N	I-MajorClaim
20	with	N	I-MajorClaim
21	gastric	N	I-MajorClaim
22	cancer	N	I-MajorClaim
23	is	N	I-MajorClaim
24	not	N	I-MajorClaim
25	known	N	I-MajorClaim
26	in	N	I-MajorClaim
27	spite	N	I-MajorClaim
28	of	N	I-MajorClaim
29	the	N	I-MajorClaim
30	extensive	N	I-MajorClaim
31	use	N	I-MajorClaim
32	of	N	I-MajorClaim
33	this	N	I-MajorClaim
34	treatment	N	I-MajorClaim
35	modality	N	I-MajorClaim
36	.	N	I-MajorClaim

37	The	N	O
38	aim	N	O
39	of	N	O
40	this	N	O
41	study	N	O
42	was	N	O
43	to	N	O
44	estimate	N	O
45	any	N	O
46	gain	N	O
47	in	N	O
48	the	N	O
49	quantity	N	O
50	and	N	O
51	quality	N	O
52	of	N	O
53	life	N	O
54	produced	N	O
55	by	N	O
56	chemotherapy	N	O
57	in	N	O
58	these	N	O
59	patients	N	O
60	.	N	O

61	Between	N	O
62	January	N	O
63	1991	N	O
64	and	N	O
65	February	N	O
66	1995	N	O
67	,	N	O
68	61	N	O
69	patients	N	O
70	with	N	O
71	gastric	N	O
72	cancer	N	O
73	were	N	O
74	randomized	N	O
75	to	N	O
76	either	N	O
77	chemotherapy	N	O
78	in	N	O
79	addition	N	O
80	to	N	O
81	best	N	O
82	supportive	N	O
83	care	N	O
84	or	N	O
85	to	N	O
86	best	N	O
87	supportive	N	O
88	care	N	O
89	.	N	O

90	Chemotherapy	N	O
91	was	N	O
92	allowed	N	O
93	in	N	O
94	the	N	O
95	latter	N	O
96	group	N	O
97	if	N	O
98	the	N	O
99	supportive	N	O
100	measures	N	O
101	did	N	O
102	not	N	O
103	lead	N	O
104	to	N	O
105	palliation	N	O
106	.	N	O

107	Chemotherapy	N	O
108	was	N	O
109	the	N	O
110	ELF-regimen	N	O
111	consisting	N	O
112	of	N	O
113	5-fluorouracil	N	O
114	,	N	O
115	leucovorin	N	O
116	and	N	O
117	etoposide	N	O
118	,	N	O
119	or	N	O
120	,	N	O
121	in	N	O
122	elderly	N	O
123	patients	N	O
124	with	N	O
125	poor	N	O
126	performance	N	O
127	,	N	O
128	a	N	O
129	5-fluorouracil/leucovorin	N	O
130	regimen	N	O
131	(	N	O
132	FLv	N	O
133	)	N	O
134	.	N	O

135	Quality	N	O
136	of	N	O
137	life	N	O
138	was	N	O
139	evaluated	N	O
140	with	N	O
141	the	N	O
142	EORTC-QLQ-C30	N	O
143	instrument	N	O
144	.	N	O

145	More	N	I-Premise
146	patients	N	I-Premise
147	in	N	I-Premise
148	the	N	I-Premise
149	chemotherapy	N	I-Premise
150	group	N	I-Premise
151	(	N	I-Premise
152	45	N	I-Premise
153	%	N	I-Premise
154	,	N	I-Premise
155	14/31	N	I-Premise
156	)	N	I-Premise
157	had	N	I-Premise
158	an	N	I-Premise
159	improved	N	I-Premise
160	or	N	I-Premise
161	prolonged	N	I-Premise
162	high	N	I-Premise
163	quality	N	I-Premise
164	of	N	I-Premise
165	life	N	I-Premise
166	for	N	I-Premise
167	a	N	I-Premise
168	minimum	N	I-Premise
169	period	N	I-Premise
170	of	N	I-Premise
171	4	N	I-Premise
172	months	N	I-Premise
173	compared	N	I-Premise
174	to	N	I-Premise
175	those	N	I-Premise
176	in	N	I-Premise
177	the	N	I-Premise
178	best	N	I-Premise
179	supportive	N	I-Premise
180	care	N	I-Premise
181	group	N	I-Premise
182	(	N	I-Premise
183	20	N	I-Premise
184	%	N	I-Premise
185	,	N	I-Premise
186	6/30	N	I-Premise
187	,	N	I-Premise
188	P	N	I-Premise
189	<	N	I-Premise
190	0.05	N	I-Premise
191	)	N	I-Premise
192	.	N	I-Premise

193	A	N	I-Premise
194	similar	N	I-Premise
195	difference	N	I-Premise
196	was	N	I-Premise
197	seen	N	I-Premise
198	in	N	I-Premise
199	the	N	I-Premise
200	treating	N	I-Premise
201	physician	N	I-Premise
202	's	N	I-Premise
203	evaluation	N	I-Premise
204	of	N	I-Premise
205	whether	N	I-Premise
206	the	N	I-Premise
207	patient	N	I-Premise
208	was	N	I-Premise
209	subjectively	N	I-Premise
210	improved	N	I-Premise
211	or	N	I-Premise
212	continued	N	I-Premise
213	to	N	I-Premise
214	do	N	I-Premise
215	well	N	I-Premise
216	for	N	I-Premise
217	at	N	I-Premise
218	least	N	I-Premise
219	4	N	I-Premise
220	months	N	I-Premise
221	(	N	I-Premise
222	17/31	N	I-Premise
223	,	N	I-Premise
224	55	N	I-Premise
225	%	N	I-Premise
226	versus	N	I-Premise
227	6/30	N	I-Premise
228	,	N	I-Premise
229	20	N	I-Premise
230	%	N	I-Premise
231	,	N	I-Premise
232	P	N	I-Premise
233	<	N	I-Premise
234	0.01	N	I-Premise
235	)	N	I-Premise
236	.	N	I-Premise

237	Overall	N	I-Premise
238	survival	N	I-Premise
239	was	N	I-Premise
240	longer	N	I-Premise
241	in	N	I-Premise
242	the	N	I-Premise
243	chemotherapy	N	I-Premise
244	group	N	I-Premise
245	(	N	I-Premise
246	median	N	I-Premise
247	8	N	I-Premise
248	vs.	N	I-Premise
249	5	N	I-Premise
250	months	N	I-Premise
251	)	N	I-Premise
252	although	N	I-Premise
253	the	N	I-Premise
254	difference	N	I-Premise
255	was	N	I-Premise
256	not	N	I-Premise
257	statistically	N	I-Premise
258	significant	N	I-Premise
259	(	N	I-Premise
260	P	N	I-Premise
261	=	N	I-Premise
262	0.12	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	After	N	I-Premise
266	corrections	N	I-Premise
267	for	N	I-Premise
268	imbalances	N	I-Premise
269	in	N	I-Premise
270	pretreatment	N	I-Premise
271	characteristics	N	I-Premise
272	,	N	I-Premise
273	chemotherapy	N	I-Premise
274	treatment	N	I-Premise
275	was	N	I-Premise
276	,	N	I-Premise
277	however	N	I-Premise
278	,	N	I-Premise
279	associated	N	I-Premise
280	with	N	I-Premise
281	a	N	I-Premise
282	survival	N	I-Premise
283	benefit	N	I-Premise
284	(	N	I-Premise
285	P	N	I-Premise
286	=	N	I-Premise
287	0.003	N	I-Premise
288	)	N	I-Premise
289	.	N	I-Premise

290	Also	N	I-Premise
291	,	N	I-Premise
292	the	N	I-Premise
293	quality-adjusted	N	I-Premise
294	survival	N	I-Premise
295	time	N	I-Premise
296	and	N	I-Premise
297	time	N	I-Premise
298	to	N	I-Premise
299	disease	N	I-Premise
300	progression	N	I-Premise
301	were	N	I-Premise
302	longer	N	I-Premise
303	for	N	I-Premise
304	patients	N	I-Premise
305	randomized	N	I-Premise
306	to	N	I-Premise
307	chemotherapy	N	I-Premise
308	(	N	I-Premise
309	median	N	I-Premise
310	5	N	I-Premise
311	vs.	N	I-Premise
312	2	N	I-Premise
313	months	N	I-Premise
314	,	N	I-Premise
315	P	N	I-Premise
316	=	N	I-Premise
317	0.03	N	I-Premise
318	)	N	I-Premise
319	.	N	I-Premise

320	The	N	I-Claim
321	results	N	I-Claim
322	show	N	I-Claim
323	that	N	I-Claim
324	chemotherapy	N	I-Claim
325	can	N	I-Claim
326	add	N	I-Claim
327	to	N	I-Claim
328	both	N	I-Claim
329	quantity	N	I-Claim
330	and	N	I-Claim
331	quality	N	I-Claim
332	of	N	I-Claim
333	life	N	I-Claim
334	in	N	I-Claim
335	advanced	N	I-Claim
336	gastric	N	I-Claim
337	cancer	N	I-Claim
338	.	N	I-Claim

339	The	N	I-Claim
340	number	N	I-Claim
341	of	N	I-Claim
342	patients	N	I-Claim
343	who	N	I-Claim
344	benefit	N	I-Claim
345	from	N	I-Claim
346	treatment	N	I-Claim
347	is	N	I-Claim
348	,	N	I-Claim
349	however	N	I-Claim
350	,	N	I-Claim
351	still	N	I-Claim
352	rather	N	I-Claim
353	limited	N	I-Claim
354	.	N	I-Claim

1	Oral	N	O
2	etoposide	N	O
3	is	N	O
4	an	N	O
5	active	N	O
6	single	N	O
7	agent	N	O
8	in	N	O
9	small-cell	N	O
10	lung	N	O
11	cancer	N	O
12	(	N	O
13	SCLC	N	O
14	)	N	O
15	and	N	O
16	is	N	O
17	widely	N	O
18	prescribed	N	O
19	as	N	O
20	first-line	N	O
21	treatment	N	O
22	as	N	O
23	an	N	O
24	alternative	N	O
25	to	N	O
26	intravenous	N	O
27	combination	N	O
28	chemotherapy	N	O
29	in	N	O
30	patients	N	O
31	with	N	O
32	extensive	N	O
33	disease	N	O
34	.	N	O

35	The	N	O
36	intention	N	O
37	of	N	O
38	this	N	O
39	study	N	O
40	was	N	O
41	to	N	O
42	determine	N	O
43	if	N	O
44	the	N	O
45	effects	N	O
46	of	N	O
47	oral	N	O
48	etoposide	N	O
49	therapy	N	O
50	on	N	O
51	survival	N	O
52	and	N	O
53	quality	N	O
54	of	N	O
55	life	N	O
56	are	N	O
57	equivalent	N	O
58	to	N	O
59	those	N	O
60	of	N	O
61	intravenous	N	O
62	chemotherapy	N	O
63	.	N	O

64	In	N	O
65	a	N	O
66	randomized	N	O
67	trial	N	O
68	of	N	O
69	palliative	N	O
70	treatment	N	O
71	in	N	O
72	advanced	N	O
73	SCLC	N	O
74	,	N	O
75	oral	N	O
76	etoposide	N	O
77	(	N	O
78	100	N	O
79	mg	N	O
80	given	N	O
81	twice	N	O
82	daily	N	O
83	for	N	O
84	5	N	O
85	days	N	O
86	)	N	O
87	was	N	O
88	compared	N	O
89	with	N	O
90	intravenous	N	O
91	chemotherapy	N	O
92	consisting	N	O
93	of	N	O
94	alternating	N	O
95	cycles	N	O
96	of	N	O
97	cisplatin	N	O
98	and	N	O
99	etoposide	N	O
100	(	N	O
101	PE	N	O
102	)	N	O
103	and	N	O
104	cyclophosphamide	N	O
105	,	N	O
106	doxorubicin	N	O
107	,	N	O
108	and	N	O
109	vincristine	N	O
110	(	N	O
111	CAV	N	O
112	)	N	O
113	.	N	O

114	Six	N	O
115	cycles	N	O
116	of	N	O
117	chemotherapy	N	O
118	were	N	O
119	administered	N	O
120	every	N	O
121	21	N	O
122	days	N	O
123	in	N	O
124	both	N	O
125	regimens	N	O
126	.	N	O

127	Symptom	N	O
128	control	N	O
129	and	N	O
130	quality	N	O
131	of	N	O
132	life	N	O
133	were	N	O
134	measured	N	O
135	with	N	O
136	the	N	O
137	Rotterdam	N	O
138	Symptom	N	O
139	Checklist	N	O
140	and	N	O
141	a	N	O
142	daily	N	O
143	diary	N	O
144	card	N	O
145	.	N	O

146	In	N	O
147	January	N	O
148	1996	N	O
149	,	N	O
150	after	N	O
151	155	N	O
152	patients	N	O
153	had	N	O
154	been	N	O
155	randomly	N	O
156	assigned	N	O
157	from	N	O
158	a	N	O
159	projected	N	O
160	intake	N	O
161	of	N	O
162	365	N	O
163	patients	N	O
164	,	N	O
165	an	N	O
166	independent	N	O
167	Data	N	O
168	Monitoring	N	O
169	Committee	N	O
170	examined	N	O
171	the	N	O
172	interim	N	O
173	results	N	O
174	.	N	O

175	Survival	N	O
176	was	N	O
177	determined	N	O
178	by	N	O
179	the	N	O
180	Kaplan-Meier	N	O
181	method	N	O
182	,	N	O
183	and	N	O
184	the	N	O
185	logrank	N	O
186	test	N	O
187	was	N	O
188	used	N	O
189	to	N	O
190	compare	N	O
191	treatments	N	O
192	.	N	O

193	For	N	O
194	quality-of-life	N	O
195	comparisons	N	O
196	,	N	O
197	average	N	O
198	scores	N	O
199	were	N	O
200	calculated	N	O
201	for	N	O
202	each	N	O
203	time	N	O
204	point	N	O
205	.	N	O

206	The	N	O
207	Mann-Whitney	N	O
208	U	N	O
209	test	N	O
210	was	N	O
211	used	N	O
212	to	N	O
213	determine	N	O
214	any	N	O
215	significant	N	O
216	overall	N	O
217	differences	N	O
218	between	N	O
219	treatments	N	O
220	.	N	O

221	For	N	O
222	the	N	O
223	Rotterdam	N	O
224	Symptom	N	O
225	Checklist	N	O
226	,	N	O
227	separate	N	O
228	analyses	N	O
229	were	N	O
230	done	N	O
231	for	N	O
232	each	N	O
233	subset	N	O
234	(	N	O
235	psychological	N	O
236	well-being	N	O
237	,	N	O
238	physical	N	O
239	symptoms	N	O
240	,	N	O
241	lung	N	O
242	cancer	N	O
243	symptoms	N	O
244	,	N	O
245	treatment	N	O
246	symptoms	N	O
247	,	N	O
248	activity	N	O
249	,	N	O
250	and	N	O
251	quality	N	O
252	of	N	O
253	life	N	O
254	)	N	O
255	.	N	O

256	Response	N	O
257	rates	N	O
258	and	N	O
259	toxicity	N	O
260	scores	N	O
261	were	N	O
262	compared	N	O
263	by	N	O
264	using	N	O
265	chi2	N	O
266	.	N	O

267	All	N	O
268	statistical	N	O
269	tests	N	O
270	were	N	O
271	two-sided	N	O
272	.	N	O

273	Survival	N	I-Premise
274	was	N	I-Premise
275	inferior	N	I-Premise
276	at	N	I-Premise
277	1	N	I-Premise
278	year	N	I-Premise
279	in	N	I-Premise
280	the	N	I-Premise
281	oral	N	I-Premise
282	etoposide	N	I-Premise
283	group	N	I-Premise
284	compared	N	I-Premise
285	with	N	I-Premise
286	intravenous	N	I-Premise
287	therapy	N	I-Premise
288	(	N	I-Premise
289	9.8	N	I-Premise
290	%	N	I-Premise
291	for	N	I-Premise
292	oral	N	I-Premise
293	versus	N	I-Premise
294	19.3	N	I-Premise
295	%	N	I-Premise
296	for	N	I-Premise
297	intravenous	N	I-Premise
298	;	N	I-Premise
299	difference	N	I-Premise
300	=	N	I-Premise
301	9.5	N	I-Premise
302	%	N	I-Premise
303	;	N	I-Premise
304	95	N	I-Premise
305	%	N	I-Premise
306	confidence	N	I-Premise
307	interval	N	I-Premise
308	of	N	I-Premise
309	difference	N	I-Premise
310	=	N	I-Premise
311	0.3	N	I-Premise
312	%	N	I-Premise
313	-18.7	N	I-Premise
314	%	N	I-Premise
315	;	N	I-Premise
316	P	N	I-Premise
317	<	N	I-Premise
318	.05	N	I-Premise
319	)	N	I-Premise
320	,	N	I-Premise
321	and	N	I-Premise
322	there	N	I-Premise
323	was	N	I-Premise
324	a	N	I-Premise
325	trend	N	I-Premise
326	toward	N	I-Premise
327	inferior	N	I-Premise
328	overall	N	I-Premise
329	survival	N	I-Premise
330	.	N	I-Premise

331	Median	N	I-Premise
332	survival	N	I-Premise
333	was	N	I-Premise
334	4.8	N	I-Premise
335	months	N	I-Premise
336	for	N	I-Premise
337	oral	N	I-Premise
338	treatment	N	I-Premise
339	and	N	I-Premise
340	5.9	N	I-Premise
341	months	N	I-Premise
342	for	N	I-Premise
343	intravenous	N	I-Premise
344	therapy	N	I-Premise
345	.	N	I-Premise

346	Progression-free	N	I-Premise
347	survival	N	I-Premise
348	was	N	I-Premise
349	worse	N	I-Premise
350	in	N	I-Premise
351	the	N	I-Premise
352	oral	N	I-Premise
353	etoposide	N	I-Premise
354	arm	N	I-Premise
355	(	N	I-Premise
356	median	N	I-Premise
357	=	N	I-Premise
358	3.6	N	I-Premise
359	months	N	I-Premise
360	versus	N	I-Premise
361	5.6	N	I-Premise
362	months	N	I-Premise
363	;	N	I-Premise
364	P	N	I-Premise
365	<	N	I-Premise
366	.001	N	I-Premise
367	)	N	I-Premise
368	,	N	I-Premise
369	as	N	I-Premise
370	well	N	I-Premise
371	as	N	I-Premise
372	overall	N	I-Premise
373	response	N	I-Premise
374	rate	N	I-Premise
375	(	N	I-Premise
376	32.9	N	I-Premise
377	%	N	I-Premise
378	versus	N	I-Premise
379	46.3	N	I-Premise
380	%	N	I-Premise
381	;	N	I-Premise
382	P	N	I-Premise
383	<	N	I-Premise
384	.01	N	I-Premise
385	)	N	I-Premise
386	.	N	I-Premise

387	With	N	I-Premise
388	the	N	I-Premise
389	exception	N	I-Premise
390	of	N	I-Premise
391	acute	N	I-Premise
392	nausea	N	I-Premise
393	and	N	I-Premise
394	vomiting	N	I-Premise
395	associated	N	I-Premise
396	with	N	I-Premise
397	intravenous	N	I-Premise
398	chemotherapy	N	I-Premise
399	,	N	I-Premise
400	all	N	I-Premise
401	aspects	N	I-Premise
402	of	N	I-Premise
403	symptom	N	I-Premise
404	control	N	I-Premise
405	and	N	I-Premise
406	quality	N	I-Premise
407	of	N	I-Premise
408	life	N	I-Premise
409	were	N	I-Premise
410	either	N	I-Premise
411	the	N	I-Premise
412	same	N	I-Premise
413	or	N	I-Premise
414	worse	N	I-Premise
415	in	N	I-Premise
416	the	N	I-Premise
417	oral	N	I-Premise
418	etoposide	N	I-Premise
419	group	N	I-Premise
420	.	N	I-Premise

421	Study	N	O
422	closure	N	O
423	was	N	O
424	recommended	N	O
425	.	N	O

426	These	N	I-Claim
427	interim	N	I-Claim
428	results	N	I-Claim
429	show	N	I-Claim
430	that	N	I-Claim
431	this	N	I-Claim
432	schedule	N	I-Claim
433	of	N	I-Claim
434	oral	N	I-Claim
435	etoposide	N	I-Claim
436	is	N	I-Claim
437	inferior	N	I-Claim
438	to	N	I-Claim
439	intravenous	N	I-Claim
440	chemotherapy	N	I-Claim
441	in	N	I-Claim
442	the	N	I-Claim
443	treatment	N	I-Claim
444	of	N	I-Claim
445	advanced	N	I-Claim
446	SCLC	N	I-Claim
447	and	N	I-Claim
448	should	N	I-Claim
449	not	N	I-Claim
450	be	N	I-Claim
451	used	N	I-Claim
452	as	N	I-Claim
453	first-line	N	I-Claim
454	treatment	N	I-Claim
455	of	N	I-Claim
456	this	N	I-Claim
457	disease	N	I-Claim
458	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	two	N	O
7	doses	N	O
8	of	N	O
9	megestrol	N	O
10	acetate	N	O
11	(	N	O
12	MA	N	O
13	)	N	O
14	compared	N	O
15	with	N	O
16	placebo	N	O
17	on	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	(	N	O
22	QoL	N	O
23	)	N	O
24	and	N	O
25	nutritional	N	O
26	status	N	O
27	(	N	O
28	NS	N	O
29	)	N	O
30	in	N	O
31	patients	N	O
32	with	N	O
33	advanced	N	O
34	endocrine-insensitive	N	O
35	cancer	N	O
36	.	N	O

37	Two	N	O
38	hundred	N	O
39	forty	N	O
40	patients	N	O
41	were	N	O
42	randomised	N	O
43	to	N	O
44	double-blind	N	O
45	MA	N	O
46	480	N	O
47	mg/day	N	O
48	,	N	O
49	MA	N	O
50	160	N	O
51	mg/day	N	O
52	,	N	O
53	or	N	O
54	matching	N	O
55	placebo	N	O
56	for	N	O
57	12	N	O
58	weeks	N	O
59	.	N	O

60	Nutritional	N	O
61	status	N	O
62	(	N	O
63	including	N	O
64	weight	N	O
65	,	N	O
66	skinfold	N	O
67	thickness	N	O
68	and	N	O
69	midarm	N	O
70	circumference	N	O
71	)	N	O
72	and	N	O
73	QoL	N	O
74	(	N	O
75	using	N	O
76	6	N	O
77	linear	N	O
78	analogue	N	O
79	self-assessment	N	O
80	(	N	O
81	LASA	N	O
82	)	N	O
83	scales	N	O
84	)	N	O
85	were	N	O
86	assessed	N	O
87	at	N	O
88	randomisation	N	O
89	and	N	O
90	after	N	O
91	four	N	O
92	,	N	O
93	eight	N	O
94	and	N	O
95	12	N	O
96	weeks	N	O
97	.	N	O

98	A	N	O
99	QoL	N	O
100	ranking	N	O
101	incorporating	N	O
102	QoL	N	O
103	and	N	O
104	death	N	O
105	was	N	O
106	also	N	O
107	used	N	O
108	ranging	N	O
109	from	N	O
110	1	N	O
111	=	N	O
112	dead	N	O
113	to	N	O
114	5	N	O
115	=	N	O
116	much	N	O
117	better	N	O
118	QoL	N	O
119	.	N	O

120	One	N	O
121	hundred	N	O
122	seventy-four	N	O
123	patients	N	O
124	were	N	O
125	assessable	N	O
126	at	N	O
127	week	N	O
128	four	N	O
129	,	N	O
130	136	N	O
131	at	N	O
132	week	N	O
133	eight	N	O
134	and	N	O
135	103	N	O
136	patients	N	O
137	at	N	O
138	week	N	O
139	12	N	O
140	.	N	O

141	Patients	N	I-Premise
142	receiving	N	I-Premise
143	MA	N	I-Premise
144	reported	N	I-Premise
145	substantially	N	I-Premise
146	better	N	I-Premise
147	appetite	N	I-Premise
148	(	N	I-Premise
149	P	N	I-Premise
150	=	N	I-Premise
151	0.001	N	I-Premise
152	)	N	I-Premise
153	,	N	I-Premise
154	mood	N	I-Premise
155	(	N	I-Premise
156	P	N	I-Premise
157	=	N	I-Premise
158	0.001	N	I-Premise
159	)	N	I-Premise
160	and	N	I-Premise
161	overall	N	I-Premise
162	quality	N	I-Premise
163	of	N	I-Premise
164	life	N	I-Premise
165	(	N	I-Premise
166	P	N	I-Premise
167	<	N	I-Premise
168	0.001	N	I-Premise
169	)	N	I-Premise
170	,	N	I-Premise
171	and	N	I-Premise
172	possibly	N	I-Premise
173	less	N	I-Premise
174	nausea	N	I-Premise
175	and	N	I-Premise
176	vomiting	N	I-Premise
177	(	N	I-Premise
178	P	N	I-Premise
179	=	N	I-Premise
180	0.08	N	I-Premise
181	)	N	I-Premise
182	than	N	I-Premise
183	patients	N	I-Premise
184	receiving	N	I-Premise
185	placebo	N	I-Premise
186	,	N	I-Premise
187	based	N	I-Premise
188	on	N	I-Premise
189	a	N	I-Premise
190	test	N	I-Premise
191	for	N	I-Premise
192	trend	N	I-Premise
193	.	N	I-Premise

194	A	N	I-Premise
195	larger	N	I-Premise
196	benefit	N	I-Premise
197	was	N	I-Premise
198	seen	N	I-Premise
199	with	N	I-Premise
200	the	N	I-Premise
201	higher	N	I-Premise
202	dose	N	I-Premise
203	which	N	I-Premise
204	(	N	I-Premise
205	unlike	N	I-Premise
206	the	N	I-Premise
207	lower	N	I-Premise
208	dose	N	I-Premise
209	)	N	I-Premise
210	was	N	I-Premise
211	significantly	N	I-Premise
212	better	N	I-Premise
213	in	N	I-Premise
214	pairwise	N	I-Premise
215	comparisons	N	I-Premise
216	with	N	I-Premise
217	placebo	N	I-Premise
218	for	N	I-Premise
219	appetite	N	I-Premise
220	,	N	I-Premise
221	mood	N	I-Premise
222	and	N	I-Premise
223	overall	N	I-Premise
224	QoL	N	I-Premise
225	(	N	I-Premise
226	each	N	I-Premise
227	P	N	I-Premise
228	<	N	I-Premise
229	or	N	I-Premise
230	=	N	I-Premise
231	0.001	N	I-Premise
232	)	N	I-Premise
233	.	N	I-Premise

234	Despite	N	I-Premise
235	some	N	I-Premise
236	missing	N	I-Premise
237	data	N	I-Premise
238	on	N	I-Premise
239	QoL	N	I-Premise
240	scores	N	I-Premise
241	,	N	I-Premise
242	QoL	N	I-Premise
243	ranking	N	I-Premise
244	was	N	I-Premise
245	available	N	I-Premise
246	on	N	I-Premise
247	227	N	I-Premise
248	(	N	I-Premise
249	95	N	I-Premise
250	%	N	I-Premise
251	)	N	I-Premise
252	of	N	I-Premise
253	patients	N	I-Premise
254	with	N	I-Premise
255	significantly	N	I-Premise
256	higher	N	I-Premise
257	QoL	N	I-Premise
258	ranking	N	I-Premise
259	associated	N	I-Premise
260	with	N	I-Premise
261	MA	N	I-Premise
262	(	N	I-Premise
263	P	N	I-Premise
264	=	N	I-Premise
265	0.002	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	Improvements	N	I-Premise
269	in	N	I-Premise
270	QoL	N	I-Premise
271	occurred	N	I-Premise
272	early	N	I-Premise
273	within	N	I-Premise
274	four	N	I-Premise
275	weeks	N	I-Premise
276	and	N	I-Premise
277	were	N	I-Premise
278	sustained	N	I-Premise
279	.	N	I-Premise

280	No	N	I-Premise
281	statistically	N	I-Premise
282	significant	N	I-Premise
283	differences	N	I-Premise
284	were	N	I-Premise
285	observed	N	I-Premise
286	in	N	I-Premise
287	NS	N	I-Premise
288	measurements	N	I-Premise
289	,	N	I-Premise
290	including	N	I-Premise
291	weight	N	I-Premise
292	(	N	I-Premise
293	P	N	I-Premise
294	=	N	I-Premise
295	0.29	N	I-Premise
296	)	N	I-Premise
297	.	N	I-Premise

298	Side	N	I-Premise
299	effects	N	I-Premise
300	of	N	I-Premise
301	therapy	N	I-Premise
302	were	N	I-Premise
303	minor	N	I-Premise
304	and	N	I-Premise
305	did	N	I-Premise
306	not	N	I-Premise
307	differ	N	I-Premise
308	significantly	N	I-Premise
309	across	N	I-Premise
310	treatments	N	I-Premise
311	.	N	I-Premise

312	Megestrol	N	I-Claim
313	acetate	N	I-Claim
314	given	N	I-Claim
315	at	N	I-Claim
316	480	N	I-Claim
317	mg/day	N	I-Claim
318	is	N	I-Claim
319	useful	N	I-Claim
320	palliation	N	I-Claim
321	in	N	I-Claim
322	patients	N	I-Claim
323	with	N	I-Claim
324	endocrine-insensitive	N	I-Claim
325	advanced	N	I-Claim
326	cancer	N	I-Claim
327	.	N	I-Claim

328	It	N	I-Claim
329	improves	N	I-Claim
330	appetite	N	I-Claim
331	,	N	I-Claim
332	mood	N	I-Claim
333	and	N	I-Claim
334	overall	N	I-Claim
335	quality	N	I-Claim
336	of	N	I-Claim
337	life	N	I-Claim
338	in	N	I-Claim
339	these	N	I-Claim
340	patients	N	I-Claim
341	,	N	I-Claim
342	although	N	I-Claim
343	not	N	I-Claim
344	through	N	I-Claim
345	a	N	I-Claim
346	direct	N	I-Claim
347	effect	N	I-Claim
348	on	N	I-Claim
349	nutritional	N	I-Claim
350	status	N	I-Claim
351	.	N	I-Claim

1	The	N	I-MajorClaim
2	choice	N	I-MajorClaim
3	of	N	I-MajorClaim
4	reconstruction	N	I-MajorClaim
5	after	N	I-MajorClaim
6	gastrectomy	N	I-MajorClaim
7	and	N	I-MajorClaim
8	the	N	I-MajorClaim
9	significance	N	I-MajorClaim
10	of	N	I-MajorClaim
11	remaining	N	I-MajorClaim
12	reservoir	N	I-MajorClaim
13	function	N	I-MajorClaim
14	is	N	I-MajorClaim
15	a	N	I-MajorClaim
16	matter	N	I-MajorClaim
17	of	N	I-MajorClaim
18	controversy	N	I-MajorClaim
19	.	N	I-MajorClaim

20	To	N	O
21	broaden	N	O
22	the	N	O
23	criteria	N	O
24	for	N	O
25	choice	N	O
26	of	N	O
27	treatment	N	O
28	,	N	O
29	we	N	O
30	conducted	N	O
31	a	N	O
32	prospective	N	O
33	randomized	N	O
34	clinical	N	O
35	trial	N	O
36	to	N	O
37	determine	N	O
38	the	N	O
39	impact	N	O
40	of	N	O
41	various	N	O
42	gastrectomy	N	O
43	procedures	N	O
44	on	N	O
45	quality	N	O
46	of	N	O
47	life	N	O
48	.	N	O

49	Consecutive	N	O
50	patients	N	O
51	(	N	O
52	n	N	O
53	=	N	O
54	64	N	O
55	)	N	O
56	eligible	N	O
57	for	N	O
58	curative	N	O
59	gastric	N	O
60	cancer	N	O
61	surgery	N	O
62	were	N	O
63	randomized	N	O
64	to	N	O
65	have	N	O
66	either	N	O
67	a	N	O
68	total	N	O
69	(	N	O
70	n	N	O
71	=	N	O
72	31	N	O
73	)	N	O
74	or	N	O
75	subtotal	N	O
76	(	N	O
77	n	N	O
78	=	N	O
79	13	N	O
80	)	N	O
81	gastrectomy	N	O
82	or	N	O
83	a	N	O
84	jejunal	N	O
85	S-shaped	N	O
86	pouch	N	O
87	(	N	O
88	n	N	O
89	=	N	O
90	20	N	O
91	)	N	O
92	implanted	N	O
93	as	N	O
94	a	N	O
95	gastric	N	O
96	substitute	N	O
97	.	N	O

98	The	N	O
99	quality-of-life	N	O
100	evaluation	N	O
101	was	N	O
102	based	N	O
103	on	N	O
104	a	N	O
105	battery	N	O
106	of	N	O
107	questionnaires	N	O
108	covering	N	O
109	both	N	O
110	general	N	O
111	and	N	O
112	specific	N	O
113	aspects	N	O
114	of	N	O
115	life	N	O
116	.	N	O

117	The	N	O
118	patients	N	O
119	were	N	O
120	rated	N	O
121	by	N	O
122	one	N	O
123	of	N	O
124	two	N	O
125	psychiatrists	N	O
126	who	N	O
127	were	N	O
128	blinded	N	O
129	to	N	O
130	the	N	O
131	patients	N	O
132	'	N	O
133	group	N	O
134	affiliation	N	O
135	.	N	O

136	Assessments	N	O
137	were	N	O
138	made	N	O
139	on	N	O
140	three	N	O
141	occasions	N	O
142	:	N	O
143	during	N	O
144	the	N	O
145	week	N	O
146	prior	N	O
147	to	N	O
148	surgery	N	O
149	and	N	O
150	3	N	O
151	and	N	O
152	12	N	O
153	months	N	O
154	after	N	O
155	the	N	O
156	surgical	N	O
157	intervention	N	O
158	.	N	O

159	The	N	I-Premise
160	postoperative	N	I-Premise
161	complication	N	I-Premise
162	and	N	I-Premise
163	mortality	N	I-Premise
164	rates	N	I-Premise
165	were	N	I-Premise
166	similar	N	I-Premise
167	in	N	I-Premise
168	all	N	I-Premise
169	treatment	N	I-Premise
170	groups	N	I-Premise
171	,	N	I-Premise
172	with	N	I-Premise
173	few	N	I-Premise
174	serious	N	I-Premise
175	complications	N	I-Premise
176	recorded	N	I-Premise
177	.	N	I-Premise

178	Irrespective	N	I-Premise
179	of	N	I-Premise
180	type	N	I-Premise
181	of	N	I-Premise
182	treatment	N	I-Premise
183	,	N	I-Premise
184	the	N	I-Premise
185	patients	N	I-Premise
186	suffered	N	I-Premise
187	from	N	I-Premise
188	alimentary	N	I-Premise
189	symptoms	N	I-Premise
190	and	N	I-Premise
191	functional	N	I-Premise
192	limitations	N	I-Premise
193	in	N	I-Premise
194	everyday	N	I-Premise
195	life	N	I-Premise
196	,	N	I-Premise
197	whereas	N	I-Premise
198	their	N	I-Premise
199	mental	N	I-Premise
200	well-being	N	I-Premise
201	improved	N	I-Premise
202	after	N	I-Premise
203	surgery	N	I-Premise
204	.	N	I-Premise

205	Patients	N	I-Premise
206	who	N	I-Premise
207	underwent	N	I-Premise
208	subtotal	N	I-Premise
209	gastrectomy	N	I-Premise
210	had	N	I-Premise
211	the	N	I-Premise
212	best	N	I-Premise
213	outcome	N	I-Premise
214	,	N	I-Premise
215	especially	N	I-Premise
216	with	N	I-Premise
217	respect	N	I-Premise
218	to	N	I-Premise
219	complaints	N	I-Premise
220	of	N	I-Premise
221	diarrhea	N	I-Premise
222	.	N	I-Premise

223	Patients	N	I-Premise
224	given	N	I-Premise
225	a	N	I-Premise
226	gastric	N	I-Premise
227	substitute	N	I-Premise
228	after	N	I-Premise
229	gastrectomy	N	I-Premise
230	showed	N	I-Premise
231	no	N	I-Premise
232	difference	N	I-Premise
233	from	N	I-Premise
234	those	N	I-Premise
235	who	N	I-Premise
236	had	N	I-Premise
237	only	N	I-Premise
238	a	N	I-Premise
239	total	N	I-Premise
240	gastrectomy	N	I-Premise
241	.	N	I-Premise

242	We	N	I-Claim
243	conclude	N	I-Claim
244	that	N	I-Claim
245	despite	N	I-Claim
246	significant	N	I-Claim
247	unfavorable	N	I-Claim
248	consequences	N	I-Claim
249	that	N	I-Claim
250	follow	N	I-Claim
251	gastrectomy	N	I-Claim
252	,	N	I-Claim
253	patients	N	I-Claim
254	recover	N	I-Claim
255	with	N	I-Claim
256	an	N	I-Claim
257	improved	N	I-Claim
258	mental	N	I-Claim
259	status	N	I-Claim
260	.	N	I-Claim

261	A	N	I-Claim
262	pouch	N	I-Claim
263	reconstruction	N	I-Claim
264	after	N	I-Claim
265	total	N	I-Claim
266	gastrectomy	N	I-Claim
267	does	N	I-Claim
268	not	N	I-Claim
269	improve	N	I-Claim
270	quality	N	I-Claim
271	of	N	I-Claim
272	life	N	I-Claim
273	,	N	I-Claim
274	but	N	O
275	a	N	I-Claim
276	subtotal	N	I-Claim
277	gastrectomy	N	I-Claim
278	has	N	I-Claim
279	advantages	N	I-Claim
280	that	N	I-Claim
281	must	N	I-Claim
282	be	N	I-Claim
283	considered	N	I-Claim
284	when	N	I-Claim
285	the	N	I-Claim
286	procedure	N	I-Claim
287	is	N	I-Claim
288	clinically	N	I-Claim
289	feasible	N	I-Claim
290	.	N	I-Claim

